CONTENTS

CROI FOUNDATION ........................................................................................................ 2
IAS–USA ........................................................................................................................... 3
CROI 2023 SCIENTIFIC PROGRAM COMMITTEE .................................................. 4
  Scientific Program Committee .............................................................................. 4
  Community Liaison Subcommittee .................................................................... 6
EXTERNAL REVIEWERS .................................................................................................... 7
CONTINUING MEDICAL EDUCATION ....................................................................... 10
GENERAL CONFERENCE INFORMATION ............................................................... 12
  Overview .................................................................................................................. 12
  Funding and Grant Support .................................................................................. 12
  Affiliated and Proximate Activities .................................................................... 12
  Conference Badges .............................................................................................. 13
  Conference Etiquette ............................................................................................ 13
HEALTH AND SAFETY ............................................................................................... 13
  COVID–19 Policies ................................................................................................ 13
  Americans with Disabilities Act .......................................................................... 14
  Emergency Services .............................................................................................. 14
TECHNOLOGY AND CONNECTIVITY ....................................................................... 15
  Wi-Fi Access at the Conference ........................................................................ 15
  Conference Platform ............................................................................................ 15
  Website .................................................................................................................. 15
  Webcasts ............................................................................................................... 15
ABSTRACT PROCESS ................................................................................................. 16
  Abstracts Related to Study Populations .............................................................. 17
PRECONFERENCE SESSIONS .................................................................................. 18
OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY ............................... 22
ORAL ABSTRACT SESSIONS AND THEMED DISCUSSIONS BY DAY ............... 33
POSTER SESSIONS BY DAY .................................................................................... 58
POSTER SESSIONS BY CATEGORY ......................................................................... 153
INDEX OF PRESENTERS ............................................................................................. 158
SCHOLARSHIP Awardee INFORMATION ................................................................. 165
CONFERENCE SERVICES .......................................................................................... 166
CONFERENCE SCHEDULE ...................................................................................... Foldout
CONVENTION CENTER FLOOR PLANS ................................................................. Foldout
CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Organizer
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Affiliation</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>President</td>
<td>University of California San Diego</td>
<td>San Diego, CA, United States</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Secretary-Treasurer</td>
<td>Tufts University</td>
<td>Boston, MA, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td></td>
<td>Columbia University</td>
<td>New York, NY, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td></td>
<td>San Francisco Department of Public Health</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td></td>
<td>University of California Los Angeles</td>
<td>Los Angeles, CA, United States</td>
</tr>
<tr>
<td>Diane V. Havlir, MD</td>
<td></td>
<td>University of California San Francisco</td>
<td>San Francisco, CA, United States</td>
</tr>
<tr>
<td>Sharon L. Hillier, PhD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>James A. Hoxie, MD</td>
<td></td>
<td>University of Pennsylvania</td>
<td>Philadelphia, PA, United States</td>
</tr>
<tr>
<td>Richard A. Koup, MD</td>
<td></td>
<td>Vaccine Research Center within NIAID</td>
<td>Bethesda, MD, United States</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh, PA, United States</td>
</tr>
<tr>
<td>Landon Myer, MD, PhD</td>
<td></td>
<td>University of Cape Town</td>
<td>Cape Town, South Africa</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td></td>
<td>University of California San Diego</td>
<td>San Diego, CA, United States</td>
</tr>
</tbody>
</table>
IAS—USA

The International Antiviral (formerly AIDS)—USA (IAS—USA) serves as the Conference Organizer for the planning and organization of CROI in partnership with the CROI Foundation and Program Committee. The IAS—USA is a 501(c)(3) tax-exempt, not-for-profit organization guided by a volunteer board of directors. The mission of the IAS—USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS—USA, please visit www.iasusa.org for:

- Live CME courses, CME webinars, and dialogues available for signup
- Archived webcasts of CME courses and webinars
- Topics in Antiviral Medicine, including the annual CROI review
- Practice guidelines
CROI 2023 SCIENTIFIC PROGRAM COMMITTEE

The CROI Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

James A. Hoxie, MD
CROI 2023 Chair
University of Pennsylvania
Philadelphia, PA,
United States

Diane V. Havlir, MD
CROI 2023 Vice Chair
University of California
San Francisco
San Francisco, CA, United States

Landon Myer, MD, PhD
CROI 2023 Vice Chair
University of Cape Town
Cape Town, South Africa

Elaine J. Abrams, MD
Columbia University
New York, NY, United States

Adaora Adimora, MD
University of North Carolina
at Chapel Hill
Chapel Hill, NC, United States

Susan P. Buchbinder, MD
San Francisco Department of Public Health
San Francisco, CA,
United States

Connie L. Celum, MD, MPH
University of Washington Seattle, WA, United States

Katharine J. Bar, MD
University of Pennsylvania
Philadelphia, PA,
United States

Richard E. Chaisson, MD
The John Hopkins University Baltimore, MD, United States

Ruanne Barnabas, MD, PhD
Massachusetts General Hospital
Boston, MA, United States

Nicholas Chomont, PhD
Université de Montréal
Montreal, Canada

Constance A. Benson, MD
University of California San Diego
San Diego, CA, United States

John M. Coffin, PhD
Tufts University
Boston, MA, United States
Judith S. Currier, MD  
University of California  
Los Angeles  
Los Angeles, CA, United States

François Dabis, MD, PhD  
University of Bordeaux  
Bordeaux, France

Carlos del Rio, MD  
Emory University  
Atlanta, GA, United States

Wafaa M. El-Sadr, MD, MPH  
Columbia University  
New York, NY, United States

Joseph J. Eron, Jr, MD  
University of North Carolina at Chapel Hill  
Chapel Hill, NC, United States

Monica Gandhi, MD, MPH  
University of California  
San Francisco  
San Francisco, CA, United States

Huldrych F. Günthard, MD  
University Hospital Zurich  
Zurich, Switzerland

Theodora Hatziioannou, MD  
The Rockefeller University  
New York, NY, United States

Sharon L. Hillier, PhD  
University of Pittsburgh  
Pittsburgh, PA, United States

Peter Hunt, MD  
University of California  
San Francisco  
San Francisco, CA, United States

Jennifer Jao, MD, MPH  
Northwestern University  
Chicago, IL, United States

Angela Kashuba, PharmD  
University of North Carolina at Chapel Hill  
Chapel Hill, NC, United States

Frank Kirchhoff, PhD  
Institute of Molecular Virology  
Ulm, Germany

Richard A. Koup, MD  
National Institute of Allergy and Infectious Diseases  
Bethesda, MD, United States

Raphael J. Landovitz, MD  
University of California  
Los Angeles  
Los Angeles, CA, United States

James McIntyre, MBChB  
University of Cape Town  
Cape Town, South Africa

John W. Mellors, MD  
University of Pittsburgh  
Pittsburgh, PA, United States

Jonathan Mermin, MD, MPH  
Centers for Disease Control and Prevention  
Atlanta, GA, United States

Jean-Michel Molina, MD, PhD  
University of Paris  
Paris, France

Penny Moore, PhD  
University of the Witwatersrand  
Johannesburg, South Africa

Stuart J. D. Neil, PhD  
King’s College  
London, United Kingdom

Peter Reiss, MD, PhD  
University of Amsterdam  
Amsterdam, Netherlands
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Dawn Averitt
The Well Project
South Strafford, VT, United States

Ntando Yola
Desmond Tutu HIV Foundation
Cape Town, South Africa

Jim Pickett
AVAC
Chicago, IL, United States
EXTERNAL REVIEWERS
We gratefully acknowledge the contributions of the following, who, in addition to the scientific program committee members, served as volunteer external reviewers of abstract submissions for CROI 2023.

K. Rivet Amico, PhD
University of Michigan School of Public Health
Ann Arbor, MI, United States

Peter L. Anderson, PharmD
University of Colorado Anschutz Medical Campus
Aurora, CO, United States

Georg Behrens, MD, PhD
Medizinische Hochschule Hannover Hannover, Germany

Marta Boffito, MD, PhD
Chelsea and Westminster Hospital London, United Kingdom

Bruce Brew, MBBS, DMedSci, Dsc
St. Vincent's Hospital Sydney, Australia

Todd T. Brown, MD, PhD
The John Hopkins University Baltimore, MD, United States

David Burger, PharmD
Radboud University Medical Center Nijmegen, Netherlands

Maria J. Buzon, PhD
Vall d’Hebron Research Institute Barcelona, Spain

Carol Camlin, PhD
University of California San Francisco San Francisco, CA, United States

Corey Casper, MD, MPH
Access to Advanced Health Institute Seattle, WA, United States

Ellen Chadwick, MD
Northwestern University Chicago, IL, United States

David B. Clifford, MD
Washington University in St. Louis St. Louis, MO, United States

Elizabeth Connick, MD
University of Arizona Tucson, AZ, United States

Blossom Damania, PhD
University of North Carolina at Chapel Hill Chapel Hill, NC, United States

Kevin M. De Cock, MD
Center for Disease Control and Prevention Nairobi, Kenya

Kelly E. Dooley, MD, PhD
Vanderbilt University Nashville, TN, United States

Kristine Erlandson, MD
University of Colorado Anschutz Medical Campus Aurora, CO, United States

David Evans, PhD
University of Wisconsin Madison Madison, WI, United States

Paul Farrell, PhD
Imperial College London London, United Kingdom

Matthew Feinstein, MD, MSc
Northwestern University Chicago, IL, United States

William Fischer, MD
University of North Carolina at Chapel Hill Chapel Hill, NC, United States

Courtney Fletcher, PharmD
University of Nebraska Medical Center Omaha, NE, United States

Charles Flexner, MD
The John Hopkins University Baltimore, MD, United States

Patricia Flynn, MD
St. Jude Children’s Research Hospital Memphis, TN, United States

Nathan Ford, MPH, Dsc, PhD
World Health Organization Geneva, Switzerland

John Frater, MD
University of Oxford Headington, United Kingdom
Dana Gabuzda, MD
Dana Farber Cancer Institute
Boston, MA, United States

Gerardo Garcia-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Carlo Giaquinto, MD, PhD
University of Padova
Padova, Italy

Beatriz Grinsztejn, MD, PhD
Instituto de Pesquisa Clinica Evandro Chagas
Rio de Janeiro, Brazil

Jessica Haberer, MD, MS
Massachusetts General Hospital
Boston, MA, United States

Richard Harrigan, PhD
University of British Columbia
Vancouver, Canada

Renee Heffron, PhD, MPH
University of Alabama at Birmingham
Birmingham, AL, United States

Sybil Hosek, PhD
Cook County Health
Chicago, IL, United States

Ya-Chi Ho, PhD
Yale University
New Haven, CT, United States

Jennifer Hoy, MBBS
Alfred Hospital
Melbourne, Australia

Priscilla Hsue, MD
University of California San Francisco
San Francisco, CA, United States

Harold Jaffe, MD
Centers for Disease Control and Prevention
Atlanta, CA, United States

Sarah Joseph, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Dennis Kolson, MD, PhD
University of Pennsylvania
Philadelphia, PA, United States

Susan E. Krown, MD
Memorial Sloan Kettering Cancer Center
New York, NY, United States

Mohammed Lamorde, MD
Makerere University
Kampala, Uganda

Maud Lemoine, MD, PhD
Imperial College London
London, United Kingdom

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, United States

Sharon Lewin, MD, PhD
Doherty Institute for Infection and Immunity
Melbourne, Australia

Anne F. Luettke, MD
University of California San Francisco
San Francisco, CA, United States

Hermione Lyall, MD
Imperial College London
London, United Kingdom

Rebecca Lynch, PhD
George Washington University
Washington, DC, United States

Patrick Mallon, MD, PhD
University College Dublin
Dublin, Ireland

Jeanne Marrazzo, MD, MPH
University of Alabama at Birmingham
Birmingham, AL, United States

Grace A. McComsey, MD
Case Western Reserve University
Cleveland, OH, United States

Graeme Meintjes, MD, PhD
University of Cape Town
Cape Town, South Africa

Ronald Mitsuyasu, MD
University of California Los Angeles
Los Angeles, CA, United States

Victor Musiime, MBChB, MMed, PhD
Makerere University
Kampala, Uganda

Susanna Naggie, MD, MPH
Duke University School of Medicine
Durham, NC, United States

Martina Penazzato, MD, MSc, PhD
World Health Organization
Geneva, Switzerland
Sari L. Reisner, DSc
Brigham and Women’s Hospital
Boston, MA, United States

Robert H. Remien, PhD
Columbia University
New York, NY, United States

Erle Robertson, PhD
University of Pennsylvania
Philadelphia, PA, United States

Michael Saag, MD
University of Alabama at Birmingham
Birmingham, AL, United States

Thomas Schulz, MD
Hannover Medical School
Hannover, Germany

Kenneth Sherman, MD, PhD
University of Cincinnati
Cincinnati, OH, United States

Euphemia Sibanda, PhD
Centre for Sexual Health and HIV/AIDS Research Zimbabwe
Harare, Zimbabwe

Viviana Simon, MD, PhD
Icahn Schol of Medicine at Mount Sinai
New York, NY, United States

Lynda Stranix-Chibanda, MBChB
University of Zimbabwe
Harare, Zimbabwe

Patrick S. Sullivan, PhD
Emory University
Atlanta, GA, United States

Susan Swindells, MBBS
University of Nebraska Medical Center
Omaha, NE, United States

Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland

Alice Tseng, PharmD
University Health Network
Toronto, Canada

Heidi van Rooyen, PhD
Human Sciences Research Council
Johannesburg, South Africa

Gert van Zyl, MD, PhD
Stellenbosch University
Stellenbosch, South Africa

Timothy Wilkin, MD
Weill Cornell Medicine
New York, NY, United States

Alan Winston, MD
Imperial College London
London, United Kingdom

David Wyles, MD
Denver Health Medical Center
Denver, CO, United States

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, United States

Markella V. Zanni, MD
Harvard Medical School
Boston, MA, United States
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The IAS—USA designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI 2023, participants will be able to describe the following as they relate to research in HIV, hepatitis viruses, SARS-CoV-2, mpox, and other viral infections and their related conditions:

• Describe basic science research advances
• List the most recent findings from clinical trials and the implications of these data for state-of-the-art treatment strategies
• Describe current epidemiologic data on the prevalence of infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public health program planning; and current advances in biobehavioral prevention.

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993, by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections, such as Covid-19 and mpox.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for their participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, symposia, meet the luminary sessions, and selected special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, certain special sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 MOC points in the ABIM MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation
During the conference, links to the daily and final evaluations will be available on the CROI website. Detailed instructions will be provided. You will need the email address that you used to register for this conference and your reference number (on your badge) to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations and claim forms must be submitted by April 28, 2023. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile on the CROI or IAS–USA website.

To determine the number CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference activities, including premeeting workshops, opening session lectures, plenary lectures, selected special sessions, and symposia. For example, if you attended 2 plenary talks (8:30 to 9:30 AM), and a symposium (4:00 to 5:30 PM), you would have a total of 2.5 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended.

A CME/ABIM MOC hour worksheet can be found on the CROI website.

Disclosure of Financial Relationships
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, the Scientific Program Committee, Community Liaison Subcommittee, invited speakers, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The information is intended to make the audience aware of speaker and contributor financial relationships with ineligible companies, enabling the audience members to form their own judgments about such associations.

Each author, contributor, or person in control of content in the CME activity is required to complete this financial relationship disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and mitigate ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information will also be included at the beginning of each presentation.

Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL CONFERENCE INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Funding and Grant Support
CROI seeks grants from commercial (ineligible) companies, particularly from companies with competing products. These companies have no input or control over the selection of faculty or the content of the CME portions of the program or abstract review and selection processes. This support is used to cover some of the costs of the conference venue, audiovisual services, and other conference expenses. CROI 2023 received grant support commitments from the following:

PLATINUM LEVEL SUPPORT
- Gilead Sciences, Inc.
- Merck & Co, Inc
- ViV Healthcare

GOLD LEVEL SUPPORT
- Janssen Therapeutics

BRONZE LEVEL SUPPORT
- Hologic, Inc.
- Theratechnologies, Inc.

Additional support received after the printing of this program book will be announced during the Conference.

Affiliated and Proximate Activities Policies
The goal of CROI is to promote meaningful and high-level interchange of scientific ideas to find better ways to prevent and treat HIV and AIDS and to one day see HIV and other viral infections, including hepatitis viruses, SARS-CoV-2, and mpox virus eradicated. In keeping with this goal, certain organizations (commercial companies and their agents, not-for-profit groups, research study groups, government agencies, etc) have been approved to host Affiliated or Proximate Activities occurring outside CROI sessions times. Affiliated or Proximate Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2023. An Affiliated and Proximate Activity is any activity, event, or meeting held at any time from 3 days before (Thursday, February 16) through 2 days after (Friday, February 24) CROI 2023, and targeted toward or including any registrants of CROI.

If an activity is found to have violated the Guidelines for Affiliated or Proximate Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated or Proximate Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and could negatively impact the registration and attendance of anyone attending an unapproved activity.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel...
may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

**Conference Badges**

Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference in order to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the meeting spaces without their CROI badge. **THE CROI BADGE MAY ONLY BE USED BY THE PERSON NAMED ON THE BADGE AND CANNOT BE TRANSFERRED OR SHARED WITH OTHERS. USING ANOTHER INDIVIDUAL’S BADGE OR GIVING YOUR BADGE TO SOMEONE ELSE TO GAIN ACCESS TO THE CONFERENCE IS STRICTLY PROHIBITED AND IS A VIOLATION OF CROI POLICIES.**

DO NOT LOSE YOUR BADGE. Payment equivalent to the full registration fee will be required to replace a lost badge.

**Conference Etiquette**

Please ensure all mobile devices are turned off or set on SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees may not photograph posters, record parts of talks, or post data without the presenter's consent.

Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster halls.

**HEALTH AND SAFETY**

**COVID-19 Policies**

For the health and safety of CROI attendees, staff, and surrounding communities, all attendees must be appropriately vaccinated. **All conference participants must wear a high-quality mask at all times (eg, N95, KN95, or KF94) while in the meeting rooms and other public spaces in the convention center. Please be conscious of physical distancing and airflow when lowering your mask to eat or drink.**

Per the World Health Organization, a fully vaccinated individual is 2 weeks or more post-initial vaccination series and may also receive a recommended booster dose after 4 to 6 months. Per the Center for Disease Control guidelines, you are up to date when you have completed a COVID-19 vaccine primary series and gotten the most recent booster dose recommended for you by the CDC.

- If you have completed your primary series — but are not yet eligible for a booster — you are considered up to date.
- If you become ill with COVID-19 after you received all vaccine doses recommended for you, you are also considered up to date. You do not need to be revaccinated or receive an additional booster.

All on-site conference attendees must verify their vaccination status with conference organizers, prior to departing for the CROI Conference via the CROI 2023 CrowdPass Site, provided in preconference communication. Visit the information desk at registration for any questions.

To accommodate any attendee who does not meet the vaccine requirement we will convert your registration to virtual attendee via the Conference Platform.
Rapid antigen tests are available on a first-come, first-served basis. Additional rapid tests are available at area pharmacies, or via a local COVID-19 testing site (see above). Contact CROIinfo@iasusa.org if you have concerns about your ability to present your abstract due to illness.

CROI conference organizers will continue to monitor the World Health Organization’s recommendations pertaining to COVID-19 and adapt these guidelines accordingly.

Americans With Disabilities Act

CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site during the conference, please visit the Conference Information desk in the registration area.

Emergency Services

In the event of an emergency, please notify CROI staff, or contact the Seattle Convention Center Security by dialing 4748 on a convention center phone or by calling +1 (206) 219-4748, available 24 hours daily. You may also use one of the red phones in the elevator lobbies for an automatic connection to security.

Emergency Medical Services are located on Level 2, near Flex C. If a medical emergency occurs while you are at the Seattle Convention Center, please contact Convention Center security directly. The Convention Center requests that guests do not contact 911 directly, when possible.
TECHNOLOGY AND CONNECTIVITY SERVICES

WiFi Access at the Conference
Complimentary WiFi access is provided at the Seattle Convention Center. Network information is as follows:

Network name: CROI2023

The WiFi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will help maximize the internet speeds for those devices actively in use. The password for each day of the conference is listed below and is case sensitive.

Saturday password: 2023saturday
Sunday password: 2023sunday
Monday password: 2023monday
Tuesday password: 2023tuesday
Wednesday password: 2023wednesday

If you are having a problem with WiFi access, please contact an IAS-USA staff member.

CONFERENCE PLATFORM

The CROI 2023 Conference Platform has many features to enhance your conference experience, including to:

- View abstracts
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- Receive the latest changes to the CROI program
- View electronic posters
- Submit questions to live streamed presentations

To access the Conference Platform, select the appropriate platform option below and log in using the email you used to register for CROI and your registration ID.

To view sessions off-site and participate in session chat, Q & A, and polling, log in to the virtual platform: https://CROI2023.e-attend.com

To participate in Q & A and polling in-person, log in to the in-person platform: https://CROIonsite.e-attend.com

Website
For additional information about the conference and to access electronic materials, please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2020 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014 to 2022 are available at www.CROIconference.org/abstracts/search-abstracts/

Webcasts
Plenary lectures, symposia, oral abstract sessions, and themed discussions will be available as webcasts within 24 hours of the end of the relevant session. Webcasts are also available as streaming videos for the Apple iPad and iPhone. Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.
ABSTRACT PROCESS

Abstract Content
Author names, institutions, titles, and abstracts in the CROI Program and Information Guide, Abstract eBook, Mobile App, and other materials are presented largely as submitted by the submitting author. The submitting author is responsible for ensuring that all coauthors have reviewed and approved the abstract before submission and for providing complete, including email addresses. **THE SUBMITTING AUTHOR MUST ENSURE THAT THE EMAIL ADDRESSES OF ALL LISTED AUTHORS IN THEIR SUBMISSION ARE CORRECT** for authors to receive important information regarding dispositions, presentation details, registration and housing information, and other CROI-related announcements.

Special Notes on Abstract Content
Presentations from randomized trials and cohorts should follow the International Committee of Medical Journal Editors (ICMJE) guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables.

Appropriate information and correct terminology should be used regarding sex and gender. For human clinical or epidemiologic studies, sex-stratified results should be provided, who was included in the study (or if the study includes only a single population). Appropriate terminology such as cisgender (people whose gender match the sex assigned at birth) or transgender (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data including use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in your presentation.

Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.”

Presenting Author Responsibilities
The presenting author is responsible for presenting the abstract at the conference and must be present at the poster during the entire session. **Submitting authors are responsible for ensuring that all coauthors have reviewed and approved the abstract contents before submission.**

Emargo Policies and Social Media
All research presented at CROI 2023 is embargoed until the conclusion of the study’s presentation at the conference. For example, if a study is presented from 2:15 PM to 2:30 PM, as part of a session that begins at 2:00 PM and ends at 3:00 PM, the embargo on that study lifts at 2:30 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented.

If a study to be presented at CROI 2023 is included in an official CROI press conference that takes place before the scheduled presentation of the study, the embargo on that study lifts at the conclusion of the press conference panel in which the study is featured.

No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs), or social media (eg, Twitter, Instagram, Facebook, etc). Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.
Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed more than 1500 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

Abstracts were reviewed for the quality and originality of the work and were scored numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were discussed. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission, as they must meet a high threshold of scientific merit).

For more information, including common reasons for abstract rejection, visit the Abstract Guidelines page of www.CROIconference.org

Statistics for Abstracts
Abstract and Presentation Statistics for CROI 2023

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Abstracts Submitted</td>
<td>1051</td>
<td></td>
</tr>
<tr>
<td>General Abstracts Accepted</td>
<td>658</td>
<td></td>
</tr>
<tr>
<td>Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Submitted</td>
<td>558</td>
<td></td>
</tr>
<tr>
<td>Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Accepted</td>
<td>347</td>
<td></td>
</tr>
<tr>
<td>Total Abstracts Submitted</td>
<td>1609</td>
<td></td>
</tr>
<tr>
<td>Total Abstracts Accepted</td>
<td>1005</td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Presentations</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Themed Discussion Presentations*</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Poster Presentations</td>
<td>834</td>
<td></td>
</tr>
<tr>
<td>Total Scientific Abstract Presentations</td>
<td>1005</td>
<td></td>
</tr>
</tbody>
</table>

*Abstracts accepted a for presentation as a themed discussion are also presented as a poster

Accepted Abstracts on Emerging Infections or Special Populations **

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>228</td>
</tr>
<tr>
<td>Mpox</td>
<td>61</td>
</tr>
<tr>
<td>Adolescents</td>
<td>76</td>
</tr>
<tr>
<td>Men who have sex with men (MSM)</td>
<td>152</td>
</tr>
<tr>
<td>People who inject drugs (PWID)</td>
<td>51</td>
</tr>
<tr>
<td>Transgender men or women</td>
<td>55</td>
</tr>
<tr>
<td>Women or girls</td>
<td>155</td>
</tr>
</tbody>
</table>

**As reported by the abstract submitter. Studies may include more than 1 special population (eg Adolescents and Transgender Men or Women)
PRECONFERENCE SESSIONS

SUNDAY, FEBRUARY 19, 2023

Workshop-01 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
Flex A (Level 2) 8:30 AM - 12:30 PM

Objectives: At the completion of the session, participants will be able to:
• Understand fundamental aspects of HIV virology and relevant immunology, including emerging understandings of host-pathogen interactions
• Identify recent advances in HIV prevention and treatment
• Gain new understanding of the experiences of people with HIV

Target Audience: This session is directed to new investigators and trainees (eg, postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Moderators
Nicolas Chomont, Université de Montréal, Montreal, QC, Canada
Serena Spudich, Yale University, New Haven, CT, USA

1 OVERVIEW SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
UPDATE ON HIV VIROLOGY

ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2
Stuart Neil, King’s College London, London, United Kingdom

ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY
Guido Silvestri, Emory University, Atlanta, GA, USA

ADVANCING RESEARCH: THE POWER OF COMMUNITY ENGAGEMENT
Dawn Averitt, The Well Project, Women’s Research Initiative on HIV/AIDS, South Strafford, VT, USA

ADVANCES IN HIV TREATMENT STRATEGIES
Monica Gandhi, University of California San Francisco, San Francisco, CA, USA

ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Raphael J. Landovitz, University of California Los Angeles, Los Angeles, CA, USA

ADVANCES IN HIV CURE
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA
**Workshop-02 FRONTIERS IN LABORATORY TECHNOLOGIES**

**Ballroom 2 (Level 5) 1:30 PM - 3:30 PM**

**Objectives:** At the completion of the session, participants will be able to:
- Describe distinct techniques for single cell analyses, transcriptomics, and imaging, including strengths and limitations
- Describe how deep learning can be applied to characterize protein dynamics

**Target Audience:** This session is directed to scientists, clinicians, stakeholders, students, and members of the community at large, who are interested in understanding the impact of novel laboratory technologies.

**Level of Knowledge:** It is assumed that the participants are familiar with the main technologic and data analysis approaches used in research.

**Moderators**
- Katharine Bar, University of Pennsylvania, Philadelphia, PA, USA
- Frank Kirchhoff, Ulm University Medical Center, Ulm, Baden-Württemberg, Germany

**2 SINGLE-CELL ANALYSIS OF THE RNA, PROTEIN, AND GLYCAN FEATURES OF HIV-INFECTED CELLS**

Nadia R. Roan, Gladstone Institutes, San Francisco, CA, USA

**3 SINGLE-CELL MULTIOMIC ANALYSES OF THE HIV RESERVOIR**

Michael R. Betts, University of Pennsylvania, Philadelphia, PA, USA

**4 SINGLE-CELL MULTIOMICS AND EXPANSION DYNAMICS OF HIV RESERVOIR OVER SPACE AND TIME**

Ya-Chi Ho, Yale University, New Haven, CT, USA

**5 NOVEL APPROACHES TO CHARACTERIZING IMMUNE RECOGNITION**

Michael Birnbaum, Massachusetts Institute of Technology, Cambridge, MA, USA
SUNDAY, FEBRUARY 19, 2023

Workshop-03 CASE-BASED LIVER WORKSHOP

Flex A (Level 2) 1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:

- Identify etiologies and diagnostic tests for children with severe viral hepatitis
- Describe strategies for the prevention of hepatitis B transmission
- Describe the burden of disease and the current treatment strategies for hepatitis D in people with HIV

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral hepatitis and liver disease in people living with and without HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the major viral causes of hepatitis and other key issues related to liver disease in people living with and without HIV infection.

Moderators
Debika Bhattacharya, University of California Los Angeles, Los Angeles, CA, USA
Christoph Boesecke, Bonn University Hospital, Bonn, Nordrhein-Westfalen, Germany

6  FULMINANT HEPATITIS IN CHILDREN
Luz Helena Gutierrez Sanchez, University of Alabama at Birmingham, Birmingham, AL, USA

7  HBV PREVENTION: NEWER VACCINES AND THE BOUNDARIES OF HBV PROTECTION
H. Nina Kim, University of Washington, Seattle, WA, USA

8  HEPATITIS DELTA INFECTION AMONG PERSONS WITH HIV
Charles Béguelin, University of Bern, Bern, Switzerland
SUNDAY, FEBRUARY 19, 2023

Workshop-04 CLINICAL TRIAL DESIGN AND ANALYSIS

Objectives: At the completion of the session, participants will be able to:
- Describe some key lessons we have learned from platform trials
- List some of the major types of modeling studies and how to interpret results from these studies
- Identify some of the central reasons why it is important to include behavioral and social science in clinical trials

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies of HIV, SARS-CoV-2, or mpox.

Moderators
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Richard Chaisson, The Johns Hopkins University, Baltimore, MD, USA

9  ADAPTIVE PLATFORM TRIALS: EXPERIENCE FROM THE COVID-19 PANDEMIC
Michael D. Hughes, Harvard TH Chan School of Public Health, Boston, Massachusetts, MA, USA

10  UNPACKING MODELING STUDIES
Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

11  SOCIAL AND BEHAVIORAL SCIENCE: THE MISSING INGREDIENT TO SUCCESSFUL CLINICAL TRIALS
Heidi van Rooyen, Human Sciences Research Council, Cape Town, Western Cape, South Africa
OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY
SUNDAY, FEBRUARY 19, 2023

OPENING-01 OPENING SESSION
Flex C (Level 2) 5:00 PM - 7:20 PM

WELCOME FROM THE CROI 2023 CHAIR
James Hoxie, University of Pennsylvania, Philadelphia, PA, USA

12 MODELING THE DYNAMICS OF HIV INFECTION: ESTABLISHING PARADIGMS FOR TREATMENT AND CURE
Alan S. Perelson, Los Alamos National Laboratory, Los Alamos, NM, USA

INTRODUCTION OF THE N’GALY-MANN LECTURE
Diane V. Havlir, University of California San Francisco, San Francisco, CA, USA

13 HIV AND GLOBAL HEALTH IN A PANDEMIC ERA
Kevin M. De Cock, Centers for Disease Control and Prevention (former), Nairobi, Kenya

INTRODUCTION OF THE MARTIN DELANEY PRESENTATION
Dawn Averitt, The Well Project, Women’s Research Initiative on HIV/AIDS, South Strafford, VT, USA

14 COMMUNITY AND ADVOCATES ARE EQUAL PARTNERS IN RESEARCH AND DEVELOPMENT
Yvette A. Raphael, Advocacy for Prevention of HIV and AIDS, Midrand, Gauteng, South Africa

CROI AT 30: PROGRESS IN HIV THROUGH THE LENS OF CROI
INTRODUCTION OF DR ANTHONY FAUCI
Robert Schooley, University of California San Diego, San Diego, CA, USA

CROI: A 30-YEAR CHRONICLE OF HIV/AIDS RESEARCH PROGRESS
Anthony S. Fauci, Former Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, DC
MONDAY, FEBRUARY 20, 2023

PLENARY-01 MONDAY PLENARY SESSION
Flex C (Level 2) 8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE CHAIR WELCOME TO MONDAY

15  20 YEARS OF PEPFAR: LOOKING BACK, STRIDING FORWARD
John Nkengasong, US Department of State, Washington, DC, USA

16  THE PATH TO HEPATITIS B CURE
Anna S. Lok, University of Michigan, Ann Arbor, MI, USA

Symposium-01 VIRAL ORIGINS AND EVOLUTION OF HIV AND SARS-CoV-2
Ballroom 2 (Level 5) 4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:
- Understand conditions for virus zoonosis and spread in a new host
- Identify factors that influence virus spread and evolution in specific populations
- Identify tools used for global virus surveillance and information obtained from sequencing data

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral evolution of HIV and SARS-CoV-2

Level of Knowledge: It is assumed that participants are familiar with the basic virology of HIV and SARS-CoV-2.

Moderators
Theodora Hatziioannou, The Rockefeller University, New York, NY, USA
Julie M. Overbaugh, University of Washington, Seattle, WA, USA

17  ORIGINS OF HIV-1 AND SARS-CoV-2
Michael Worobey, University of Arizona, Tucson, AZ, USA

18  FROM PROMISE TO REALIZATION: SEQUENCING AND SURVEILLANCE FROM HIV-1 TO SARS-CoV-2
Emma B. Hodcroft, University of Bern, Basel, Basel-Stadt, Switzerland

19  ANTIBODY DRIVEN EVOLUTION OF HIV-1 AND SARS-CoV-2
Paul Bieniasz, The Rockefeller University, New York, NY, USA
Symposium-02 FROM ROCKET SCIENCE TO REALITY: MONITORING ANTIRETROVIRALS AND ADHERENCE

Objectives: At the completion of the session, participants will be able to:

- Identify the strengths and weaknesses of current adherence measures; identify new adherence measures currently in development
- Describe current digital technologies for supporting patient adherence
- Identify what might be most useful in HIV treatment and prevention with advanced adherence forgiveness of current ARV therapies; list adherence implementation considerations in low and middle income countries

Target Audience: This session is directed to physicians and researchers interested in strategies for monitoring and improving antiretroviral therapy adherence.

Level of Knowledge: It is assumed that participants are familiar with the basic understanding of monitoring and improving antiretroviral therapy adherence.

Moderators

K. Rivet Amico, University of Michigan, Ann Arbor, MI, USA
Alice Tseng, University Health Network, Toronto, ON, Canada

20 THE LANDSCAPE OF ADHERENCE TESTING

Peter L. Anderson, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

21 DIGITAL TECHNOLOGIES FOR SUPPORTING ADHERENCE

Lisa Hightow-Weidman, Florida State University, Pittsboro, NC, USA

22 CONSIDERATIONS FOR MEASURING ADHERENCE WITH LA/ED THERAPIES IN LOW- AND MIDDLE-INCOME COUNTRIES

Catherine Orrell, Desmond Tutu Health Foundation, Cape Town, Western Cape, South Africa

Symposium-03 DELIVERING ON THE SUCCESS OF INJECTABLE PrEP

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of evidence for long-acting injectable cabotegravir across at-risk populations, including current guidelines for use
- Describe the barriers and data gaps that threaten the population-level impact of novel HIV PrEP strategies
- Identify actions that can mitigate or eliminate disparities in benefit of novel HIV PrEP strategies in key populations

Target Audience: This session is directed to physicians and researchers interested in injectable modalities for the delivery of preexposure prophylaxis.

Level of Knowledge: It is assumed that participants are familiar with contemporary modalities for the delivery of preexposure prophylaxis.
23 FROM EFFICACY TO EFFECTIVENESS: CATALYZING ROLLOUT OF LONG ACTING PrEP

Nyaradzo M. Mgodi, University of Zimbabwe, Harare, Harare, Zimbabwe

24 AVOIDING DISPARITIES: NOT MAKING THE SAME MISTAKE AGAIN

LaRon Nelson, Yale University, New Haven, CT, USA

25 LA PrEP: WHAT WE KNOW AND WHAT WE STILL NEED TO KNOW

Sunil S. Solomon, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
TUESDAY, FEBRUARY 21, 2023

Plenary-02 TUESDAY PLENARY SESSION

Flex C (Level 2) 8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO TUESDAY

Landon Myer, University of Cape Town, Cape Town, Western Cape, South Africa

26 HIV RESERVOIRS: OBSTACLES TO A CURE

Janet M. Siliciano, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

27 RESTRICTIONS ON REPRODUCTIVE RIGHTS AND THEIR IMPACT ON PEOPLE LIVING WITH HIV

Denise J. Jamieson, Emory University, Decatur, GA, USA

Symposium-04 PEDIATRIC HIV CURE

Ballroom 2 (Level 5) 4:00 PM - 5:30 PM

Objectives:

At the completion of the session, participants will be able to:

• List contemporary approaches to research in pediatric cure of HIV
• Describe the progress in clinical trials of HIV prevention and cure

Target Audience: This session is directed to adult and pediatric HIV clinicians and clinical investigators as well as trainees in these areas.

Level of Knowledge: It is assumed that the participants are familiar with antiretroviral regimens commonly used for HIV treatment and prevention.

Moderator
Deborah Persaud, The Johns Hopkins University, Baltimore, MD, USA

28 APPROACHES TO PEDIATRIC CURE

Philip J.R. Goulder, University of Oxford, Oxford, United Kingdom

29 NONHUMAN PRIMATE STUDIES OF PEDIATRIC CURE INTERVENTIONS

Ann Chahroudi, Emory Vaccine Center, Atlanta, GA, USA

30 PROGRESS IN CLINICAL TRIALS OF PEDIATRIC HIV CURE

Roger Shapiro, Harvard University, Boston, MA, USA
TUESDAY, FEBRUARY 21, 2023

Symposium-05 COVID-19: WHERE ARE WE NOW?  
Flex A (Level 2)  
4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:
- Identify the strengths and weaknesses of current adherence measures, and describe existing and next generation approaches to outpatient antiviral and immune-based (monoclonal antibody) treatment for mild to moderate COVID-19 disease and the impact of treatment on attendant complications of SARS-CoV-2 infection.
- Identify key features of the biology and pathogenesis of SARS-CoV-2 viral rebound in the setting of acute infection and antiviral treatment.
- Describe emerging syndromes associated with Long COVID and emerging data about its pathogenesis, treatment, and prognosis

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of the state of the COVID-19 pandemic.

Level of Knowledge: It is assumed that participants are familiar with the basic understanding of COVID-19 epidemiology.

Moderators

- Brenda E. Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Distrito Federal, Mexico
- Irini Sereti, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

31  FUTURE DIRECTIONS IN OUTPATIENT THERAPY FOR MILD TO MODERATE COVID-19

Kara W. Chew, University of California Los Angeles, Los Angeles, CA, USA

32  VIRAL REBOUND DURING AND AFTER SARS-CoV-2 TREATMENT

Jonathan Z. Li, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA

33  WHAT WE KNOW NOW ABOUT LONG COVID SYNDROMES

Michael J. Peluso, University of California San Francisco, San Francisco, CA, USA

TUESDAY, FEBRUARY 21, 2023

Symposium-06 GETTING PrEPped (AND PEPped) FOR SEX: FROM HIV TO STIs TO MPOX

Ballroom 1 (Level 5)  
4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:
- List strategies for incorporating HIV PEP/PrEP into clinical practice
- Describe different strategies for prevention of STIs in adults and adolescents
- Identify methods for prevention of mpox pre- and post-exposure

CME
Target Audience: This session is directed to physicians interested in applying preventative strategies for HIV, sexually transmitted infections, and mpox in practice.

Level of Knowledge: It is assumed that participants are familiar with the contemporary strategies for preventing HIV, sexually transmitted infections, and mpox.

Moderators

Bridget G. Haire, Kirby Institute, Sydney, New South Wales, Australia
Maryam Shahmanesh, Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa

34 IMPLEMENTING THE PrEP AND PEP TOOLKIT

Colleen Kelley, Emory University School of Medicine, Atlanta, GA, USA

35 PREVENTION OF STIs IN ADULTS AND ADOLESCENTS A SEXUAL REPRODUCTIVE HEALTH PERSPECTIVE

James Kiarie, World Health Organization, Geneva, Geneve, Switzerland

36 MPOX PREVENTION

Jade Ghosn, University of Paris Cité Department: Infectious Diseases, Bichat hospital, Paris, Ile-de-France, France

SPECIAL SESSION-1 RESULTS FROM THE MOSAICO HIV VACCINE TRIAL AND FUTURE DIRECTIONS FOR HIV VACCINES

Flex A (Level 2) 5:40 PM - 6:00 PM

Moderators

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

OVERVIEW OF THE MOSAICO HIV VACCINE TRIAL

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

HIV VACCINE DEVELOPMENT POST-MOSAICO

Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
WEDNESDAY FEBRUARY 22, 2023

PLENARY-03 WEDNESDAY PLENARY SESSION
Flex C (Level 2)

8:30 AM - 9:30 AM

WEDNESDAY FEBRUARY 22, 2023

PLENARY-03 WEDNESDAY PLENARY SESSION

Flex C (Level 2)

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY
Diane V. Havlir, University of California San Francisco, San Francisco, California, USA

37 HOW THE HUSH COMPLEX PROTECTS YOUR GENOME FROM RNA-DERIVED RETROELEMENTS

Paul J. Lehner, Cambridge University, Cambridge, England, United Kingdom

38 THE SCIENCE OF AGING: LESSONS FOR HIV

George A. Kuchel, University of Connecticut, Farmington, CT, USA

SPECIAL SESSION-2 SPECIAL SESSION ON THE MPOX VIRUS OUTBREAK

Ballroom 1 (Level 5)

12:15 PM - 1:15 PM

Moderators
Diane V. Havlir, University of California San Francisco, San Francisco, California, USA
Robert Schooley, University of California San Diego, San Diego, CA, USA

39 STAGE THE SETTING: THE EPIDEMIOLOGY OF THE MPOX VIRUS

John Brooks, Centers for Disease Control and Prevention, Atlanta, GA, USA

40 MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGETS FOR MPOX VIRUS

Stuart N. Isaacs, University of Pennsylvania, Philadelphia, PA, USA

41 IMMUNOLOGY AND VACCINOLOGY PERSPECTIVES FOR MPOX VIRUS

Sharon Frey, Saint Louis University, St. Louis, MO, USA
SYMPOSIUM-07 THE VIRUSES THEY ARE A CHANGING: HOW THE IMMUNE SYSTEM RESPONDS

Ballroom 3 (Level 5)  4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe how the presence of antibodies against a given epitope may affect the response to that epitope during vaccination
- Describe how B cells respond to new viral variants of SARS-CoV2 during infection and vaccination
- Describe how HIV and SARS-CoV-2 serum antibody responses adapt to virus variation

Target Audience: This session is directed to physicians and researchers interested in obtaining a contemporary understanding of the how the immune system responds to virus variation.

Level of Knowledge: It is assumed that participants are familiar with the basic understanding of immune responses to virus variation.

Moderators

Shelly Krebs, Walter Reed Army Research Institute, Sliver Spring, MD, USA
George K. Lewis, University of Maryland School of Medicine Baltimore, Baltimore, MD, USA

42  EFFECT OF NEW VIRAL VARIANTS ON NEUTRALIZING ANTIBODY POTENCY AND BREADTH

Penny L. Moore, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

43  MEMORY B CELL RESPONSES TO NEW VIRUS VARIANTS: RELEVANCE TO THE CONCEPT OF ORIGINAL ANTIGENIC SIN

Marion Pepper, University of Washington, Seattle, WA, USA

44  EPITOPE MASKING DURING A RECALL RESPONSE: IMPLICATIONS FOR COVID AND HIV VACCINES

Facundo Batista, Harvard University, Cambridge, MA, USA
SYMPOSIUM-08 CASE-BASED DISCUSSION OF CARDIO-METABOLIC COMPLICATIONS OF HIV AND CONSEQUENCES FOR MANAGEMENT

Ballroom 1 (Level 5)  
4:00 PM - 5:30 PM

**Objectives:** At the completion of the session, participants will be able to:

- Describe implications of cardiovascular disease in patients with HIV infection
- Describe implications of patients with HIV experiencing weight gain or obesity
- Describe implications of NASH and nonalcoholic fatty liver disease (NAFLD) in patients with HIV infection

**Target Audience:** This session is directed towards clinical care providers and researchers with an interest in cardiometabolic complications of HIV and its treatment, including potential management implications.

**Level of Knowledge:** It is assumed that the participants are familiar with the management of HIV and cardiometabolic comorbidities associated with HIV.

**Moderators**

Georg Behrens, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany  
Vidya Mave, Center for Infectious Diseases, Pune, Maharashtra, India

**SESSION FORMAT:** This case-based and interactive session will provide an up-to-date overview of the pathogenesis, prevention, and treatment of cardiovascular disease and heart failure in HIV medicine.

**Panelists**

Pam S. Douglas, Duke University School of Medicine, Durham, NC, USA  
Ntobeko Ntsui, University of Cape Town, Cape Town, South Africa  
Donal O’Shea, University College Dublin, Dublin, Ireland  
Giada Sebastiani, McGill University, Montreal, QC, Canada

SYMPOSIUM-09 SCIENCE COMMUNICATION IN THE AGE OF MISINFORMATION

Ballroom 2 (Level 5)  
4:00 PM - 5:30 PM

**Objectives:** At the completion of the session, participants will be able to:

- Describe the history and current state of traditional media, social media and internet-based health information, misinformation, and disinformation
- Evaluate approaches to proactively address health literacy, vaccine uptake, and health communications
- Design effective communications to proactively address vaccine hesitancy
**Target Audience:** This session is directed to physicians and researchers interested in the communication of information to audiences with and without a training in science.

**Level of Knowledge:** It is assumed that participants are familiar with the contemporary issues in SARS-CoV-2, mpox, HIV, and related conditions.

**Moderators**

Jonathan Mermin, *Centers for Disease Control and Prevention, Atlanta, GA, USA*

Jon Cohen, *Science, Cardiff By The Sea, CA, USA*

46  **COUNTERING VACCINE AND HEALTH MIS AND DISINFORMATION: AN EVIDENCE-BASED APPROACH**

Scott C. Ratzan, *City University of New York, Princeton, NJ, USA*

47  **WHAT CAN I DO? THE CHALLENGE OF HEALTH MISINFORMATION ONLINE**

Emily Vraga, *University of Minnesota, Minneapolis, MN, USA*

48  **WHAT’S FUELING THE SPREAD OF MISINFORMATION: LOOKING BEYOND FAKE FACTS**

Heidi J. Larson, *London School of Hygiene & Tropical Medicine, Brussels, Brussels Hoofdstedelijk Gewest, Belgium*
MONDAY FEBRUARY 20, 2023

ORAL ABSTRACTS AND THEMED DISCUSSIONS BY DAY

Oral Abstract Session-01 VIROLOGY/PATHOGENESIS
Ballroom 2 (Level 5) 10:00 AM - 12:00 PM

Moderators

Stuart Neil, King’s College London, London, United Kingdom
Molly Ohainle, University of California Berkeley, Berkeley, CA, USA

100 LENACAPAVIR INHIBITS VIRION MATURATION BY BLOCKING FORMATION OF CAPSID PENTAMERS
10:05
Szu-Wei Huang, Lorenzo Briganti, Guochao Wei, Arun Annamalai, Stephanie Bester, Nikoloz Shkriabai, Mamuka Kvaratskhelia

101 INHIBITION OF NEUTRAL SPHINGOMYELINASE 2 BLOCKS HIV-1 MATURATION
10:13
Abdul Waheed, Yanan Zhu, Seung-Wan Yoo, Ferri Soheilian, Eva Agostino, Lwar Naing, Pragney Deme, Yun Song, Peijun Zhang, Barbara S Slusher, Norman Haughey, Eric O. Freed

102 INVESTIGATING THE ROLE OF CAPSID STABILITY IN INNATE IMMUNE SENSING OF HIV-1 CORES
10:21
Jenna E. Eschbach, Sebla B. Kutluay

103 MUTATIONS OUTSIDE INTEGRASE LEAD TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR
10:29
Yuta Hikichi, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed

104 MX2 ANTIVIRAL SPECIFICITY IS AFFECTED BY GTPase ACTIVITY AND CAPSID-CypA INTERACTIONS
11:00
Bailey Layish, Haley Flick, Ram Goli, Mariah Cashbaugh, Robert Z Zhang, Melissa Kane

105 HOST CELL GLYCOSYLATION DIFFERENTIALLY AFFECTS CCR5- AND CXCR4-TROPIC HIV-1 INFECTION
11:08
Hannah L. Itell, Julie M. Overbaugh

106 THE FRACTION OF CELLS WITH UNSPLICED HIV RNA IS NOT ASSOCIATED WITH PLASMA VIREMIA
11:16
Adam A. Capoferri, Ann Wiegand, Francis Hong, Jana Jacobs, Jonathan Spindler, Andrew Musick, Michael J. Bale, Wei Shao, Michele D. Sobolewski, Anthony Cillo, Rebecca Hoh, Steven G. Deeks, John M. Coffin, John W. Mellors, Mary F. Kearney

107 HUMAN ANTI-ACE2 MONOCLONAL ANTIBODIES AS PAN-SARBEVIRUS PROPHYLACTIC AGENTS
11:24
Fengwen Zhang, Jesse Jenkins, Renan de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan Abernathy, Elisabeth Nyakatura, Ivo Lorenz, H.-Heinrich Hoffmann, Charles Rice, Gabriel Victoria, Christopher Barnes, Theodora Hatzioannou, Paul D. Bieniasz
**Oral Abstracts and Themed Discussions by Day**

**CROI 2023**

**Oral Abstracts and Themed Discussions by Day**

**• Monday**

**Continuing Medical Education**

**Late-Breaking**

**New Investigator Scholarship**

**Nonauthor Presenter**

---

**Oral Abstract Session-02 TB AND HEPATITIS**

**Ballroom 1 (Level 5)**

**10:00 AM - 12:00 PM**

**Moderators**

Constance A. Benson, *University of California San Diego, San Diego, CA, USA*

David Wyles, *Denver Health Medical Center, Denver, CO, USA*

---

**108 SARS-CoV-2 VARIANTS EVOLVED CONVERGENT STRATEGIES TO REMODEL THE HOST RESPONSE**


---

**109 SimplicitB RESULTS AND HEPATIC SAFETY OF PRETOMANID REGIMENS +/- PYRAZINAMIDE**

Marika Erstavi, Ebrahim Variava, Fredrick Haraka, Margareth Pretti Dalcolmo, Harriet Mayanaka-Kizza, Morounfolu Olugbosi, Mengchun Li, Leandra Lombard, Muge Cevik, Lindsay Thompson, Derek Sloan, Mel Spigelman, Jerry Nedelman, Maria Beumont, Eugene Sun

---

**110 STANDARD VS DOUBLE DOSE Dolutegravir in HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS**

Rulan Griesel, Ying Zhao, Bryony Simmons, Zaayid Omar, Andrew Hill, Graeme Meintjes, Gary Maartens

---

**111 INCREASED TB PREVENTIVE THERAPY COVERAGE WITH INTEGRATED COMMUNITY-BASED IPT AND ART**

Adrienne E. Shapiro, Adam Szpiro, Kombi Sausi, Nsika Sithole, Olivier Koole, Meighan Krows, Torin Schaafsma, Maryam Shahmanesh, Heidi van Rooyen, Connie Celum, Alastair van Heerden, Ruanne Barnabas

---

**112 RCT OF ECONOMIC INCENTIVES FOR REDUCED ALCOHOL USE AND INH ADHERENCE AMONG PWH**

Gabriel Chamie, Judith A. Hahn, Allen Kekibiina, Nneka Emenyonyu, Brian Beesiga, Karo Marson, Robin Fatch, Sara Lodi, Julian Adong, Harsha Thirumurthy, Michael McDonell, Monica Gandhi, Kendall Bryant, Moses Kamya, Winnie Muyindike

---

**113 EFFICACY AND SAFETY OF 8-WK TUBERCULOSIS TREATMENT REGIMENS IN THE TRUNCATE-TB TRIAL**

Nicholas Paton, Christopher Cousins, Qingshu Lu, Rajesh Moorakonda, Celina Suresh, Erлина Burhan, Vincent Balanag, Christine Sekaggya-Wiltshire, Anchalee Avihingsanon, Rohit Sarin, Angela Crook

*Research Group: The TRUNCATE-TB trial team*

---

**114 PanACEA SUDOCU COMBINATION DOSE-FINDING TRIAL SHOWS SUTEZOLID IS A SAFE OXAZOLIDINONE**

Norbert Heinrich, Christina Manyama, Nyanda E. Ntinginya, Stellah Mpamaga, Alphonce Liyoyo, Francis Mhmmbira, Benno Mbeya, Modulakgotla Sebe, Robert Wallis, Patrick Phillips, Leticia Wildner, Rob Aarnoutse, Larissa Hoffmann, Michael Hoelscher, Elin Svensson

Oral Abstracts and Themed Discussions by Day

35

Oral Abstracts and Themed Discussions by Day
CROI 2023

• Monday

Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter

115 11:16 cccDNA SILENCING AND LIMITED DECAY OF INFECTED CELLS IN HIV-HBV (HBeAg-) DURING NUCs
Chloe L. Thio, Maraake Taddese, Yasmeen S. Saad, Kristina Zambo, Tanner Gruda, Mark S. Sulkowski, Richard K. Sterling, Hyon Hwang, Ashwin Balagopals

116 11:24 PREDICTORS OF HEPATITIS B RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION
Anchalee Avihingsanon, Chee L. Leong, Chien-Ching Hung, Ellen Koenig, Man-Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Hongyuan Wang, Hal Martin, Jason Hindman, Jared M. Baeten, Sasisopin Kiertiburanakul

117 11:32 PAGE-B SCORE TO ESTIMATE THE HEPATOCELLULAR CARCINOMA RISK IN PEOPLE WITH HIV AND HBV
Bernard Surial, Adrià Ramírez Mena, Marie Roumet, Andreas Limacher, Colette Smit, Olivier Leeleux, Amanda Mocroft, Marc van der Valk, Fabrice Bonnet, Lars Peters, Juergen K. Rockstroh, Huldrych F. Günthard, Annalisa Berzigotti, Andri Rauch, Gilles Wandelers

Research Group: Swiss HIV Cohort Study, EuroSIDA, ATHENA and Aquitaine

Oral Abstract Session-03 HIV AND STI PREVENTION: NEW TOOLS AND APPROACHES
Flex C (Level 2) 10:00 AM - 12:00 PM

Moderators
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Renee Heffron, University of Alabama at Birmingham, Birmingham, AL, USA

118 10:05 MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN
Richard Haaland, Jeffrey Fountain, Chuong Dinh, Tiancheng Edwards, Amy Martin, Deborah Omoeyege, Christopher Conway-Washington, Colleen Kelley, Walid Heneine

119 10:13 ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Algarte-Genin Michele, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Cecile Bebear, Nicolas Dupin, Jean-Paul Viard, Juliette Pavie, Claudine Duvivier, Jade Ghosn, Dominique Costagliolase

Research Group: ANRS 174 Doxyvac Group

120 10:21 DOXYPEP & ANTIMICROBIAL RESISTANCE IN N. GONORRHOEAE, COMMENSAL NEISSERIA, & S. AUREUS
Anne F. Luetkemeyer, Deborah Donnell, Julia C. Dombrowski, Stephanie Cohen, Cole Grabow, Clare Brown, Cheryl Malinksis, Sharon K. Martens, Alison Cohee, Veronica Viar, Phong Pham, Susan P. Buchbinder, Diane V. Havlir, Connie Celum, Olusegun O. Soges

Research Group: DoxyPEP Study Team

Research Group: DoxyPEP Study Team

Research Group: DoxyPEP Study Team

Research Group: DoxyPEP Study Team

Research Group: DoxyPEP Study Team
DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN

10:29

Jenell Stewart, Kevin Oware, Deborah Donnell, Lauren R. Violette, Josephine Odoyo, Caitlin W. Scoville, Olusegun O. Soge, Victor Omollo, Felix Mogaka, Fredricka A. Sesay, R. Scott McClelland, Elizabeth A. Bukusi, Jared M. Baeten

Research Group: the dPEP Kenya Study Team

POTENTIAL IMPACT AND EFFICIENCY OF DOXY-PEP AMONG PEOPLE WITH OR AT RISK OF HIV

11:00

Michael W. Traeger, Kenneth H. Mayer, Douglas S. Krakower, Sy Gitin, Samuel Jenness, Julia L. Marcus

CLUSTER RANDOMISED TRIAL OF RISK-DIFFERENTIATED CARE FOR FEMALE SEX WORKERS: AMETHIST

11:08


RANDOMIZED TRIAL OF COMMUNITY HEALTH WORKER DELIVERED DYNAMIC CHOICE HIV PREVENTION

11:16

Elijah Kakande, James Ayieko, Helen Sunday, Edith Biira, Marilyn Nyabuti, George Agengo, Jane Kabami, Gabriel Chamie, James Peng, Melanie Bacon, Moses Kamya, Diane V. Havlir, Maya Petersen, Laura Balzer

Research Group: SEARCH Study Team

CLUSTER RANDOMIZED TRIAL OF INTEGRATED HIV AND SEXUAL & REPRODUCTIVE HEALTH SERVICES

11:24

Rashida Ferrand, Ethel Dauya, Chido Dziva Chikwari, Tsitsi Bandason, Sarah Bernays, Katharina Kranzer, Constance Mackworth-Young, Constancia Mavodza, Owen Mugurungi, Victoria Simms, Mandikudza Tembo, Richard Hayes

Research Group: CHIEDZA Trial Group

126

RECENT HIV INFECTION SURVEILLANCE IN BREASTFEEDING WOMEN IN MALAWI: JUL 2019-JUL 2022

10:05

Davie D. Chalira, Bridget Miller, Danielle Payne, Melissa Arons, Alinune N. Kabaghe, Joe Theu, Romance Thawi, Reno Stephens, Irene Namakoma, Joseph Njala, Alexandra Ernst, Gabrielle O’Malley, Kerry A. Thomason, Nellie Wandoenda-Kabondo

127

DELIVER: A SAFETY STUDY OF A DAPIVIRINE VAGINAL RING AND ORAL PrEP DURING PREGNANCY

10:13

Katherine E. Bunge, Jennifer Balkus, Felix Mhlanga, Ashley Mayo, Lee Fairlie, Clemensia Nakabiito, Luis Gadama, Catherine Chappell, Nyaradzo M. Mgodi, Jeanna Piper, Nahida Chakhtoura, Daniel szydlo, Barbra Richardson, Sharon L. Hillier

Research Group: MTN-042 DELIVER Study Team

128

RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV PREVENTION IN ANTE/POSTNATAL CARE CLINICS

10:21

Jane Kabami, Catherine Koss, Helen Sunday, Edith Biira, Marilyn Nyabuti, Laura Balzer, Shalika Gupta, Gabriel Chamie, James Ayieko, Elijah Kakande, Melanie Bacon, Diane V. Havlir, Moses Kamya, Maya Petersen

Research Group: SEARCH Study Team
129 MATERNAL POINT-OF-CARE VIRAL LOAD AT DELIVERY IMPACTS INFANT ARV PROPHYLAXIS REGIMEN
Research Group: LIFE Study consortium

130 MULTICOMPONENT INTERVENTION IMPROVES VIRAL SUPPRESSION FOR PREGNANT/POSTPARTUM WOMEN
Jane Kabami, Laura Balzer, Faith Kagoya, Jaffer Okiring, Joanita Nangendo, Elizabeth Arinitwe, Stella Kabageni, Michael Ayebare, Anne Katahoire, Philipps Musoke, Moses Kamya

131 IMPROVED STRATEGY TO PREVENT HIV POSTNATAL TRANSMISSION: A RANDOMIZED TRIAL
Chipepo Kankasa, Anaïs Mennecier, Souleymane Tassambedo, Catherine Chunda-Liyoka, Leticia Sakana, Morgana D’Ottavi, Melany Tonga, Dramane Kania, Jean-Pierre Moles, Mwiya Mwiya, Paulin Fao, David Rutagwera, Thorkild Tylleskär, Nicolas Nagot, Philippe Van de Perre
Research Group: ANRS 12397 PROMISE-EPI Study group

132 BIRTH POINT-OF-CARE TEST & TREAT REDUCES EARLY MORTALITY AMONG HIV INFECTED INFANTS
Research Group: LIFE Study Consortium

133 POSTMORTEM CHARACTERIZATION OF HIV-ASSOCIATED UNDER-5 DEATHS IN FOUR CHAMPS SITES
Inacio Mandomando, Dickens Onyango, Zachary Madewell, Kurt Vyas, Sana Mahtab, Portia Mutevedzi, Victor Akelo, Dianna Blau, Facila Helena Francisco Nhampossa, Ikechukwu Ogbaru, Carrie Cain, Cynthia Whitney, Beth Tippett Barr, Quiko Bassat

134 SARS-CoV-2 IN CHILDREN & ADOLESCENTS LIVING WITH HIV IN EUROPE & SOUTH AFRICA
Charlotte Jackson, Siobhan Crichton, Alasdair Bamford, Arantxa Berzosa, Kimberly Gilmour, Tessa Goetghueber, Sarah May Johnson, Ali Judd, Antoni Noguera, Marthe Le Prevost, Vana Spoulou, Kate Sturgeon, Alla Volokha, Heather J Zar, Intira Jeannie Collins
Research Group: EPPICC (European Pregnancy and Paediatric Infections Cohort Collaboration)

129 10:29
130 11:00
131 11:08
132 11:16
133 11:24
134 11:32

Themed Discussion-01 HIV AND THE MICROBIOME: NEW THEMES
Flex C (Level 2) 1:30 PM - 2:30 PM
Moderator
Ronald G. Collman, University of Pennsylvania, Philadelphia, PA, USA

248 1:35
CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF
Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos
Oral Abstracts and Themed Discussions by Day

Monday

Continuing Medical Education

Late-Breaking

New Investigator Scholarship

Nonauthor Presenter

Oral Abstracts and Themed Discussions by Day

249  PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET
Jacob K. Flynn, Alexandra Ortiz, Marlon DeLeon, Samantha Knodel, Kenzie Birse, Laura Noel-Romas, Adam Burgener, Jason Brenchley

250  THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME
Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong

251  COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION

252  BACTERIAL DYSBIOSIS PERSISTS IN WOMEN LIVING WITH HIV-1 AFTER ART-TREATMENT
Katherine M. Bricker, Andrea Lisco, Alessandra Borgognone, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Noguera Julian, Irini Sereti

Themed Discussion-02 STEATOHEPATITIS: SEX DIFFERENCES AND OTHER RISK FACTORS

Ballroom 2 (Level 5)

1:30 PM - 2:30 PM

Moderator

Susanna Naggie,  Duke University, Durham, NC, USA

609  PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV
Louise E. van Eekeren, Marc J.T. Blaauw, Nadira Vadaq, Vasiliki Matzarakis, Wilhelm A.J.W. Vos, Albert L. Groenendijk, Adriana Navas, Gert Weijers, Mike van der Kolk, Andre J.A.M. van der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa

Research Group: 2000HIV

610  LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE
Cecile D. Lahiri, Michael Yu, Logan Geric, Cyra C. Mehta, Joffi Musonge-Effoe, Jennifer C. Price, Phyllis C. Tien, Amanda B. Spence, Svenja Albrecht, Maria L. Alcaide, Adaoara Adimora, Audrey French, Michael H. Augenbraun, Kathryn Anastos, Jessica A. Alvarez

611  SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE
Dana Kablawi, Thierry Fotsing Tadjo, Jovana Milic, Wesal Elgretli, Claudia Goe, Bertrand Lebouché, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani

612  NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV
Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungsirisap, Thanathip Wichangsan, Hay Mar Su Lwin, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon
Themed Discussion-03 PREDICTORS OF TB TREATMENT OUTCOMES
Ballroom 1 (Level 5) 1:30 PM - 2:30 PM

Moderator
Amita Gupta, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

740 1:35
TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS

742 1:40
PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS

745 1:45
TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT
Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindhran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stembridge Mpemba, Lihle Mchunu, Dolphina Cogill, Pren Naidoo, Catherine Orrell, Katherine Fielding

Themed Discussion-04 UNDERSTANDING MORTALITY IN PEOPLE WITH HIV
Ballroom 3 (Level 5) 1:30 PM - 2:30 PM

Moderator
Maureen Syowai, ICAP at Columbia University, Nairobi, Nairobi Area, Kenya

870 1:35
TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)
Erich Tusch Research Group: The RESPOND Study Group

872 1:40
PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS
Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauso Mussa, Amos Nyaka, kondwani Nkanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo

873 1:45
MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT
Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

874 1:50
ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION
Nicholas Bakewell, Caroline Sabin, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanayake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banwari Agarwal, Robert Miller
Oral Abstracts and Themed Discussions by Day

REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA

Themed Discussion-05 NEW INSIGHTS THROUGH RECENTY TESTING Flex A (Level 2) 1:30 PM - 2:30 PM

HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA
Amobi A. Onovo, Pamela Gado, Angela Agweye, Abiye Kalaiwo, Ugwweroghene Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein

PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA
Vichea Ouk, Sovannarith Samreth, Bora Ngaui, Bunthoeun Eng, Rommel Bain, Chhaly Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Yang, Vanthy Ly, Amitabh B Suthar, Rachel Albalak

AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI

HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: ImPrEP STUDY
Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Dereche, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarzwald, Carlos Caceres, Valdiea Veloso

HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES: 2018-2021
Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Panneer, Rashida Hassan, Anne Marie France, Alexandra M. Oster
TUESDAY FEBRUARY 21, 2023

Oral Abstract Session-05 HIV RESERVOIRS AND CURE STRATEGIES
Ballroom 1 (Level 5)  
10:00 AM - 12:00 PM

Moderators
Katharine Bar, University of Pennsylvania, Philadelphia, PA, USA
Linos Vandekerckhove, HIV Cure Research Center, Ghent University, Ghent, Oost-Vlaanderen, Belgium

135 ■ SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS
10:05  

136 ■ THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL
10:13  

137 ■ VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA
10:21  
Abbas Mohammadi, Behzad Etemad, Xin Zhang, Yijia Li, Steven G. Deeks, Michael M. Lederman, Sigal Yawetz, Daniel Kuritzkes, Mathias Lichterfeld, Athe Tsibris, Mary Carrington, Zabrina Brumme, Jose R. Castillo Mancilla, Gaurav Gaith, Jonathan Z. Li

138 ■ PROVIRUSES IN SELF-REACTIVE CD4+ T CELLS ARE A COMMON SOURCE OF RESIDUAL HIV VIREMIA
10:29  

139 ■ EX VIVO HIV DNA INTEGRATION IN STAT3 DRIVES T CELL PERSISTENCE AND OVERGROWTH
11:00  
Michael Rist, Machika Kaku, Michael Freeman, John M. Coffin

140 ■ THERAPEUTIC VACCINATION OF SHIV-INFECTED, ART-SUPPRESSED INFANT RHESUS MACAQUES
11:08  

141 ■ VIRAL RESERVOIR LANDSCAPE OF CHILDREN WITH HIV IN BOTSWANA TREATED WITH DUAL bNAbS
11:16  
Aischa Niesar, Xiaodong Lian, Renee Hua, Gbolahan Ajibola, Molly Prentors Holme, Kenneth Maswabi, Sikhulile Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Maureen Mosetlhi, Kathleen M. Powis, Daniel Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld

142 ■ SINGLE-CELL EPIGENETIC, TRANSCRIPTIONAL, AND PROTEIN STATES OF HIV RESERVOIR
11:24  
Yulong Wei, Timothy C. Davenport, Jack Collora, Katherine H. Ma, Delia Pinto-Santini, Javier Lama, Ricardo Alfaro, Ann Duerr, Ya-Chi Ho
Oral Abstracts and Themed Discussions by Day

143  ANTI-IL-10/PD-1 IMMUNE MEDIATED CONTROL OF VIRAL REBOUND IN SIV INFECTED MACAQUES
11:32
SB
Susan Pereira Ribeiro, Zachary Strongin, Felipe Ten Caten, Khader Ghneim, Mohamed Abdel Halekeem, Timothy N. Hoang, Kevin Nguyen, Justin Harper, Luca Micci, Jeffrey D. Lifson, Bonnie Howell, Daniel Gorman, Daria J. Hazuda, Mirko Paiardini, Rafpic P. Sékaly

Oral Abstract Session-06 CONSTERNATION ABOUT COMPLICATIONS
Flex A (Level 2)
10:00 AM - 12:00 PM

Moderators
Judith S. Currier, University of California Los Angeles, Los Angeles, CA, USA
Roger Bedimo, University of Texas Southwestern, Dallas, TX, USA

144  EFFECTS OF EPLERENONE ON MYOCARDIAL PERFUSION AND FUNCTION: THE MIRACLE HIV STUDY
10:05
SB
Suman Srinivasa, Allie Walpert, Teresa Thomas, Daniel Huck, Michael Jerosch-Herold, Sabeeh Islam, Hang Lee, Gregory Robbins, Tricia H. Burdor, Christopher DeFilippi, Carolyn Dunderdale, Raymond Kwong, Marcelo DiCarli, Gail Adler, Steven K. Grinspoon

145  DEPRESSION AND ANXIETY ASSOCIATED WITH INCIDENT TYPE I AND II MI AMONG PWH
10:13
SB
Emily P. Hyle, Elizabeth Humes, Shibani Mukerji, Sally B. Coburn, Heidi Crane, Svetlana Eden, Kelly Gebo, Maile Karris, Raynall Lang, Vincent C. Marconi, Richard Moore, Sonia Napravnik, Leah H. Rubin, Virginia Triant, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

146  WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR
10:21
SB
Darrell H. S. Tan, Andrea Antinori, Beng Eu, Maria José Galindo, Clifford Kinder, Donna Sweet, Cornelius N. Van Dam, Kenneth Sutton, Denise Sutherland-Phillips, Alessandro Berni, Feifan Zhang, William R. Spreen, Harmony P. Garges, Parul Patel, Ronald D’Amico

147  A LOSS OF ERA ATTENUATES DTG-MEDIATED DISRUPTION OF THERMOGENESIS IN BROWN ADIPOCYTES
10:29
SB
Fikrak Jung, Sunghee Jin, Becky Tu-Sekine, Frederick Anokye-Danso, Todd T. Brown, Sangwon Kim

148  MICROBIOTA-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION
11:00
SB
Sergio Serrano-Villar, Camilla Tincati, Sajan C Raju, Johan Sebastian Saenz Medina, Elena Moreno, Rafael Bargiela, Alfonso Cabello, Elena Sendagorta, José A. Pérez-Molina, Johaness Roak, Laura Fernández-López, Amparo de Benito, Marius Troseid, Jana Seifert, Manuel Ferrer

149  IMPACT OF INTEGRASE INHIBITORS ON CARDIOVASCULAR EVENTS IN PERSONS STARTING ART
11:08
SB
Bernard Surial, Frédérique Chammartin, José Damas, Alexandra Calmy, David Haerry, Marcel Stöckle, Patrick Schmid, Enos Basnasio, Philip Tarr, Huldrych F. Guntard, Gilles Wandeler, Andri Rauch
Research Group: Swiss HIV Cohort Study

150  HIV-RELATED KAPOSI SARCOMA IN EAST AFRICA: CONTEMPORARY UPDATE ON STAGE AND SURVIVAL
11:16
SB
Helen Byakwaga, Aggrey Semeere, Miriam Laker-Ocketta, Megan Wenger, Elyne Rotich, Charles Kasozi, Winnie Muyindeke, Philippa Kadama-Makanga, Sigrid Collier, Hilda Muwando, Toby Maurer, Esther Freeman, Samson Kiprano, Andrew Kambugu, Jeffrey Martin
NEW RECOMMENDATIONS FOR INFANT FEEDING AND PREVENTION OF PEDIATRIC HIV INFECTION IN THE US: WHAT AND WHY NOW?

11:50 – 12:10
Moderator: Elaine Abrams, Columbia University, New York, NY, USA
Presenter: Judy Levison, Baylor College of Medicine, Houston TX, USA

Oral Abstract Session-07 GLOBAL EPIDEMIOLOGY OF HIV
Ballroom 2 (Level 5) 10:00 AM - 12:00 PM

Moderators
Connie Celum, University of Washington, Seattle, WA, USA
Andrew Mujugira, Makerere University, Auburn, WA, USA

151 PHYLODYNAMICS OF HIV-1 VARIANT ACROSS POLAND AND UKRAINE
10:05
Karol Serwin, Miłosz Parczewski, Kaja Scheibe, Bogusz Aksak-Was, Piotr Żąbek, Iwona Cielniak, Monika Bociąga-Jaski, Adam Witor, Szymczak Aleksandra, Paweł Jakubowski, Antoine Chaillon

152 TIME TO KEY MILESTONES IN THE HIV INDEX TESTING/CONTACT TRACING PATHWAY IN INDIA
10:13
Parthasarathy Mugundu Ramien, Padum Narayan, Shruti H. Mehta, Ajay Enugu, Allison M. McFall, Devanga Ashok, Anthony Reddy, Jade Bell, Viswanathan Arumugam, Maria Salvat Ballester, Sunil S. Solomon, Aditya Singh

153 ASSISTED PARTNER SERVICES FOR PWID TO IDENTIFY PARTNERS LIVING WITH HIV & HCV
10:21

154 HIV INCIDENCE DIFFERENCES MEASURED BY SERIAL CROSS-SECTIONAL TESTING: HPTN 071
10:29
Oliver Laeyendecker, Ethan Wilson, Owen Baker, Estelle Piwowar-Manning, Barry Kosloff, Anneen van Deventer, Ayana Moore, Peter Bock, Helen Ayles, Sian Floyd, Sarah Fidler, Richard Hayes, Susan H. Eshleman, Deborah Donnell
Research Group: HPTN 071 (PopART study team)

155 INCIDENCE OF CANCER AMONG MEDICAID BENEFICIARIES WITH AND WITHOUT HIV: 2001-2015
11:00
Jacqueline E. Rudolph, Keri Calkins, Bryan Lau, Corinne Joshu
Research Group: HPTN 071 (PopART study team)

156 CAUSES OF DEATH AMONG ADULTS WITH HIV ON ART IN EUROPE AND NORTH AMERICA: 1996-2019
11:08
Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hesamfar, Peter Reiss, Lei Zhang, Suzanne M Ingle, Jonathan AC Sterne
Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

157 MOLECULAR HIV CLUSTERING OF INDIVIDUALS WITH MPXV/HIV CO-MORBIDITY
11:16
Randall Colluru, Thomas O’Grady, Carol-Ann Swain, Wendy Patterson, Deepa Rajulu

158 ISOLATING THE EFFECT OF COVID-19 RELATED DISRUPTION ON HIV DIAGNOSES IN THE US, 2020
11:24
Alex Viguerie, Ruiguang Song, Anna Satcher Johnson, Cynthia Lyles, Angela Hernandez, Paul Farnham
159  CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084
Mark A. Marzinke, Xu Guo, James Hughes, Brett Hanscom, Estelle Piwowar-Manning, Craig Hendrix, Scott Rose, Jim Rooney, Alex R. Rinehart, Susan Ford, Adeola Adeyeye, Myron S. Cohen, Mina Hosseinipour, Sinead Delany-Moretllwe
Research Group: HPTN 084 Study Team

160  THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP
Research Group: for the HPTN 083 and 084 Study Teams

161  CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN
Hyman Scott, Brett Hanscom, Craig Hutchinson, Jonathan Lucas, Aditya Gaur, Colleen Kelley, Debora Dubar, Paul Richardson, Jim Rooney, Alex R. Rinehart, Adeola Adeguye, Beatriz Grinsztejn, Raphael J. Landovitz, Sheldon Fields
Research Group: HPTN 083 Study Team

162  CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01)
Research Group: HPTN 08-01 Study Team

163  8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP
Jeanne Marrazzo, Marissa Becker, Linda-Gail Bekker, Connie Celum, Michael Kiragu, Ashley Leech, Allan Taylor, Faith Ussery, Juan Yang, Melanie de Boer, Christoph Carter, Moupalai Das, Jared M. Baeten, Li Tao

164  SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ELVITEGRAVIR INSERT ADMINISTERED RECTALLY
Sharon A. Riddler, Clifton Kelly, Craig Hoesly, Ken Ho, Jeanna Piper, Stacey Edick, Faye Heard, Yuqing Jiao, Gustavo F. Doncel, Sherri Johnson, Ratiya Pamela Kunjara Na Ayudhya, José Bauermeister, Craig Hendrix
Research Group: MTN-039 Protocol Team

165  ULTRA-LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
Fernanda Pons-Faudoa, Nicola Di Trani, Corrine Ying Xuan Chua, Lane Bushman, Simone Capuani, Jocelyn Nikita Campa Caranza, Kathryn Shelton, Pramod Neheete, John Nichols, Jason Kimata, Peter L. Anderson, Roberto C. Arduino, Alessandro Grattoni
Oral Abstract Session-09 LATE-BREAKING CLINICAL STUDIES ON COVID-19 AND MPox

Flex C (Level 2) 10:00 AM - 12:00 PM

**Moderators**
Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Anne F. Luetkemeyer, University of California San Francisco, San Francisco, CA, USA

**166 10:05**
ENSITRELVIR FOR MILD-TO-MODERATE COVID-19: PHASE 3 PART OF PHASE 2/3 STUDY
Genki Ichihashi, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Takumi Imamura, Takuhiro Sonoyama, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae

**167 10:13**
EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA FOR COVID-19
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Vitoria Helena de Souza Campos, Thiago Santiago Ferreira, Castilho Vitor Quirino dos Santos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimarães Almeida, Leonardo Cancado Monteiro Savassi, Adhemar Dias de Figueiredo Neto, Ana Carolina Filho Dias Rocha, Carina Bitaraes, Lindsay Wilson, Edward Mills, Jeffrey S. Glenn

**168 10:21**
CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MAB AGAINST SARS-CoV-2
Manish C. Choudhary, Rinki Deo, Teresa H. Evering, Kara W. Chew, Mark Giganti, Carlee Moser, Justin Ritz, David A. Wohl, Joseph J. Eron, David A. Margolis, Yun Ji, Michael D. Hughes, Davey M. Smith, Eric S. Daar, Jonathan Z. Li

**169 10:29**
SAFETY AND EFFICACY OF INHALED INTERFERON-B1A (SNG001) IN OUTPATIENTS WITH COVID-19

**170 11:00**
METFORMIN REDUCED SARS-CoV-2 VIRAL LOAD IN A PHASE 3 RANDOMIZED CLINICAL TRIAL
David R. Boulware, Carolyn Bramante, Matthew Pullen, John Buse, David Odde, Tanvi Mehta, Christopher Tignanelli, Kenneth Beckman, Amy Karger, David Liebovitz, Hirshikesh Belani, Jacinda Nicklas, Michael Puskarich, Spencer Erickson, Thomas A. Murray

**171 11:08**
SYMPTOM AND VIRAL REBOUND IN UNTREATED COVID-19 INFECTION
Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li

Research Group: ACTG A5401 Study Team

Research Group: ACTV-2/A5401 Study Team

Research Group: The TOGETHER Investigators

Research Group: ACTIV-2/A5401 Study Team
172  COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT  
Heather Henderson, David A. Wohl, William Fischer, Luther Bartelt, David van Duin, Joseph J. Eron, Sonia Napravnik

173  MPXV IN PEOPLE LIVING WITH HIV AND CD4 COUNTS <350 CELLS/MM³ - A GLOBAL CASE SERIES  
Oriol Mitjà, Andrea Alemany, Jezer Ivan Lezama Mora, Juan Carlos Rodríguez-Aldama, Ever Arturo Corral Herrera, Beatriz Grinsztejn, Nicolò Girometti, Valentina Mazzotta, Aniruddha Hazra, Jade Ghosh, María Fernanda Peña Vázquez, Juan J. Montenegro Idrogo, Cristina Galvan-Casas, Michael Marks, Chloé Orkin  
Research Group: SHARE-net writing group

| Themed Discussion-06 DYNAMICS OF PROVIRAL INTEGRATION  
Flex A (Level 2) 1:30 PM - 2:30 PM  
Moderator  
Lillian Cohn, Fred Hutchinson Cancer Research Center, Seattle, WA, USA  |
|---|---|
| 1:35 | DISTINCT INTEGRATION SITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLLERS  
Isabelle C. Roseto, Xiaodong Lian, Kyra Seiger, Elizabeth Parsons, Gregory Gladkov, Ce Gao, Karam Mounzer, Emmanouil Papasavvas, Pablo Tebas, Tae-Wook Chun, Luis J. Montaner, Xu G. Yu, Mathias Lichterfeld |
| 1:40 | CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO  
| 1:45 | IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION  
Carmen Gasca-Capote, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos |
| 1:50 | EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4⁺ T CELL PROLIFERATION  
| 1:55 | A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE  
Sam Weissman, Marilia Pinzone, Alfonso Oceguera, Ashley Ginda, Liam Swiggard, LaMont Cannon, Ryan Zurakowski, Una O’Doherty |
Themed Discussion-07 A VIRUS ON MY MIND: UNRAVELING LINKS BETWEEN HIV AND MENTAL HEALTH SYMPTOMS
Ballroom 1 (Level 5) 1:30 PM - 2:30 PM

Moderator
Sean Rourke, University of Toronto, Toronto, ON, Canada

469 1:35 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV

476 1:40 (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION
Arish Mudra Rakshasa-Loots, Nicholas Bakewell, David Sharp, Magnus Gisslén, Henrik Zetterberg, Jasmini Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, Jaime Vera
Research Group: COmorBidity in Relation to AIDS (COBRA) cohort

472 1:45 PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCES, INTERACTIONS AND CONSEQUENCES
Research Group: 2000HIV

474 1:50 BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT
Bin Tang, Ronald J. Ellis, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre

473 1:55 SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV
Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin
999  A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA  
Ingrid Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile Ngcobo, Taing N. Aung, Jana Jarolimova, Danielle Zions, Christina Psaros, Nduduzo Dube, Robert Parker  

1:35

978  PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION  
Stephanie Roche, Victor Omollo, Peter Mogere, Magdaline Asewe, Stephen Gakuo, Preetika Banerjee, Kendall Harkey, Josephine Odoyo, Jared M. Baeten, Patricia Ongwen, Daniel Were, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad  

1:40

977  EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA  
Ashley R. Bardon, Kenneth Ngure, Peter Mogere, Katherine Thomas, Stephen Gakuo, Catherine Kiptinness, Sarah Mbaire, Dorothy Mangale, Jacinta Nyokabi, Nelly Mugo, Jared M. Baeten, Katrina F. Ortblad  

1:45

Themed Discussion-08 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?  
Flex C (Level 2)  
1:30 PM - 2:30 PM

Moderator  
Babafemi Taiwo, Northwestern University, Chicago, IL, USA

516  PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTETRAVIR/RLIPVIRINE  
Stephanie Kenney, Nimish Patel, Lucas Hill  

1:35

518  HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION  
Monica Gandhi, Jorge Salazar, Matthew D. Hickey, Katerina Christopoulos, Jon Oskarsson, Mary Shiels, John Szumowski, Janet Grochowski, Francis Munoz-Mayorga, John Sauceda, Elizabeth Imbert, Janet Nguyen, David V. Glidden, Diane V. Havlir  

1:40

517  PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART  
Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilian, Justine Scott, Timothy Wilkin, Andrea L. Ciaramello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle  

1:45

Themed Discussion-09 ADVANCES IN PrEP DELIVERY IN SUB-SAHARAN AFRICA  
Ballroom 2 (Level 5)  
1:30 PM - 2:30 PM

Moderator  
Andrew Mujugira, Makerere University, Auburn, WA, USA

977  EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA  

1:45

978  PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION  

1:40

999  A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA  

1:35

517  PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART  
Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilian, Justine Scott, Timothy Wilkin, Andrea L. Ciaramello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle  

1:45

516  PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTETRAVIR/RLIPVIRINE  
Stephanie Kenney, Nimish Patel, Lucas Hill  

1:35

518  HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION  
Monica Gandhi, Jorge Salazar, Matthew D. Hickey, Katerina Christopoulos, Jon Oskarsson, Mary Shiels, John Szumowski, Janet Grochowski, Francis Munoz-Mayorga, John Sauceda, Elizabeth Imbert, Janet Nguyen, David V. Glidden, Diane V. Havlir  

1:40
975 RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA
1:55
Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chamie, Maya Petersen, Moses Kamya, Diane V. Havlir
Research Group: SEARCH Study Team

976 INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH
1:50
Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Theresa Smit, Osee Behuhuma, Jean-Michel Molina
WEDNESDAY FEBRUARY 22, 2023

Oral Abstract Session-10 IMMUNOPATHOGENESIS AND VACCINES
Ballroom 3 (Level 5)  
10:00 AM - 12:00 PM

Moderators
Richard A. Koup, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
Cynthia Derdeyn, University of Washington, Seattle, WA, USA

174  CD8+ T CELLS INDUCE HIV LATENCY IN CD4+ T CELLS THROUGH THE DOWNMODULATION OF NF-κB
10:05
Simona Mutascio, Hong Wang, Mirko Paiardini, Guido Silvestri, Deanna A. Kulpa

175  BLOCKING CD4+ T CELL MIGRATION DELAYS VIRAL SPREAD FOLLOWING VAGINAL SIV CHALLENGE
10:13
Christine M. Fennessey, David R. Morcock, Jorden L. Welker, James A. Thomas, Charles M. Trubey, Caroline Widmaier, Kristin Killoran, Jeffrey D. Lifson, Brandon F. Keele, Claire Deleage

176  DEPLETION OF SIV-SPECIFIC CD8+ T CELLS DOES NOT ALTER VIRAL LOAD DURING SIV INFECTION
10:21
Jennifer Simpson, Carly Starke, Alexandra Ortiz, Amy Ransier, Sam Darko, Daniel C. Douek, Sian Llewellyn-Lacey, David Price, Jason Brenchley

177  PROTECTION AGAINST HTLV-1 CHALLENGE BY VACCINATION INDUCING ANTIBODIES IN MACAQUES
10:29
Midori Nakamura-Hoshi, Hiroshi Ishii, Takushi Nomura, Midori Okazaki, Yuriko Suzuki, Kenzo Yonemitsu, Yasushi Ami, Tetsuro Matano

178  SHIFTS IN SYSTEMIC INFLAMMATION AFTER FECAL MICROBIOTA TRANSPLANT IN PEOPLE WITH HIV
11:00
Claudio Díaz-García, Elena Moreno, Alba Talavera, José A. Pérez-Molina, Fernando Dronda, María José Gosalbes, Jorge Díaz-Álvarez, Javier Martínez-Sanz, Raquel Ron, María Jesús Vivancos, Santiago Moreno, Sergio Serrano-Villar

179  AUTOLOGOUS NEUTRALIZING ANTIBODY RESPONSES IN bNAb-TREATED RHEUS MACAQUES
11:08
Elise Viox, Ryan Krause, Emily Lindemuth, Jin Wang, Sadia Samer, Kevin Nguyen, Steffen Docken, Suadip Mallick, Brandon F. Keele, Michael R. Betts, Miles Davenport, Mirko Paiardini, Katharine Bar

180  ANALYSIS OF EPITOPE-SPECIFIC T CELLS IN SARS-CoV-2 INFECTION AND VACCINATION
11:16
Kristin L. Boswell, Lauren A. Bowman, Amy Ransier, Jesmine Roberts-Torres, Jakob T. Samsel, David R. Ambrozak, Phillip A. Swanson, Giuse Padilla, Sam Darko, Ingelise Gordon, Irini Sereti, Adrian B. McDermott, Martin Gaudinski, Daniel C. Douek, Richard A. Koup

181  ANTI-PD-1 THERAPY INDUCED RAPID INNATE INTERFERON RESPONSES DRIVE HIV RESERVOIR DECAY
11:24
Ashish Arunkumar Sharma, Aarthi Tall, Ana B. Enriquez, Gabriela Sanchez, Adam Pelletier, Leonard D’Amico, Nicolas Chomont, Sharon Lewin, Steven G. Deeks, Kathryn Lurain, Elad Sharon, Steven Fling, Martin Cheever, Thomas Ulbricht, Rafick P. Sékaly
Oral Abstract Session-11 NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-CoV-2
Ballroom 2 (Level 5) 10:00 AM - 12:00 PM

Moderators
Serena Spudich, Yale University, New Haven, CT, USA
Michael Corley, Weill Cornell Medicine, New York, NY, USA

183  SEX MODIFIES THE ASSOCIATION OF AGE AND VIREMIA WITH STROKE RISK IN HIV
10:05
Felicia C. Chow, Robin Nance, Emily Ho, Andrew Huffer, Rizwan Kalani, Christina Marra, Joseph Zunt, Laura Bamford, Greer Burkholer, Edward Cachay, Mari Kitahata, Sonia Napravnik, David Tirschwell, Joseph Delaney, Heidi Crane

184  INCREASED IMMUNE ACTIVATION IN HIV+ MSM ON ART, BUT NOT WHEN COMPARED TO MSM ON PreEP
10:13
Josefina Robertson, Arvid Eden, Aylin Yilmaz, Lars Haagberg, Lars-Magnus Andersson, Johanna Gostner, Dietmar Fuchs, Henrik Zetterberg, Magnus Gisslen

185  CEREBROSPINAL FLUID HIV RNA AND VIRAL NUCLEIC ACID DETECTION IN PERSONS WITH HIV
10:21
Merle Henderson, Nuala Pepper, Manraj Bawa, David Muir, Alex Everitt, Nicola Mackie, Alan Winston

186  HIV CLINICAL, COMORBID, AND SOCIAL DETERMINANTS OF HEALTH ARE LINKED WITH BRAIN AGING
10:29
Kalen J. Petersen, Tina Lu, Julie Wisch, June Roman, Nicolas Metcalf, Sarah Cooley, Beau Ances

187  CHANGES TO MICROGLIAL GENOME STRUCTURE AND FUNCTION IN THE HIV-INFECTED HUMAN BRAIN
11:00
Amara Plaza-Jennings, Aditi Valada, Benjamin K. Chen, Susan Morgello, Hyejung Won, Schahram Akbarian

188  BRAIN AND BEHAVIOR PREDICTORS OF SARS-CoV-2 INFECTION AMONG PEOPLE WITH HIV
11:08
Robert Paul, Jacob Bolzenius, Somchai Sripilanchan, Carlo Scolaldan, Napapon Sailsut, Julie A. Ake, Donn Colby, Phillip Chan, Ferron F. Ocampo, Denise Hsu, Lishomwa Ndhlouv, Adam W. Carrico, Sandhya Vasan, Victor Valcour, Serena Spudich

189  NO CSF BIOMARKER EVIDENCE OF PERSISTING CNS INFECTION AFTER SARS-CoV-2 INFECTION
11:16
Arvid Eden, Anna Grahn, Nelly Kanberg, Erika Stentoft, Staffan Nilsson, Aylin Yilmaz, Daniel Bremell, Marie Studahl, Daniel Romero, Mingyue Wang, Martin Stengelin, George Sigal, Michael Schöll, Henrik Zetterberg, Magnus Gisslen
Research Group: SEARCH 010/RV254 Study Team

190  CSF & PLASMA SOLUBLE BIOMARKERS IN NEURO-PASC: PRELIMINARY RESULTS FROM COVID MIND
11:24
Shelli Farhadian, Lindsay S. McAlpine, Halley Reisert, Jennifer Yoon, Jennifer Chiarella, Priya Kosana, PeiXi Chen, Kaj Blennow, Debanjana Chakravarty, Samuel Pleasure, Michael Wilson, Magnus Gisslen, Henrik Zetterberg, Serena Spudich
Oral Abstract Session-12 ANTIVIRAL STRATEGIES FOR TREATMENT AND PREVENTIONS
Ballroom 1 (Level 5)  10:00 AM - 12:00 PM

Moderators
Angela DM. Kashuba, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Anton L. Pozniak, Chelsea and Westminster Hospital, London, England, United Kingdom

191  10:05  SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF

192  10:13  EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNT
Kathleen E. Squires, Todd A. Correll, Michael N. Robertson, Stephanie O. Klopfer, Peggy May Tan Hwang, Yun-Ping Zhou, Elizabeth Martin, Elizabeth G. Rhee

193  10:21  LENACAPAVIR WITH bNabs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV
Joseph J. Eron, Susan R. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyant Jayaweeera, Edwin DeJesus, Sarah E. Waldman, Megha L. Mehrotra, Laurie A. VanderVeen, Hailin Huang, Sean E. Collins, Jared M. Baeten, Marina Caskey

194  10:29  TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION
Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, Margaret Hellard, Andrew Ustianowski, Ranjababu Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory Dore, Mark Nelson, Gail Matthews

195  11:00  LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV
Emma Rubenstein, Myriam Diemer, Laraurie Goldwirt, Caroline Lacouxa, Matthieu Lafaurie, Jeremy Zeggagh, Mariagrazia Tateo, Diane Pons Carme, Julien Gras, Blandine Denis, Agathe Rami, Pierre Sellier, Marie-Laure Chaix, Constance Delaugerre, Jean-Michel Molina

196  11:08  SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL
Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani Saud, Alexandra Calmy, Shinichi Oka, Federico Hinesdota, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Isaaks Noel Gendrano, Karen Eves, Jason Kim, Todd A. Correll

197  11:16  SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL
Anthony M. Mills, Giuliano Rizzardini, Moti Ramgopal, Olayemi Osiyemi, Johannes R. Bogner, Debbie Hagins, Roger paredes, Jacques Reynes, Jürgen Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O. Klopfer, Rebeca M. Plank, Michelle C. Fox, Todd A. Correll
198
D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY
Gail Matthews, Margaret Borok, Nnekelu Eriobou, Richard Kaplan, N Kumarasamy, Anchalee Avihingsanon, Marcelo H. Losso, Iskander Shah Azwa, Muhammad Karyana, Sounkalo Dao, Mohamed Cisse, Emmanuelle Papot, Simone Jacoby, Jolie Hutchison, Matthew G. Law, Research Group: D2EFT Study Group

Oral Abstract Session-13 OPTIMIZING THE HIV TREATMENT CASCADE Flex A (Level 2) 10:00 AM - 12:00 PM
Moderators
Landon Myer, University of Cape Town, Cape Town, Western Cape, South Africa
Euphemia Sibanda, Centre for Sexual Health & HIV/AIDS Research, Harare, Zimbabwe

199
HIV RECENCY TESTING WITH INDEX TESTING CAN IDENTIFY NEW INFECTIONS EARLIER IN RWANDA

200
RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV CARE FOR HIGHLY MOBILE PERSONS IN EAST AFRICA
James Ayieko, Colette Inviolata, Elijah Kakande, Fred Opel, Erick Wafula Mugoma, Laura Balzer, Jane Kabami, Elizabeth A. Bukusi, Carol Camlin, Edwin Charlebois, Melanie Bacon, Maya Petersen, Diane V. Havlir, Moses Kamya, Gabriel Chamie, Research Group: SEARCH Study Team

201
THE IMPACT OF PATIENT-CENTRED CARE ON HIV TREATMENT IN ZAMBIA: A STEPPED-WEDGE TRIAL
Kombatunde Sikombe, Aaloke Mody, Charles Goss, Ingrid Eshun-Wilson, Sandra Simbeza, Anjali Sharma, Laura K Beres, Jane M. Pry, Njewka Mukamba, Brian Rice, Jacob Mutale, Carolyn Bolton Moore, Charles B Holmes, Izunganji Sikazwe, Elvin Geng

202
A RANDOMIZED CONTROL TRIAL OF MHEALTH TOOL EFFECT ON VIRAL SUPPRESSION IN YOUTHS
Agnes Bwanika Naggirinya, Maria S. Nabaggala, David B. Meya, Joseph Rujumba, Peter Waiswa, Rosalind Parkes-Ratanshi

203
SUPPRESSING VIRAL LOAD IN PEOPLE WITH HIV WHO INJECT DRUGS IN RUSSIA: LINC-II RCT
Jeffrey H. Samet, Elena Blokhina, Debbie M Cheng, Sydney Rosen, Dmitry Lizov, Karsten Lunze, Ve Truong, Natalia Gnatienko, Emily Quinn, Natalia Bushara, Anita Raj, Evgeny Krupitsky

204
URINE TENOFOVIR LEVELS PREDICT VIRAL SUPPRESSION IN PATIENTS ON TENOFOVIR ALAFENAMIDE
Kelly A. Johnson, Okochi Hideaki, Mineya Arrequin, Joseph Watabe, David V. Glidden, Anindita Chattopadhyay, Elizabeth Imbert, Matthew D. Hickey, Monica Gandhi, Matthew A. Spinelli
Oral Abstracts and Themed Discussions by Day

205  
11:16  
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS AND HIV-1 RESISTANCE IN SOUTH AFRICA  
Yashna Singh, Jose Castillo-Mancilla, Lauren Jennings, Richard Madimabe, Christopher Ferraris, Reuben N. Robbins, Peter L. Anderson, Robert H. Remien, Catherine Orrell

206  
11:24  
ART SHARING IS COMMON AND ASSOCIATED WITH VIREMIA: A POPULATION-BASED STUDY IN UGANDA  
Caitlin E. Kennedy, Xinyi Feng, Joseph G. Rosen, Joseph Ssekasanvu, Robert Ssekubugu, Godfrey Kigozi, David M. Serwadda, Joseph Kabanda, Ping Teresa Yeh, Joseph Kagaayi, Steven J. Reynolds, Larry William W. Chang, Fred Nalugoda, Mary K. Grabowski  
Research Group: The Rakai Health Sciences Program

Oral Abstract Session-14 EPIDEMIOLOGY AND PREVENTION OF MPOX AND SARS-CoV-2  
Flex C (Level 2)  
10:00 AM - 12:00 PM

207  
10:05  
EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL  

208  
10:13  
IMPACT OF VACCINATION ON MPOX INCIDENCE IN MSM ON PrEP IN THE ANRS 174 DOXYVAC TRIAL  
Jade Ghoosn, Lambert Assoumou, Moussa Ouattara, Michele Allegarte-Genin, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Claudine Duviuver, Juliette Pavia, Jean-Paul Viard, Severine Gibowski, Manon Ollivier, Dominique Costagliola, Jean-Michel Molina

209  
10:21  
HOUSEHOLD TRANSMISSION OF MONKEYPOX TO CHILDREN AND ADOLESCENTS  
Darpun Sachdev, Rilene Ng, Cameron Stainken, Meredith Haddix, Erin Peterson, Kristen Wendorf

210  
10:29  
ASSOCIATION BETWEEN OBSERVED MASKING AND SARS-CoV-2 PRESENCE IN SCHOOL WASTEWATER  
Rebecca Fielding-Miller, Tommi Gaines, Ashkan Hassani, Vinton Omaleki, Marlene Flores, Araz Majnoonian, Carrissa Wijaya, Richard Garfein

211  
11:00  
VARIABLE REDUCTIONS IN SARS-CoV-2 VARIANT IMPORTATIONS FOLLOWING TRAVEL RESTRICTIONS  
Angela McLaughlin, Jeffrey B Joy

212  
11:08  
INTERVENTION EFFICACY ON COVID-19 TESTING AND VACCINATION IN PEOPLE WHO INJECT DRUGS  
Angela R. Bazzi, Daniela Abramovitz, Alicia Harvey-Vera, Tara Stamos-Buesig, Charles F. Vera, Irina Artamonova, Janna Logan, Thomas L. Patterson, Steffanie A. Strathdee

Moderators
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
François Dabis, University of Bordeaux, Bordeaux, Aquitaine, France
Oral Abstracts and Themed Discussions by Day

CROI 2023

Oral Abstracts and Themed Discussions by Day

Wednesday

Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter

Themed Discussion-10 CELLULAR IMMUNE CONTROL OF HIV
Ballroom 2 (Level 5)
1:30 PM - 2:30 PM

Moderator
Marcus Altfeld, Leibniz Institute for Virology, Hamburg, Germany

313 11:16 CLUSTER-RANDOMIZED TRIAL COMPARING TWO SARS-CoV-2 TESTING MODELS IN AFRICA

214 11:24 COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION
Jing Sun, Yifan Zhang, Alfred J. Anzalone, Amy L. Olex, Eric Hurwitz, Jomol Mathew, Nasia Safdar, Jessica Y. Islam, Roslyn Mannion, Amanda J. Vinson, Christopher Chute, Melissa A. Haendel, Rena Patel, Greg Kirk
Research Group: National COVID Cohort Collaborative

Themed Discussion-10 CELLULAR IMMUNE CONTROL OF HIV
Ballroom 2 (Level 5)
1:30 PM - 2:30 PM

315 1:35 ELITE CONTROLLERS WITH DISTINCT VIRAL RESERVOIR HAVE ROBUST CTL TO NETWORKED EPITOPES
David Collins, Clarety Kaseke, Umar Urshad, Xiaodong Lian, Bridget Coffey, Daniel Worrall, Aliça Piechocka-Trocha, Micayla George, Benjamin R. Bone, Mathias Lichterfeld, Xu G. Yu, Bruce D. Walker, Gaurav Gaiha

311 1:40 IL-15 DEPENDENT NK CELLS AND DENDRITIC CELLS CROSS-TALK IN HIV-1 ELITE CONTROLLERS
Ciputra A. Hartana, Ce Gao, Yezizaveta Rassadkina, Mathias Lichterfeld, Xu G. Yu

337 1:45 NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI
Ashley F. George, Tongcui Ma, Min-Gyoung Shin, Reuben Thomas, Mauricio Montano, Satish Pillai, Martin Tolstrup, Ole S. Sogaard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Katherine S. Pollard, Warner C. Greene, Nadia R. Roan

312 1:50 DISTINCT NK CELL RESPONSES DEFINE DURABLE CONTROL IN ELITE CONTROLLERS
Nerea Sánchez Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José Miguel Benito, Ézeguel Ruiz-Mateos, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research Group

313 1:55 MONOCYTES OF HIV-1 ELITE CONTROLLERS AND RELATIVES SHOW ENHANCED TRAINED IMMUNITY
Research Group: 2000HIV
Oral Abstracts and Themed Discussions by Day

**Themed Discussion-11 WEIGHT GAIN: DOES WHAT GOES UP ALWAYS COME DOWN?**

**Ballroom 1 (Level 5)**

**Moderator**

Peter W. Hunt,  University of California San Francisco, San Francisco, CA, USA

1:35  **WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG**  
Bronwyn E. Bosch, Godpower Akpomiemie, Nomathembela Chandiwa, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, Francois Venter

1:40  **FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC**  
Sophie Degroote, Sophie Vanherrewege, Els Tobbak, Els Caluwe, Lara Vincze, Wim Tryptsteen, Mareva Delporte, Evy Blommme, Linos Vandekerckhove, Marie-Angélique De Scheerder

1:45  **REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN**  
Myrthe L. Verburgh, Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk  
Research Group: the ATHENA national observational cohort

1:50  **WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA**  
Kassem Bourgi, Susan Ofner, Beverly Musick, Kara Wools-Kaloustian, Lameck Diero, Constantin Yannoutsos, Samir Gupta

**Themed Discussion-12 HIV SERVICES IN TIMES OF CRISIS**

**Flex A (Level 2)**

**Moderator**

Siobhan Crowley,  The Global Fund, Geneva, Switzerland

1:35  **A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI**  
Jean Bernard Marc, Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Homeus, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Guiteau, Jean William Pape, Serena Koenig

1:40  **CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL**  

1:45  **EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA, 2022**  

Research Group: National and Amhara Regional Emergency Response Team
Oral Abstracts and Themed Discussions by Day

Themed Discussion-13 PRECLINICAL STUDIES OF NEW PREVENTION INTERVENTIONS
Ballroom 3 (Level 5)  1:30 PM - 2:30 PM

Moderator
Ariane van der Straten, University of California San Francisco, Kensington, CA, USA

992  LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL
1:35
Elena Bekerman, Stephen Yant, Laurie A. VanderVeen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

990  EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS
1:40
Natalia Makarova, Tyana Singleary, Missy Peet, James Mitchell, Angela Holder, Chuong Dinh, Yi Pan, Maria Corazon Bueno Mendoza, Meredith Clark, Wald Heneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

989  VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES
1:45
Michele B. Daly, Daniel Kim, Linying Li, Archana Krovi, Chasity Norton, Catalina Forero, Marie Brake, Chuong Dinh, Tiancheng Edwards, Mackenzie Cottrell, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

991  PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT
1:50
Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

Please Note: The bolding of presenting authors in the Poster Sessions By Day may be inconsistent and incorrect. Please refer to the Abstract eBook and CROI 2023 Conference Platform for the correct notation of presenting authors.
POSTER SESSIONS BY DAY
MONDAY FEBRUARY 20, 2023

Poster Session-A1 EARLY EVENTS

2:30 PM - 4:00 PM

215 LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE
Chenglei Li, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak

216 SINGLE-VIRUS IMAGING OF HIV-1 NUCLEAR IMPORT
Anayat Bhat, Ivan Nombela, Barbara V. Remoortel, Frauke Christ, Zeger Debyser
Research Group: Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

217 RESTRICTION OF LENTIVIRAL CAPSIDS BY PRIMATE TRIM34
Joy Twentyman, Abby Felton, Michael Emerman, Molly Ohainle

Poster Session-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL

2:30 PM - 4:00 PM

240 EARLY EVOLUTION OF HIV-1 FROM TRANSMITTED FOUNDERS DURING ACUTE INFECTION
Valerie F. Boltz, Wei Shao, Clarissa Halpern, Adam A. Capoferri, Morgane Rolland, Nittaya Phanuphak, Denise Hsu, Carlo Scaalahan, John W. Mellors, John M. Coffin, Mary F. Kearney
Research Group: RV254/SEARCH 0101 Study Team

241 ASSOCIATION OF MBL2 GENE POLYMORPHISMS WITH HIV-1 INFECTION IN MOROCCO
Meryem Bouqdayr, Haná Baba, Asmae Saih, Anass Abbad, Salsabil Hamdi, Anass Kettani, Lahcen Wakrim

242 DIFFERENTIAL INFECTION OF ECTO- AND ENDOCERVIX BY TRANSMITTED/FOUNDER HIV-1 EX VIVO
Teresia A. Muhomah, Robert Langat, Michael McRaven, Ramon Redondo, Ann Marie Carias, Marianne Mureithi, Omu Anzala, Thomas J. Hope

243 PD-1 IS AN INSENSITIVE MARKER FOR HIV/SIV RNA+ LYMPH NODE TFH IN UNTREATED INFECTION
Joy Folkvord, Matthew Ollerton, Andria Albert, Eva Rakasz, Pamela Skinner, Elizabeth Connick

244 IDENTIFICATION OF HIV-2 EXTREME ELITE CONTROLLERS OFFERS INSIGHT TO FUNCTIONAL CURE
Research Group: SWEGUB CORE group

245 T CELLS HOMEOSTASIS DISTURBANCES IN A COHORT OF LONG-TERM ELITE CONTROLLERS
Norma Rallón, Daniel Jiménez-Carretero, Maria A. Navarrete-Muñoz, José M. Ligos, Jaime Valentín-Quiroua, Clara Restrepo, Alfonso Cabello, Miguel Górgolas, Eduardo López-Collazo, Fátima Sánchez-Cabo, José M. Benito
246 LOW Tryptophan Catabolism Marks Immune Preservation in HIV+ Viremic Non-Progressors

Angel Bayon-Gil, Aaron Goldman, Judith Dalmau, Kai Ying Hong, Jane Koshy, Leila Giron, Mohamed Abdel-Mohsen, Javier Martinez Picado, Maria C. Puertas

247 PHENOTYPE OF SIV-INFECTED CELLS IN BLOOD AND TISSUES USING A NEW SINGLE-CELL APPROACH

César A. Trifone, Manon Nayrac, Michael Nekorchuk, Kathleen Busman-Sahay, Rémi Fromentin, Daniel Kaufmann, Jacob Estes, Nicolas Chomont

Poster Session-B6 SARS-CoV-2 PATHOGENESIS
2:30 PM - 4:00 PM

271 PLASMA LIPIDS AND AMINO ACIDS LINKED TO LOW SARS-CoV-2 SUSCEPTIBILITY

Elena Moreno, Oihane E Albóniga, Javier Martínez-Sanz, Pilar Vizcarra, Raquel Ron, Jorge Díaz-Álvarez, Matilde Sanchez-Conde, Claudio Díaz-García, Juan Carlos Galán, Santiago Moreno, Coral Barbas, Sergio Serrano-Villar

272 EARLY INFLAMMATORY PROFILES PREDICT MAXIMAL DISEASE SEVERITY IN COVID-19

Grace Kenny, Gurvin Saini, Colette Marie Gaillard, Riya Negi, Dana Alalwan, Alejandro García Leon, Willard Tinago, Eoin R. Feeney, Aoife Cotter, Eoghan Debarra, Mary Horgan, Obada Yousef, Cecilia O’Kane, Danny McAuley, Patrick Mallon

Research Group: All Ireland Infectious Diseases Study Group

273 DIFFERENTIAL ASSOCIATION OF CYTOMEGALOVIRUS WITH ACUTE AND POST-ACUTE COVID-19

Michael J. Peluso, Harry Pickering, Fay Chan, Gabrielle C. Ambayec, Gabriele Beck-Engeser, Katherine Wick, Michael Matthay, Carolyn Calfee, Jeffrey Martin, Steven G. Deeks, Smita Iyer, Holden Maecker, Timothy Henrich, Elaine F. Reed, Peter W. Hunt

Research Group:IMPACC, COMET, and LIINC study teams

274 BASELINE AND TEMPORAL DIFFERENCES IN PROTEOMICS FOLLOWING SARS-CoV-2 INFECTION IN PWH

Márton Kolossváry, Christopher Defilippi, Sara McCallum, Kathleen V. Fitch, Heather J. Ribaudo, Carl J. Fichtenbaum, Judith A. Aberg, Carlos Malvestutto, Judith S. Currier, Jose L. Casado, Félix Gutiérrez, Irini Sereti, Pam S. Douglas, Markella V. Zanni, Steven K. Grinspoon

275 SARS-CoV-2 BA.5 CAUSES HIGHER REPLICATION AND LETAL INFECTION IN K18-hACE2 MICE

Rahul K. Suryawanshi, Maria McCavitt-Malvido, Melanie Ott

276 AUTOPHAGY AND Aeryl-CoA-BINDING PROTEIN INFLUENCE COVID-19 SEVERITY

Stephane Isnard, Léna Royston, Tsoarello Mabanga, Simeng Bu, Carolina Berini, John Lin, Brandon Fombuena, Cecilia Costiniuk, Bertrand Lebouché, Nicole Bernard, Guido Kroemer, Madeleine Durand, Jean-Pierre Routy

Research Group: BQC-19 Biobank

277 INFLAMMATORY PATHWAYS ASSOCIATED WITH COVID-19 SEVERITY DIFFER BASED ON OBESITY STATUS

Stefano Savinelli, Grace Kenny, Colm O’Brien, Kathleen McCann, Alejandro García Leon, Gurvin Saini, Colette Marie Gaillard, Rya Negi, Dana Alalwan, Alan Landay, Cecilia O’Kane, Aoife Cotter, Patrick Mallon, Eoin R. Feeney, Eoghan de Barra, Obada Yousif

Research Group: All Ireland Infectious Diseases Cohort
278 SARS-CoV-2 VARIANTS-DEPENDENT INFLAMMASOME ACTIVATION
Elisa Teyssou, Stephane Marot, Adelie Gothland, Isabelle Malet, Karen Zafilaza, Valentín Leducq, Théophile Coccherie, Cathia Soulé, Anne-Geneviève Marcelin, Vincent Calvez

279 HIGH FAT AND SUGAR DIET INDUCES GUT LEUKOCYTE DISRUPTIONS EXACERBATED BY SARS-CoV-2
Kelsie Brooks, Quentin Le Hingrat, Anna Jasinska, Lilas Tarnus, Makheni Jean Pierre, Ankur Sharma, Christine Nelson, Mark Lewis, Daniel Barber, Cristian Apetrei, Jason Brenchley, Ivona Pandrea

280 ACE2 SUBSTRATE CLEAVAGE EFFECT ASSOCIATED WITH COVID-19 PATIENT PLASMA IMMUNOGLOBULIN
Yufeng Song, Regan Myers, Lila Murphy, Bailey Brooks, Alexandre Kadl, Judith Woodfolk, Steven Zeichner

281 SARS-CoV-2 VARIANTS’ TEMPORAL AND VL DISTRIBUTIONS IN IMMUNOCOMPROMISED PATIENTS
Research Group: ANRS MIE – EMERGEN Consortium

Poster Session-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES 2:30 PM - 4:00 PM

298 MYCOBACTERIUM TUBERCULOSIS ASSOCIATES WITH HIGHER HIV-1-SPECIFIC ANTIBODY RESPONSES
Bukola Adeoye, Lydia Nakijyingi, Yvetane Moreau Moreau, Ethel Nankya, Alex Olson, Mo Zhang, Karen Jacobson, Amita Gupta, Yukari C. Manabe, Mina Hosseinipour, Johnstone Kumwenda, Manish Sagar, Joseph B. McWhirter
Research Group: AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

299 IMPACT OF THE INTRATEMPERINE HIV EXPOSURE ON THE INFANTS VIRUS ANTIBODY REPERTOIRE
Rachael Gachogo, Anna-Ursula Happel, Berenice Alinde, Clive M Gray, Heather Jaspan, Sonwabile Dzanibe

300 VIRUS PANEL CLASSIFICATION: A STRATEGY TOWARD DENEALIZATION OF PLASMA bNab ACTIVITY
Research Group: Swiss HIV Cohort Study

301 INFERRING IMMUNOCENIC PROPERTIES OF ENV TRIMERS BY REACTIVITY TO bNab INDUCER PLASMA
Irene A. Abela, Chloe Pasin, Nikolaus Friedrich, Peter Ruset, Merle Schanz, Rogier W. Sanders, Ralf Wagner, Marit J. van Gils, Winfried Weissenhorn, Peter D. Kwong, Huldrych F. Gündthard, Roger D. Koyouso, Alexandra Trkola
Research Group: Swiss HIV Cohort Study

302 GLYCAN-DEFICIENT SHIVS TO ELICIT BROADLY NEUTRALIZING ANTIBODIES IN MACAQUES
Daniel Morris, Hui Li, Shuyi Wang, JFinery Lora, Craig Lauer, Kirsten Sowers, Tongqing Zhou, Peter D. Kwong, George Shaw
303 IDENTIFICATION OF HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES TARGETING MPER
Lauren N. Smith, Gina Donofrio, Rajeshwer Sankhala, Vincent Dussupt, Letzibeth Mendez-Rivera, Bonnie Sliker, Nicole Doria-Rose, Victoria Polonis, Sandhya Vasan, Julie A. Ake, Merlin L. Robb, Gordon Joyce, Shelly Krebs

304 NASCENT HIV-1 ENV-REACTIVE bNAb INDUCTION IN SHIV-INFECTED NEONATAL RHESUS MACAQUES
Bhavna Hora, Hui Li, Shaunna Shen, Mitchell Martin, Yue Chen, Madison Berry, Thomas Denny, M. Anthony Moody, Mark Lewis, Kevin Wiehe, Derek Cain, David Montefiori, George Shaw, Wilton B. Williams

305 AUTOLOGOUS NEUTRALIZING ANTIBODIES DEVELOP AFTER EARLY BUT NOT ACUTE ART INITIATION
Greg Whitehill, Ryan Krause, Francesco Marino, Jaimy Joy, Suvadip Mallick, Rebecca Hoh, Steven G. Deeks, Rebecca M. Lynch, Sulggi Lee, Katharine Bar

306 ART-DIX: A NOVEL STRATEGY TO MONITOR BROADLY NEUTRALIZING ANTIBODY ACTIVITY ON ART
Magdalena Schwarzmüller, Merle Schanz, Irene A. Abela, Selina Epp, Martina Curcio, Peter Rusert, Roger D. Kouryos, Huldrych F. Günthard, Alexandra Trkola

307 EFFICACY AND COMPLEMENTARITY OF HIV-1 SUPPRESSION BY CD4-BINDING bNAbs
Sabrina Helmold Hait, Hannah Shrader, Sarah Lovelace, Emily Coates, Ro Shauna Rothwell, Eileen Donaghy, Carl J. Fichtenbaum, Jorge Santana, Rachel Presti, Jhoanna Roa, Anjali Bhattragar, Rebecca M. Lynch, Pablo Tebas, John R. Mascola, Amarendra Pegu

Research Group: Virology Laboratory, Vaccine Research Center, NIAID, NIH

308 ASSESSING IMMUNOGENICITY BARRIERS OF THE HIV-1 ENVELOPE TRIMER
Nikolas Friedrich, Liridona Maliqi, Matthias Glögl, Peter Rusert, Maryam Zaheri, Chloe Pasin, Stefan Schmutz, Irene A. Abela, Roger D. Kouryos, Huldrych F. Günthard, Marit J. van Gils, Rogier W. Sanders, Ralf Wagner, Andreas Plückthun, Alexandra Trkola

309 ISOLATION OF PAN-SARBEUVIRUS mABs THAT NEUTRALIZE SARS-CoV-1 AND SARS-CoV-2 VARIANTS
Felicitas Ruiz, Jamie Guenthoer, Michelle Lilly, Vrasha Chohan, Will Foreman, Ashley Taylor, Jesse Bloom, Helen Chu, Tyler Starr, Julie M. Overbaugh

310 BROAD ANTIBODIES TO FUNCTIONALLY CONSTRAINED REGIONS OF SARS-CoV-2 SPIKE
Jamie Guenthoer, Michelle Lilly, Tyler Starr, Bernadeta Dadonaite, Klaus Lovendahl, Jacob Croft, Caitlin Stoddard, Vrasha Chohan, Shilei Ding, Felicitas Ruiz, Andrés Finzi, Jesse Bloom, Helen Chu, Kelly Lee, Julie M. Overbaugh, Mackenzie Kopp

Poster Sessions-D2 ELITE CONTROLLERS
2:30 PM - 4:00 PM

311 IL-15 DEPENDENT NK CELLS AND DENDRITIC CELLS CROSS-TALK IN HIV-1 ELITE CONTROLLERS
Ciputra A. Hartana, Ce Gao, Yelizaveta Rassadkina, Mathias Lichterfeld, Xu G. Yuk
312 DISTINCT NK CELL RESPONSES DEFINE DURABLE CONTROL IN ELITE CONTROLLERS
Nerea Sánchez Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José Miguel Benito, Ezequiel Ruiz-Mateos, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research Group

313 MONOCYTES OF HIV-1 ELITE CONTROLLERS AND RELATIVES SHOW ENHANCED TRAINED IMMUNITY
Research Group: 2000HIV

314 TRAINED IMMUNITY FEATURES IN NK CELLS OF HIV-1 ELITE CONTROLLERS
Albert L. Groenendijk, Adriana Navas, Willem A. J. W. Vos, Marc J. T. Blaauw, Louise E. van Eekeren, Mike van Der Kolk, Casper Rokx, Annelies Verbon, Mihai G. Netea, Leo A. B. Joosten, Andre J.A.M. van Der Ven, Jéssica C. Dos Santos
Research Group: 2000HIV

315 ELITE CONTROLLERS WITH DISTINCT VIRAL RESERVOIR HAVE ROBUST CTL TO NETWORKED EPITOPES
David Collins, Clarety Kaseke, Umar Urshad, Xiaodong Lian, Bridget Coffey, Daniel Worrall, Alicja Piechocka-Trocha, Micya Y George, Benjamin R. Bone, Mathias Lichterfeld, Xu G. Yu, Bruce D. Walker, Gaurav Gaiha

331 AGING IMPAIRS HIV RESPONSES IN NEUTROPHILS FROM BLOOD AND THE FEMALE GENITAL TRACT
Laura Moreno de Lara, Anna Borchers, Alexandra Werner, Francisco J. Carrillo-Salinas, Christina Ochsenbauer, Charles R. Wira, Marta Rodriguez Garcia

332 EARLY ART TREATMENT PREVENTS B CELL LOSS AND DYSFUNCTION IN PEOPLE LIVING WITH HIV
Samantha Townsley, Yuwadee Phuang-Nger, Ningbo Jian, David Leggat, Vincent Dussupt, Suteeraporn Pinyakorn, Merlin L. Robb, Suchada Sukhumvitattaya, Julie A. Ake, Sandhya Vasan, Denise Hsu, Nittaya Phanuphak, Shelly Krebs, Alexandra Schuetz
Research Group: RV217 and RV254/RV304 study groups
337  NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI  
Ashley F. George, Tongcui Ma, Min-Gyoun Shin, Reuben Thomas, Mauricio Montano, Satish Pillai, Martin Tolstrup, Ole S. Søgaard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Katherine S. Pollard, Warner C. Greene, Nadia R. Roan

338  CHARACTERIZATION OF TISSUE-RESIDENT NK CELLS IN A TISSUE MODEL OF HIV INFECTION  
David Perea-Pérez, Nerea Sánchez Gaona, Ana Gallego Cortés, Stefania Landolfi, Félix Pumarola, Núria Ortiz, Juan Lorente, Vicenç Falcó, Meritxell Genescà, Maria J Buzon  
Research Group: HIV Translational Research

339  LOW-DENSITY GRANULOCYTES DISPLAY IMMATURE CELLS WITH PRIMED PHENOTYPE IN PLWH  
Juwon Park, Logan Dean, Jack Heckl, Michelle Tallquist, Dominic Chow, Cecilia Shikuma  
Research Group: Hawaii Center for AIDS

Poster Session-D6 SARS-CoV-2 IMMUNOPATHOGENESIS  
2:30 PM - 4:00 PM

340  NK CELLS ARE CRITICAL FOR IN VIVO CONTROL OF SARS-CoV-2 REPLICATION AND DISEASE  
Harikrishnan Balachandran, Rhianna Jones, Kyle Kroll, Cordelia Manickam, Brady Hueber, Matthew Mosher, Andrew Hudson, Karen Terry, Amanda Martinot, Griffin Woolley, R. Keith Reeves

341  SIGLEC-9 RESTRAINS ANTIBODY-DEPENDENT NK CELL CYTOTOXICITY AGAINST SARS-CoV-2  

342  ICAM-1 MEDIATES PLASMACYTOID DENDRITIC CELL SENSING OF SARS-CoV-2-INFECTED CELLS  
Chenrongrong Cai, Tram N. Q. Pham, Eric Cohen

343  POLYFUNCTIONAL SARS-CoV-2-SPECIFIC T CELLS PERSIST IN TISSUE OF COVID19 CONVALESCENTS  
Kyrlia C. Young, Ashley F. George, Matthew McGregor, Xiaoyu Luo, Rebecca Marquez, KaiLin Yin, Tongcui Ma, Trimble Spitzer, Nadia R. Roan

344  HIGH RNAemia ASSOCIATES WITH SKewed T-CELL RESPONSE IN PLWH HOSPITALIZED FOR COVID-19  
Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Silvia Bianchi, Lucia Taramasso, Antonio Di Biagio, AnnaPaola Callegaro, Franco Maggiolo, Elisa Borghi, Antonella D’Arminio Monforte, Giulia C. Marchetti

345  HIGH-RESOLUTION MAPPING OF T-CELL HYBRID IMMUNITY TO THE ENTIRE SARS-CoV-2 PROTEOME  
Raúl Pérez-Caballero, Laia Bernad, Athina Kilpeläinen, Oscar Blanch-Lombarte, Luis Romero, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Josep Maria Manresas-Dominguez, Bonaventura CLOTET, Alex Olvera, Christian Brander, Eva Maria Martinez Caceres, Concepció Violán, Pere Torán-Monserrat, Julia G. Prado
346 **UNIQUE DIFFERENTIATION AND HOMING FEATURES OF T CELLS IN INDIVIDUALS WITH LONG COVID**  
Kailin Yin, Michael J. Peluso, Reuben Thomas, Jason Neidleman, Xiaoyu Luo, Rebecca Hoh, Scott Lu, Sarah A. Goldberg, Sulggi Lee, Kara Lynch, John D. Kelly, Jeffrey Martin, Steven G. Deeks, Timothy Henrich, Nadia R. Roan

347 **LONGITUDINAL CORONAVIRUS ANTIBODY RESPONSES IN AFRICA BETWEEN 2013 AND 2021**  
Yifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, Bradley Beckman, Thembi Mdluli, Allahna L. Esber, Jonah Maswai, John Owwooth, Hannah Kibuuka, Michael Iroezindu, Emmanuel Bahemana, Kayvon Modjarrad, Sandhya Vasan, Julie A. Ake, Morgane Rolland

348 **IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV**  

349 **LYMPHOCYTE TRAJECTORIES AND OUTCOMES OF COVID-19 INFECTION IN PEOPLE WITH HIV**  
Jerry Liu, Richard Medford, Roger Bedimo, John Hanna

350 **CHRONIC HIV INFECTION IMPACTS THE IMMUNE RESPONSE DURING ACUTE SARS-CoV-2**  
Skye Opsteen, Tim Fram, Nathan Erdmann, Dustin M. Long

351 **PRIOR SARS-CoV-2 INFECTION PROTECTS AGAINST SYMPTOMATIC COMMON COLD CORONAVIRUSES**  
David Bean, Janet Monroe, Janice Weinberg, Manish Sagar

352 **RESPIRATORY DISEASE FACTORS LINK WITH REDUCED SARS-CoV-2 SUSCEPTIBILITY IN PWH**  
Irene A. Abela, Anthony Hauser, Chloe Pasin, Magdalena Schwarzmüller, Huldrych F. Günthard, Alexandra Trkola, Roger Kouryos  
**Research Group:** Swiss HIV Cohort Study

353 **DELINEATING FACTORS ASSOCIATED WITH ASYMPTOMATIC PRIMARY SARS-CoV-2 INFECTION**  
Irene A. Abela, Chloe Pasin, Magdalena Schwarzmüller, Agne Ulyte, Radtke Thomas, Audige Annette, Huber Michael, Berger Christoph, Barbara Hasse, Peter Ruset, Huldrych F. Günthard, Roger Kouryos, Milo Puhan, Kriemler Susi, Alexandra Trkola

354 **HIGHER SPIKE GENETIC DIVERSITY OF DELTA/OMICRON VARIANTS IN IMMUNOCOMPROMISED HOSTS**  

Poster Session-E1 CONTROLLERS AND POSTTREATMENT CONTROLLERS  
2:30 PM - 4:00 PM

380 **CD103 EXPRESSION ON CD8 T CELLS PREDICTS LONGER TIME REBOUND OF HIV AFTER ATI**  
Tongcui Ma, Ashley F. George, Min-Gyoung Shin, Mauricio Montano, Satish Pillai, Katherine S. Pollard, Jonathan Z. Li, Davye M. Smith, Steven G. Deeks, Reuben Thomas, Warner C. Greene, Nadia R. Roan
381 THE CIRCULATING CELL-FREE DNA METHYLOME PREDICTS HIV POST-TREATMENT CONTROL
Akshay Gala, Zain Dossani, Prerna Dabral, Michael J. Peluso, Steven G. Deeks, Jonathan Z. Li, Satish K. Pillai

382 WHICH ENDPOINT TO CHOOSE DURING ANTIRETROVIRAL TREATMENT INTERRUPTION?
Rodolphe Thiebaut, Marie Alexandre, Mélanie Prague, Yves Levy
Research Group: ANRS 118 ILLIAD, ANRS 149 VRI02 LIGHT, ANRS VR1 DALLIA trials

383 PREEXISTING HOST EPIGENETIC STATES ASSOCIATED WITH HIV REBOUND KINETICS
Michael Corley, Nathalia Mantovani, Leila Giron, Alina Pang, Juliana Galinskas, Danilo Dias, Paolo Ferreira, Gisele Gousoen, James Hunter, Andrea Savarino, Ricardo Diaz, Lishomwa Ndlovu

384 PARTICIPANT EXPERIENCES IN A CURE-DIRECTED LONG-TERM ANALYTIC TREATMENT INTERRUPTION
Eion Plenn, Frances K. Barg, Katharine Rendle, Andrea Bilger, William B. Carter, Andrea Lamour-Harrington, Christopher Roebuck, Beth Peterson, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dube

385 PLASMA CD33 LEVEL IS A MARKER OF VIRUS CONTROL POST-KICK-AND-KILL CURE INTERVENTION
Clara Duran Castells, Anna Prats, Bruna Oriol Tordera, Anuska Llano, Cristina Galvez, Javier Martinez Picado, Ester Ballana, Edurne Garcia-Vidal, Bonaventura Clotet, Jose A. Munoz Moreno, Tomas Hanke, Jose Moltó, Beatriz Mothe Pujades, Christian Brandler, Marta Ruiz Riol

386 COMPREHENSIVE ANALYSIS OF VIRAL RESERVOIRS IN HIV-INFECTED ELITE CONTROLLER

387 PREDICTORS OF HIV REBOUND AFTER INTERRUPTION OF ART STARTED DURING PRIMARY INFECTION
Antoine Chaillon, Caroline Ignacio, Merle Schanz, Tingting Yu, Rui Wang, Roger D. Koyos, Gemma Caballero, Noah Gaitan, Stephen Rawlings, Celsa Spina, Herbert Kuster, Karin Metzner, Huldrych F. F. Günthard, Davey M. Smith, Sara Gianella Weibel

Poster Session-E2 DYNAMICS OF THE HIV RESERVOIR
2:30 PM - 4:00 PM

388 SHORT- AND LONG-TERM DYNAMICS OF SIV-INFECTED CELL POPULATIONS ON ART
Emily Fray, Fengting Wu, Francesco R. Simonetti, Carolin Zitzmann, Narmada Sambaturu, John Ventura, Thomas Leitner, Ruy Ribeiro, Alan S. Perelson, Dan Barouch, Janet M. Siliciano, Robert F. Silicianon

389 PRESENTATION OF COGNATE ANTIGENS BY DENDRITIC CELLS CAUSES STOCHASTIC HIV EXPRESSION
Milica Moskovljevic, Filippo Dragoni, Hao Zhang, Fengting Wu, Nathan L. Board, Jun Lai, Rebecca Hoh, Steven G. Deeks, Luis J. Montaner, Janet M. Siliciano, Robert F. Siliciano, Francesco R. Simonetti

390 STABILITY AND INSTABILITY OF THE CELLULAR HIV RESERVOIR AFTER REBOUND DURING ATI
Vincent Wu, Jayme Nordin, Son Nguyen, Katharine Bar, Laura Vella, Michael R. Betts
ACK OF DETECTABLE ONGOING REPLICATION ON ART IN SIV-INFECTED RHESUS MACAQUES
Taina T. Immonen, Christine M. Fennessey, Brandon F. Keele

SLOWING OR REVERSAL OF DECAY OF INTACT PROVIRUSES OVER 2 DECADES OF SUPPRESSIVE ART
Research Group: AIDS Clinical Trials Group A5321 Team

DIFFERENTIAL TRANSCRIPTION LEVELS OF HIV-1 FULL-LENGTH AND HIGHLY DELETED PROVIRUSES
Thuy Thi Thu Nguyen, Lindsey Adams, Mary-Elizabeth Zipparo, Annie Glassy, Erin Madeen, Ulisses Santamaria, Catherine Rehm, Jessica Earhart, Wei Shao, Chuen-Yen Lau, Frank Maldarelli

HUMAN GALECTIN-9 PROMOTES THE EXPANSION OF HIV RESERVOIRS IN VIVO IN HUMANIZED MICE
Zhe Yuan, Leila Giron, Colin Hart, Kwasi Gyampoh, Jane Koshy, Kai Ying Hong, Toshiro Niki, Thomas Premeaux, Lishomwa Ndhlovu, Luis J. Montaner, Mohamed Abdel-Mohsen

DIFFERENTIAL TRANSCRIPTION LEVELS OF HIV-1 FULL-LENGTH AND HIGHLY DELETED PROVIRUSES
Thuy Thi Thu Nguyen, Lindsey Adams, Mary-Elizabeth Zipparo, Annie Glassy, Erin Madeen, Ulisses Santamaria, Catherine Rehm, Jessica Earhart, Wei Shao, Chuen-Yen Lau, Frank Maldarelli

HUMAN GALECTIN-9 PROMOTES THE EXPANSION OF HIV RESERVOIRS IN VIVO IN HUMANIZED MICE
Zhe Yuan, Leila Giron, Colin Hart, Kwasi Gyampoh, Jane Koshy, Kai Ying Hong, Toshiro Niki, Thomas Premeaux, Lishomwa Ndhlovu, Luis J. Montaner, Mohamed Abdel-Mohsen

PERSISTANCE OF INDUCIBLE REPLICATION-COMPETENT HIV-1 AFTER LONG-TERM ART
Natalie F. McMyn, Joseph Varriale, Jun Lai, Anushka Singhal, Mauro A. Garcia, Vivek Hariharan, Brianna Lopez, Robert F. Siliciano, Janet M. Siliciano

IN-DEPTH TRANSCRIPTOMIC ANALYSIS OF THE TRANSLATION-COMPETENT HIV-1 RESERVOIR
Marion Pardons, Basiel Cole, Laurens Lambrechts, Willem van Snippenberg, Sofie Rutsaert, Ytse Noppe, Nele De Langhe, Annemieke Dhondt, Jerel Vega, Erik Nijs, Ellen Van Gulck, Daniel Boden, Linos Vandekerckhove

DIFFERENTIATION ENHANCES REACTIVATION OF HIV-1 IN CD4+ T CELLS AFTER LONG-TERM ART
Yury V. Kuzmichev, Krupa Subramanian, Sonia Bakkour, Carol Lackman-Smith, Mars Stone, Christina H. Mallarino-Haeger, Roger G. Ptak, Michael P. Busch, Elizabeth R. Wonderlich, Deanna A. Kulpa

A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV
Zichong Li, Melanie Ott, Warner C. Green
Research Group: The HOPE Collaboratory

CCNT1 IS A NONESSENTIAL GENE IN JURKATT CELLS REQUIRED FOR HIV RELEASE FROM LATENCY
Terry L. Hafer, Emily Hsieh, Carley Gray, Michael Emerman
441 ncRNA PROFILE IN EXTRACELLULAR VESICLES REVEALS A POTENTIAL MECHANISM OF HIV-CONTROL
Maria A. Navarrete-Muñoz, Ignacio Maillo, Héctor Peinado, Ricardo Ramos, María L. García-Gil, Alfonso Cabello, Miguel Górgolas, José M. Benito, Norma Rallón

442 c-Myc AND NR4A REGULATE STOCHASTIC REACTIVATION OF LATENT HIV-1
Rajiv Pathak, Annalena La Porte, Carolina Eliscovich, Estah L. Bock, Laura J. Martins, Adam Spivak, Masako Suzuki, Vicente Planelles, Robert H. Singer, Ganjam V. Kalpana

443 HIV TEM-SEQ: TARGETED ENZYMATIC METHYLATION SEQUENCING OF HIV-1 PROVIRUSES
Alina Pang, Lishomwa Ndhlouvo, Michael Corley

444 EX-VIVO IMPACT OF LRAa AND SPECIFIC LIGANDS ON ESTROGEN RECEPTOR IN CD4+ T CELLS
Cristina Ceriani, Anthony Abeyta-Lopez, Kena J. Lemu, Brigitte Allard, Katherine S. James, David Margolis, Nancie Archin

445 ENHANCED HIV-INDUCED LINEAGE TRACING REPORTER SYSTEM REVEALS EARLY LATENCY PHENOTYPE
Don Nguyen, Namita Satija, Tia Robinson, Gerrit Schmidt, Foramben Patel, Benjamin K. Chen

446 TARGETING 2 NEUTRAL SPHINGOMYELINASE 2 PROMOTES DEATH OF HIV-INFECTED CELLS
Seung-Wan Yoo, Abdul A. Waheed, Pragnay Deme, Rana Rais, Ajit Thomas, Matthew D. Smith, Peter A. Calabresi, Eric O. Freed, Barbara S. Slusher, Norman J. Haughey

447 DPP9 INHIBITION ENHANCES NNRTI-MEDIATED CLEARANCE OF HIV-1 LATENT RESERVOIRS
Kolin Clark, Josh Kim, Qiankun Wang, Liang Shan

448 INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK) INHIBITION PREVENTS HIV LATENCY REVERSAL
Prerna Dabral, Li Du, Mohamed Bouzidi, Richard Miller, Steven G. Deeks, Satish K. Pillai

Poster Session-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV 2:30 PM - 4:00 PM

460 COGNITIVE TRAJECTORIES AMONG PEOPLE WITH HIV MODELED BEFORE AND AFTER SUSTAINED ART
Robert Paul, Jacob Bolzenius, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Kevin Robertson, Ann Duerre

461 THE COURSE OF NEUROCOGNITIVE PERFORMANCE OVER FOUR YEARS IN WELL-TREATED PLWH
José Damas, Bruno Ledergerber, Mélanie Bieler-Aeschlimann, Philip Tarr, Marcel Stöckle, Hachfeld Anna, Alexandra Calmy, Frédéric Assal, Patrick Schmid, Thomas Hundsberger, Caroline Di Benedetto, Barbara Hasse, Renaud Du Pasquier, Katherine Darling, Matthias Cavassini
Research Group: Swiss HIV Cohort Study

462 NEUROCOGNITIVE IMPAIRMENT NEGATIVELY AFFECTS VIRAL CONTROL IN ART-TREATED PWH
Mattia Trunfio, Elisa Vuaran, Daniela Vai, Alessandro Di Stefano, Daniele Imperiale, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno
463 ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS
Nicholas Bakewell, Caroline Sabin, Patrick Mallon, Memory Sachikonye, Nicki Doyle, Alan Winston, Ken M. Kunisaki

Poster Session-F2 INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV
2:30 PM - 4:00 PM

464 VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 6 YEARS OF ART
Kathryn Holroyd, Carlo Sacdalan, Suteeraporn Pinyakorn, Varaporn Unsombut, Somchai Sripriench, Robert Paul, Nittaya Phanuphak, Denise Hsu, Sandhya Vasan, Serena Spudich, Phillip Chan
Research Group: RV254/SEARCH 010 Study Team

465 NON-CLASSICAL MONOCYTES CORRELATE NEGATIVELY WITH HIV-ASSOCIATED COGNITIVE IMPAIRMENT

466 COCAINE USE INDEPENDENTLY PREDICTS WHITE MATTER LESION BURDEN IN HIV DISEASE
Christina Meade, Ryan Bell, Sheri Towe, Christopher Lascola

467 EXTRACELLULAR VESICLES IN ALWH PROMOTE CEREBRAL ENDOTHELIAL PROFILES LINKED TO STROKE
Hannah Fandl, Vinicius Garcia, Kelly Stockelman, William Hollenbach, John Treuth, Aubrey Berry, Hannah Cardenas, Noah Desouza, Cynthia Finnhaber, Jared Greiner, Brian Stauffer, Elizabeth Connick, Christopher Desouza

468 NEUROFILAMENT LIGHT IS ASSOCIATED WITH CARDIORESPIRATORY AND METABOLIC HEALTH IN HIV
Sarah Cooley, Beau Ances

Poster Session-F3 ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES
2:30 PM - 4:00 PM

469 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV

470 DTG IMPACTS ZEBRAFISH BEHAVIOUR THROUGH DOPAMINERGIC PATHWAYS: RESCUE BY FOLATE
Daniela Zizioli, Sara Ferretti, Luca Mignani, Samuele Storti, Isabella Zanella, Francesco Castelli, Eugenia Quiros-Roldan

471 DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV
Poster Session-F8 POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV

2:30 PM - 4:00 PM

492 POST-COVID COGNITIVE IMPAIRMENT MRI BRAIN SCAN ABNORMALITIES: A POTENTIAL BIOMARKER
Joga Chaganti, Lucette Cysique, Xin Zhang, Benjamin Heng, David Darley, Anthony Byrne, Chansavath Phetsouphanh, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, Bruce Brew
Research Group: St Vincent’s Centre for Applied Medical Research

493 COGNITIVE, MOTOR, & NEGATIVE VALENCE SYSTEMS IN NEUROLOGIC PASC: A PRELIMINARY STUDY
Lindsay S. McAlpine, Raha M. Dastgheyb, Jennifer Chiarella, Robert K. Fulbright, Todd Constable, Cheryl Lacadie, Jennifer Yoon, Hailey Reisert, Shelli Farhadian, Serena Spudich, Leah H. Rubin
Research Group: The COVID Mind Study

494 CHARACTERISTICS AND OUTCOMES OF COVID-19 IN AN EARLY-TREATED HIV COHORT IN THAILAND
Ferron F. Ocampo, Misti Paudel, Carlo Sacdalan, Suteeraporn Pinyakorn, Suwanna Puttamaswin, Somchai Sriplienchan, Robert Paul, Nittaya Phanuphak, Phillip Chan, Denise Hsu, Serena Spudich
Research Group: RV254/SEARCH010 Study Team

495 TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV
Alisha Dziarski, Nuria Gallego Marquez, Armaan Jamal, Samantha N. Walch, Arianna Romero, Mariana Araujo-Pereira, Artur T L Queiroz, Christina Bunch, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay, Tracy Vannorsdall, Annukka A R. Antar

496 INFLAMMATORY AND BLOOD-BRAIN BARRIER MARKERS AFTER COVID-19 AMONG PEOPLE WITH HIV
Daniel Adesse, Maria L. Alcaide, Deborah Jones Weiss, Michal Toborek

Poster Session-G1 IMPORTANT ISSUES IN CLINICAL PHARMACOLOGY

2:30 PM - 4:00 PM

497 MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPPRESSED PWH
Ryan Vargo, Seth Robey, Xiaowei Zang, Lihong Du, Bhargava Kandala, Jessica Roberts, Stephanie O. Klopf, Kathleen E. Squires

498 ESTRADIOL CONCENTRATIONS IN TRANS WOMEN ON InSTIs COMPARED TO THOSE WITHOUT HIV
Mona Loutfy, Ashley Lacombe-Duncan, Yasmeen Persad, Ian Armstrong, Raymond Fung, Kimberly K. Scarsi, Alice Tseng, Louie Chan, Quang Nguyen, Thea Weisdorf, Sue Hranilovic, Roberta Halpeny, Ninarini Jeyarajah, George Kovchazov, Harshita Iyer

499 N6LS WITH rHuPH20 ENABLES SAFE HIGH-DOSE MONOCLONAL ANTIBODY SUBCUTANEOUS DELIVERY
Research Group: VRC 609 Study Team

500 TFV-DP & FTC-TP IN BLOOD CELL SUBSETS OF PERSONS WITH HIV
Vincent A. Mainella, Jose R. Castillo Mancilla, Brian Branchford, Travis Nemkov, Seth Hosford, Bethany Johnson, Ye Ji Choi, Pang Xiong, Martin Williams, Jia-Hua Zheng, Lucas Ellison, Lane Bushman, Jennifer Kiser, Peter L. Anderson, Kristina M. Brooks

CME Continuing Medical Education Late-Breaking New Investigator Scholarship Poster Sessions NP Anastashevski Presenter

CROI 2023
501 IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE
Yeleen Fromage, Najwa Jamal, Cyrielle Codde, Jean-François Faucher, Jean-Baptiste Woillard

502 SCREENING APPROACHES AND CLINICAL DESCRIPTION OF THE ANTICHOLINERGIC BURDEN IN PWH
Maria Mazzitelli, Mattia Trunfio, Alessandra Coin, Lolita Sasset, Jacopo Farina, Monica Brundu, Vincenzo Scaglione, Giuseppe Sergi, Anna Maria Cattelan

503 PHARMACOKINETICS & SAFETY OF SUSTAINED-RELEASE FLUCYTOSINE PELLET FORMULATION
Edrich Krantz, Francois Simon, Jean-Yves Gillon, Amaria Saayman, Anousk Neven, Stephen Robinson, Johanna Eriksson, Sarika Victor, Carol Ruffell, Aljosa Celebic, Henri Captain, Mathieu Louis, Vishal Goyal, Isabela Ribeiro
Research Group: SFC-HIV-CRYPTO Consortium

504 POPULATION PK ANALYSIS TO GUIDE DOSING WINDOW FOLLOWING LENACAPAVIR SC ADMINISTRATION
Naveed A. Shaik, Francesco Bellanti, Craig Comisar, Martin S. Rhee, Sandhya Girish, Ramesh Palaparthi, Renu Singh

Poster Session-H3 ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH
2:30 PM - 4:00 PM

528 HIGH SUPPRESSION AMONG PLHIV ON DOLUTEGRAVIR WITH VIROLOGICAL FAILURE IN UGANDA
Grace Namayanja, Juliana de Fatuma Da Silva, Elur Bill, Pamela Nasirumbi Munina, Elliot Raizes, Julius Ssempira, Esther Nazziwa, Miriam Nabukinya, Jennifer Balaba, Matali Jonathan, Jackie Calnan, Estella Birabwa, Juliet Akao, Christina Mwangi, Emilio Diirkov

529 EARLY VIROLOGICAL OUTCOME OF DTG-BASED REGIMEN IN ADULT ARV-NAIVE PLHIV IN RWANDA
Simeon Tuyishime, Bienvenu Niyongabo, Michel Gasana, Madeleine M. Uwungutse, Damascene J. Nirere, Benjamin Bizimana, Gallican N. Rwibasira, Samuel Malamba

531 TRENDS IN TDR TO FIRST-LINE ANTIRETROVIRALS IN SPAIN: 2007-2021
Laura Viñuela, Adolfo de Salazar, Ana Fuentes, Adriana Pinto, José Antonio Iribarren, Mar Masí, Marta Montero, Iker Falces-Romero, Nuria Espinosa, Begoña Baza, Antonio Aguilera, Joaquim Peraire, Rebeca de Miguel, Federico Garcia
Research Group: CoRIS group

532 WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE?
Paul Sax, Joseph J. Eron, Janna Radtchenko, Megan Dunbar, Joshua Gruber, Moshe Fridman, Moti Ramgopal, Karam Mounzer, Gregory Huhn, Steven Santiago, Richard A. Elion

533 ASSOCIATION OF WEIGHT GAIN ON DOLUTEGRAVIR WITH CHANGES IN ADHERENCE AND VIRAL LOAD
Matthew L. Romo, Ajay Parikh, Allahna L. Esber, Joseph S. Cavanaugh, Susannah Colt, Emma Duff, Trevor A. Crowell, Valentine Sing’Oei, John Owuoth, Jonah Maswai, Michael Iroezindu, Emmanuel Bahemana, Hannah Kibuuka, Neha Shah, Julie A. Ake

534 PREDICTIVE VALIDITY OF A MEASURE OF BARRIERS TO ART ADHERENCE FOR HIV CARE (I-SCORE)
Kim Engler, Serge Vicente, David Lessard, Karine Lacombe, Dominic Chu, Hayette Rougier, Lucas Delvallez, Jean-Pierre Routy, Alexandra De Pokomandy, Marina Klein, Bertrand Leboucé
Poster Sessions

535 US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT
Susan M. Graham, Douglas Barthold, Brett Hauber, Aaron Brah, Enrique Saldarriaga, Ann C. Collier, Rodney Ho, Vincent C. Marconi, Jane Simoni
Research Group: Emory PREFER Team

536 ANTIRETROVIRAL THERAPY CONCEALMENT, ADHERENCE, AND PREFERENCES IN PEOPLE WITH HIV
Christina E. Parisi, Rebecca Fisk-Hoffman, Nanyangwe Siuluta, Delaney D. Ding, Maya Widmeyer, Charurut Somboonwit, Robert L. Cook
Research Group: Southern HIV and Alcohol Research Consortium

530 VIROLOGIC FAILURE AFTER ROUTINE SWITCHING TO DTG-BASED FIRST-LINE ART

Poster Session-H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES 2:30 PM - 4:00 PM

542 ZINC ADJUVANT TREATMENT IN SARS-CoV-2: A RANDOMIZED CLINICAL TRIAL
Silvia Gómez-Zorrilla, Juan Du, Elena Sendra, Merce Espona, Ana Siverio, Alicia Rodríguez-Alarcon, Claudia Navarro-Valls, Oriol Rins-Lozano, Esperanza Cañas-Ruano, Itziar Arrieta-Aldea, Alejandro Fierro-Villegas, Cristina Plata, Natalia Garcia-Giralt, Ruben Vicente, Robert Guerri-Fernandez

543 RETHINKING REMDESIVIR: ENHANCING ANTI-SARS-CoV-2 ACTIVITY OF ORAL LIPID RVn PRODRUGS
Aaron Carlin, James Beadle, Alex Clark, Kendra Gully, Fernando Moreira, Ralph Baric, Rachel Graham, Nadejda Valiava, Sandra Leibel, William Bray, Rachel McMillan, Xing-Quan Zhang, Joyce Murphy, Robert Schooley, Karl Hostetler

544 SARS-CoV-2 ANTIVIRAL ACTIVITY OF ZOTATIFIN, A HOST-TARGETING EIF4A INHIBITOR
Sam Sperry, Peggy Thompson, Craig Stumpf, Gary Chiang, Stephen Worland, Amy Patick

545 A PHASE 1B STUDY OF ZOTATIFIN FOR THE TREATMENT OF MILD TO MODERATE COVID (proPel)
Harry Malech, Almena Free, Enola Okonkwo, Patricia Littel, Nicole Rooots, Priscilla Quackenbush, Martha Marquesen, Michael Hodges, Amy Patick, Sam Sperry, Bin Yao, Nawaid Rana, Doug Warner

546 WITHDRAWN

547 SMALL MOLECULE INHIBITOR FOR BLOCKING SARS-CoV-2 ENTRY
Enming Xing, Yuxi Zhang, Rajni Kant Shukla, Jianrong Li, Valarmathy Murugaiah, Xiaolin Cheng, Pui Kai Li, Amit Shama
Research Group: The Ohio State University

548 PLITIDEPSIN IS A BROAD-SPECTRUM ANTIVIRAL SHAPING THE CELL PROTEOSTATIC BALANCE
Research Group: Broad-Spectrum Antivirals Study Group

CME Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter
TARGETING THE HOST-VIRUS INTERFACE TO BLOCK SARS-CoV-2 ASSEMBLY IN AIRWAY CELLS
Li Du, Fred Deiter, Mohamed Bouzidi, Jean-Noël Billaud, Graham Simmons, Prerna Dabral, Suganya Selvarajah, Anuradha Lingappa, Maya Michon, Shaofeng Yu, Kumar Paulvannan, Vishwanath Lingappa, Homer Boushey, John Greenland, Satish K. Pillai

SAFETY AND PHARMACOKINETICS OF A NOVEL DOUBLE PRODRUG ASC10 IN HEALTHY SUBJECTS
Yunqing Qiu, Jian Liu, You Zhai, Qingwei Zhao, Yuemei Yan, Handan He, Jinzi J. Wu

MECHANISM AND RESISTANCE STUDIES OF SARS-CoV-2 MPRO INHIBITOR POMOTRELVIR (PBI-0451)
Xiao Tong, Laura Stevens, Walter Keung, Lee Arnold, Uri Lopatin, Mark Denison, Ann Kwong

SARS-CoV-2 E-PROTEIN ViroP1nIBIT1225 Active IN HaCE2 Transgenic Mice
Michelle Miller, Gary Ewart, Michael Bobardt, Bo Bentzen, Audrey Thomson, Klaus Klumpp, Stephen Becker, Mette Rosenkilde, Gallay Philippe

NAFAMOSTAT AS NASAL CHEMOPROPHYLAXIS FOR SARS-CoV-2 IN HAMSTERS
Megan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Helen Cox, Lee Tatham, Paul Curley, James Hobson, Steve Rannard, Anja Kipar, James Stewart, Andrew Owen
Research Group: CELT Pharmacology

PHASE 1 CLINICAL TRIALS OF A Q-GRiffThSIN NASAL SPRAY FOR SARS-CoV-2 PROPHYLAXIS

NIRMATRELVIR AND MOLNUPIRAVIR COADMINISTRATION MODIFIES PRECLINICAL VIRAL EXPOSURE
Lee Tatham, Henry Pertinez, Megan Neary, Joanne Sharp, Edyta Kijak, Joanne Herriott, Anthony Valentijn, Chloe Bramwell, Helen Cox, Paul Curley, Usman Arshad, Rajith Rajoli, Richard Pleass, James Stewart, Andrew Owen
Research Group: Drugs for Neglected Diseases initiative (DNDi) Study Group

SUSCEPTIBILITY SCREENING TO bNAbs GS-5423 AND GS-2872 IN ART-SUPPRESSED PARTICIPANTS
Lisa Selzer, Laurie A. Vanderveen, Aiyappa Parvangada, Ross Martin, Sean E. Collins, Megha L. Mehrotra, Christian Callebaut

Poster Session-H6 CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION?
2:30 PM - 4:00 PM

Poster Session-I2 HIV RESISTANCE TO NEUTRALIZING ANTIBODIES
2:30 PM - 4:00 PM
581  PHENOTYPIC SUSCEPTIBILITY TO VRC07-523LS AND ITS CORRELATES IN THE ACTG A5357 STUDY
Research Group: AIDS Clinical Trials Group

582  HIGH PREDICTED bNAb RESISTANCE AMONG ADULTS WITH HIV-1 SEROCONVERSION IN BOTSWANA

Poster Session-J5 STEATOSIS AND STEATOHEPATITIS
2:30 PM - 4:00 PM

609  PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV
Louise E. van Eekeren, Marc J. T. Blaauw, Nadira Vadaq, Vasiliki Matzaraki, Wilhelm A. J. W. Vos, Albert L. Groenendijk, Adriana Navas, Gert Weijers, Mike van Der Kolk, Andre J.A.M. van Der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa
Research Group: 2000HIV

610  LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE
Cecile D. Lahiri, Michael Yu, Logan Gering, Cyra C. Mehta, Joffi Musonge-Effoe, Jennifer C. Price, Phyllis C. Tien, Amanda B. Spence, Svenja Albrecht, Maria L. Alcaide, Adaora Adimora, Audrey French, Michael H. Augenbraun, Kathryn Anastos, Jessica A. Alvarez

611  SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE
Dana Kablawi, Tierry Fotsing Tadjo, Jovana Milic, Wesal Elgretli, Claudia Goe, Bertrand Lebouché, Antonio Cacio, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani

612  NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV
Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungsirisap, Thanathip Wichiangsan, Hay Mar Su Lwin, Sivaporn Gateompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsan

613  AUTOMATED LIVER ATTENUATION ASSESSMENT FOR STEATOSIS IN CLINICAL IMAGES BY HIV STATUS
Research Group: Veterans Aging Cohort Study

614  CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD
Wesal Elgretli, Nathalie Paiseble, Cecilia Costiniuk, Joseph Cox, Dana Kablawi, Marina Klein, Nadine Kronfl, Jean-Pierre Routy, Julian Falutz, Giovanni Guaraldi, Bertrand Lebouché, Giada Sebastiani
Poster Session-K3 KAPOSI SARCOMA AND KHSV-RELATED DISEASES: PATHOGENESIS AND TREATMENT
2:30 PM - 4:00 PM

630 RATIONALE FOR THE USE OF PACRITINIB IN KHSV-MULTICENTRIC CASTLEMAN DISEASE
Yiquan Wu, Victoria Wang, Robert Yarchoan

631 IFN-IL18 AXIS CYTOKINES DISCERN MYCOBACTERIAL AND KHSV INFLAMMATORY SYNDROMES IN PWH
Joseph Rocco, Ramya Ramaswami, Kathryn Lurain, Elizabeth Laidlaw, Andrea Lisco, Frances Galindo, Adam Rupert, Denise Whitby, Maura Manion, Robert Yarchoan, Irini Sereti

632 STUDY OF CHARACTERISTICS AND OUTCOMES OF KHSV INFLAMMATORY CYKTOINE SYNDROME (KICS)
Ramya Ramaswami, Kathryn Lurain, Mark Polizzotto, Anaia Widell, Ralph Mangusan, Irene Ekweed, Tishiya Carey, Crystal Lu, Jomy George, Denise Whitby, Thomas Uldrick, Robert Yarchoan

633 KAPOSI SARCOMA IN ART-TREATED PLWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS
Léna Royston, Stephane Isnard, Aude Jarry, Carolina Berini, Tsoarello Mabanga, John Lin, Valentin Leducq, Vincent Calvez, Anne-Geneviève Marcelin, Jean-Pierre Routy

Poster Session-K4 CERVICAL CANCER: SCREENING AND TREATMENT
2:30 PM - 4:00 PM

634 IMPLICATIONS OF CERVICAL CANCER SCREENING AND TREATMENT PROGRAM ROLL OUT IN UGANDA

635 INTEGRATING POINT-OF-CARE HPV TESTING INTO HIV CARE FOR KENYAN WOMEN LIVING WITH HIV
James Kangethe, John Kinuthia, Kenneth Mutai, Jillian Pintye

636 PROGRESS TOWARDS THE ELIMINATION OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV
Laura J. McCormick Viens, Catherine Godfrey, Oluwatosin Adeoye, Ismael Ahmed, Fana Tefera, Michele Montandon, Elizabeth Carter, Michelle Chevalier, Daniel Magesa, Timothy A. Efuntaye, Emily Coard, Catherine Motswere Chirwa, Julius Namonyo Kalamya, Jessica Setswalo Mafa, Brigitte Zemburuka
637  HUMAN PAPILLOMA VIRUS INFECTION PREVALENCE AMONG WOMEN LIVING WITH HIV IN ETHIOPIA
Fana Tefera, Ismael Ahmed, Yared Tedla, Hiwot Berhanu, Daniel Atnafu, Agraw Abdulkadir, Addis Zewdie, Dessie Adugna, Takelech Moges, Daniel M. Desalegn, Hezkiel Petros

646  CORONARY ARTERY PLAQUE COMPOSITION AND SEVERITY RELATE TO THE INFLAMMASOME IN HIV

647  BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV

648  MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE & PHYSICAL FUNCTION IN PWH
Research Group: REPRIEVE Study Team

649  PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV
Borek Foldyna, Thomas Mayrhofer, Markella V. Zanni, Asya Lyass, Tricia H. Burdo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Udo Hoffmann, Heather J. Ribaudo, Joseph Massaro, Michael T. Lu, Pam S. Douglas, Steven K. Grinspoon
Research Group: REPRIEVE Study Team

650  SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV
Celestine N. Wanjalla, Kenji Kawai, Saikat Kumar B. Ghosh, Alok Finn, Renu Virmani, Meghan Hogan, Rama Gangula, Samuel S. Bailin, Mona Mashayekhi, Curtis L. Gabriel, Davey M. Smith, Sara Gianella, David G. Harrison, Simon A. Mallal, John R. Koethe

651  HIGH PLASMA APOE IN PEOPLE WITH HIV COMPARED WITH UNINFECTED CONTROLS
Anne Marie Reimer Jensen, Ruth Frikkie-Schmidt, Marco Gelpi, Thomas Lars Benfield, Børge G. Nordestgaard, Tor Biering-Sørensen, Susanne Dam Poulsen

652  PERFORMANCE OF LDL CHOLESTEROL POLYGENIC RISK SCORE IN INDIVIDUALS WITH HIV INFECTION
Roger S. Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T. Lu, Heather J. Ribaudo, Hilary C. Martin, David A. van Heel, Kathleen V. Fitch, Markella V. Zanni, Pam S. Douglas, Steven K. Grinspoon, Aniruddh P. Patel, Pradeep Natarajan
653  CHOLESTEROL EFFLUX IS REDUCED IN ART TREATED PWH BUT ASSOCIATED WITH SUBCLINICAL CAD


689  ANY LEVEL OF DETECTABLE VIREMIA IS ASSOCIATED WITH SERIOUS NON-AIDS EVENTS

Anuradha Ganesan, Hsing-Chuan Hsieh, Xiuping Chu, Rhonda Colombo, Catherine Berjohn, Tahaniyat Lalani, Jason Blaylock, Karl Kronmann, Jason Okulicz, Brian Agan

Research Group: Infectious Disease Clinical Research Program

690  CD4/CD8 AT 2 YEARS OF ANTIRETROVIRAL THERAPY AND INCIDENCE OF SERIOUS NON-AIDS EVENTS

Javier Martínez-Sanz, Jorge Díaz-Álvarez, Marta Rosas, Raquel Ron, Cristina Roca-Oporto, Carmen Busca, María José Galindo, Miguel Cervero, Roberto Muga, Santiago Moreno, Sergio Serrano-Villar

Research Group: CoRIS

691  SOLUBLE IMMUNOREGULATORY PROTEINS PREDICTIVE FOR COMORBID EVENTS IN PEOPLE WITH HIV

Julen Cadiñanos, Javier Rodríguez-Centeno, Rocio Montejano, Andrés Esteban-Cantos, Beatriz Mena-Garay, María Jiménez-González, Gabriel Saiz-Medrano, Rosa de Miguel, Fernando Rodríguez-Artalejo, José Ignacio Bernardino, Cristina Marcelo-Calvo, Lucía Gutiérrez-García, Patricia Martínez-Martín, Berta Rodes, José R. Arribas, Mario Mayoral-Muñoz

Research Group: AIDS Clinical Trials Group NWCS 411 study team

692  BLOOD TELOMERE LENGTH GAIN IN AVIREMIC PWH: HOW DIFFERENT IS IT FROM PERSONS WITHOUT HIV?

Francesca Lombardi, Alessia Sanfilippo, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Iolanda Mozzetta, Enrica Tamburrini, Simona Di Giambenedetto

693  BLOOD TELOMERE LENGTH GAIN IN PLWH SWITCHING TO DTG+3TC VS CONTINUING TRIPLE REGIMEN

Mark Underwood, James Oyee, Joseph Horton, Tatini Chakraborty, Chris Parry, Ruolan Wang, Jue Lin, Myooran Sithamparanathan, Bryn Jones, Brian Wynne, Choy Man, Andrew Zolopa

694  COMPARISON OF TELOMERE LENGTH CHANGES OVER 48 WEEKS IN SALSA STUDY: DTG/3TC VS CAR

Elke Wynberg, Alvin X. Han, Lisa van Pul, Irma Maurer, Ester van Leeuwen, Anouk Verveen, Hugo van Willigen, Menno D. de Jong, Maria Prins, Neeltje Kootstra, Godelieve de Bree

Research Group: The RECoVERED Study Group
711  CYTOKINE PROFILE IN DIFFERENT POST-COVID-19 CONDITION PHENOTYPES
   Maria Nevot, Francisco Muñoz-López, Marina Martínez-Velasco, Macedonia Trigueros, Sergio España-Cueto, Gemma Lladós, Cora Loste, Cristina Lopez, Jose Ramon Santos, Ruth Toledo, Bonaventura Clotet, Roger Paredes, Lourdes Mateu, Marta Massanella

712  NEW ONSET AUTOIMMUNE DISEASE MORE COMMON AFTER COVID-19
   Corrilynn O. Hileman, Nirav T. Patil, Grace A. McComsey

713  INCIDENT NEW ONSET DIABETES AFTER COVID-19 INFECTION: A NATIONAL MULTICENTER COHORT
   Sokratis N. Zisis, Jared C. Durieux, Jamie A. Perez, Christian Mouchati, Mary Chong, Betul Hatipoglu, Grace A. McComsey

714  WORSE ARTERIAL STIFFNESS, AND NOT ENDOTHELIAL DYSFUNCTION, IS ASSOCIATED WITH PASC
   Sokratis N. Zisis, Jared C. Durieux, Christian Mouchati, Mary Chong, Danielle Labbato, Grace A. McComsey

715  OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS
   Lucette Cysique, Faye Yang, Amy Regan, Valerie Bramah, Benjamin Heng, Sharron Chow, David Darley, Anthony Byrne, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, Bruce Brew

716  OLFACTORY FUNCTION AND BRAIN STRUCTURAL EFFECTS FOLLOWING SARS-CoV-2 INFECTION
   Erin E. O'Connor, Nikita Rednam, Andrea Levine, Thomas Zeffiro, James Becker

717  SEX MODIFIES THE EFFECT OF COVID-19 AND PASC STATUS ON ARTERIAL STIFFNESS
   Jared C. Durieux, Sokratis N. Zisis, Christian Mouchati, Mary Chong, Jamie C. Perez, Grace A. McComsey

718  INCIDENCE OF LONG COVID SYMPTOMS IN PATIENTS PREVIOUSLY HOSPITALIZED FOR COVID-19
   Mark Berry, Amanda Kong, Julie Paone, Rohan Shah, Rebecca Taylor, Essy Mozaffari, Rikisha Gupta, Jason Goldman, Anand Chokkalingam

719  FACTORS ASSOCIATED WITH LONG COVID-19 IN ZAMBIA, 2020 TO 2022
   Warren Malambo, Lily Besa, Duncan Chanda, Danielle Engamba, Linos Mwiinga, Mundia Mwitumwa, Jonas Hines, Sombo Fwoloshi

720  15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS
   Max Augustin, Melanie Stecher, Hauke Wuestenberg, Veronica Di Cristanziano, Elisabeth Pracht, Dominic Rauschnig, Henning Gruell, Florian Klein, Michael Hallek, Philipp Schommers, Clara Lehmann

721  POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL
   Research Group: ACTIV-2/A5401 Study Team
722 SYMPTOMS AND BIOMARKERS OF LONG COVID IN PEOPLE LIVING WITH AND WITHOUT HIV
Annukka A R. Antar, Nuria Gallego Marquez, Armaan Jamal, Alisha Dziarski, Jia Fu, Samantha N. Walch, Arianna Romero, Artur T L Queiroz, Mariana Araújo-Pereira, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay

723 SEVERITY CLUSTERS AND LIKELIHOOD OF RECOVERY FROM POST-COVID-19 CONDITION
Lourdes Mateu, Christian Tebe, Cora Loste, Cristina López, Sergio España, José Ramón Santos, Gemma Lladós, Maria Nevot, Francisco Muñoz-López, Bonaventura Clotet, Roger Paredes, Marta Massanella

Poster Session-01 PREDICTORS OF TB TREATMENT OUTCOMES
2:30 PM - 4:00 PM

741 ADVERSE DRUG REACTIONS ON TB TREATMENT: A PREDICTION MODEL INCLUDING HIV AND HBA1C
Felipe Ridolfi, Lauren Peetluk, Gustavo Amorim, Mariana Araújo-Pereira, Marcelo Cordeiro-Santos, Afranio Kritski, Marina Figueiredo, Bruno B. Andrade, Valeria Rolla, Timothy R. Sterling
Research Group: Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil consortium

743 ISONIAZID TOXICITY AMONG PWH WITH LATENT TB WHO CONSUME ALCOHOL: A SINGLE ARM TRIAL
Judith A. Hahn, Christine Ngabirano, Robin Fatch, Nneka Emenyonu, Debbie M. Cheng, Julian Adong, Adah Tumwegamire, Karen Jacobson, Benjamin Linas, Kendall Bryant, Winnie Muyindike

744 RISK FACTORS FOR ADRS RELATED TO IPT AMONG PLHIV ON DOLUTEGRAVIR-BASED ART IN UGANDA
Stella Z. Muyanja, Joseph Musaazi, Esther Nalugga, Eva Laker, Nelson Kalema, Barbara Castelnuovo, Mary G. Mudiope, Grace Namayanja, Deus Lukoye, Mukela C. Manabe

740 TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS
Rob van Wijk, Vincent Chang, Marjorie Imperial, Patrick Phillips, Susan Swindells, Richard Chaisson, Payam Nahid, Rodney Dawson, Ian Sanne, Ziyaad Waja, Susan Dorman, Ekaterina Khubatova, Rada Savic
Research Group: Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team

742 PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS

745 TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT
Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stembridge Mpemba, Lihle McHunu, Dophina Cogill, Pren Naidoo, Catherine Orrell, Catherine Orrell
Poster Session-02 OUTCOMES ASSOCIATED WITH OPPORTUNISTIC INFECTIONS IN THE CURRENT ERA
2:30 PM - 4:00 PM

746 HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA
Firdaus Nabeemeeah, Kennedy Otmwome, Khadhazo Hlongwane, Nadia Sabet, Pattamukkil Abraham, Alex Van Blydenstein, Phetho Mangena, Ebrahim Variava, Neil Martinson
747  **LONG-TERM OUTCOMES OF PNEUMOCYSTIS JIROVECCI PNEUMONIA IN THE ANTIRETROVIRAL ERA**  
Brian Epling, Maura Manion, Arlene Sirajuddin, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Anela Kellogg, Irini Sereti

748  **RISK FACTORS ASSOCIATED WITH NEURO-COGNITIVE IMPAIRMENT IN CRYPTOCOCCAL MENINGITIS**  
Laura J. Nsangi, Mahsa Abassi, David B. Meya, David R. Boulware, Biyue Dai, Darlisha A. Williams, Kenneth Ssebambulidde, Lillian Tugume, Edwin Nuwagira, Abdu Musubire

749  **CEREBROSPINAL FLUID PROTEIN CLINICAL IMPACT IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS**  

**Research Group:** ASTRO-cm group

---

**Poster Session-P5 NOVEL UNDERSTANDINGS OF BIRTH OUTCOMES WITH ART**  
2:30 PM - 4:00 PM

787  **ANGIOGENIC BIOMARKERS OF POOR OUTCOMES IN PREGNANT WOMEN WITH HIV IN BOTSWANA**  
Caroline E. Dunk, Kathleen M. Powis, Justine Legbedze, Shan Sun, Keoleboqile Mmasa, Samuel W. Kgole, Gosego Masasa, Sinkilile Moyo, Terence Mohammed, Lynn Yee, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides

788  **DOLUTEGRAVIR EXPOSURE AND CONGENITAL ANOMALIES IN SUB-SAHARAN AFRICA**  
Rena Patel, Ushma Mehta, John Humphrey, Emma Kalk, Alexa Heekes, Audrey Chepkemoi, Steve Brown, Beverly Musick, Constantin Yianoutsos, Edwin Were, Andrew Boulle, Mary-Ann Davies, Kara Wool-Waloustian

**Research Group:** IeDEA Multiregional MANGO Collaboration

789  **ALLOSTATIC LOAD AND SPONTANEOUS PRETERM BIRTH AMONG WOMEN WITH HIV IN LUSAKA, ZAMBIA**  
Joan T. Price, Yuri Sebastiao, Katelyn Rittenhouse, Humphrey Mwape, Bellington Vwalika, Mwansa Ketty Lubeya, Margaret Kasaro, **Kristina De Paris**, Jeffrey Stringer

790  **NEURAL TUBE AND OTHER BIRTH DEFECTS BY HIV STATUS AND ART REGIMEN IN ESWATINI**  
Michelle M. Gill, Philsiwhe Khumalo, Caspian Chouraya, Mthokozisi Kunene, Futhi Dlamini, Heather J. Hoffman, Angela E. Scheuerle, Bonisile Nhlabatsi, Wiseman Mgometulu, Lynne Mofenson

791  **VAGINAL INFLAMMATORY MARKERS ASSOCIATED WITH PRETERM BIRTH IN ZAMBIA WOMEN WITH HIV**  
Dominique Davis, Hazel Milla, Humphrey Mwabe, Yuri Sebastian, Margaret Kasara, Bellington Vwalika, Joan T. Price, Kristina De Paris, Jeffrey Stringer

792  **MATERNAL ART USE AND PRETERM DELIVERY: THE IMPACT OF DATA SOURCES AND DATA QUALITY**  
793 PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES
Kathleen M. Powis, Caroline E. Dunk, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Justine Legbedze, Shan Sun, Sikhulile Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides

797 HIV-EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES
Li Yin, Bernard Fischer, Guglielmo Venturi, Upasana Nepal, Shivangi Choudhary, Jerry Shen, Kai-Feng Chang, Isaac Raplee, Samiksha Borkar, Julie Kim-Chang, Kristina De Paris, Maureen Goodenow, John Sleasman

798 NO EVIDENCE OF PERTURBATIONS OF THE BREAST MILK MICROBIOME BY ANTIRETROVIRAL THERAPY
Nicole H. Tobin, Fan Li, Sean Brummel, Patricia Flynn, Sufia Dadabhai, Dhayendre Moodley, Lameck Chinula, Mandisa Nyati, Mary Glenn Fowler, Grace Aldrovandi
Research Group: 1077BF/1077FF PROMISE (Promoting Maternal and Infant Survival Everywhere) Team

799 RBC FOLATE CONCENTRATIONS IN MOTHERS/INFANTS RANDOMIZED IN PREGNANCY: DTG VS EFV
Denise L. Jacobson, Krista Crider, Patricia Demarrais, Sean Brummel, Mindy Zhang, Christine Pfeiffer, Cynthia Moore, Katie McCarthy, Sikhulile Moyo, Tichaona Vhembo, Enid Kabugho, Gerald Muzorah Agaba, Nahida Chakhtoura, Lameck Chinula, Shaihin Lockman

800 EFFECT OF IN-UTERO HIV AND ANTIRETROVIRAL THERAPY EXPOSURE ON GROWTH DURING INFANCY
Ashenafi S. Cherko, Sylvia M. Lacourse, John Kinuthia, Jerphason Mecha, Daniel A. Enquobahrie, Jaclyn Escudero, Grace John-Stewart

801 IPT DURING INFANCY HAS NO ADVERSE EFFECT ON GROWTH AMONG HEU CHILDREN
Ashenafi S. Cherko, Sylvia M. Lacourse, Daniel A. Enquobahrie, Jaclyn Escudero, Jerphason Mecha, Daniel Matemo, John Kinuthia, Grace John-Stewart

802 IMPACT OF IN-UTERO EXPOSURE TO HIV AND LATENT TB ON INFANT HUMORAL RESPONSES
Kimberly Shankwitz, Lesley de Armas, Grace Montepiedra, Suresh Pallikkuthy, Lynda Stranix-Chibanda, Gaerolwe Masheto, Philippa Musoke, Enid Kabugho, Jyoti Mathad, Renee Browning, Rajendra Pahwa, Galit Alter, Adriana Weinberg, Amita Gupta, Savita Pahwa
Research Group: for the IMPAACT P1078/TB APPRISE Study Team

803 LOWER ACADEMIC PERFORMANCE AMONG CHILDREN WITH PERINATAL HIV EXPOSURE IN BOTSWANA
Kathleen M. Powis, Lesedi Lebanna, Sara Schenkel, Gosego Masasa, Samuel W. Kgole, Martha Ngwaca, Paige L. Williams, Amy L. Slogrove, Roger L. Shapiro, Shahin Lockman, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Adam R. Cassidy

804 PSYCHIATRIC DISORDERS IN HIV-EXPOSED UNINFECTED VS NON-HIV-EXPOSED CHILDREN
Ellen Moseholm, Sammy Ameri, Merete Storgaard, Gitte Pedersen, Isik S. Johansen, Terese L. Katzenstein, Nina Weis

Poster Sessions
CROI 2023
805 EVALUATING ASSOCIATIONS BETWEEN IN UTERO HIV/ART EXPOSURE AND PUBERTAL STATUS
Lena Serghides, Denise L. Jacobson, Jessica Lee, Mitchell E. Geffner, Elizabeth J. McFarland, Linda Dimeglio, Kathleen M. Powis, Paige L. Williams, Jennifer Jao
Research Group: Pediatric HIV/AIDS Cohort Study

826 PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/r GRANULES IN NEONATES: PETITE STUDY
Adrie Bekker, Helena Rabie, Nicolas Salvadori, Samantha Du Toit, Kanchana Than-In-At, Maria Groenewald, Edmund Capparelli, Ratchada Cresssey, Marc Lallemant, Mark Cotton, Tim R. Cresssey
Research Group: PETITE Study Team

827 TWICE DAILY 50 MG DOLUTEGRAVIR IN TUBERCULOSIS-HIV COINFECTED CHILDREN 20-35 KG
Anushka Naidoo, Kogieleum Naidoo, Gabriella Cromhout, Marothi Letsoalo, Mounir Almett, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Kelly E. Dooley, Moherdran Archary

828 CAREGivers of CHILDren with HIV in Botswana Prefer MONTHLY IV bNAbs TO DAILY ORAL ART
Maureen Mosetlhi, Gbolahan Ajibola, Roxanna Haghighat, Oganne Batlang, Kenneth Marshawi, Molly Pretorius Rolme, Kathleen M. Powis, Shahin Lockman, Joseph Makhema, Mathias Lichterfeld, Daniel Kuritzkes, Roger L. Shapiro

829 SIX-MONTH OUTCOME OF F/TAF COBICISTAT-BOOSTED DARUNAVIR IN CHILDREN 14 TO < 25KG
Hilda A. Mujuru, Renate Strehlau, Natella Rakhmanina, Kulkanya Chokephaibulkit, Pope Kosalaraksa, Vinicius Vieira, Kathryn Kersey, Rory Leisegang, Shaolan Xiang

830 BIC/FTC/TAF IN FRENCH CHILDREN: FREQUENT VIRAL FAILURE BUT RARE ACQUIRED RESISTANCE
Pierre Frange, Florence Veber, Stephane Blanche, Veronique Avettand-Fenoel

831 ADEQUATE DTG EXPOSURE IN INFANTS ON RIFAMPICIN TREATMENT RECEIVING TWICE-DAILY DTG
Tom G. Jacobs, Vivian Mumbiro, Uneisse Cassia, Damalie Nalwanga, Kevin Zimba, Sara Dominguez, Constantine Mutata, W. Chris Buck, Chishala Chabala, Victor Musime, Mutsa Bwakura-Dangarembizi, Cinta Moraleda, David Burger, Pablo Rojo, Angela Colbers, Hilda A. Mujuru
Research Group: EMPIRICAL clinical trial group

832 MODEL-INFORMED DOLUTEGRAVIR DOSE SELECTION IN PEDS WITH 1ST GENERATION InSTI-R
Hardik Chandasana, Ann Buchanan, Michael McKenna, Cindy Vavro, Linda Lewis, Mary Paul, Ana Puga, Lionel Tan, Cindy Brothers, Theodore Ruel

833 IMPACT OF MALNUTRITION ON DOLUTEGRAVIR EXPOSURE AND ALTERNATIVE DOSING
Alexander J. Floren, Belen Perez Solans, Kendra K. Radtke, Rada Savic
Poster Session-R1 MOLECULAR HIV EPIDEMIOLOGY
2:30 PM - 4:00 PM

843  STUDY ON THE FREQUENCY OF DUAL INFECTIONS IN NEW HIV-1 DIAGNOSES IN SPAIN
Ana Donoso, Javier Enrique Cañada-García, Elena Delgado, Sara Monzón, Horacio Gil, María Moreno-Lorenzo, Mónica Sánchez, Isabel Cuesta, Ángel Zaballos, Pilar Jiménez, Michael M. Thomson
Research Group: the Spanish Group for the Study of New HIV Diagnoses

844  EPIDEMIOLOGICAL AND MOLECULAR EVOLUTION OF THE HIV-1 CRF94: BIRTH OF CRF132
Marc Wirden, Fabienne De Oliveira, Marie-Laure Chaix, Stephanie Marque Juillet, Sidonie Lambert-Niclot, Basma Abdi, Benedicte Roquebert, Charlotte Charpentier, Jean-Christophe Plantier, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Benoit Visseaux
Research Group: ANRS-MIE AC43 Medical Virology Network

845  ACCURACY OF MOLECULAR EPIDEMIOLOGICAL INFERENCES IN A SIMULATED EPIDEMIC
Fabricia Naciemento, Sanjay Mehta, Susan R. Little, Erik Volz

846  PRESENCE OF CXCR4-USING HIV-1 VIRUS IN NEWLY DIAGNOSED INDIVIDUALS IN NORTH CAROLINA
Shuntai Zhou, Nathan Long, Matt Moeser, Erika Samoff, Scott Shone, Collin Hill, Michael Clark, Ronald Swanstrom, Ann Dennis
Poster Session-R2 RECENT HIV INFECTIONS

2:30 PM - 4:00 PM

847 HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA
Amobi A. Onovo, Pamela Gado, Angela Agweye, Abiya Kalaiwo, Ughweroghene Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein

848 PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA
Vichea Ouk, Sovannarith Samreth, Bora Ngaug, Buntheouen Eng, Rommel Bain, Chhailly Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Vanthy Ly, Amitabh B. Suthar, Rachel Albalak

849 AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI

850 HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: ImPrEP STUDY
Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrico, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarcwald, Carlos Caceres, Valdilea Veloso
Research Group: ImPrEP Seroincidence Study Group

851 HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES, 2018-2021
Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Fannee, Rashida Hassan, Anne Marie France, Alexandra M. Oster

Poster Session-R3 HIV INFECTION CLUSTERS

2:30 PM - 4:00 PM

852 EVOLUTION OF CLUSTERS TRANSMISSION PATTERNS IN FRANCE DURING THE LAST DECADE
Benoit Visseaux, Mathilde Roussel, Stéphanie Teixeira, Eric Hedbaut, Laura Verdurme, Sabine Trombert, Stéphanie Haim-Boukobza, Benedicte Roquebert

853 BEYOND FAST-TRACK CITIES: DYNAMIC OF HIV CLUSTERS IN A FRENCH REGION NEAR PARIS
Nived Collercandy, Antoine Chaillon, Marc-Florent Tassi, Leslie Grammatico-Guillon, Emeline Laurent, Laurent Hocqueloux, Jerome Guinard, Clémence Guillaume, Adrien Lemaignen, Guillaume Gras, Karl Stefic

854 NOT ALL CLUSTERS ARE EQUAL: STATEWIDE MOLECULAR HIV CLUSTER DYNAMICS IN RHODE ISLAND
Vlad Novitsky, Jon A. Steingrimsson, Mark Howison, Casey Dunn, Fizza Gillani, John Fulton, Thomas Bertrand, Katharine Howe, Lila Bhattarai, Guillermo Ronquillo, Meghan MacAskill, Utpala Bandy, Joseph W. Hogan, Rami Kantor

855 HIV SEQUENCING AT DIAGNOSIS ENHANCES DETECTION OF CLUSTERS AND POTENTIAL CARE GAPS
856  MOLECULAR CLUSTER TYPES SUSTAINING HIV SPREAD AMONG MSM IN QUEBEC: 2014-2020
Bluma G. Brenner, Vladimir Novitsky, Ruxandra-Ilinca Ibanescu, Maureen Oliveira, Michel Roger, Jean-Pierre Routy, Rami Kantor
Research Group: Montreal PHI Cohort Study Group

857  CHANGING RISK OF HIV BEHAVIORAL AND DEMOGRAPHIC CLUSTERS IN RAKAI, UGANDA
Victor O. Popoola, Mary K. Grabowski, Joseph Kagaayi, Joseph Ssekasanzu, Robert Ssekubugu, Anthony Ndyabanu, Fred Nalugoda, Larry William W. Chang, Godfrey Kigozi, Stella Alamo, Maria Wawer, Steven J. Reynolds, David M. Serwadda, Justin Lessler

Poster Session-R6 HIV MORTALITY 2:30 PM - 4:00 PM

870  TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)
Erich Tusch
Research Group: The RESPOND Study Group

871  NON-AIDS DEFINING MALIGNANCY MORTALITY IN PEOPLE LIVING WITH HIV
Marta Rava, Félix Gutiérrez, José A. Pérez-Molina, Inés Suarez-García, Francisco J. Vera Méndez, Fernando Baigorria Feltrin, Mar Masiá, Juan Macías, Gemma Navarro, Santiago Moreno, Inmaculada Jarrín
Research Group: Cohorte de la Red de Investigación en Sida (CoRIS)

872  PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS
Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauso Musa, Amos Nyaka, Kondwani Nikanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo
Research Group: The RESPOND Study Group

873  MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT
Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

874  ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION
Nicholas Bakewell, Caroline Sabin, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanayake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banwari Agarwal, Robert Miller

875  REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA
Gabriela Carriquiry, Yaninck Caro-Vega, Paula Luz, Ahra Kim, Karu Jayathilake, Eduardo Gotuzzo, Lara É. Coelho, Antonio G. Pacheco, Claudia M. Cortes, Regina Succi, Lorena Guerrero-Torres, Bryan E. Shepherd, Stephany Duda, Peter F. Rebeiro
Research Group: Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

Poster Session-S1 COVID-19 CHARACTERISTICS AND OUTCOMES 2:30 PM - 4:00 PM

884  12-MONTH CONSEQUENCES IN PEOPLE WITH HIV/SARS-CoV-2 COINFECTION: NATIONAL EHR COHORT
Yuanzhen Yue, Chen Liang, Sharon Weissman, Tianchu Lyu, Bankole Olatosi, Xiaoming Li
Research Group: National COVID Cohort Collaborative Consortium
TRENDS IN COVID-19 ADMISSIONS AND DEATHS AMONG PEOPLE WITH HIV IN SOUTH AFRICA
Waa silica Jassat, Lovelyn Ozouguw, Caroline Mudara, Richard Welch, Tracy Arendse, Maureen Masha, Lucille Blumberg, Tendesayi Kufa, Adrian Puren, Michelle Groome, Pedro Pisa, Ian Sanne, Heena Brahmbhatt, Lauren Parmley, Cheryl Cohen, Sharlene Govender, Pappie Majuba, Petro Rousseau, Milani Wolmarans
Research Group: DATCOV author group

A MULTICENTER STUDY OF COVID-19 INFECTION IN PEDIATRIC INTENSIVE CARE UNITS IN THE US
German A. Contreras, Gabriela Delbianco, Michael Chang, Gilhen Rodriguez, Elizabeth Aguillera, James Murphy, Gloria Heresi

IDENTIFICATION OF CLINICAL FEATURES ASSOCIATED WITH SARS-CoV-2 REINFECTIONS
Francisco Muñoz-López, Antoni E. Bordoy, Ignacio Blanco, Elisa Matró, Pere-Joan Cardona, Roger Paredes, Bonaventura Cotet, Marc Noguera Julian, José Ramón Santos, Marta Massanella, Lourdes Mateu, Cristina Casañ, Ana Blanco-Suárez
Research Group: Translational Research in Immunology and Ageing (TRIA)

ANEMIA AS A PREDICTOR OF POOR CLINICAL OUTCOME IN PATIENTS ADMITTED FOR COVID-19
Francesco Di Gennaro, Francesco Vladimir Segala, Luca Carruba, Anna La Carrubba, Diletta Agnello, Davide Fiore Bavaro, Mario Barbagallo, Nicola Veronese, Annalisa Saracino

CLINICAL OUTCOMES BY SARS-CoV-2 VARIANT AT A SINGLE ACADEMIC MEDICAL CENTER
Pankaja Desai, Juan Rojas, Yi-Shuan Chen, Susan Gavel, Hannah Barbian, Anthony Orzechowski, Gavin Cloherty, Alan Landay

EXCESS OF MORTALITY IN OLDER PEOPLE DURING THE COVID-19 PANDEMIC IN MOZAMBIQUE
Inacio Mandomando, Richard Sheppard, Arsenia Massinga, Rita Ernesto, Auria de Jesus, Augusto Messa Jr, Ariel Nhacolo, Arsenio Nhacolo, Charfudin Sacoor, Patrick Walker, Alfredo Mayor

HIV VIRAL LOAD SUPPRESSION AND RACIAL DISPARITIES DURING THE COVID-19 PANDEMIC IN NYC
Emma Tucker, Harry Reyes Nieva, Kayla Schiffer, Lindsay Grant, Michael T. Yin, Delivette Castor, Peter Gordon, Noémie Elhadad, Jason Zucker

HIV AND CHRONIC COMORBIDITIES: MEDICATION ADHERENCE AND CLINICAL ENDPOINT COVARIATION
Michael J. Miller, Celeena R. Jefferson, Lindsay G. Eberhart, Michael A. Horberg

HIGH PANDEMIC-RELATED MORTALITY AMONGST PEOPLE WITH HIV IN SASKATCHEWAN, CANADA
Kirsten Hall, Molly Trecker, Sarah Craddock, Raynell Lang, Danielle Myrah, Kumudhini Karunakaran, Lanre Medu, Alexander Wong

IMPACT OF THE COVID-19 PANDEMIC ON MALARIA SERVICES IN UGANDA: A TIME SERIES ANALYSIS
Francesco Di Gennaro, Francesco Vladimir Segala, Jerry Ictho, Mariangela L'Episcopia, Emmanuelle Onapa, Davide Fiore Bavaro, Samuel Okori, Giovanni Dall'Oglio, Giovanni Putoto, Carlo Severini, Peter Lohoro, Annalisa Saracino
928  WITHDRAWN

929  HIGH PERFORMANCE OF BLOOD-BASED HIV SELF-TESTS AT PRIVATE PHARMACIES IN KENYA
Katrina F. Ortblad, Benn Kwach, Shengruo Zhang, Magdaline Asewe, Kendall Harkey, Rachel Malen, Josephine Odoyo, Daniel Were, Kenneth Ngure, Victor Omollo, Elizabeth A. Bukusi

930  REMOVAL OF A SUBSIDY FOR HIV SELF-TESTING KITS REDUCES ONLINE KIT SALES IN KENYA
Obinna I. Ekwunife, Carlos Culquichicon, Maeve Rafferty, Paulami Naik, Nicky Nyamasyo, Tony Wood, Daniel Were, Kenneth Ngure, Melissa Mugambi, Annie Haakenstand, Katrina F. Ortblad

931  VIRTUAL SUPPORT IMPROVES CLIENT EXPERIENCES WITH AN ONLINE HIV SELF-TESTING SERVICE

932  PEOPLE WHO INJECT DRUGS’ WILLINGNESS TO USE AND DELIVER HIV SELF-TEST KITS TO PEERS
Heather A. Pines, William H. Eger, Britt Skaathun, Claire C. Bristow, Carlos F. Vera, Alicia Harvey-Vera, Steffanie A. Strathdee, Irina Artamonova, Angela R. Bazzi

933  OVERCOMING ACCESS BARRIERS TO VIRAL SUPPRESSION TESTING BY SELF-MICROCOLLECTED BLOOD
Poster Session-U1 MPOX TESTING
2:30 PM - 4:00 PM

948 CLINICAL DIAGNOSIS IS HIGHLY PREDTIVE OF LAB-CONFIRMED MPOX IN A SEXUAL HEALTH CLINIC
Chase Cannon, Ellora Karmarkar, Meena Ramchandani, Julia C. Dombrowski, Matthew Golden

949 WITHDRAWN

950 MPOX TESTING AMONG MEN WHO HAVE SEX WITH MEN WHO REPORTED RECENT HIV OR STI TESTING
Yasmin Ogale, Alison Ridpath, Travis H. Sanchez, Marissa Hannah, Kevin Delaney, Stefan Baral, Patrick S. Sullivan, Thomas Carpino, Kaitlyn Atkins, Eboni Galloway, Bruce Furness, Laura H. Bachmann, Winston Abara

951 FACTORS ASSOCIATED WITH MPOX SYMPTOMS AND TESTING AMONG MSM IN THE US, AUGUST 2022

952 UTILITY OF A VIRAL VESICULAR PANEL MULTIPLEX PCR ASSAY FOR THE DIAGNOSIS OF MPOX
Eli Wilber, Paulina A. Rebolledo, Vyjayanti Kasinathan, Stephanie Merritt, Boghuma K. Titanji, Bruce Aldred, Sheetal Kandiah, Susan Ray, Anandi N. Sheth, Jonathan Colasanti, Yun Wang

953 MPOX VIRAL LOAD BY SPECIMEN TYPE AND DIAGNOSTIC TESTING IN A CLINICAL LABORATORY
Nancy Matic, Matthew Young, Gordon Ritchie, Christopher F. Lowe, Marc G. Romney

954 MPOX VIRUS (MPXV) OUTBREAK IN BERLIN: IMPLEMENTATION OF MOLECULAR DIAGNOSTICS
Martin J. Obermeier, Ivanka Krznaric, Stefan Breuer, Kudor Harb, Robert Ehret

955 PERFORMANCE OF A DUAL TARGET MPOX VIRUS REAL-TIME PCR ASSAY
Ron M. Kagan, Susan E. Realegeno, Gwynngelle A. Borillo, Amy A. Rogers, Taekkyun Kim, Lamela Umaru, Clemente I. Montero, Hollis J. Baterman, Elizabeth M. Marlowe

Poster Session-V1 COST EFFECTIVENESS OF PEP AND PrEP
2:30 PM - 4:00 PM

967 COST-EFFECTIVENESS OF THE DUAL PREVENTION PILL FOR CONTRACEPTION AND HIV PROPHYLAXIS
Masabho Milali, David Kaftan, Ingrida Platais, Hae-Young Kim, Danielle Resar, Danny Edwards, Jenny Campbell, Sarah Jenkins, Anna Bershteyn

968 POTENTIAL IMPACT & COST-EFFECTIVENESS OF WIDELY ACCESSIBLE TLD IN SUB-SAHARIAN AFRICA
Andrew Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, James Hargreaves, Paul Revill, Euphemia Sibanda, Jens Lundgren, Catherine Godfrey, Frances M. Cowan, Valentina Cambiano
Research Group: The HIV Modelling Consortium
969  POPULATION IMPACT OF EXPANDING PrEP USAGE IN SOUTH AFRICA: MODEL COMPARISON ANALYSIS
Sarah E. Stansfield, Jesse Heitner, Lise Jamieson, Gesine Meyer-Rath, Leigh Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi-Matharu, Andrew Phillips, Mia Moore, Ruanne Barnabas, Marie-Claude Boily, Dobromir Dimitrov

Poster Session-V2 PrEP AND PEP: ADHERENCE MEASURES AND STIs
2:30 PM - 4:00 PM

970  RANDOMIZED EVALUATION OF THE IMPACT OF STI POINT-OF-CARE TESTING ON PrEP INITIATION
Alex de Voux, Miriam Silliman, Rufaro Mvududu, Nyiko Mashele, Landon Myer, Dvora Joseph Davey

971  SEXUAL BEHAVIOR AND STI INCIDENCE DURING THE FIRST 4 YEARS OF PrEP USE AMONG MSM
Mark van den Elshout, Eline Wijstma, Vita Jongen, Liza Coyer, Anders Boyd, Udi Davidovich, Henry de Vries, Maria Prins, Maarten Schim Van Der Loeff, Elske Hoornenborg
Research Group: Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative

972  PEP-IN-POCKET (PIP): LONG-TERM FOLLOW-UP OF ON DEMAND HIV POST-EXPOSURE PROPHYLAXIS
Maxime J. Billick, Karla N. Fisher, Samantha Myers, Darrell H. S. Tan, Isaac I. Bogoch

973  ACCEPTABILITY AND FEASIBILITY OF A NEW URINE-BASED TENOFOVIR ADHERENCE TEST IN KENYA
Kenneth Ngure, Phelix Okello, Vallery Ogello, Peter Mogere, Stephen Gakuo, Deepalika Chakravarty, Charlene Biwott, Purba Chatterjee, Jennifer Velloza, Nelly Mugo, Monica Gandhi

974  WITHDRAWN

Poster Session-W1 MPOX PREVENTION
2:30 PM - 4:00 PM

1000  DISPARITIES IN MPOX VACCINATION UPTAKE IN SAN FRANCISCO AMONG PLWH AND PEOPLE ON PrEP
Elise S. Mara, Ling Hsu, Julia Janssen, Melissa Ongpin, Michelle Kirian, Melissa A. Sanchez, Stephanie Cohen

1001  ESTABLISHING AN OBSERVATIONAL MPOX VACCINATION STUDY WHILE THE OUTBREAK EVOLVES
Angelica C. Kottkamp, Marie Samanovic, Ellie Carmody, Lalitha Parameswaran, Heekoung Allison Youn, Olivia Frank, Stephanie Retting, Lisa Zhao, Julia Wagner, Celia Engelson, Miguel Rodriguez, Trishala Karmacharya, Jane R. Zucker, Jennifer B. Rosen, Mark J. Mulligan, Aaron Oom
Research Group: NYC OSMI Study Group
1002 EVALUATING THE USE OF DOSE-SPARING VACCINATION STRATEGIES FOR MPOX
Dobromir Dimitrov, Blythe Adamson, Laura Matrajt

1003 IDENTIFYING DISPARITIES IN MPOX VACCINATION IN A SOUTHEASTERN ACADEMIC HIV CLINIC
Edwin Wilbur. Woodhouse, Ahmad Mourad, Emily Niehaus, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout

1004 MPOX AWARENESS, RISK REDUCTION, AND VACCINE ACCEPTANCE AMONG PWH IN WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Anne Monroe, Jose Lucar, Rachel Lee, Debra Benator, Alan Greenberg
Research Group: The DC Cohort Executive Committee

Poster Session-X1 SPECIAL TOPICS IN SRH AND HIV
2:30 PM - 4:00 PM

1021 COMPARISON BETWEEN HIV+ WOMEN TRANSITIONING THROUGH MENOPAUSE AND MEN OF SIMILAR AGE
Hachfeld Anna, Andrew Atkinson, Catrina Mugglin, Petra Stute, Alexandra Calmy, Philip Tarr, Katherine Darling, Baharak Babouee-Flury, Christian Polli, Leila Sultan-Beyer, Irene Abela, Chloé Pasin, Andri Rauch, Karoline Aebi-Popp
Research Group: Swiss HIV Cohort Study (SHCS)

1022 DISTINCT EFFECT OF SEX HORMONE INTAKE ON IMMUNITY IN CIS AND TRANS WOMEN WITH HIV
Chloé Pasin, David García Nuñez, Katharina Kusejko, Hachfeld Anna, Karoline Aebi-Popp, Hélène Buvelot, Matthias Cavassini, Lauro Damonti, Christoph Fux, Begoña Martinez de Tejada, Julia Notter, Alexandra Trkola, Huldrych F. F. Günthard, Roger D. Kouyos, Irene A. Abela
Research Group: Swiss HIV Cohort Study

1023 ACCEPTABILITY OF EMERGENCY CONTRACEPTION IN ACTG A5375
Elizabeth Barr, Laura Smeaton, Maxine Olefsky, Susan E. Cohn, Rosie Mngqibisa, Kimberly K. Scarsi, Catherine Godfrey
Research Group: A5375 Protocol Team

1024 THE EFFECT OF FP EDUCATION ON KNOWLEDGE AND USE OF FP IN UGANDAN FISHING COMMUNITIES

Poster Session-Y01 ACCESS TO ART
2:30 PM - 4:00 PM

1036 WITHDRAWN

1037 INEQUITIES IN TRAVEL-TIME TO HIV TREATMENT IN AFRICA: A 3- COUNTRY COMPARISON
Justin T. Okano, Andrea Low, Luckson Dullie, Wongani Mzumara, Sally Blower
1038  EVALUATION OF MEDICAL DRONES FOR ANTIRETROVIRAL DELIVERY IN AN ISLAND POPULATION
Rosalind Parkes-Ratanshi, Patrick Mr. Ssesaazi, Agnes Bwanika Naggirinya, Jackie Lydia N. Ssemata, Joan Akullo, Dickson Masoni, Agnes Kiragga, Theresa Pattery, Robert Kimbui, Andrew Kambugu, Tom Kakaire

1038.5  A LOW-COST, RAPID URINE TEST FOR TFV INCREASES ART ADHERENCE AND VIRAL SUPPRESSION
Leonard Bikinesi, Matthew A. Spinelli, Ntombizodwa Nyoni, Jesaya Hifindwako, Assegid Mengistu, Jacques Kamangu, Gram Mutandik, Daniella Mouton, Fekir Negussie, Guohong Wang, Rachel Suzanne Beard, Monica Gandhi, Steven Y. Hong

1039  DOES TYPE OF PICK-UP POINT INFLUENCE 12-MONTH VIROLOGIC SUPPRESSION IN SOUTH AFRICA?
Ingrid Bassett, Joyce Yan, Sabina Govere, Anele Khumalo, Zinhle Shazi, Mpionhle Nzuza, Taing N. Aung, Danielle Zions, Nduduzo Dube, Laura Bogart, Robert Parker

1040  AN ADAPTIVE INTERVENTION TRIAL TO SUPPORT VIRAL SUPPRESSION AMONG FEMALE SEX WORKERS
Sheree Schwartz, Carly Comins, Mfezi McNgana, Siyanda Makama, Lillian Shipp, Ntambule Mulumba, Rene Phetlhu, Vijay Guddera, Katherine Young, Pravi Moodley, Kerusha Govender, Harry P. Hauser, Stefan Baral
Research Group: Siyaphambili study team

1041  TRENDS IN PERSISTENT HIV VIREMIA DURING UNIVERSAL TEST-AND-TREAT SCALING-UP IN UGANDA

1042  USAGE PATTERNS AND OUTCOMES IN A LARGE COMMUNITY ART PROGRAMME IN SOUTH AFRICA
Lara Lewis, Yukteshwar Sookrakh, Johan van Der Molen, Muntha Devi Maraj, Thokozani Khubone, Rosemary Van Heerden, Francesca Little, Reshma Kassanjee, Nigel Garrett, Jienchi Dorward

1043  HIGH COVERAGE OF HIV TREATMENT, LOW COVERAGE OF PREVENTION SERVICES AMONG KP IN INDIA
Allison M. McFall, Viswanathan Arumugam, Jade Bell, Saya Okram, Aditya Singh, Rose Pollard, Ajay Enugu, Shruiti H. Mehta, Sunil S. Solomon

1044  ACHIEVING THE EHE INCIDENCE REDUCTION GOALS AMONG AT-RISK POPULATIONS IN THE SOUTH
Deven T. Hamilton, Karen Hoover, Dawn Smith, Kevin Delaney, Li Yan Wang, Jingjing Li, Tamika Hoyte, Samuel Jenness, Steven M. Goodreau

1045  PROGRESS ON UNAIDS 95-95-95 TARGETS AMONG KEY POPULATIONS IN 3 TANZANIA REGIONS
Tara Pinto, Werner Maokola, Gulam Abdulkarim, George Mgomella, Mucho Mizinduko, Joyce Neale, Prince Mutalemwa, Samwel Sumba, Mark Breda, Ananthy Thambinayagam, Nyambura Moremi, Jessica Greene, Mahesh Swaminathan, Shannon M. Farley, Elias Bukundi

Poster Session-Y02 MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION
2:30 PM - 4:00 PM

Poster Session-Y03 ACHIEVING TARGETS
2:30 PM - 4:00 PM
1046 INCREASING IN LIFE EXPECTANCY OF THAI LIVING WITH HIV IN THE ERA OF TREAT ALL
Sirinya Teeraananchai, Stephen J. Kerr, Cheewanan Lertpiperiyasuwat, Rattaphon Triamwichanont, Patchara Benjarattanaporn, Win Min Han, Matthew G. Law, Anchalee Avihingsanon, Kiat Ruxrungtham

1047 REACHING THE THIRD 95 IN UGANDA AFTER LOWERING HIV VIRAL LOAD SUPPRESSION CUTPOINTS

1048 GETTING TO ZERO: ACHIEVEMENT OF 95-95-95 AND DECLINING HIV INCIDENCE IN ESWATINI
Harriet Nuwagaba-Biribonwoha, Sindisiwe Dlamini, Neena Philip, Choice Ginindza, Michelle Li, Kristin Brown, Nokuthula Mahlalela, Yvonne Movengere, Daniel Catano, Kelsie Decker-Pulice, Jessica Justman, Ruben Sahabo, Rejoice Nkambule, David Hoos, Wafaa El-Sadr
Research Group: SHIMS3 Team

Poster Session-Y04 HIV TESTING
2:30 PM - 4:00 PM

1049 EARLY CASE-FINDING IS STILL NEEDED IN THE HIV TEST-AND-TREAT ERA TO PREVENT MORTALITY
Sasi Jonnalagadda, Jacques Muthusi, Anthony Waruru, Wanjiru Waruiru, Kevin Kintungu, Margaret Ndisha, Mary Mwangome, Kenneth Masamaro, Abraham Katana, Appolonia Aoko, Lucy Nganga, Rachael Joseph

1050 RE-NORMING OF HIV TESTING IN TB CONTACT INVESTIGATION: A RANDOMIZED CONTROLLED TRIAL
Mari Armstrong-Hough, Joseph Ggita, Amanda Gupta, Joanita Nangendo, Achilles Katamba, J. Lucian Davis
Research Group: Uganda TB Implementation Research Consortium (U-TIRC)

1051 MODELED IMPACT OF HIV SELF-TESTING FOR PrEP SCALE-UP ON DRUG RESISTANCE IN KENYA
**Poster Session-A2 IFN AND ANTIVIRAL FACTORS**

**2:30 PM - 4:00 PM**

218 HIV INFECTION OF TFH: INTERROGATING THE SAMHD1 CONTRIBUTION THROUGH HIV-2  
 Andrei Pires, Rita Moura, Guilherme B. Farias, Carolina M. Conceição, Ana V. Antão, Tiago Ferreira, Bárbara Tavares, Amelia C. Trombetta, Ana Godinho-Santos, Ana E. Sousa, Robert Badura

219 NEF FROM PRIMARY HIV INFECTION COUNTERACTS IFITM3 AND RESTORES VIRION INFECTIVITY  
 Mahesh Agarwal, Salimah Majdoul, Abigail A. Jolley, Alex A. Compton

220 Vpu OF AN SIV ISOLATE CAN TARGET HUMAN BST-2  
 Weitong Yao, Akhil Chennuru, Preston Moore, Klaus Strebel, Tetsuro Matano, Taisuke Izumi, Takeshi Yoda

221 STINGING CD4+ T CELLS TO RENDER THEM REFRACTORY TO HIV INFECTION  
 Naseem Sadek, Sarah Welbourn, David Gordon, Rafick P. Sékaly, Jeffrey A. Tomalka

222 PAN-CASPASE INHIBITION PREVENTS HIV REPLICATION BY THE INDUCTION OF THE IFN I PATHWAY  
 Jordi Senserrich, Sónia Pedreño, Elisabet García, Elisabet Gómez, Bonaventura Clotet, Cecilia Cabrera

223 THE SPIKE OF SARS-CoV-2 VARIANTS ALLOWS FOR MORE EFFICIENT COUNTERACTION OF BST2  
 Yuhang Shi, Yuexuan Chen, Ruth Serra-Moreno

224 cGAS-STING PATHWAY LIMITS SARS-CoV-2 REPLICATION IN ACE2+ AIRWAY CELL LINES  
 Maritza N. Puray-Chavez, Kyle M. Lapak, Ria Jasuja, Shawn Mohammed, Dana Q. Lawson, M. Ben Major, Dennis Goldfarb, Sebla B. Kutluay

225 LONG NON-CODING RNA REGULATES IFN-I RESPONSE AND SARS-CoV-2 REPLICATION  
 Smita Kulkarni

**Poster Session-B3 HIV NON IMMUNOPATHOGENESIS, COINFECTION**

**2:30 PM - 4:00 PM**

253 BODY MASS INDEX AND INFLAMMATION IN PEOPLE LIVING WITH HIV AND UNINFECTED CONTROLS  
 Marco Gelpi, Rebekka Faber Thudium, Malene Hove-Skovsgaard, Thomas Lars Benfield, Sisse Rye Ostrowski, Susanne Dam Poulsen

254 IRON METABOLISM IN CHRONIC HIV: IMPAIRED HEPcidIN-Soluble Transferrin Receptor Axis  
 Vanesa Garrido-Rodriguez, Ana Isabel Alvarez-Rios, Israel Olivas-Martinez, Maria Del Mar Pozo-Balado, Angel Bulnes-Ramos, Manuel Leal, Yolanda Pacheco

255 ENDOTHELIAL GM-CSF IN PLWH CONTRIBUTES TO PROINFLAMMATORY VASCULAR MICROENVIRONMENT  
 Soumya Panigrahi, Elizabeth Mayne, Nicholas Funderburg, Archeesa Chakraborty, Michael M. Lederman, Michael L. Freeman, Scott F. Sieg
256  EFFECT OF P. FRAGILE COINFECTION ON ART AND IMMUNITY IN SIV-INFECTED RHESUS MACAQUES
Sydney Nemphos, Hannah Green, Kelly Goff, Matilda Moström, Coty Tatum, Chad Massey, Robert Blair, Carolina Allers, Monica Embers, Nicholas Maness, Preston Marx, Brooke Gasperge, Amitinder Kaur, Jennifer Manuzak

257  INNATE IMPAIRMENT DURING SIV INFECTION ALTERS ZIKV VIRAL PATHOGENESIS
Jennifer Tisonck-Go, Thomas B. Lewis, Skyler Niemeyer, Andrew Gustin, Rene A. Ruiz, Paul Kim, Kai Hubbell, Naoto Iwayama, Solomon Wangari, Chul Ahrens, Robert Murnane, Kathryn A. Guerriero, Michael Gale, Deborah H. Fuller, Megan A. O’Connor

258  LYMPHOID TISSUE VOLUMES AND GLUCOSE METABOLISM IN EARLY SIV INFECTION OF AGM AND RM
Hyukjin Jang, Dongzhu Ma, Sharat Srinivasula, Brad Long, Heather Brown, Cui Ling Xu, Cristian Apetrei, Ivona Pandrea, Michele Di Mascio

259  THE BREADTH AND POLYFUNCTIONALITY OF T CELL RESPONSES TO CMV DIFFER BY HIV STATUS
Weiyiing Zhang, Tricia L. Nilles, Jay H. Bream, Huifen Li, Sean X. Leng, Joseph B. Margolick

Poster Session-B5 HIV IMMUNOPATHOGENESIS
2:30 PM - 4:00 PM

265  GERMINAL CENTER B CELLS INDUCE TFH ACTIVATION AND HIV REPLICATION
Matthew Ollerton, Joy Folkvord, David Parry, Elizabeth Connick

266  SIALIDASE INHIBITION PREVENTS HIV-MEDIATED INFLAMMATION AND IMMUNE ACTIVATION IN VIVO
Leila Giron, Shalini Singh, Kai Ying Hong, Joshua Glover, Eric Balboa, Derrick Dogpin, Michelle Burrows, Anthony Secreto, Nicolas Skuli, Todd T. Brown, Alan Landay, Ali Keshavarzian, Ivona Pandrea, Paul Denton, Mohamed Abdel-Mohsen

267  EXPRESSION OF UNSPLICED HIV-1 RNA INDUCES INFLAMMASOME ACTIVATION IN MYELOID CELLS
Sallieu Jalloh, Ivy Hughes, Chelsey Skeete, Hisashi Akiyama, Aldana Gojanovich, Gustavo Mostoslavsky, Rahm Gummuluru

268  IMPACT OF EARLY ART ON TISSUE RESIDENT MEMORY T CELLS IN THE GASTROINTESTINAL TRACT
Aloysious Ssemaganda, Yuwadee Phuang–Ngern, Chayada Sajjaweerawan, Phil Ehrenberg, Henok Gebrebrhan, Sandra Choi, Michael Corley, Giulia Severini, Nittaya Phanuphak, Carlo Sacdalan, Denise Hsu, Rasmi Thomas, Lyle McKinnon, Alexandria Schuetz
Research Group: RV254/SEARCH010 and SEARCH013/RV304 study groups

269  MULTOMIC BIOMARKERS ACROSS ART INITIATION TIMEPOINTS REVEAL INTERFEROME ENRICHMENT
Harrison B. Lindley, Cheryl Cameron, Brian Richardson, Jillian Petroski, Wendy Lin, Jared M. Baeten, Connie Celum, Florian Hladik, Jairam Lingappa, Romel Mackelprang, Mark Cameron

270  HIV SUPPRESSION IS LINKED TO SHIFTING EPIGENETIC/TRANSCRIPTOME FEATURES IN MONOCYTES
Guido Massaccesi, Brittany White, Eric S. Rosenberg, Todd Allen, Eileen P. Scully
282 PLASMA-BASED ANTIGEN PERSISTENCE IN THE POST-ACUTE PHASE OF SARS-CoV-2 INFECTION
Michael J. Peluso, Zoe Swank, Sarah A. Goldberg, Yasmineh Senussi, Scott Lu, Rebecca Hoh, Khamal Anglin, Beatrice Huang, Matthew S. Durstenfeld, John D. Kelly, Timothy Henrich, Steven G. Deeks, David V. Glidden, David Walt, Jeffrey Martin
Research Group: LIINC study team

283 PLASMA ANTIBODY AND N ANTIGEN STATUS PREDICT OUTCOMES IN OUTPATIENTS WITH COVID-19
Nikolaus Jilg, Mark Giganti, Kara W. Chew, Katy Shaw-Saliba, Justin Ritz, Carlee Moser, Teresa H. Evering, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Henry C. Lane, Robin Dewar, Davey M. Smith, Jonathan Z. Li

284 VIRAL DYNAMICS AND FACTORS FAVOURING THE DURATION OF COVID-19 POSITIVITY IN CAMEROON
Research Group: Chantal Biya International Reference Center COVID-19 team

285 MITOCHONDRIAL DYSFUNCTION IS ASSOCIATED WITH POST-ACUTE SEQUELAE OF COVID-19
Saheera Dirajlal-Fargo, Jared C. Durieux, Anastasia Andrukhiv, David Maison, Mariana Gerschenson, Grace A. McComsey

286 SINGLE-CELL ANALYSIS REVEALS CHARACTERISTICS OF MYELOID CELLS IN PULMONARY PASC
Hyundong Yoon, Boonyanudh Jiyarom, Logan Dean, Dominic Chow, Cecilia Shikuma, Gehan Devendra, Youngil Koh, Juwon Park

287 ADAPTIVE IMMUNITY DYSREGULATION IS ASSOCIATED TO THE DEVELOPMENT OF LONG COVID
Roberta Rovito, Valeria Bono, Matteo Augello, Francesca Bai, Camilla Tincati, Guillaume Beaudoin-Bussières, Alexandra Tausin, Silvia Bianchi, Joanna Mikulak, Elisa Borghi, Antonella D’Arminio Monforte, Silvia Della Bella, Andrés Finzi, Domenico Mavilio, Giulia C. Marchetti

288 INCREASED GUT PERMEABILITY AND OXIDIZED LIPIDS IN PASC
Christian Mouchati, Jared C. Durieux, Sokratis N. Zisis, Mary Chong, Danielle Labbato, Grace A. McComsey

289 NONHUMAN PRIMATE MODEL OF LONG COVID: IMMUNE INSIGHTS OF GLYCOMETABOLIC DYSFUNCTIONS
Clovis C. Palmer, Chrysostomos Perdios, Mohamed Abdel-Mohsen, Nicholas Maness, Gabrielle Lehrnicke, Joseph mudd, Kasi Russell-Lodrigue, Angela Birnbaum, Rudolf Bohm, Jason Dufour, Robert Blair, Ahmed Saied, Jay Rappaport, Cecily Midkiff, Carol Coyne, Nadia Golden

290 PROLONGED SARS-CoV-2 VIRAL BURDEN IN SIV/SARS-CoV-2 COINFECTED MACAQUES
Megan N. Fredericks, Hillary C. Tunggal, Cecily C. Midkiff, Jeanne E. Barrow, Anthony L. Cook, Robert Blair, Ankur Sharma, Deborah H. Fuller, Megan A. O’Connor
### Poster Session-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES

2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>294</td>
<td>INNATE IMMUNITY IN HTLV-1 INFECTION: IFN-GAMMA LEVELS ARE UP-REGULATED IN EARLY HAM</td>
<td>Marta S. Porto, Sandy V. Teixeira, Gabriela S. Prates, George Gonçalves, Jorge Casseb</td>
</tr>
<tr>
<td>295</td>
<td>HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH HIF-1α</td>
<td>Min Xu, Charlotte Warner, Xiaogong Duan, Andre Jeyarajan, Zhiming Cheng, Zachary Manickas-Hill, Tuo Shao, Shadi Salloum, Xu G. Yu, Raymond Chung, Wenyu Lin</td>
</tr>
<tr>
<td>296</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>297</td>
<td>ENDOGENOUS RETROVIRAL DYSREGULATED EXPRESSION IN PEDIATRIC CROHN’S DISEASE</td>
<td>Konstantina Kitsou, Vana Spoulou, Pagona Lagiou, Gikkas Magiorkinis</td>
</tr>
</tbody>
</table>

### Poster Session-D3 IMMUNE MODULATION AND VACCINES

2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>Poster #</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>317</td>
<td>LAIR-1: NEGATIVE REGULATOR OF SIV-SPECIFIC CD8 T CELLS DURING CHRONIC SIV INFECTION</td>
<td>Sakthivel Govindaraj, Ashish Arunkumar Sharma, Syed Ali, Hemalatha Babu, Kathleen Busman-Sahay, Deepa Machiah, Steven Bosinger, Jacob Estes, Rafick P. Sékaly, Francois Villinger, Rama R. Amara, Vijayakumar Velu</td>
</tr>
<tr>
<td>318</td>
<td>TIGIT/CD155 BLOCKADE BOOSTS T-CELL IMMUNITY AND HIV-SPECIFIC DEGRANULATION IN PLWH</td>
<td>Miguel Marin, Julieta Carabelli, Eudald Vehi, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Natalia Isabel Rodrigo, Carlos Carolis, Luis Álvarez-Vallina, Jorge Carrillo, Bonaventura Clotet, Julia G. Prado Research Group: VIRAL IMMUNE EVASION AND VACCINES (VIRIEVAC)</td>
</tr>
<tr>
<td>319</td>
<td>EVALUATION OF HIV-SPECIFIC T CELL RESPONSE IN BEAT2 CLINICAL TRIAL</td>
<td>M.Betina Pampena, Pablo Tebas, Livio Azzoni, Emmanouil Papasavvas, Matthew Fair, Karam Mounzer, Luis J. Montaner, Michael R. Betts</td>
</tr>
<tr>
<td>320</td>
<td>ONE-YEAR TREATMENT WITH PONATINIB INDUCES SUSTAINED CYTOTOXIC ACTIVITY AGAINST HIV</td>
<td>Fernando Ramos-Martín, Mario Manzanares, Montserrat Torres, Elena Mateos, Lorena Vigón, Guiomar Casado Fernández, Sara Rodríguez Mora, Vicente Planelles, Valentín García-Gutiérrez, Mayte Coiras</td>
</tr>
<tr>
<td>321</td>
<td>DECREASED HIV-SPECIFIC POLYFUNCTIONAL RESPONSES FOLLOWING DIPYRIDAMOLE TREATMENT</td>
<td>Benjamin C. Morris, Emily Hixson, Cynthia Klamar-Blain, Edwin Jackson, Kaleab Abebe, Lori Caruso, John W. Mellors, Charles Rinaldo, Sharon A. Riddler, Bernard Macatangay</td>
</tr>
</tbody>
</table>
322 URACIL TREATMENT DOES NOT INCREASE SUSCEPTIBILITY TO RECTAL SIV INFECTION
Alexandra Ortiz, Charlotte Langner, Jason Brenchley

323 HETEROLOGOUS ChAd/samRNA SIV VACCINE INDUCES ROBUST T CELL RESPONSES IN MACAQUES
Amy Rappaport, Elena Bekerman, Greg Boucher, Janette Sung, Brian Carr, Cesar Corzo, Sue-Jean Hong, Heather Larson, Ciaran Scallan, Bill Wang, Romas Geleziunas, Devi Sengupta, Karin Jooss

324 CD40.HIVRI.Env VACCINE INDUCES STRONG AND DURABLE IMMUNE RESPONSES: ANRS VR106 TRIAL
Jean-Daniel Lelievre, Christiane Moog, Aurélie Wiedemann, Christine Lacabarat, Fabio Candotti, Melany Durand, Véronique Rieux, Lucile Hardel, Alpha OB, Diallo, Song Ding, Mireille Centlivre, Rodolphe Thiebaut, Giuseppe Pantaleo, Laura Richert, Yves Levy

325 THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS IN STI-MEDIATED ENHANCED HIV INFECTION
Daan K.J. Pieren, Núria Massanasa, Vicente Descalzo, Maider Arando, Jorge García-Pérez, Patricia Álvarez, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Desideria Martínez, Josep Castellvi, Clara Ramirez Serra, Daniel Álvarez-de la Sierra, Vicenç Falcó, Maria J Buzon, Meritxell Genescà

326 BEAT2: PEG-IFN-ALPHA + 3BNC117 & 10-1074 REBOUND VIRUS PHENOTYPE AND EVOLUTION

327 TIGIT BLOCKADE RESTORES FUNCTIONAL NKG2C+ NK CELLS AND LIMITS SPREAD OF HIV-1 IN Vivo
Ildefonso Sánchez-Cerrillo, Marta Calvet-Mirabent, Olga Popova, Ignacio De Los Santos, Jesús Sanz, Patricia Fuentes, Juan Alcaín, Ilya Tsukalov, Arantza Alfranca, Maria J Buzon, Maria Luisa Toribio, Ángeles Muñoz-Fernández, Francisco Sánchez-Madrid, Enrique Martin-Gayo Research Group: CIBERINFEC

328 GERMLINE-TARGETING ENV TRIMER ELICITS bNAb PRECURSORS IN INFANT, NOT JUVENILE MONKEYS
Yasmine Iassah, John Isaac, Xintao Hu, Shaunna Shen, Gabe Orozowski, Shiyu Zhang, Andrew Ward, David Montefiori, Rogier Sanders, Koen Van Rompay, Kristina De Paris, Sallie R. Permar

Poster Session-D7 SARS-CoV-2 VACCINES AND PREVENTION
2:30 PM - 4:00 PM

355 REAL-WORLD EFFECTIVENESS OF mRNA, SUBUNIT, AND VECTOR-BASED VACCINES AGAINST COVID-19

356 IMMUNOGENICITY OF SARS-CoV-2 VACCINES BY VACCINE TYPE IN RANDOMISED CLINICAL TRIALS
Sreenidhi Venkatesh, Andrea Navarro Perez, Andrew Hill

357 IVSV-BASED COVID VACCINE FOR THE PREVENTION OF BREAKTHROUGH SARS-CoV-2 INFECTIONS
Ryan Troyer, Mansour Haeryfar, Stephen Barr, C. Yong Kang
**Poster Sessions**

**CROI 2023**

**358**  
**HOSPITAL PROTECTION CORRELATES IN OUTPATIENT COVID-19 CONValescent Plasma Recipients**  
Anna Yin, Caelan Barranta, Han-Sol Park, John Lee, Christopher Caputo, Judith S. Currier, Sonya L. Heath, Moises A. Huaman, Oliver Laeyendecker, Aaron Tobian, Andrew Pekosz, Kelly Gebo, David J. Sullivan, Sabha L. Klein, Daniel F. Hanley, Arturo Casadevall, Evan M. Bloch, Shmuel Shoham  
Research Group: CSGC Group

**359**  
**SARS-CoV-2 INFECTIONS AMONG 275 PATIENTS WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS**  
Valentine M. Ferré, Laura Kramer, Christophe Rioux, Tiphaine Goulenc, Nathan Peiffer-Smadja, Mathilde Salpin, Quentin Le Hingrat, Eric Daugas, Michael Thy, Richard Dorent, Sébastien Ottaviani, Yazdan Yazdanpanah, Diane Descamps, Jade Ghoos, Veronique A. Joly

**360**  
**CD8+ T CELL CLONES FROM PRIOR SARS-CoV-2 INFECTION PREDOMINATE AFTER mRNA VACCINATION**  

**361**  
**LIMITED INDUCTION OF LUNG-RESIDENT MEMORY T CELLS BY SARS-CoV-2 mRNA VACCINATION**  
Daan K.J. Pieren, Sebastián Kuguel, Joel Rosado, Alba González Robles, Joan Rey-Cano, Cristina Mancebo Pérez, Juliana Esperalba, Vicenç Falcó, Maria J Buzon, Meritxell Genescà

**362**  
**CD40.SARS-CoV2 VACCINE, BUT NOT mRNA, INDUCES SPECIFIC CD8+ T MEMORY STEM CELLS**  
Laury Nguema, Manwa El Hajj, Florence Picard, Craig Fenwick, Sylvain Cardinaud, Aurélie Wiedemann, Giuseppe Pantaleo, Sandy Zurawski, Mireille Centlivre, Gerard Zurawski, Yves Lévy, Veronique Godot

**363**  
**SARS-CoV-2 VACCINE-INDUCED T CELL RESPONSES IN CANCER PATIENTS UNDERGOING TREATMENT**  
Chad Poloni, Xiaojiao Wang, Andrew Sze, Stephen Chia, Laura Cook, Ted Steinier

**364**  
**NEUTRALIZING ACTIVITY AND T CELL RESPONSE AFTER BIVALENT THIRD BOOSTER DOSE IN PLWH**  
Alessandra Vergori, Giulia Matusali, Alessandro Cozzi Lepri, Eleonora Cimini, Marisa Fusto, Francesca Colavita, Stefania Cicalini, Stefania Notari, Valentina Mazzotta, Davide Mariotti, Roberta Gagliardini, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Silvia Meschi, Gianluca Prota, Massimo Francalancia, Marika Rubino, Giuseppina Giannico  
Research Group: HIV-VAC Study Group

**365**  
**12-MONTH HUMORAL RESPONSE AFTER mRNA COVID-19 VACCINATION IN PEOPLE LIVING WITH HIV**  
Paul Loubet, Linda Wittkop, Alexis Francois, Karine Lacombe, Valérie Pourcher, Alain Makinson, Pierre-Olivier Girodet, David Chirio, Philippe Vanhems, Maeva Lefebvre, Catherine Schmidt-Mueller, Xavier de Lamballerie, Julie Longobardi, Jean-Daniel Lelièvre, Odile Launay  
Research Group: ANRS0001S COV-POPART cohort study group

**366**  
**SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AFTER FOUR COVID-19 VACCINE DOSES IN PWH ON ART**  
Research Group: COVID-19 vaccine immunity study team
367 IMMUNOGENICITY OF SARS-CoV-2 mRNA VACCINATION IN IDIOPATHIC CD4 LYMPHOPENIA

368 RESTORATION OF HUMORAL RESPONSE TO COVID-19 VACCINATION IN RITUXIMAB-TREATED PATIENTS
Wang-Da Liu, Tai-Chung Huang, Jann-Tay Wang, Hsin-Yun Sun, Shang-Ju Wu, Huai-Hsuan Huang, Chia-Yi Lin, Guei-Chi Li, Sui-Yuan Chang, Chien-Ching Hung

369 THREE DOSES OF COVID-19 VACCINES IN PWH: IMMUNOGENICITY AND EFFECTS ON HIV RESERVOIR
Vitaliy Matveev, Erika Benko, Erik Mihelic, Terry Lee, Karen Colwill, Robert Reinhard, Sebastian Grocott, Patrick Budylowski, Lela Kardava, Susan Moir, Jennifer Gommerman, Anne-Claude Gingras, Colin Kovacs, Mario Ostrowski

370 EFFECTS OF COVID-19 mRNA VACCINATION ON HIV VIREMIA AND RESERVOIR SIZE IN PWH ON ART
Maggie Duncan, F Harrison Omondi, Natalie Kinloch, Hope Lapointe, Sarah Speckmaier, Nadia Moran-Garcia, Tanya Lawson, Mari Demarco, Janet Simons, Daniel Holmes, Christopher F. Lowe, Marc G. Romney, Marianne Harris, Mark Brockman, Zabrina Brumme

371 COVID-19 VACCINATION IMPACTS FUNCTIONAL IMMUNE RESPONSES AND PLASMA PROTEOME IN PLWH
Research Group: 2000HIV Functional Genomics Partnership Program

372 IMPACT OF GUT MICROBIOTA ON IMMUNOGENICITY TO COVID-19 VACCINES IN PLWH
Shilpa Ray, Aswathy Narayanan, Jan Vesterbacka, Giorgio Gabarrini, Yu Gao, Hans-Gustaf Ljunggren, Marcus Buggert, Soo Åleman, Anders Sönnerborg, Margaret Sällberg Chen, Piotr Nowak

373 SEQUENTIAL IMMUNIZATION OF UPDATED COVID-19 DNA AND RNA VACCINES IN NONHUMAN PRIMATES
Sandra Dross, Megan N. Fredericks, Mathias D. Maughan, Justin T. Ulrich-Lewis, Thomas B. Lewis, Yuqi Dong, James T. Fuller, Solomon Wangari, Alexander Cohen, Pamela J. Bjorkman, Arlene I. Ramsingh, Janice Pata, Jesse Erasmus, Kenneth C. Bagley, Deborah H. Fuller

415 UNRAVELING ONGOING INFLAMMATION AFTER EARLY ART BY IN-DEPTH ANALYSIS OF LYMPH NODES
Jozefien De Clercq, Kathleen Busman-Sahay, Laurens Lambrechts, Sofie Rutsaert, Sol Taylor-Brill, Stephen Bondoc, Marie-angélique De Scheerder, Jacob Estes, Sarah Gerlo, Linoas Vandekerckhove
Research Group: HIV Cure Research Center

416 UNEQUAL DISTRIBUTION OF INTACT HIV PROVIRUSES IN CELLS
Katie Fisher, Timothy Schlub, Zoe Boyer, Thomas Rasmussen, Ajantha Rhodes, Rebecca Hoh, Frederick Hecht, Steven G. Deeks, Sharon Lewin, Sarah Palmer
417 DECIPHERING THE SOURCE OF VIRAL REBOUND IN SIV-INFECTED RHESUS MACAQUES
Antonio Solís-Leal, Nongthombam Boy, Suvadip Mallick, Yilun Cheng, Fei Wu, Grey De La Torre, Jason Dufour, Xabier Álvarez, Vinay Shivanna, Jeffrey D. Lifson, Qingsheng Li, Brandon F. Keele, Binhua Ling

418 AN INTESTINAL TISSUE MODEL FOR TARGETED STRATEGIES DIRECTED TO TISSUE RESERVOIRS
Ana Gallego Cortés, Nerea Sánchez Gaona, Cristina Mancebo Pérez, Stefania Landolfi, Vicenç Falcó, Meritxell Genescà, María J Buzon

419 MONOCYTE-DERIVED MACROPHAGES CONTAIN LONG-LIVED LATENT HIV RESERVOIRS
Rebecca Veenhuis, Celina Abreu, Pedro Costa, Edna Ferreira, Janaysha Ratliff, Lily Pohlenz, Erin Shirk, Joel N. Blankson, Lucio Gama, Janice Clements

420 SYSTEMIC INFLAMMATION, GUT DYSBIOSIS AND GUT MICROBIOME IMPACT HIV MIGRATION DYNAMICS
Ravi Goyal, Sara Gianella, Christophe Vanpouille, Wendy Fitzgerald, Gemma Caballero, Caroline Ignacio, Magali Porrachia, Victor De Gruttola, Davey M. Smith, Antoine Chaillon

421 T-TRACE ENABLES SINGLE-CELL MULTI-OMICS ANALYSIS OF HIV RESERVOIR CELLS FROM TISSUES
Julie Frouard, Xiaoyu Luo, Jason Neidleman, Kailin Yin, Sushama Telwatte, Steven Yukl, Jennifer Cohen, Anastasia Polos, Carol Thuman, Rebecca Hoh, Steven G. Deeks, Pavitra Roychoudhur, Sulggi Lee, Phyllis C. Tien, Nadia R. Roan

422 HIV VIRION PROFILING SUGGEST THAT CXCR3+CD4 T CELLS ARE THE MAIN HIV-PRODUCING CELLS
Olivia Muñoz, Riddhima Banga, Alessandra Noto, David Vinals, Francesco Procopio, Andrea Mastrangelo, Rachel Schelling, Craig Fenwick, Christine Lacabartat, Yves Levy, Laurent Perez, Matthias Cavassini, Giuseppe Pantaleo, Matthieu Perreau

Poster Session-E6 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
2:30 PM - 4:00 PM

428 REDUCTION IN HIV RESERVOIR MARKERS WITH GAG/POL/IL-12 DNA THERAPEUTIC VACCINATION
Kara W. Chew, David V. Glidden, Rémi Fromentin, Jana Jacobs, Amélie Pagliuzza, Gregory M. Laird, Nicolas Chomont, Mansi Purwar, Laurent Humeau, John W. Mellors, David B. Weiner, Rafick P. Sékaly, Steven G. Deeks, Rachel L. Rutishauser

429 DOUBLING DOLUTEGRAVIR DOSAGE REDUCES HIV PERSISTENCE MARKERS IN ART-TREATED ADULTS
Céline Fombellida-Lopez, Alexander Pasternak, Aurelija Cicilionyté, Nathalie Maes, Céline Vanwinge, Aurélie Ladang, Etienne Cavalier, Lee Winchester, Courtney V. Fletcher, Fabrice Susin, Dolores Vaira, Marie-Pierre Hayette, Catherine Reenaers, Michel Moutschen, Gilles Darcis

430 RANDOMIZED CONTROLLED TRIAL OF VIRCO1 MONOCLONAL ANTIBODY DURING ACUTE HIV INFECTION
Research Group: RV398 Study Team
431 BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-α2B +3BC117 & 10-1074 IN CHRONIC HIV INFECTION

432 LONG-TERM PROTECTION OF CD4+ T CELLS AGAINST HIV BY ONE-YEAR TREATMENT WITH PONATINIB
Mario Manzanares, Fernando Ramos-Martín, Guiomar Casado-Fernández, Montserrat Torres, Elena Mateos, Lorena Vigón, Vicente Planelles, Sara Rodriguez Mora, Valentin Garcia-Gutierrez, Mayte Coiras

433 A PLACEBO-CONTROLLED RANDOMIZED TRIAL OF THE HTI IMMUNOGEN VACCINE AND VESATOLIMOD
Beatriz Mothe Pujades, Adrià Curran, Juan Carlos López, Julen Cadiñanos, Ignacio De Los Santos, Juan Ambrosioni, Arkaitz Imaz, Santiago Moreno, Pere Domingo, Yanhui Cai, Romas Geleziunas, Devi Sengupta, Ian McGowan, Christian Brander, Jose R. Arribas, Álvaro Aranguren, Margarida García-Garcia, Isabel Leal, Heinz Lubenau
Research Group: The AELIX-003 Study Team

434 HIV-1 VIRAL RESERVOIR REACTIVATION AFTER CCR5 DELTA 32/32 STEM CELL TRANSPLANTATION

435 REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR9 AGONIST, AND bnAb
Michael J. Peluso, Amelia Deitchman, Gesham Magomedbedzhe, Meghann Williams, Nitsuka Kumar, James Mullins, Barbara K. Felber, George Pavlakis, Rowena Johnston, Jackie Reeves, Lucio Gama, Michel C. Nussenzweig, Timothy Henrich, Rachel L. Rutishauser, Steven G. Deeks
Research Group: UCSF-amfAR Clinical Trial Team

436 VESATOLIMOD PHARMACODYNAMIC RESPONSE IS ASSOCIATED WITH TIME TO HIV REBOUND
Liao Zhang, Mary Wire, Yanan Zheng, Susie SY. Huang, Lisa Selzer, Donovan Verrill, Christiaan R. de Vries, Devi Sengupta, Jeffrey J. Wallin, Yanhui Cai

Poster Session E8 DYNAMICS OF PROVIRAL INTEGRATION SITES
2:30 PM - 4:00 PM

449 IN-DEPTH ASSESSMENT OF THE HIV-1 VIRAL RESERVOIR IN EARLY TREATED INDIVIDUALS
Tine Struyve, Marion Pardons, Liesbet Termote, Jozefien De Clercq, Laurents Lambrechtbs, Jerel Vega, Daniel Boden, Mathias Lichterfeld, Sofie Rutsaert, Linos Vandekerckhove

450 HIV-1 RESERVOIRS IN YOUNG ADULTS AFTER LONG-TERM ART FOR CONGENITAL INFECTION
Benjamin R. Bone, Nicola Cotugno, Cao Gao, Catherine Koofhethile, Xiaodong Lian, Isabelle C. Roseto, Libera Sessa, Seoyhun Hong, Xu G. Yu, Paolo Palma, Mathias Lichterfeld
**Poster Sessions**

**CROI 2023**

**Poster Sessions • Tuesday**

**Continuing Medical Education**

**Late-Breaking**

**New Investigator Scholarship**

**Nonauthor Presenter**

---

**Poster Session-E9 HIV RESERVOIRS IN CHILDREN AND YOUTH**

**2:30 PM - 4:00 PM**

---

**451**

**CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO**

*NIS*


---

**452**

**IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION**

*Carmen Gasca-Capote*, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos

---

**453**

**DISTINCT INTEGRATION SITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLLERS**


---

**454**

**EFFECTS OF CHEMORADIATION ON EXPANDED PROVIRAL CLONES IN AN ELITE CONTROLLER**

*Filippo Dragoni*, Abena K. Kwaa, Caroline C. Garliss, Bezwit A. Woldemeskel, Angelica Camilo-Contreras, Rebecca Veenhuis, Haley Raymond, Eileen P. Scully, Amanda M. Rosecrans, Frederic D. Bushman, Francesco R. Simonetti, Joel N. Blankson

---

**455**

**EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4+ T CELL PROLIFERATION**


---

**456**

**A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE**

*Sam Weissman*, Marília Pinzone, Alfonso Oceguera, Ashley Ginda, Liam Swiggard, Lamont Cannon, Ryan Zurakowski, Uma O’Doherty

---

**457**

**ACUTE/RECENT HIV INFECTION IN YOUTH: HIV RESERVOIRS AND ANTIBODY FOLLOWING EARLY ART**

*Karin Nielsen-Saines*, Ruth Cortado, Myung Shin-Sim, Tara Kerin, Manuel Ocasio, Sue Ellen Abdalian, Risa Flynn, Robert Bolan, Dallas Swendeman, Sophia Paiola, Yetunde Adebambo, Bonnie Ank, Yvonne Bryson, Maria Isabel Fernandez

*Research Group*: CARES ATN Team

---

**458**

**LEUKAPHERESIS: A FEASIBLE TOOL TO INFORM ATI THROUGH HIV RESERVOIR STUDY IN CHILDREN**

*Nicola Cotugno*, Giuseppe Rubens Pascucci, Elena Morrocchi, Benjamin R. Bone, Chiara Pighi, Chiara Medri, Marco Sanna, Nicole Colontoni, Simona Tedde, Giovanna Leone, Giovanna Del Principe, Stefania Bernardi, Paolo Rossi, Mathias Lichterfeld, Paola Palma

---

**459**

**SIV CLEARANCE FROM NEONATAL MACAQUES FOLLOWING TRANSPORT CCR5 DEPLETION**

*Jesse Deere*, David Merriam, Kathar Legatt, Wen-Lan William Chang, Gema Méndez-Lagares, Joseph Dutra, Ning Chin, Corey Miller, Steven G. Deeks, Kathleen Engelman, Diogo Magnani, Keith Reimann, Jeffrey D. Lifson, Mario Stevenson, Dennis Hartigan-O’Connor, Connie Chen, Justin Fontaine, Hung Kieu, Wenze Lu, Jessica Salinas
Poster Sessions

Poster Session-F4 PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV

102
CROI 2023

2:30 PM - 4:00 PM

472 PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCES, INTERACTIONS, AND CONSEQUENCES
Research Group: 2000HIV

473 SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV
Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribbs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin

474 BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT
Bin Tang, Ronald J. Ellis, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre

475 SEX-SPECIFIC ASSOCIATION BETWEEN IL-6 AND DEPRESSION IN PERSONS WITH AND WITHOUT HIV
Kalen J. Petersen, Xiaoying Yu, Judith Lobo, Mary Clare Masters, Tina Lu, Scott L. Letendre, Ronald J. Ellis, Erin Sundermann

476 (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION
Arish Mudra Rakshasa-Loots, Nicholas Bakewell, David Sharp, Magnus Gisslen, Henrik Zetterberg, Jasmin Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, Jaime Vera
Research Group: COmorBidity in Relation to AIDS (COBRA) cohort

Poster Session-F5 CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES

2:30 PM - 4:00 PM

477 ESTABLISHMENT OF HIV LATENCY AND MICROGLIOSIS IN PRIMARY HUMAN MICROGLIA CELLS
Eun Hye Grace. Kim, Roy Missall, Lubbertus C. Mulder, Lotje De Witte, Viviana Simon

478 REBOUND HIV-1 IN CSF AFTER TI IS DOMINATED BY CLONALLY AMPLIFIED T CELL-TROPIC VIRUS

479 IMPACT OF IL-15 NEUTRALIZATION ON CNS PATHOGENESIS IN ACUTE HIV/SIV INFECTION
Raja Gopalakrishnan, Daniel Ram, Malika Boudries, Caitlin Davis, Gikundiro Eunice, Rhanna Jones, Valerie Varner, Elizah McAuley, Lifton Michelle, Steven Bosingher, Dan Barouch, Brandon F. Keele, R. Keith Reeves, C. Sabrina Tan

480 A FRESH SINGLE-CELL STUDY DETECTS MULTI-COMPARTMENT PERSISTENT HIV RNA DESPITE ART
Michael Corley, Supranee Buranapraditkun, Alina Pang, Alexandre Schuetz, Sodai Tovanabutra, Shelli Farhadian, Morgane Rolland, Nittaya Phanuphak, Jennifer Chiarella, Carlo Saccal, Denise Hsu, Sandhya Vasan, Serena Spudich, Lishomwa Ndlovu
Research Group: SEARCH013/RV304 study group

481 INTERACTIONS BETWEEN GUT MICROBIOTA SIGNATURES AND CNS STATUS IN A HIV CURE STRATEGY
Alessandra Borgognone, Anna Prats, Bonaventura Clotet, José Moltó, Beatriz Mothe Pujades, Roger Paredes, Jose A. Muñoz-Moreno

Research Group: 2000HIV
506 IMPACT OF OBESITY ON THE DRUG-DRUG INTERACTION BETWEEN DOLUTEGRAVIR AND RIFAMPICIN
Mattia Berton, Sara Bettonte, Felix Stader, Manuel Battegay, Catia Marzolini

507 PHARMACOKINETICS OF STANDARD VS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCH FROM EFAVirenZ
Rulan Griesel, Clifford Banda, Ying Zhao, Phumla Sinxadi, Zaayid Omar, Graeme Meintjes, Gary Maartens

510 SWITCHING OFF EFAVirenZ TO NON-EFAVirenZ ART LOWERS NICOTINE METABOLITE RATIO IN PWH
Robert Gross, Warren Bilker, Xiaoyan Han, Jessica Merlin, Michael Plankey, Jeffrey Martin, Heidi Crane, Leila Hojat, Laura Bamford, Robert Schnoll, Rachel Tyndale, Rebecca Ashare
Research Group: CNICS

516 PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE
Stephanie Kenney, Nimish Patel, Lucas Hill

517 PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART
Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilan, Justine Scott, Timothy Wilkin, Andrea L. Ciaramello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle

519 THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1
Franco Felizarta, Ronald D’Amico, Kehui Wang, Herta Crauwels, Mar Masià, Miguel García Deltoro, Olaf Defen, Jonathan Angel, Chiu-Bin Hsiao, Vasiliki Chounta, Kelong Han, Conn Harrington, Kelly Rimler, William R. Spreen, Susan Ford
**Poster Session-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESIVIR**

**2:30 PM - 4:00 PM**

**556 REMDESIVIR REDUCES MORTALITY IN HOSPITALIZED COVID-19 PATIENTS ACROSS VARIANT ERAS**

Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Chidinma Chima-Melton, Stephanie H. Read, Heng Jiang, Celine Der-Torossian, Eunyoung Lee, Lauren Dau, Mark Thrun, Mark Berry, Richard Haubrich, Andre C. Kalil

**557 REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19**

Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Stephanie H. Read, Heng Jiang, Mel Chiang, Eunyoung Lee, Rikisha Gupta, Mark Thrun, Chidinma Chima-Melton

**558 REMDESIVIR IS ASSOCIATED WITH REDUCED READMISSION AFTER COVID-19 HOSPITALIZATION**

Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas Oppelt, Lauren Dau, Mark Berry, Chidinma Chima-Melton

**559 RISK OF DEATH IN REMDESIVIR TREATED AND UNTREATED PATIENTS WITH COVID-19 INFECTION**

Adeel Butt, Victor Talisa, Peng Yan, Obaid Shaikh, Florian G. Mayr

**560 REMDESIVIR IN HOSPITALIZED COVID-19 PATIENTS: INDIVIDUAL PATIENT DATA META-ANALYSIS**

Alain Amstutz, Benjamin Speich, France Mentré, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Dominique Costagliola, Inge Christoffer Olsen, Matthias Brié

**561 REMDESIVIR RESISTANCE ANALYSES FROM THE PINETREE STUDY IN OUTPATIENTS WITH COVID-19**

Lauren Rodriguez, Hery W. Lee, Jiani Li, Ross Martin, Dong Han, Simin Xu, Gregory Camus, Jason K. Perry, Robert Hyland, Danielle P. Porter, Mazin Abdelghany, Matthias Götte, Charlotte Hedskog

**562 REMDESIVIR RETAINS POTENT ACTIVITY AGAINST SARS-CoV-2 VARIANTS OF CONCERN**

Lauren Rodriguez, Tien-Ying Hsiang, Jiani Li, Dong Han, Xianghan Lu, Ross Martin, Nicholas C. Riaola, Jared Pitts, Jason K. Perry, John P. Bilello, Michael Gale, Danielle P. Porter, Charlotte Hedskog

---

**Poster Session-I1 HIV RESISTANCE EMERGENCE AND OUTCOMES**

**2:30 PM - 4:00 PM**

**573 FACTORS ASSOCIATED WITH HIV-1 RESISTANCE TO INTEGRASE STRAND TRANSFER INHIBITORS**

Horacio Gil, Elena Delgado, Sonia Benito, María Moreno-Lorenzo, Michael M. Thomson

*Research Group:* Spanish Group for the Study of Antiretroviral Drug Resistance

**574 EFFICACY OF 3TC+DTG VS 3-DRUG REGIMENS IN Virologically-Suppressed PLWH**

Alberto Borghetti, Arturo Ciccillo, Francesca Lombardi, Rosanna Passerotto, Francesco Lamanna, Damiano Farinacci, Alex Dusina, Gianmaria Baldin, Maurizio Zazzi, Simona Di Giambenedetto

**575 INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS**

Hanwei Suaddruddin, Walter Scott, Charlotte Beelen, Anh Le, Tetyana Kalynyak, Rob Hollebakken, Amanda Granados, Sakshi Khanna, Weiyan Dong, Viviane D. Lima, Julio Montaner, Chanson J. Brumme
576 **DRUG RESISTANCE IN PEOPLE FAILING DOLUTEGRAVIR-BASED ART: HIV COHORT COLLABORATION**


577 **LOW-FREQUENCY NNRTI MUTATIONS CORRELATE WITH HIV ART FAILURE IN PREGNANT WOMEN**


578 **EMERGING INTEGRASE INHIBITOR HIV DRUG RESISTANCE MUTATIONS: TANZANIAN NATIONAL SURVEY**

Doreen D. Kamori, Godfrey Barabona, Werner Maokola, Joan Rugemalila, Salim Masoud, Mucho Mizinduko, Aman Sabasaba, George Mgomella, Macdonald R. Mahiti, Anath Rwebembera, Takamasa Ueno, Prosper Njau, Bruno F. Suganya

579 **INCIDENCE OF ACQUIRED INTEGRASE RESISTANCE AFTER TRANSITION TO DOLUTEGRAVIR IN UGANDA**


**Poster Session-J1 HBV PREVENTION AND TREATMENT**

2:30 PM - 4:00 PM

586 **KINETICS OF HBV RNA AND CORE-RELATED ANTIGEN LEVELS IN PLWTH WITH FUNCTIONAL HBV CURE**


Research Group: Swiss HIV Cohort Study

587 **LONG-TERM HEPATITIS B OUTCOMES IN ZAMBIA WITH TENOFOVIR-TREATED HBV/HIV COINFECTION**

Michael Vinikoor, Kalongo Hamusonde, Guy Muula, Mah Asombang, Debika Bhattacharya, Édford Sinkala, Georg Lauer, Raymond Chung, Wilson Mbewe, Matthias Egger, Samuel Bosomprah, Gilles Wandeler

Research Group: IeDEA Southern Africa

588 **"MICRO-INFECTION" OF HBV CAN OCCUR IN MSM WITH VACCINATION OR TENOFOVIR-BASED PrEP**

Daisuke Mizushima, Misao Takano, Takahiro Aoki, Koji Watanabe, Haruka Uemura, Hiroyuki Gatanaga, Shinichi Oka

589 **BULEVRTIDE +/- PEG-IFN IN HIV/HBV/HDV COINFECTED PATIENTS IN REAL-LIFE SETTINGS**

Victor de Ledinghen, Anne Gervais, Marie-Noelle Hilleret, Karine Lacombe, Patrick Mialhles, Bruno Roche, Louis D'Altercobe, Jean-Pierre Arpurt, Isabelle Rosa, Antonia Le Gruyer, Marc-Antoine Valantin, Helene Regnault, Christiane Stern, Tarik Asselah, Stanislas Pol

Research Group: cATU

**Poster Session-J2 NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT**

2:30 PM - 4:00 PM

590 **HCV INCIDENCE AMONG MSM ON PrEP AND MSM WITH HIV IN NEW YORK CITY OVER 2 DECADES**

Richard J. Silvera, Antonio Urbina, Keith Sigel, Daniel Fierer
Poster Sessions
CROI 2023

Poster Sessions
• Tuesday
Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter

**591** HEPATITIS C BURDEN IN GREECE, ITALY, PORTUGAL, AND SPAIN: 2000-2019
Claudia Palladino, Ifeanyi Jude Ezeonwumelu, Nuno Taveira, Verónica Briz

**592** USABILITY AND ACCEPTABILITY OF HCV SELF-TESTING IN THE GENERAL POPULATION FROM BRAZIL
Hugo Perazzo, Cristiane Villela-Nogueira, Maria Kátia Gomes, Andre Daher, Cristiane Valle, Ana Cristina G. Ferreira, Elton C. Almeida, Sandra Cardoso, Beatriz Grinsztejn, Valdirea Veloso
Research Group: Grupo de Pesquisa Clínica em Hepatologia (GPC-HEPATOL)

**593** UPTAKE AND LINKAGE TO CARE FOR HCV SELF-TESTING: RESULTS FROM A MULTI-COUNTRY RCT
Sonjelle Shilton, Saeed Hamid, Muhammad Radzi Abu Hassan, Ketevan Stvilia, Aliya Hasnain, Xiaohui Liu, Maia Japaridze, Nino Tsereteli, Dali Usharidze, Anushiya Karunanithy, Niklas Luhmann, Brooke Nichols, Jessica Markby, Elena Reploid

**594** MOBILIZING PRIMARY CARE PROVIDERS TO TREAT HEPATITIS C IN RURAL WEST VIRGINIA
Judith Feinberg, Adam Baus, Garret Cooper, Joy Juskowich, Andrea Calkins, John Guilfoose

**595** OPTIMAL FREQUENCY OF HCV RNA TESTING FOR PLWH AT RISK FOR ACUTE HCV INFECTION

**596** SVR12 OUTCOMES FOR NOVEL HCV GENOTYPE/SUBTYPES WITH SOF/VEL IN MINMON STUDY
Win Min Han, Sunil S. Solomon, Sandra Wagner-Cardoso, Jiani Li, Aiyappa Parvargada, Mark S. Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evgenia Maiorova, David Wyles

**597** SOFOSBUVIR/VELPATASVIR PHARMACOKINETICS IN PREGNANT WOMEN WITH HEPATITIS C VIRUS
Catherine Chappell, Jennifer Kiser, Riley Randolph, Ingrid Macio, Leslie Meyn, Sam Mawhinney, Anne-Marie Rick, Gysella Muniz, Kyung-Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Sharon L. Hillier

Poster Session-L3 HYPERTENSION, VASCULAR DISEASE, AND PLATELET FUNCTION

**654** SMOKING CESSATION AND SHORT-TERM VASCULAR IMPROVEMENT IN A COHORT OF PEOPLE WITH HIV
Rodrigo Moreira, Angela Rodrigues, Carla Renata, Beatriz Leonardo, Daniel Arabe, Sandra Wagner-Cardoso, Beatriz Grinsztejn, Valdirea Veloso, Antonio G. Pacheco

**655** AORTIC ANEURYSMS AND MARKERS OF ENDOTHELIAL AND PLATELET ACTIVATION IN PLWH
Sylvester Gronbaek, Julie Hogh, Michael Pham, Andreas D. Knudsen, Andreas Fuchs, Sisse Ostrowski, Thomas Lars Benfield, Klaus Kofoed, Susanne Dam Poulsen
Research Group: COCOMO study

**656** BMI MEDIATES THE LINK BETWEEN HIV-RELATED FACTORS AND HYPERTENSION BUT NOT DIABETES
Peter-Vanes Ebasone, Anastase Dzudie, Nasheeta Peer, Andre Pascal Kengne
657  RACIAL AND HIV DISPARITIES IN HYPERTENSION TREATMENT CASCADE AMONG WOMEN  
Jessica Blair, Mirjam Colette-Kempf, Jodie Dionne-Odom, Zenoria Causey-Pruit, Jenni Wise, Elizabeth Jackson, Paul Muntner, David B. Hanna, Jorge R. Kizer, Margaret Fischl, Iggo Ofotokun, Adaora Adimora, Stephen Gange, Emily B. Levitan

658  DOLUTEGRAVIR EXPOSURE, BUT NOT BICTEGRAVIR, INCREASES IN VITRO PLATELET AGGREGATION  
Renos Keniyopouloos, Akif A. Khawaja, Mike Emerson

659  MARIJUANA USE AND THE RISK OF INCIDENT VENOUS THROMBOEMBOLISM IN PEOPLE WITH HIV  
Lara Haidar, Robin Nance, Stephanie Ruderman, Alekhyra Lavu, Laila Aboolatta, Payam Peymani, Andrew Hahn, Amanda Willig, Katerina Christopoulos, Jeannie Keruly, Kristina Crothers, Joseph Delaney, Heidi Crane, Sherif Eltonsy

Poster Session-M2 METABOLIC COMPLICATIONS

2:30 PM - 4:00 PM

675  RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO BIC/F/TAF (MOBETTA TRIAL)  
Ana Hyatt, Han Feng, Paula Debroy, Aaren Kettelhut, Hongyu Miao, Liming Peng, Shalender Bhasin, Todd T. Brown, Nicholas Funderburg, Jordan E. Lake

676  METABOLIC PROFILING SHOWS MORE LIPID ABNORMALITIES IN NNRTI COMPARED TO InSTI USERS  
Wilhelm A. J. W. Vo, Nadira Vadaq, Albert L. Groenendijk, Marc J. T. Blaauw, Louise E. van Eekeren, Vasiliki Matzaraki, Kees Brinkman, Quirijn De Mast, Mike van Der Kolk, Jan van Lunzen, Janneke E. Stalenhoef, Willem L. Blok, Andre J.A.M. van Der Ven
Research Group: 2000HIV

677  INSULIN RESISTANCE, DM 2, AND POTENTIAL IMPACT OF FIRST ART IN NAIVE HIV-SUBJECTS  
Maria Luisa Montes, Carmen Busca, Maria Lagarde, Inés Suárez-Garcia, Maria Rivero, Arkaitz Imaz, Julián Olalla, Cristina Hernández-Gutierrez, Félix Gutierrez, José Antonio Iribarren, Miguel Górgolas, Miguel de Zarraga, José Ignacio Bernardino, Luz Martín-Carbonero, Juan González-García
Research Group: RIS, Red Investigación en SIDA

678  MITOCHONDRIAL HAPLOGROUHS, ANTIRETROVIRAL DRUGS, AND DIABETES RISK AMONG MEN WITH HIV  
Jing Sun, Todd T. Brown, David Samuel, Weiqun Tong, Sudipa Sarker, Alison Abraham, Jeremy Martinson, Shehnaz Hussain, Steven Wolinsky, Todd Hulgan
Research Group: MWCCS

679  ASSOCIATION OF SEX HORMONES WITH INCIDENT DIABETES IN WOMEN WITH AND WITHOUT HIV  
Rebecca A. Abelman, Michael Schneider, Christopher Cox, Jennifer C. Price, Maradge Cohen, Deborah Gustafson, Michael Plankey, Anjali Sharma, Phyllis C. Tien

680  IMMUNE CHECKPOINTS AND PANCREATIC BETA CELL DYSFUNCTION IN HIV  
Luke Pryke, Ziyue Liu, Alka Khaitan, Emily Sims, Samir Gupta

681  AGREEMENT BETWEEN HBA1C AND INTERSTITIAL GLUCOSE IN PEOPLE LIVING WITH HIV  
Harriet Daultrey, Belinda Chihota, Nick Oliver, Matthias Egger, Gilles Wandelier, Carolyn Bolton Moore, Guy Muula, Juliet Wright, Tom Levett, Jaime Vera, Ali Chakera
682 A RANDOMIZED CONTROLLED TRIAL OF BERBERINE EFFICACY ON METABOLIC SYNDROME PLUS HIV

Poster Session-M3 BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE
2:30 PM - 4:00 PM

683 HIV, GENOTYPE, AND CKD: DOES TENOFVIR EXPOSURE MATTER IN AFRICAN AMERICAN PWH?
Skye Opsteen, Ashutosh Tamhane, Chris Mathews, Cheryl Winkler, Christina Wyatt, Mari Kitahata, Heidi Crane, Richard Moore, Jeffrey Jacobson, Katerina Christopoulos, Kenneth Mayer, Michael S. Saag, Michael J. Mugavero, Thibaut Davy Mendez, Ellen Eaton
Research Group: Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)

684 VITAMIN C DYSREGULATION IN HIV: CROSS-SECTIONAL STUDY OF RENAL LEAK IN HIV+ WOMEN
Ifechukwude C. Ebenuwa, Pierre-Christian Violet, Kate Michel, Hongbin Tu, Kenneth Wilkins, Seble Kassaye, Daniel Merenstein, Mark Levine

685 RECOVERY OF BONE MASS IN WOMEN ON DEPO-PROVERA AND TDF-BASED ART SWITCHED TO B/F/TAF
Flavia Matovu Kiweewa, Mags E. Bekinsinsa, Martin Nabwana, Juliet Allen Babirye, Esther Isingel, Noah Kivuwanu, John Pettiford, Todd T. Brown
Research Group: BONE:STAR STUDY TEAM

686 QUARTERLY VITAMIN D3 SUPPLEMENTATION TO MITIGATE TENOFVIR-ASSOCIATED BONE LOSS
Evelyn Hsieh, Wei Caop, Hongxin Zhao, Wen Wang, Wei Pan, Xiaoqing Song, Yang Han, Wenmin Guan, Yunshan Xu, Michael T. Yin, Karl Ingosna, Liana Fraenkel, Wei Yu, Weibo Xia, Taisheng Li, Fuping Guo, Ting Zhu

687 IL-1β AND IL-10 ARE ASSOCIATED WITH FASTER LUNG FUNCTION DECLINE IN PEOPLE WITH HIV
Rebekka Faber Thudium, Nicoline Stender Arentoft, Hedda Hoel, Jakob Hjorth Von Stemann, Julie Lyng Forman, Jon Torgny Wilcke, Thomas Lars Benfield, Marius Træseid, Alvaro Humberto Borges, Sisse Rye Ostrowski, Jørgen Vestbo, Ken M. Kunisaki, Jens-Ulrik Stæhr Jensen, Susanne Dam Poulsen

688 ASSOCIATION OF ANEMIA ON SURVIVAL AMONG PEOPLE WITH HIV AFTER ART INITIATION
Raynell Lang, Sally B. Coburn, M. John Gill, Ronald J. Bosch, Michael A. Horberg, Amy C. Justice, Mona Loufty, Angel Mayor, Richard Moore, Charles Rabkin, Michael J. Silverberg, Kelly Gebo, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

Poster Session-M5 FRAILTY, FUNCTIONAL STATUS, AND HEALTH
2:30 PM - 4:00 PM

696 SARCOPENIA, FRAILTY, NUTRITION, AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV
Hay Mar Su Lwin, Win Min Han, Tanakorn Apornpong, Thanathip Wichiangsa, Jedsadakorn Bonrungrisisap, Chanya Chatjitanikul, Matthew Sirisukasakulchai, Papitchaya Sukruen, Sivapon Gatechompol, Stephen J. Kerr, Anchalee Avihingsanon
Research Group: HIV-NAT
697  CMV IgG IS ASSOCIATED WITH MUSCLE FUNCTION BUT NOT QUALITY OR MASS IN PEOPLE WITH HIV
Research Group: REPRIEVE Study Team

698  VALIDITY OF A SELF-REPORTED MODIFIED FRAILTY PHENOTYPE AMONG PEOPLE WITH HIV
Stephanie Ruderman, Allison Webel, Amanda Willig, Lydia Drumright, Annette Fitzpatrick, Michelle Odden, John Cleveland, Christine Davey, Julia Fleming, Thomas Buford, Raymond Jones, Meredith Greene, Charles Kamen, Chintan Pandya, Heidi Crane

699  COMORBIDITIES AND SYMPTOMS ASSOCIATED WITH FALLS: 2020-2021
Lydia Drumright, Stephanie Ruderman, Amanda Willig, Bridget Whitney, Robin Nance, Andrew Hahn, Sarah Mixson, Jimmy Ma, Rob Fredericksen, Jeff Jacobson, Katerina Christopoulos, Sonia Napravnik, Edward Cachay, Allison Webel, Heidi Crane

700  PREVALENCE, INCIDENCE, AND RISK FACTORS FOR FALLS IN OLDER PEOPLE WITH AND WITHOUT HIV
Emanuele Focà, Stefania Arsuffi, Jovana Milic, Chiara Mussi, Alessandra Marengoni, Micof Ferrara, Benedetto Maurizio Celesia, Giordano Madeddu, Anna Maria Cattelan, Stefano Calza, Andrea Calcagno, Giovanni Guaraldi

701  A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV
Fátima Brañas, Jorge Díaz-Álvarez, Jesús Fernández-Luna, Brian Vásquez, Rafael García-Molina, Elena Moreno, Pablo Ryan, Javier Martínez-Sanz, Laura Luna, Marta Martinez, Fernando Dronda, Matilde Sánchez-Conde

702  SMOKING CESSATION AND ASSOCIATED FACTORS IN THE HIV OUTPATIENT STUDY: 2007-2021
Jun Li, Carl Armon, Alexander Ewing, Jonathan Mahnken, Ellen Tedaldi, Frank Palella, Richard Novak, Cynthia Firnhaber, Stockton Mayer, Andrea Wendrow, Gina Simoncini, Linda Battalora, Kimberly Carlson, Marcus Durham, Kate Buchacz
Research Group: HIV Outpatient Study (HOPS) Investigators

Poster Session-N2 COVID-19 IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS
2:30 PM - 4:00 PM

724  HIV INFECTION INCREASES RISK OF PASC WHILE COVID-19 VACCINATION IS PROTECTIVE
George A. Yendewa, Jamie A. Perez, Nirav T. Patil, Grace A. McComsey

725  IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS
Yijia Li, Carlee Moser, Evgenia Aga, Judith S. Currier, David A. Wohl, Eric S. Daar, Justin Ritz, Robert Coombs, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Kara W. Chew, Jonathan Z. Li
Research Group: ACTIV-2/A5401

726  PROLONGED VIABLE VIRAL SHEDDING IN IMMUNOCOMPROMISED PATIENTS WITH COVID-19
Sung-Woon Kang, Jun-Won Kim, Jeong-Sun Yang, Kyung-Chang Kim, Hee-Chang Jang, Daesol Kim, Younmin Shin, Joo-Yeon Lee, Sung-Han Kim

727  SUICIDAL RISK AMONG PEOPLE WITH HIV AFTER LOCKDOWN DUE TO COVID-19 PANDEMIC
Yanink Caro-Vega, Jessica Mejía-Castrejón, Atenea Alvarez, Alvaro López Iñiguez, Juan Sierra-Madero, Brenda E. Crabtree-Ramírez
Poster Session-N3 COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS

2:30 PM - 4:00 PM

728 SIGNIFICANCE OF ELEVATED SARS-CoV-2 ANTIGEN LEVELS DURING EARLY HOSPITALIZATION
Mamta K. Jain
Research Group: ACTIV-3/TICO Study Group

729 IMMEDIATE AND CONTRIBUTORY CAUSES OF DEATH IN PATIENTS HOSPITALIZED WITH COVID-19

730 ANTI-S-RBD TITER AND RISK OF CLINICAL PROGRESSION IN PATIENTS WITH COVID-19 PNEUMONIA
Giuseppe Lapadula, Luca Mezzadri, Giustina Lo Cacio, Sergio Malandrin, Alice Ranzani, Silvia Limonta, Annalisa Cavallero, Paolo Bonfanti

731 AL-BASED PREDICTION OF LUNG TISSUE INVOLVEMENT IS PREDICTIVE OF COVID-19 SEVERITY
Miłosz Parczewski, Bogusz Aksak-Wąs, Daniel Chober, Laura Lesiewska, Malwina Karasińska-Cieślak, Krystian Awgul, Adam Majchrzak, Karol Serwin

732 A JOINT ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS ON ENOXAPARIN FOR COVID-19
Giovanni Dolci, Cinzia Del Giovane, Massimo Arquati, Valeria Coluccio, Erica Franceschini, Roberto D’Amico, Roberto Vicini, Pasquale Migliari, Riccardo Colombo, Alba Taino, Pietro Facchinetti, Lucia Trombetta, Francesca Tonelli, Marco Marietta, Maddalena Alessandra Wu

733 THE IMPACT OF EARLY OUTPATIENT TREATMENTS FOR COVID-19: A RETROSPECTIVE STUDY
Silvia Amadasi, Paola Bertuccio, Melania Degli Antoni, Francesca Viola, Davide Minisci, Francesco Rossini, Alex Francesco Bolandrini, Francesco Castelli, Anna Odone, Eugenia Quiros-Roldan

Poster Session-O3 STRATEGIES FOR OPTIMIZING TB TREATMENT AND PREVENTIVE THERAPY

2:30 PM - 4:00 PM

750 HIGH-DOSE ISONIAZID EARLY BACTERICIDAL ACTIVITY AGAINST DRUG-RESISTANT TUBERCULOSIS
Research Group: ACTG A5312 study team

751 TWICE-DAILY DOSING OF ATAZANAVIR SAFELY OVERCOMES THE INTERACTION WITH RIFAMPICIN
Kamunkhwala Gausi, Henry Mugerwa, Marco Siccardi, Maiara Montanha, Antonio D’Avolio, Lubbe Wiesner, Letisha Najjumba, Gary Maartens, Shamim Nakubaye, Cissy Kityo, Helen Mcclleron, Saye Khoo, Mohammed Lamorde, Paolo Denti, Catriona Waitt

752 LINEZOLID REACHES TARGET SITE IN PATIENTS WITH TB MENINGITIS AND HIV COINFECTION
Rob van Wijk, Freddie Kibengo, Paddy Kafeero, Anita Kabarambi, Patrick Muhumuza, Maria Nakimbugwe, Anthony Ssemaganda, Colman Tayebwa, Matthew Zimmerman, Fiona Cresswell, Veronique Dartois, Payam Nahid, Rada Savic, Felicia C. Chow
753  **PREDICTIVE VALIDITY OF POPULATION MODELS FOR LINEZOLID EXPOSURE AND TOXICITY IN ZeNIX**  
Marjorie Imperial, Belen Perez Solans, Jerry Nedelman, Rada Savic

754  **HARD-TO-TREAT PHENOTYPES INCREASE TIME TO CULTURE CONVERSION IN DRUG-RESISTANT TB**  
Belen Perez Solans, Marjorie Imperial, Morounfolu Olugbosi, Rada Savic

755  **EFFECTIVENESS OF DOLUTEGRAVIR IN PEOPLE ON RIFAMPIN-BASED TUBERCULOSIS TREATMENT**  
N. Sarita Shah, Cissy Kityo, Michael D. Hughes, Caitlyn McCarthy, Carole Wallis, Mina Hosseinipour, Deborah Langat, Mulinda Nyirenda, Mohammed Rassool, Rodney Dawson, Elizabeth Woolley, Catherine Godfrey, John W. Mellors, Charles Flexner, Gary Maartens  
**Research Group:** AIDS Clinical Trials Group A5381/Hakim Study Team

756  **DIFFERENTIATED SERVICE DELIVERY FOR PEOPLE COINFECTED WITH DRUG RESISTANT TB AND HIV**  
Karl Reis, Jennifer Zelnick, Allison Wolf, Rubeshan Perumal, Kogieulem Naidoo, Boitumelo Seepamore, Kevin Guzman, Jesse Ross, Ken Cheung, K. Rivet Amico, Gerald Friedland, Amrita Daftary, Max O’Donnell  
**Research Group:** PRospective study of Adherence in M/XDR-TB Implementation Science (PRAXIS) Research Group

757  **ACCELERATING TUBERCULOSIS PREVENTIVE TREATMENT AMONG TANZANIANS LIVING WITH HIV**  
Alexander Kailembo, Jaiving Kazitanga, Daniel Magesa, Peter Neema, Diana Forno Rodriguez, Anand Date, Eva Matiko, Nicolas Schaad, Jonathan Grund, Brian Baker, Mahesh Swaminathan, Mohamed Jalloh

758  **LOWER TB INCIDENCE AMONG PWH AFTER PREVENTIVE TREATMENT IN HIGH-BURDEN MDR TB SETTING**  
Olutomi Sodeke, Juliana de Fatuma Da Silva, Snigdha Vallabhaneni, Sherril L. Pals, N. Sarita Shah

**Poster Session-P2 OBESITY, INFLAMMATION, AND HIV IN PREGNANCY**  
2:30 PM - 4:00 PM

774  **ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES: A MEDIATION ANALYSIS**  
**Research Group:** IMPAACT 2010

775  **UNIQUE EICOSANOID/LIPID PROFILES IN PREGNANT WOMEN LIVING WITH HIV IN BOTSWANA**  
Jennifer Jao, Lauren Bonner, Shan Sun, Justine Legbedze, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Sikhulile Moyo, Joseph Makhma, Mitchell E. Geffner, Elaine J. Abrams, Mariana Gerschenson, Yunping Qiu, Kathleen M. Powis, Irwin Kurland

776  **CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV**  
Hlengiwe P. Madlala, Landon Myer, Azetta Fisher, Mushii Matjila, Gregory Petro, Zandile Maqwatini, Angela Bengtson

**Poster Session-P4 USING ANTIRETROVIRALS IN PREGNANCY**  
2:30 PM - 4:00 PM

782  **PBPK MODEL PREDICTION OF LONG-ACTING CAB AND RPV CONCENTRATIONS IN PREGNANCY**  
Yifan Yu, Adrie Bekker, Xinrong Li, Robert Bies, Rachel Scott
783  **PHARMACOKINETICS AND VIROLOGIC OUTCOMES OF BICTEGRAVIR IN PREGNANCY AND POSTPARTUM**

Kathleen M. Powis, Mauricio Pinilla, Lauren Bergam, Alice Stek, Kristina M. Brooks, David Shapiro, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Priyanka Arora, Brookie M. Best, Mark Mirochnick, Jeremiah D. Momper

**Research Group:** IMPAACT 2026 Protocol Team

784  **LONG-ACTING NANOFORMULATIONS REDUCE DULTEGRAVIR EXPOSURE TO EMBRYO BRAIN**

Emma G. Foster, Benson Edagwa, Howard E. Gendelman, Aditya Bade

785  **DAPIVIRINE RING SAFETY AND DRUG DETECTION IN BREASTFEEDING MOTHER-INFANT PAIRS**


**Research Group:** MTN-043/B-PROTECTED Study Team

786  **PREGNANCY AND BIRTH OUTCOMES FOLLOWING ORAL PrEP USE BY OBJECTIVE LEVELS OF TDF/FTC**

Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer

**Research Group:** PrEP-PP Study Group

---

**Poster Session-P6 COVID-19 IN PREGNANCY: EVOLVING INSIGHTS**

2:30 PM - 4:00 PM

794  **SARS-CoV-2 ANTIBODY RESPONSES POST-INFECTION IN PREGNANCY BY VACCINATION STATUS**

Sylvia M. Lacourse, Erica Wetzler, Morgan C. Aurelio, Jaclyn Escudero, Stacy Selke, Alexander L. Greninger, Alisa B. Kachikis, Janet A. Englund, Alison L. Drake

795  **SARS-CoV-2 SEROPREVALENCE TREND AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022**

Elizabeth Heilmann, Taniya Tembo, Felix Chilambe, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Warren Malambo, Victoria Seffren, Ruchi Yadav, Theodora Savory, Andrew Auld, Jonas Hines, Lloyd B. Mulenga, Izuankanji Sikazwe

795.5  **SARS-CoV-2 SEROPREVALENCE BY HIV STATUS AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022**

Elizabeth Heilmann, Taniya Tembo, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Julie Gutman, Victoria Seffren, Ruchi Yadav, Theodora Savory, Izuankanji Sikazwe, Jonas Hines

796  **COVID-19 VACCINATED MATERNAL/CORD BLOOD DON'T HAVE NEUTRALIZATION FOR OMICRON VARIANTS**

Sakthivel Govindaraj, Narayanaiah Cheedarla, Suneetha Cheedarla, Les’Shon S Irby, Andrew Neish, John Roback, Alicia K. Smith, Vijayakumar Velu

**Research Group:** EPIICAL Consortium

---

**Poster Session-Q2 INFLAMMATION AND IMMUNITY IN CHILDREN**

2:30 PM - 4:00 PM

806  **MORTALITY LINKED TO HIGHER INFLAMMATION IN PERINATALLY-INFECTED HIV+ KIDS**

Elena Morrocchi, Giuseppe Rubens Pascucci, Nicola Cotugno, Chiara Medri, Chiara Pighi, Sara Dominguez, Alfredo Tagarro, Lesley de Armas, Savita Pahwa, María Raffaella Pettrara, Anita De Rossi, Ofer Levy, Paolo Rossi, Carlo Giaquinto, Paolo Palma

**Research Group:** EPIICAL Consortium
807 INFECTED NAIVE CD4+ T CELLS IN CHILDREN WITH HIV CAN PROLIFERATE AND PERSIST ON ART
Mary Grace Katusiime, Shuang Guo, Victoria Neer, Sean C. Patro, Xiaolin Wu, Anna Horner, Ann Chahroudii, Maud Mavignier, Mary F. Kearney

808 LONGITUDINAL T CELL IMMUNE PROFILING IN HIV-EXPOSED INFECTED AND UNINFECTED INFANTS
Lesley de Armas, Suresh Palilikkuth, Stefano Rinaldi, Vinh Dinh, Paula Vaz, Nadia Sitone, Nicola Cotugno, Rajendra Pahwa, Paolo Palma, Maria Grazia Lain, Savita Pahwa

809 TORQUETENOVIRUS: MARKER OF IMMUNE RECONSTITUTION IN PERINATALLY HIV-INFECTED PATIENTS
Laura Taranco-Diez, Itziar Carrasco, Laura Montes, Iker Falces, Santiago Jimenez de Ory, Marta Dapena, Luis López-Cortés, Elena Colino, Ana Isabel Menasalvas, Jose Antonio Iribarren, Cristina Díez, José Ignacio Bernardino, Mª Angeles Muñoz-Fernández, Marisa Navarro, Talía Sainz

Poster Session-Q3 REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV

2:30 PM - 4:00 PM

810 HIGH MORTALITY IN AFRICAN INFANTS HOSPITALIZED WITH SEVERE PNEUMONIA AND ADVANCED HIV
Alfeu Passanduca, W. Chris Buck, Alfredo Tagarro, Victor Musiime, Hilda A. Mujuru, Chishala Chabala, Lola Madrid, Sara Dominguez, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magalhaes-Bramugy, Raoul Moh, Álvaro Ballesteros, Cinta Moraleda, Pablo Rojo
Research Group: EMPIRICAL Clinical Trial Group

811 MORTALITY RISK AMONG CHILDREN < 5 YEARS OLD LIVING WITH HIV ON ART
Nickolas T. Agathis, Iyiola Faturiyele, Kiva Fisher, Stephanie Hackett,Elfriede Agyemang, Susan Hrapcak, George Siberry, Catherine Godfrey

812 RELATIVE GAP IN HIV VIRAL LOAD SUPPRESSION IN YOUNGER CHILDREN IN ETHIOPIA
Dereje Habte, Alemayehu Mekonnen, Tekeste Kebede, Wondimu Teferi, Daniel M. Desalegn, Caroline A Ryan

813 FANMI: A RANDOMIZED TRIAL OF COMMUNITY COHORT HIV CARE FOR ADOLESCENT GIRLS, HAITI
Vanessa Rouzier, Lindsey Reif, Joseph Marie Bajo Joseph, Rose Riche, Heejung Bang, Elaine J. Abrams, Jean William Pape, Daniel W. Fitzgerald, Margaret McNairy
Research Group: The FANMI Clinical Trial Team

814 ECONOMIC STRENGTHENING INTERVENTION TO IMPROVE ART ADHERENCE IN HIV-INFECTED YOUTH
Samuel Kizito, Flavia Namuwonge, Proscoiva Nabunya, Josephine Nabayinda, Fred Ssewamala
Research Group: TransCITAR Study Group

Poster Session-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES

2:30 PM - 4:00 PM

858 SEX DIFFERENCES IN NON-FATAL OVERDOSES: A POPULATION-BASED COHORT STUDY
Megan E. Marziali, Katherine W. Kooij, Jason Trigg, Michael O. Budu, Monica Ye, Viviane D. Lima, Julio Montaner, Robert S. Hogg

859 TRANSGENDER WOMEN BASELINE PROFILE IN transCITAR: TRANS-SPECIFIC COHORT IN ARGENTINA
Claudia E. Frola, Romina Caballero, Carina César, Emilia Frontini, María I. Figueroa, Carolina F. Pérez, Nicolás Doudchitzky, Nadir Cardozo, Virginia Zalazar, Ana Gun, Pedro E. Cahn, Valeria Fink, Inés Arístegui
Research Group: transCITAR Study Group
Poster Sessions

860 INTIMATE PARTNER VIOLENCE IN A COHORT OF PERSONS WITH HIV IN CARE
Rob Fredericksen, Lydia Drumright, Sarah Mixson, Robin Nance, Bridget Whitney, Stephanie Ruderman, Jimmy Ma, Andrew Hahn, Sonata Napravnik, Amanda Willig, Jeff Jacobson, Katerina Christopoulos, Edward Cachay, Mari Kitahata, Heidi Crane

861 SYNERGISM BETWEEN VIOLENCE & HIV STATUS ON SUICIDAL IDEATION AMONG TRANSGENDER WOMEN
Evelyn Olansky, Kathryn Lee, Ruthanne Marcus, Susan Cha, Patrick C. Eustaquio
Research Group: NHBS-Trans Study Group

862 PREVALENCE AND CORRELATES OF VIOLENCE AMONG PARTNERS OF PWID LIVING WITH HIV IN KENYA

Poster Session-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION 2:30 PM - 4:00 PM

863 PERSISTENTLY HIGH HIV INCIDENCE AMONG MSM AND PWID ATTENDING CARE CENTRES IN INDIA

864 NOT GETTING TO ZERO HIV FOR PEOPLE WHO INJECT DRUGS, SAN FRANCISCO
Moranda Tate, Bow Suprasert, Danyion Reagan, Katherine Gao, Katherine McNaughton, Raul Ruiz, Kassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson

865 RACIAL DISPARITIES IN HIV PRE-EXPOSURE PROPHYLAXIS-RELATED OUTCOMES IN MALE VETERANS
Dagan Coppock, Benjamin Viernes, Michael Kauth, Robert Gross, Kristine Lynch

866 BEHAVIOR CHANGE AMONG HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN NOT USING PrEP IN THE US
Steven M. Goodreau, Michael P. Barry, Deven T. Hamilton, Travis H. Sanchez, Kevin Delaney

867 REASONS FOR MIGRATION AND ASSOCIATIONS WITH HIV RISK AMONG SEXUAL MINORITY MEN
Jane J. Lee, Roxanne P. Kerani, Gabriel Robles, Travis H. Sanchez, David A. Katz

868 SEXUAL RISK AND ROLE OF LOW-LEVEL VIREMIA TO HIV TRANSMISSION IN SUB-SAHARAN AFRICA
Olanrewaju Edun, Lucy Okell, Helen M. Chun, Kyle Milligan, Emilio Dirlkiv, Ray W. Shiraishi, Jeffrey W. Eaton
Research Group: Viremia HIV Transmission Investigation Group

869 REDUCTION OF HIV INCIDENCE AFTER ELIMINATION OF LYMPHATIC FILARIASIS
Poster Session-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA
2:30 PM - 4:00 PM

895 NEW HIV DIAGNOSES IDENTIFIED FROM LINKAGE TO CARE AFTER MPOX INFECTION, TEXAS 2022
Anaîse Monterosso, Kristyn Krolikowski, Kenneth Davis, Rania Millerson, Stephen White

896 MPOX VIRUS IN THE PHARYNX OF MEN HAVING SEX WITH MEN: A CASE SERIES
Silvia Limonta, Laura Corsico, Giuseppe Lapadula, Francesca Rovida, Alice Ranzani, Fausto Baldanti, Paolo Bonfanti

897 MPOX AMONG MSM IN THE NETHERLANDS PRIOR TO MAY 2022, A RETROSPECTIVE STUDY
Elske Hoornenborg, Henry de Vries, Hannelore Götz, Sylvia Bruisten, Annemiek van Der Eijk, Maria Prins, Bas Oude Munnik, Matthijs Welkers, Marcel Jonges, Richard Molenkamp, Benda Westerhuis, Daphne Mulders, Leonard Schule, Mariken van Der Liubben, Marion Koopmans, Arjen Stam

898 CHANGES IN SEXUAL BEHAVIORS DUE TO MPOX: A CROSS-SECTIONAL STUDY OF SGM IN ILLINOIS
Gregory Phillips, Michael Curtis, Dylan Felt, Shahniv Davoudpour, Anthony Rodriguez-Ortiz, Alfred Cortez, Audrey French, Sybil Hosek, Pedro Serrano

899 SEXUAL BEHAVIOR REDUCTION DO NOT EXPLAIN DECREASED MPOX INCIDENCE AMONG PRÈP USERS.
Roberto Rossotti, Daniele Calzavara, Massimo Cernuschi, Anna De Bona, Alessandro Tavelli, Simona Bossolasco, Camilla Muccini, Daniele Tesoro, Davide Moschese, Giovanni Mulé, Antonella D’Arminio Monforte

900 STIGMA RELATED TO HUMAN MPOX VIRUS AMONG MSM IN THE US, AUGUST 2022
Thomas Carpino, Kaitlyn Atkins, Kevin Delaney, O. Winslow Edwards, Evan Eschilman, Amrita Rao, Saskia Vos, Sarah Murray, John Mark Wiginton, Travis H. Sanchez, Stefan Baral

Poster Session-S4 MPOX CHARACTERISTICS AND OUTCOMES
2:30 PM - 4:00 PM

902 CHARACTERISTICS AND DISPARITIES AMONG HOSPITALIZED PERSONS WITH MPOX IN CALIFORNIA

903 CD4 COUNT < 350 CELLS/MM³ INCREASES RISK OF HOSPITALIZATION WITH MPOX IN PWH
David CE. Philpott, Robert Bonacci, Paul J. Weidle, Kathryn G. Curran, John Brooks, George Khalil, Lauren Barrineau-Vernejayva, Amanda Feldpausch, Jessica Pavlick, Pascale Worthley, Jesse O’Shea
Research Group: CDC Mpx Special Studies Team

904 MPOX VIRUS INFECTION IS MORE SEVERE IN PATIENTS WITH UNCONTROLLED HIV INFECTION
Anaís Corma-Gómez, Marta Santos, Alfonso Cabello, Miguel Morante-Ruiz, Aws Waleed Al-Hayani, Irene Carrillo Acosta, Lucio García-Fraile, Cristina Gómez-Ayerbe, David Rodrigo-Dominguez, Sergio Reus, Ana C. Silva Klug, Sandra De la Rosa-Riestra, Ana Ferrer-Ribera, Juan A. Pineda, Juan Maclás
905 IMPACT OF HIV INFECTION ON MPOX-RELATED HOSPITALIZATIONS IN BRAZIL
Research Group: INI-Fiocruz Mpxox Study Group

906 CHARACTERISTICS OF THE 2022 MPOX OUTBREAK IN A SOUTHEASTERN US CITY
Bruce Aldred, Colleen Kelley, Jonathan Colasanti, Vincent C. Marconi, Anandi N. Sheth, Minh Nguyen, Jane Yoon Scott, Sheetal Kandiah, Aley G. Kalapila, Daniel Gromer, Amalia Aldredge, Brittany Szabo, Betsy Hall, Valeria D. Cantos
Research Group: Emory MAPS Study Group

907 CLINICAL OUTCOMES AMONG IN- AND OUTPATIENTS WITH MPOX IN AN URBAN HEALTH SYSTEM
William M. Garneau, Joyce L. Jones, Gabriella Dashler, Nathan Kwon, Matthew Hamill, Elizabeth Williams, David Rudolph, Jeannie Keruly, Eili Klein, Bhakti Hansoti, Kelly Gebo

908 HIV CARE AND PREVENTION CHARACTERISTICS AMONG PERSONS WITH MPOX AND HIV, TEXAS 2022
Kristyn Krolikowski, Kenneth Davis, Rania Millerson, Stephen White

909 MPOX OUTBREAK IN PLWHA AND PrEP USERS IN A BRAZILIAN STI CENTER: DIFFERENT CHALLENGES
Alvaro Costa, Simone Queiroz Rocha, MyIva Fonsi, Roberto Schiavon Nogueira, Arthur Olhoffetchi Kalichman, Jose V. Madruga, Maria Clara Gianna, Rosa Alencar, Rosangela Rodrigues, Angela Taya, Lucas Ramos, Marisa Vono Tancredi
Research Group: MONKEYPOX GROUP - CRT CASA DA PESQUISA

910 MPOX IN THE CONTEXT OF POPULATION-LEVEL HIV TREATMENT AND HIV PrEP PROGRAMS IN BC
K. Junine Toy, Raquel M. Espinoza, Paul Sereda, Erin Ready, Wendy W. Zhang, Viviane D. Lima, Kate Salters, Rolando Barrios, Julio Montaner

911 MPOX IN AMSTERDAM: CROSS-SECTIONAL STUDY AMONG MSM AT THE CENTRE FOR SEXUAL HEALTH
Elske Hoornenborg, Matthijs Siegenbeek Van Heukelom, Vita Jongen, Jason Schouten, Sylvia Bruisten, Benda Westerhuis, Matthijs Welkers, Maria Prins, Maarten Schim Van Der Loeff, Henry de Vries

912 CHARACTERISTICS OF PATIENTS HOSPITALIZED WITH MPOX DURING THE 2022 US OUTBREAK
Research Group: Centers for Disease Control Severe Mpox Investigations Team

913 EQUITY FOCUSED EVALUATION OF MPOX CARE METRICS IN KING COUNTY, WA
Ellora Karmarkar, Chase Cannon, Matthew Golden, Sargs Pogosjans, Eric Chow, Meena Ramchandani, Kaitlin Zinsli, Julia C. Dombrowski

914 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MPOX WITHIN A NEW YORK CITY HEALTH SYSTEM
Christopher A. Vo, Rustin Zomorodi, Richard J. Silvera, Logan Bartram, Amarilis Lugo, Erna Kojic, Antonio Urbina, Judith A. Aberg, Keith Sigel, Rachel Chasan, Gopi Patel

915 MPOX INFECTION IN WOMEN: A CASE SERIES FROM BRAZIL
Carolina Coutinho, Luciane Velasque, Mayara Silva, Thiago S. Torres, Eduardo Peixoto, Sandra Wagner Cardoso, Gabriella Nazário, Maira Mendonça, Marriana Menezes, Paula Maria Almeida, Shenon Bia Bedin, Aline Maria Almeida, Silvia Carvalho, Valdilea Veloso, Beatriz Grinsztejn
Research Group: The INI-Fiocruz Mpxox Study Group
**Poster Session-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING**  
*2:30 PM - 4:00 PM*

**Poster Session-U2 SARS-CoV-2 SELF-TESTING**  
*2:30 PM - 4:00 PM*
Poster Sessions

959  COST-EFFECTIVENESS OF WORKPLACE COVID-19 SELF-TESTING: A MATHEMATICAL MODELING STUDY
Ethan Klock, Alvin X. Han, Joshua M. Chevalier, Megan A. Hansen, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols

960  HOME VERSUS FACILITY SARS-CoV-2 TESTING AMONG OLDER ADULTS IN NEW YORK CITY
Abigail R. Greenleaf, Shannon M. Farley, David Hoos, Melissa Reyes, Takura Kupamupindi, Kimberly Geoffrey, Wafaa El-Sadr

Poster Session-V3 OPTIMIZING PrEP ROLLOUT
2:30 PM - 4:00 PM

975  RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA
Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chanie, Maya Petersen, Moses Kamya, Diane V. Havlir
Research Group: SEARCH Study Team

976  INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH
Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Thembelihle Zuma, Osee Behuhuma, Jean-Michel Molina
Research Group: Isisekelo Sempilo Research Group

977  EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA
Ashley R. Bardon, Kenneth Ngure, Peter Mogere, Katherine Thomas, Stephen Gaku, Catherine Kiptinness, Sarah Mbaire, Dorothy Mangale, Jacinta Nyokabi, Nelly Mugo, Jared M. Baeten, Katrina F. Ortblad

978  PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION
Stephanie Roche, Victor Omollo, Peter Mogere, Magdaline Asewe, Stephen Gaku, Preetika Banerjee, Kendall Harkey, Josephine Odoyo, Jared M. Baeten, Patricia Ongwen, Daniel Were, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad

979  PREDICTIVE VALUES OF URINE PrEP (TFV) TEST SHOW STRONG CLINICAL AND RESEARCH UTILITY
Brian Mustanski, Richard D'Aquila, Monica Gandhi, Daniel Ryan, Matthew A. Spinelli, Michael Newcomb
Research Group: RADAR Study Investigators

980  ORAL AND INJECTABLE PrEP USE IN THE UNITED STATES, 2013 TO 2022
Weiming Zhu, Ya-Lin Huang, Athena P. Kourtis, Karen W. Hoover

981  BREAKTHROUGH HIV-1 INFECTION IN SETTING OF LONG-ACTING CABOTEGRAVIR FOR PrEP
Aniruddha Hazra, Connor Quinby, Cathy Creticos

Poster Session-V6 PrEP PRODUCT UPDATE AND EFFECTIVENESS
2:30 PM - 4:00 PM

993  EFFECTIVENESS OF HIV PRE-EXPOSURE PROPHYLAXIS AMONG FEMALE SEX WORKERS IN RWANDA
Eric Remera, Gallican N. Rwibasira
994  PRE-EXPOSURE PROPHYLAXIS PRODUCT CHOICE IN US PARTICIPANTS IN HPTN 083
Meredith E. Clement, Zhe Wang, Carl J. Fichtenbaum, Schuyler Thomas, Jose A. Bazan, Paul Richardson, Matthew A. Spinelli, Brett Hanscom, Alex R. Rinehart, Jim Rooney, Adeola Adeyeye, Marybeth McCauley, Myron S. Cohen, Beatriz Grinsztejn, Raphael J. Landovitz
Research Group: HPTN 083 Study Team

995  OPTIMIZING PRE-EXPOSURE PROPHYLAXIS WITH TDF-FTC AND TAF-FTC FOR INSERTIVE SEX
Carolina Herrera, Laura J. Else, Emily Webb, Azure-Dee Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Jennifer Serwanga, Andrew Sentooogo Ssemata, Patricia Namubiru, Geoffrey Odoch, Clive M Gray, Francesca Chioldi, Saye Khoo, Neil Martinson, Julie Fox
Research Group: CHAPS study team

996  INTERACTION BETWEEN TAF-BASED PREP AND HORMONE THERAPY IN TRANSGENDER WOMEN: iFACT 3
Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen J. Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatala Boonruang, Nipat Teeratakulsarn, Tim R. Cresssey, Nittaya Phanuphak
Research Group: the iFACT3 study team

997  PREP USE AMONG US VETERANS USING VETERAN HEALTH ADMINISTRATION SERVICES: 2017-2021
Ya-Lin A. Huang, Elliot Lowy, Lei Yu, Weiming Zhu, Wei Wei, Karen Hoover, Lauren A. Beste

998  ALIGNMENT OF PrEP USE WITH HIV RISK IN YOUNG WOMEN AND MEN IN UGANDA
Linxuan Wu, Andrew Mujugira, Timothy Muwonge, Timothy Ssebuliba, Felix Bambia, Olivia Nampeyo, Renee Heffron

999  A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA
Ingrid Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile Ngcobo, Taing N. Aung, Jana Jarolimova, Danielle Zions, Christina Psaros, Nduduzo Dube, Robert Parker

Poster Session-W2 SARS-CoV-2 VACCINE STRATEGIES
2:30 PM - 4:00 PM

1005  LONG-TERM COVID-19 BOOSTER EFFECTIVENESS AND IMMUNE IMPRINTING
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, Laith J. Abu-Raddad

1006  RESIDENTIAL SEGREGATION AS A BARRIER TO COVID-19 BOOSTER COVERAGE IN DEEP SOUTH
Chengbo Zeng, Jiajia Zhang, Zhenlong Li, Xiaowen Sun, Huan Ning, Xueying Yang, Sharon Weissman, Bankole Olatosi, Xiaoming Li, Chen Liang

1007  SARS-CoV-2 VACCINE EFFECTIVENESS IN A COHORT OF ACTIVE-DUTY US MILITARY PERSONNEL
Jessica J. Cowden, Vanessa Cox, Diane Epperson, Elissa Thomas, Genice Jacques, Sonya Arzola, Kelly McKee, Jason Okulicz
Research Group: VIRAMP Study Group

1008  EFFECTS OF PUBLIC HEALTH INTERVENTIONS AGAINST COVID-19 IN FRANCE
Iris Ganser, David L. Buckeridge, Melanie Prague, Rodolphe Thiebaut

1009  EQUITY-BASED OPTIMIZATION FOR COVID-19 VACCINE ALLOCATION
Erin Stafford, Dobromir Dimitrov, Rachel Ceballos, Laura Matrajt
1010 VACCINE UPTAKE IN A PREDOMINANTLY BLACK AND LATINX COHORT HOSPITALIZED FOR COVID-19
Michelle Chang, Jennifer Chang, Simian Huang, Joan Bosco, Meredith McNairy, Sade Tukuru, Yi Hao Wu, Jonathan Kunkel-Jure, Jessica Weidler, Carlie Dorr, Renee Roberts, Brett Gray, Jason Zucker, Delivette Castor, Magdalena E. Sobieszczuk

1011 PREVALENCE AND CORRELATES OF SARS-CoV-2 VACCINE HESITANCY AMONG US PEOPLE WITH HIV
Matthew A. Spinelli, Mallory O. Johnson, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burkholler, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Katerina Christopoulos

1012 SAFETY OF HETEROLOGOUS MRNA-1273 BOOST AFTER AD26. CoV2.S PRIME IN SOUTH AFRICA
Research Group: SHERPA Study Team

1013 REACTOGENICITY AMONG PEOPLE LIVING WITH HIV AFTER MRNA-1273 VACCINE IN UBUNTU STUDY
Asa Tapley, Jessica Andriesen, Yunda Huang, Azwidihwi Takalani, Bongile M abilane, Manuel V. Villaran, Taraz Samandari, Sufia Dhadabhi, Linda-Gail Bekker, Margaret Yacovone, Aaron Hudson, Lawrence Corey, Glenda E. Gray, Philip Kotze, Nigel Garrett
Research Group: CoVPN 3008 Ubuntu Study Team

1014 COVID-19 VACCINATION IN PERSONS WITH AND WITHOUT HIV: VETERANS AGING COHORT STUDY
Emily J. Cartwright, Kathleen McGinnis, Janet P. Tate, Christopher T. Rentsch, Kendall Bryant, Emily C. Williams, Sheldon T. Brown, Evelyn Hsieh, Amy C. Justice, Lesley S. Park

1015 THE CHANGING IMPACT OF VACCINES IN THE COVID-19 PANDEMIC: A MODELING STUDY
Robyn Stuart, Jamie Cohen, Jasmina Panovska-Griffiths, Edinah Mudimbu, Romesh Abey suriya, Cliff Kerr, Michael Famulare, Daniel Klein

1016 HIV VIRAL LOAD AND TIME-TO-COVID-19 VACCINATION AMONG PEOPLE WHO INJECT DRUGS
Pieter Baker, Javier Cepeda, Becky Genberg, Greg Kirk, Shruti H. Mehta, Kenneth Feder, Jacqueline E. Rudolph, Jing Sun

1017 COVID-19 VACCINE COVERAGE AMONG PEOPLE WITH HIV IN THE VACCINE SAFETY DATALINK
Rulin Hechter, Lei Qian, In-Lu Amy Liu, Lina Sy, Denison Ryan, Joshua Williams, Laura Hurley, Nicola Klein, Robyn Kaiser, Elizabeth Liles, Hung Fu Tseng

1018 CORRELATES OF COVID-19 VACCINE UPTAKE IN MALAWIAN ADULTS
Hannah Whitehead, John Songo, Pericles Kalande, Khumbo Phiri, Eric Lungu, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, Risa Hoffman, Corrina Moucheraud

NP
Lucky D. Makonokaya, Lester Kapanda, Thulani Maphosa, Louiser Kalitera, Harrid Nkhoma, Rachel Chamanga, Cathy Golowa, Suzzo Zimba, Godfrey Woelk, Malocho Phoso, Nilesh Bhatt

1020 COMPARISON OF THE EFFECTIVENESS OF DIFFERENT COVID-19 VACCINES AMONG PLWH
Wang-Da Liu, Pei-Ying Wu, Ling-Ya Chen, Hsin-Yun Sun, Yu-Shan Huang, Kuan-Yin Lin, Guei-Chi Li, Wen-Chun Liu, Yi-Ching Su, Yi-Chen Yeh, Yi-Ting Chen, Hsi-Yen Chang, Yu-Zhen Luo, Sui-Yuan Chang, Chien-Ching Hung
Poster Sessions

Poster Session-X2 STI EPIDEMIOLOGY IN POPULATIONS AFFECTED BY HIV
2:30 PM - 4:00 PM

1025 INCREASED HIV, HCV & STIs AMONG ADULTS REPORTING SEX WORK IN ALABAMA: 2008-2022
Kaitlyn Atkins, Josh Bruce, Emma Kay, Karen Musgrove, Polly Kellar, Sarah MacCarthy

1026 PREVALENCE OF CHLAMYDIA AND GONORRHEA AMONG ADOLESCENTS IN KISUMU, KENYA
Hong-Ha M. Truong, Elsa Heylen, Kevin Kadede, Sayo Amboka, Damaris Odeny, Maurice Opioy, Marien Hewa, Fidel Opondo, Beatrice Otieno, Hannington Odhiambo, David Ogolla, Mary Guzé, Lara E. Miller, Craig R. Cohen, Elizabeth A. Bukusi
Research Group: Maneno Yetu Study Team

1027 PATTERNS OF STI AMONG TRANSGENDER WOMEN LIVING WITH AND WITHOUT HIV IN THE US
Research Group: American Cohort To Study HIV Acquisition Among Transgender Women (LITE) Study Group

Poster Session-X4 INTERTWINED: MPOX and STI EPIDEMIOLOGY
2:30 PM - 4:00 PM

1033 MPOX AND SEXUALLY TRANSMITTED INFECTION AMONG MEN WHO HAVE SEX WITH MEN
Jesse J. Carlson, Karen Wendel, Kellie Hawkins, Oluyomi Obafemi, Edward M. Gardner, Michael Breyer, Laura Podewils

1034 HIV AND SEXUALLY TRANSMITTED INFECTIONS AMONG MPOX CASES, TEXAS 2022
Analise Monterosso, Kacey Russell, Enyinnaya Merengwa, Kristyn Krolikowski, Abigail Jordan, Kenneth Davis, Rania Milleron, Stephen White

1035 CONCURRENT STI TESTING AMONG PATIENTS TESTED FOR MPOX AT DUKE UNIVERSITY HEALTH
Emily Niehaus, Ahmad Mourad, Edwin Wilbur, Woodhouse, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout

Poster Session-Y05 PRESENTATION TO CARE
2:30 PM - 4:00 PM

1052 PREDICTORS OF PLWH NEWLY PRESENTING TO CARE WITH VIRAL SUPPRESSION IN LUSAKA, ZAMBIA
Jake M. Pry, Chilambwe Mwila, Herbert Kapesa, Musunge Mulabe, Christiana Frimpong, Theodora Savory, Carolyn Bolton Moore, Michael E. Herce, Shilpa S. Iyer

1053 LATE PRESENTATION IN OLDER PWH IS ASSOCIATED WITH MORTALITY AND POOR IMMUNE RESPONSE
Win Min Han, Sirinya Teeraananchai, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Anchalee Avihingsanon, Stephen J. Kerr, Kiat Ruxrungham
Poster Session-Y06 LONG-ACTING ART
2:30 PM - 4:00 PM

1054 POTENTIAL IMPACT OF LONG-ACTING ANTIRETROVIRAL THERAPY ON LOCAL HIV INCIDENCE
Preetham Bachina, Paramas Kasaie, Melissa Schnure, David Dowdy, Maunank Shah, Anthony Fojo

1055 IDENTIFYING PREFERRED PROGRAM DELIVERY ATTRIBUTES FOR LONG-ACTING INJECTABLE ART
Jose Gutierrez, Elizabeth Montgomery, Moira McNulty, Jonathan Colasanti, Mallory O. Johnson, Torsten Neilands, Kimberly Koester, John Sauceda, Samantha E. Dilworth, Xavier Erquera, Kaylin Dance, Manami Diaz Tszuki, John Schneider, Elvin Geng, Katerina Christopoulos

Poster Session-Y07 ART REGIMENS
2:30 PM - 4:00 PM

1056 UPTAKE AND OUTCOMES OF FIRST-LINE DOLUTEGRAVIR IN A LARGE SOUTH AFRICAN COHORT
Jienchi Dorward, Yukteshwar Sookrajh, Thokozani Khubone, Johan van Der Molen, Riona Govender, Sifiso Phakathi, Lara Lewis, Christian Bottomley, Munthu Maraj, Richard Lessells, Kogieulem Naidoo, Christopher Butler, Rosemary Van Heerden, Nigel Garrett

1057 SEX DISPARITIES IN THE ROLLOUT OF DOLUTEGRAVIR IN LATIN AMERICA AND THE CARIBBEAN
Fernanda F. Fonseca, Paridhi Ranadive, Bryan E. Shepherd, Beatriz Grinsztejn, Sandra Wagner Cardoso, Valdilea Veloso, Flavia Ferreira, Maria Fernanda Rodriguez, Daisy Maria Machado, Vanessa Rouzier, Diana Varela, Emilia M. Jalil, Jessica L. Castilho Research Group: CCASAnet

1058 MONITORING HIV DUAL-THERAPY IMPLEMENTATION AS REGIMEN SIMPLIFICATION POLICY IN BRAZIL
Nazle Veras, Rosana Pinho, Alexandre Ferreira, Ana Cristina G. Ferreira, Beatriz Kamienisky, Ana Francisca Kolling, Gerson Fernando M. Pereira, Ana Roberta Pascom

1059 A NATIONWIDE OPTIMIZATION STRATEGY USING SECOND-GENERATION InSTIs IN MEXICO
Alicia Piñeirúa-Menéndez, Yanink Caro-Vega, Juan Luis Mosqueda-Gómez, Santiago Ávila-Ríos, Florentino Bialdz-Hernández, Andrea González-Rodríguez, Gustavo Reyes-Terán, Juan Sierra-Madero, Alethse De La Torre-Rosas

1060 PEOPLE FAILING FIRST-LINE REGIMENS REMAIN AT RISK FOR ADVERSE SECOND-LINE OUTCOMES
Pupe Sudsila, Sirinya Teeraananchai, Saisopin Kiertiburanakul, Cheewanan Lertpibulaysut, Rattaphon Triamwichanon, Sivaporn Gatechompol, Opas Putcharoen, Ploenchon Chutchotisakd, Anchalee Aivingsanon, Stephen J. Kerr, Kiat Ruxrungtham

1061 PREDICTORS OF TRANSITIONING TO A FIRST-LINE DOLUTEGRAVIR REGIMEN IN WEST AFRICA

1062 TRANSITION TO DOLUTEGRAVIR-BASED ART IN LOW- AND MIDDLE-INCOME COUNTRIES IN IeDEA
1063 NATIONAL TRENDS IN ART REGIMENS FILLED FOR PEOPLE WITH HIV ON MEDICARE: 2013-2019
Jose Figueroa, Jessica Phelan, Luke Ang, Emily P. Hyle

Poster Session-Y12 ADVANCED HIV DISEASE
2:30 PM - 4:00 PM

1085 COST DRIVERS OF PROVIDING ADVANCED HIV DISEASE CARE THROUGH HUB/SPOKE MODEL IN MALAWI
Mario Songane, Sushant Mukherjee, Rachel Chamanga, Barry Longwe, Joseph Namathanga, Thulani Maphosa, Allan Ahimbisibwe, Rebecca Bailey, Appolinaire Tiam

1086 ADVANCED HIV DISEASE CARE PACKAGE IMPLEMENTATION IN LESOTHO AND SOUTH AFRICA
Tinne Gils, Lutgarde Lynen, Kamele Mashaete, Josephine Muhairwe, Thulani Ngubane, Philip Joseph, Klaus Reither, Moniek Bresser, Alastair van Heerden

Poster Session-Y13 PREVENTION AND PrEP MODELS
2:30 PM - 4:00 PM

1087 ARE VENUE-BASED STRATEGIES THE TICKET TO THE LAST MILE IN HIV PREVENTION IN MALAWI?
Emmanuel Singogo, Sharon Weir, Evaristar Kudowa, Maganizo Chagomeranana, Jessie Edwards, John Chapola, Confidence Banda, Gift Kawai, Andreas Jahn, Yohane Kamgwira, Lucy Platt, Brian Rice, James Hargreaves, Mina Hosseinipour, Thomas Hartney
Research Group: CLOVE Study

1088 COMMUNITY-ENGAGED PrEP DEMONSTRATION PROJECT FOR MSM IN CHINA
Bin Yu, Cao Fang, Zhuoheng Yin, Chunyan Li, Haojie Huang, Kun Wang, Quanmin Li, Linghua Li, Ke Liang, Ivy Jiang, Joseph Tucker, Renslow Sherer, Jonathan Lio, Aniruddha Hazra, Weiming Tang

1089 RANDOMIZED TRIAL LEVERAGING ELECTRONIC HEALTH RECORD DATA TO INCREASE HIV PrEP UPTAKE

1090 COSTS OF PROVIDING PHARMACY-INITIATED PrEP IN KENYA: FINDINGS FROM A PILOT STUDY
Alexandra Kuo, Obinna I. Ekwunife, Peter Mogere, Victor Omollo, Josephine Odoyo, Yilin Chen, Jared M. Baeten, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad, Monisha Sharma

1091 CLIENT PREFERENCES FOR PrEP REFILLS AT FACILITIES VS PHARMACIES: A PILOT IN KENYA
Peter Mogere, Alexandra Kuo, Stephen Gakuo, Njeri Wairimu, Stephanie Roche, Mary Muga, Jared M. Baeten, Kenneth Ngure, Katrina F. Ortblad

1092 MALE CIRCUMCISION IN BOTSWANA: EFFECT OF QUALITY IMPROVEMENT ON ADVERSE EVENT RATES
Ludo S. Monene, Mooketsi Molefi, Keikantse Matlalga, Billy M. Tsimane

Poster Session-Y14 COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES
2:30 PM - 4:00 PM

1093 HIV OUTCOMES AFTER EXTENDED 12-MONTH SCRIPTS FOR ART DURING COVID-19 IN SOUTH AFRICA
Lara Lewis, Yukteshwar Sookraj, Johan van Der Molen, Thokozani Khubone, Phelile Nkosi, Riona Govender, Sifiso Phakathi, Munthra Maraj, Rosemary Van Heerden, Francesca Little, Reshma Kassanjee, Nigel Garrett, Jienchi Dorward
1094 VIRAL SUPPRESSION TRAJECTORIES DESTABILIZED AFTER COVID-19 AMONG US PEOPLE WITH HIV
Matthew A. Spinelli, Katerina Christopoulos, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burholder, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Mallory O. Johnson

1095 HIV CARE DURING THE SARS-CoV-2 PANDEMIC IN BLACK PEOPLE WITH HIV IN THE UK
Zoe Ottaway, Lucy Campbell, Laura Cechin, Julie Fox, Fiona Burns, Lisa Hamzah, Stephen Kegg, Greer Rosenzweig, Sarah Schoeman, David Price, Rachael Jones, Denis Onyango, Robert Miller, Shema Tariq, Frank Post Research Group: CoV-AFRICA study group

1096 DISRUPTIONS IN HEALTH CARE AMONG MWCCS PARTICIPANTS DURING THE COVID-19 PANDEMIC
Jenni Wise, Lorie Benning, Mackey Friedman, Tracey Wilson, Catalina Ramirez, Adaora Adimora, Bradley Aouizerat, Anjali Sharma, Matthew Mimiaga, Anandi N. Sheth, Michael Plankey, Margde Cohen, Deborah Jones Weiss, Gypsyamber D’Souza, Mirjam Colette-Kempf Research Group: Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study Combined Cohort Study (MWCCS) Research Group

1097 UTILITY OF DIGITAL SOLUTIONS IN SUSTAINING ACCESS AND IMPROVING EFFICIENCY OF HIV VL
Ughweroghene Omo-Emmanuel, Victor Obianeri, Omosalewa Oyelaran, Helina Meri, Abiye Kalaiwo, Dolapo Ogundehin, Rachel Goldstein, Jason Williams, Timothy Yakubu

1098 MITIGATING THE IMPACT OF COVID-19 ON HIV VIRAL LOAD ACCESS AMONG KEY POPULATIONS
Ughweroghene Omo-Emmanuel, Victor Obianeri, Abiye Kalaiwo, Omosalewa Oyelaran, Jason Williams, Timothy Yakubu, Mark Akhigbe, Usman Haliru

1099 IMPACT OF COVID-19-INDUCED PROGRAM ADAPTATIONS ON HIV SUPPRESSION IN THREE COUNTRIES
Vamsi Vasireddy, Neha Shah, Allahna L. Esber, Trevor A. Crowell, Joseph S. Cavanaugh, Hannah Kibuuka, Ajay Parikh, Jonah Maswai, Valentine Sing Oei, Emmanuel Bahemana, Michael Iroezindu, Julie A. Ake Research Group: African Cohort Study (AFRICOS) group

1100 CHANGES IN SERVICE ACCESS AMONG PEOPLE WHO INJECT DRUGS IN PHILADELPHIA, 2018-2022
Tanner B. Nassau, Kathleen A. Brady
### WEDNESDAY FEBRUARY 22, 2023

#### Poster Session-A3 VIRUS REPRODUCTION

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>#</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>226</td>
<td>ELEVATED HIV VIRAL LOAD IS ASSOCIATED WITH HIGHER VIRAL RECOMBINATION RATE IN VIVO</td>
<td>Elena V. Romero, Alison F. Feder</td>
</tr>
<tr>
<td>227</td>
<td>Vpr ENHANCES HIV REPLICATION BY INHIBITING T CELL PROLIFERATION</td>
<td>Rodrigo A. Matus Nicodemos, David R. Ambrozak, Daniel C. Douek, Richard A. Koup</td>
</tr>
<tr>
<td>228</td>
<td>A HUMAN-SPECIFIC CARD8 MUTATION AFFECTS INFLAMMASOME ACTIVATION AFTER HIV-1 INFECTION</td>
<td>Jessie Kulsuptrakul, Elizabeth Turcotte, Michael Emerman, Patrick Mitchell</td>
</tr>
<tr>
<td>229</td>
<td>CARD8 INFLAMMASOME MODULATES HIV-1 INFECTION IN CD4+ T CELLS</td>
<td>Qiankun Wang, Liang Shan</td>
</tr>
<tr>
<td>230</td>
<td>VHH DIMER P559-R45L NEUTRALIZES SARS-CoV-2 BY STABILIZING SPIKE IN UP CONFORMATION</td>
<td>Kayoko Nagata, Junso Fujita, Ryota Maeda, Kotaro Shirakawa, Tsuyoshi Inoue, Keihi Meura, Akihiro Imura, Akifumi Takaori-Kondo, Akihide Ryo, Kei Sato</td>
</tr>
<tr>
<td>231</td>
<td>FC RECEPTOR-MEDIATED INFECTION OF MYELOID CELLS BY SARS-CoV-2</td>
<td>Suzanne Pickering, Harry D. Wilson, Enrico Bravo, Marianne R. Perera, Nathalia Almeida Dos Santos, Katie J. Doores, Michael H. Malim, Stuart Neil</td>
</tr>
<tr>
<td>232</td>
<td>OMICRON SPIKE ENDOWS SARS-CoV-2 WITH ENHANCED INFECTIVITY IN NASAL EPITELIA</td>
<td>Guoli Shi, Tiansheng Li, Kinkui Lai, Jonathan Yewdell, Alex A. Compton</td>
</tr>
<tr>
<td>233</td>
<td>SARS-CoV-2 REPLICONS REVEAL SPIKE-INDEPENDENT ATTENUATION OF THE OMICRON VARIANT</td>
<td>Taha Y. Taha, Irene Chen, Melanie Ott</td>
</tr>
<tr>
<td>234</td>
<td>SARS-CoV-2 USES ENDOSOMAL MEMBRANES TO BUILD REPLICATION ORGANELLES</td>
<td>Yuexuan Chen, Ruth Serra-Moreno</td>
</tr>
<tr>
<td>235</td>
<td></td>
<td>WITHDRAWN</td>
</tr>
</tbody>
</table>

#### Poster Session-A4 VIRUS DIVERSITY IN POPULATIONS

**2:30 PM - 4:00 PM**

<table>
<thead>
<tr>
<th>#</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>236</td>
<td>MPOX VIRUS SEQUENCES DIVERSITY IN PARIS AREA DURING THE 2022 OUTBREAK</td>
<td>Géraldine Piorkowski, Jade Ghosn, Valentine M. Ferré, Morgane Mailhe, Romain Coppée, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Quentin Le Hingrat, Hervé Raoul, Charlotte Charpentier, Diane Descamps, Xavier de Lamballerie</td>
</tr>
</tbody>
</table>
237

WITHDRAWN

238

WITHDRAWN

239  GENOMIC SURVEILLANCE OF SARS-CoV-2 REVEALS SEVERITY OF DELTA VARIANT IN CAMEROON


Poster Session-B2 HIV AND THE MICROBIOME  2:30 PM - 4:00 PM

248  CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF

Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos

249  PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET

Jacob K. Flynn, Alexandra Ortiz, Marlon Deleon, Samantha Knodel, Kenzie Birse, Laura Noel-Romas, Adam Burgener, Jason Brenchley

250  THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME

Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong

251  COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION


252  BACTERIAL DYSBIOSIS PERSISTS IN WOMEN LIVING WITH HIV-1 AFTER ART

Katherine M. Bricker, Andrea Lisco, Alessandra Borgognone, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Noguera Julian, Irini Sereti

Poster Session-B4 HIV AND AGING  2:30 PM - 4:00 PM

260  GLYCOMIC BIOMARKERS OF BIOLOGICAL AGING ARE ALTERED DURING SUPPRESSED HIV INFECTION

Leila Giron, Xiangfan Yin, Susan Langan, Jining Zhang, Jane Koshy, Igho Ofotokun, Jason M. Lazar, Margaret Fischl, Sabina Haberlen, Lawrence Kingsley, Alan Landay, Wendy Post, Qin Liu, Todd T. Brown, Mohamed Abdel-Mohsen

Research Group: MACS/WHI Combined Cohort Study

261  SEX DIFFERENCES IN CYTOKINE DYNAMICS IN PEOPLE WITH HIV ON ART DURING AGING

Alan B. Wells, Christophe Vanpouille, Victor De Gruttola, Miranda Lynch, Xinyi Huang, Jinyuan Liu, Wendy Fitzgerald, Xin Tu, Antoine Chaillon, Alan Landay, Eileen P. Scully, Leonid Margolis, Jonathan Karn, Sara Gianella

Research Group: MACS/WHI Combined Cohort Study
262 AGING IN WOMEN WITH HIV: SINGLE-CELL TRANSCRIPTOME ANALYSIS OF THE IMMUNE SYSTEM
Konstantin Leskov, Sara Gianella, Eileen P. Scully, Alan Landay, Antoine Chaillou, Jennifer Kinslow, Kathleen Weber, Saba Valadkhani, Victor De Gruttola, Alan B. Wells, Mary Ann Checkley, Benjamin Luttge, Jonathan Karn

263 MULTIPARAMETRIC CHARACTERIZATION OF TELOMERE LENGTH IN T CELLS FROM PLWH BY Flow-FISH
Macedonia Trigueros, Cora Loste, Maria Nevo, Francisco Muñoz-López, Diana Hernández, Ana Martínez, Marco A. Fernández, Yacine Kharraz, Julià Blanco, Eugenia Negredo, Marta Massanella
Research Group: TRANSLATIONAL RESEARCH IN IMMUNOLOGY AND AGEING (TRIA)

264 DURABLE ART SUPPRESSION IN AGED RHESUS MACAQUES IS ASSOCIATED WITH MHC-I ALLELES
Alejandra Marenco, Candice Nkoy, Benjamin Varco-Merth, Aparna N. Govindan, He Li, Devin N. Fachko, Anne Lewis, BRANDY DOZIER, Caryn Labriola, Michael Axthelm, Scott W. Wong, AFAM A. OKOYE

291 DELAYED POSITIVIZATION OF NON-LESION SPECIMENS AMONG INDIVIDUALS WITH MPOX
Angelo Roberto Raccagni, Davide Mileto, Alberto Rizzo, Nicola Gianotti, Vincenzo Spagnuolo, Caterina Candela, Elena Bruzzesi, Riccardo Lolatto, Benedetta Trentacapilli, Emanuela Messina, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

292 LONGITUDINAL ASSESSMENT OF VIRAL SHEDDING AMONG PATIENTS WITH MPOX IN TORONTO, CANADA
Darrell H. S. Tan, Robert Kozak, Jacklyn Hurst, Maedeh Naghibosadat, Hui Ting Ma, Oscar Pico Espinosa, Shreya Shah, Natasha Christie-Holmes, Jessica Lam, Angel Ly, Reva Persaud, Charlie Tan, Matthew Muller, Sharmistha Misra

293 MPOX DNA CLEARANCE IN SEMEN OVER SIX MONTHS FOLLOW-UP
Caterina Candela, Alberto Rizzo, Laura Galli, Davide Mileto, Diana Canetti, Nicola Gianotti, Maria Francesca Lucente, Costanza Bertoni, Angelo Roberto Raccagni, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

291 DELAYED POSITIVIZATION OF NON-LESION SPECIMENS AMONG INDIVIDUALS WITH MPOX
Angelo Roberto Raccagni, Davide Mileto, Alberto Rizzo, Nicola Gianotti, Vincenzo Spagnuolo, Caterina Candela, Elena Bruzzesi, Riccardo Lolatto, Benedetta Trentacapilli, Emanuela Messina, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

292 LONGITUDINAL ASSESSMENT OF VIRAL SHEDDING AMONG PATIENTS WITH MPOX IN TORONTO, CANADA
Darrell H. S. Tan, Robert Kozak, Jacklyn Hurst, Maedeh Naghibosadat, Hui Ting Ma, Oscar Pico Espinosa, Shreya Shah, Natasha Christie-Holmes, Jessica Lam, Angel Ly, Reva Persaud, Charlie Tan, Matthew Muller, Sharmistha Misra

293 MPOX DNA CLEARANCE IN SEMEN OVER SIX MONTHS FOLLOW-UP
Caterina Candela, Alberto Rizzo, Laura Galli, Davide Mileto, Diana Canetti, Nicola Gianotti, Maria Francesca Lucente, Costanza Bertoni, Angelo Roberto Raccagni, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

329 DYNAMICS AND ROLE OF TOX+ TCF1+ CD39+ CD8 T CELLS IN LYMPHOID TISSUE IN SIV INFECTION
Zachary Strongin, Claire Deleage, Gregory Tharp, Kevin Nguyen, Andrew Rahmberg, Jason Brenchley, Steven Bosingher, Haydn Kissick, Mirko Paiardini

330 SPATIAL MAPPING OF SIV-INFECTED RHESUS MACAQUE LYMPH NODE ENVIRONMENT DURING REBOUND
Kristen Olivera, Muhammad Shoab Arif, Yanique Thomas, Christopher Thruthiyil, Michael McRaven, Yanxiang Deng, Yang Liu, Graham Su, Archibald Enninful, Jack Collora, Rong Fan, Thomas J. Hope, Ya-Chi Ho

331 LYMPH NODE IMMUNE MICROENVIRONMENT FOLLOWING ART INITIATED DURING ACUTE HIV INFECTION
Andrea Papadopoulos, Trevor Nkaba, Thandeka Nkosi, Krista Dong, Thumbi Ndung’U, Zaza Ndlovu

Poster Session-B8 MPOX PATHOGENESIS
2:30 PM - 4:00 PM

Poster Session-D4 LYMPH NODES
2:30 PM - 4:00 PM
332 DEVELOPMENT OF A LYMPHOID ORGAN-CHIP TO EVALUATE COVID VACCINE BOOSTING STRATEGIES
Raphaël Jeger-Madiot, Jérôme Kerveyan, Isabelle Staropoli, Delphine Planas, Héloïse Mary, Cassandre Garnier, Rémy Robinot, Stacy Gellenoncourt, Olivier Schwartz, Michael Bscheider, Céline Marban-Doran, Lorna Ewart, Samy Gobaa, Lisa A. Chakrabarti

Poster Session-D8 MPOX VACCINES AND IMMUNOPATHOGENESIS
2:30 PM - 4:00 PM

374 NEUTRALIZING AND T-CELL RESPONSE AGAINST MPOX VIRUS AFTER MVA-BN VACCINE
Valentina Mazzotta, Giulia Matusali, Alessandro Cozzi Lepri, Eleonora Cimini, Simone Lanini, Francesca Colavita, Stefania Notari, Roberta Gagliardini, Silvia Meschi, Serena Vita, Emanuele Nicasiri, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputti, Flavia Cristofanelli, Francesca Faraglia, Daniele Lapa, Giorgia Natalini
Research Group: MPOX Vaccine Lazio Study Group

375 COMPARISON OF SUBCUTANEOUS VERSUS INTRADERMAL ROUTE OF ADMINISTRATION OF MVA VACCINE
Research Group: MPOX Vaccine Lazio Study Group

376 HUMORAL AND CELLULAR IMMUNE RESPONSE AFTER 3 MONTHS FROM MPOX VIRUS INFECTION
Valentina Mazzotta, Giulia Matusali, Eleonora Cimini, Francesca Colavita, Rita Casetti, Carmela Pinnetti, Annalisa Mondi, Aurora Bettini, Germana Grassi, Serena Vita, Emanuele Nicasiri, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Marta Camici, Silvia Di Barì, Silvia Meschi, Gianluca Prota, Elena Tartaglia
Research Group: MPOX Vaccine Lazio Study Group

377 IMMUNOGENICITY OF MVA-BN VACCINATION WITH HYBRID ADMINISTRATION ROUTE
Davide Moschese, Micol Bianchi, Maria Vittoria Cossu, Federica Salari, Andrea Giacomelli, Alberto Rizzo, Samuel Lazzarin, Federico Sabaini, Silvia Nozza, Davide Mileto, Andrea Gori, Spinello Antinori, Maria Rita Gismondo, Giuliano Rizzardini

378 IMMUNE RESPONSES AND VIRAL DYNAMICS AFTER MPOX INFECTION IN THE 2022 OUTBREAK
Susana Benet, Julieta Carabelli, Clara Suner, Adrià Mendoza, Angel Rivero, Vicente Descalzo, Aurélien Marc, Michael Marks, Christian Brander, Alex Olvera, Nuria Izquierdo-Useros, José Moltó, Jorge Carrillo, Oriol Mitjà, Beatriz Mothe Pujades
Research Group: MoViE-Immune Study Group

379 NOVEL SEROASSAYS DETECT MPOX-SPECIFIC AND VACCINE-INDUCED ORTHOPXVIRUS IMMUNITY
Jonah Kupritz, Savita Pahwa, Suresh Pallikkuth

Poster Session-E3 IMMUNE PRESSURE ON THE HIV RESERVOIR
2:30 PM - 4:00 PM

398 CTL RESPONSES ARE NOT ASSOCIATED WITH DECAY OF INTACT PROVIRUSES OR HIV RNA ON ART
Research Group: ACTG A5321 Team

Poster Sessions
399 TSCM/TCM-ENRICHED ANTI-HIV duoCAR-T CELLS EXERT POTENT HIV CONTROL
Kim Anthony-Gonda, Alex Ray, Hang Su, Vanessa Chilunda, Danica Lee, Jessica Weiselberg, Lily Zemelko, Yen Wang, Jane Reese, Rimas Orentas, Steven G. Deeks, Rachel L. Rutishauser, Joan W. Berman, Harris Goldstein, Boro Dropulic

400 bNAb ESCAPE HIV-ENV VARIANTS IN ORALLY SHIV-INFECTED, ART-TREATED INFANT MACAQUES
Ria Goswami, Stella J. Berendam, Sedem Dankwa, Elena E. Giorgi, Joshua Eudailey, Caroline Phan, Diane G. Carnathan, Bhrugu Yagnik, Chiamaka A. Enemuo, Veronica Obregón-Perko, Rama R. Ámara, Ann Chahroudi, Sallie R. Permar, Genevieve G. Fouda

401 BISPECIFIC ANTIBODIES PROMOTE NK CELL-MEDIATED ELIMINATION OF THE HIV-1 RESERVOIR
Nathan L. Board, Meghana Ravi, Fenting Wu, Milica Moskovljevic, Srona Sengupta, Francesco R. Simonetti, Kenneth Lynn, Luis J. Montaner, Rebecca Hoh, Steven G. Deeks, Janet M. Siliciano, Robert F. Siliciano

402 DONOR-DERIVED ENV MUTATION SCANNING REVEALS anAb AND bNAb VULNERABILITIES
Joseph Varriale, Brianna Lopez, Kshitij Wagha, Elena E. Giorgi, Robert F. Siliciano, Janet M. Siliciano

403 HIV-RESISTANT CAR T CELLS BY CRISPR/Cas-MEDIATED CAR INTEGRATION INTO THE CCR5 LOCUS
Frederik H. Rothemejer, Nanna P Lauritsen, Anna Karina Juhl, Mariane Høgsbjerg Schleimann, Saskia König, Ole Schmeltz Søgaard, Rasmus O. Bak, Martin Tolstrup

404 GENERATING BROADLY NEUTRALIZING ANTIBODY-SECRETING CAR-T-CELLS AGAINST HIV INFECTION
Hang Su, Jianhua Zheng, Scott Garforth, Kim Anthony-Gonda, Boro Dropulic, Steven Almo, Harris Goldstein

405 CIRCULATING IMMUNE PREDICTORS OF INTACT HIV RESERVOIR DECAY DURING LONG-TERM ART
Sergio Serrano-Villator, Akshay Gala, Peter Bacchetti, Clara Di Germanio, Lillian Cohn, Peter W. W. Hunt, Gregory M. Laird, Satish K. Pillai, Steven G. Deeks, Michael J. Peluso

406 THE LEAKY RESERVOIRS ARE ASSOCIATED WITH HIV-SPECIFIC CD4 AND CD8 T CELL RESPONSES
Mathieu Dubé, Olivier Tastet, Géralyman Sannier, Nathalie Brassard, Gloria Gabrielle Ortega-Delgado, Amélie Pagliuca, Alexandre Prat, Jean-Pierre Routy, Rémi Fromentin, Nicolas Chomont, Daniel Kaufmann

407 CTL EPITOPES FROM STRUCTURALLY IMPORTANT HIV PROTEINS ARE IDENTIFIED IN REBOUND HIV
Eunok Lee, Gabriel Duette, Katie Fisher, Anthony D. Kelleher, Steven G. Deeks, Sarah Palmer

408 IMMUNE FEATURES ASSOCIATED WITH HIGHER T-CELL RESPONSES TO AN HIV THERAPEUTIC VACCINE
Lily Zemelko, Naseem Sadek, Kara W. Chew, Mansi Purwar, Laurent Humeau, David V. Glidden, Matthew H. Spitzer, David B. Weiner, Steven G. Deeks, Rafick P. Sékaly, Jeffrey A. Tomkola, Rachel L. Rutishauser

409 ANTIRETROVIRAL THERAPY REPAIRS CD4 T-CELL DYSREGULATION IN PEOPLE LIVING WITH HIV
Poster Sessions

130 CROI 2023

Poster Session-E5 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR

2:30 PM - 4:00 PM

423 GLYCOENGINEERING ENHANCES HIV 10-1074 bNAb-DEPENDENT NATURAL KILLER CELL CYTOTOXICITY
Angela Corrigan, Samson Adeniji, Leilia Giron, Shalini Singh, Costin Tomescu, Luis J. Montaner, Mohamed Abdel-Mohsen

424 SINGLE-CELL QUANTIFICATION OF HIV-1 AND LENTIVIRAL VECTOR IN GENE THERAPY STUDIES
Amanda M. Buck, Joanna Donnatelli, Corinna Gartner, Tyler-Marie Deveau, Isaac Thomas, Julie Beegle, Kim Anthony-Gonda, Mehrdad Abedi, Joseph Anderson, Timothy Henrich

425 MULTI-SEROTYPE NANOBODY-ENGINEERED AAV VECTORS FOR CD4-TARGETED GENE THERAPY
Martin Hamann, Daniel Foth, Priti Kumar, Ulrike Lange

426 AN IMMUNOCYTOCHEMISTRY METHOD TO INVESTIGATE THE TRANSLATIONALLY ACTIVE HIV RESERVOIR
Guoxin Wu, Yuan Li, Jan Kristoff, Carol Cheney, Jill Wiler Maxwell, Tracy Lauren Diamond, Paul Zuck, Carl Ballbar, Jay Grobler, Bonnie Howell, Luca Sardo

427 DUAL ANTIRETROVIRAL-LOADED NANOPARTICLES FOR LONG-ACTING SUPPRESSIVE HIV THERAPY
Josiane Fofana, Behnaz Eshaghi, Erik Schiferle, Chandra Roy, Zandrea Ambrose, Bjoern Reinhard, Rahm Gummuluru

Poster Session-F6 MECHANISMS OF HIV NEUROPATHOGENESIS

2:30 PM - 4:00 PM

483 CSF COMPLEMENT IS CORRELATED TO IMMUNE ACTIVATION IN UNTREATED BUT NOT TREATED HIV
Arvid Eden, Lars-Magnus Andersson, Aylin Yilmaz, Dietmar Fuchs, Lars Hagberg, Magnus Gisslen

Poster Sessions - Wednesday
484 **LONGITUDINAL ASSESSMENT OF GRAPH THEORY MEASURES IN EARLY HIV INFECTION**
Yufen Chen, Guixiang Ma, James Higgins, Ann Ragin

485 **SINGLE-COPY HIV AND NEURODEGENERATION, OXIDATIVE STRESS, AND NEUROINFLAMMATION**
Albert Anderson, Patricia K. Riggs, Anita McClernon, Daniel McClernon, Ronald J. Ellis, David B. Clifford, Benjamin Gelman, Susan Morgello, Payal Patel, Leah H. Rubin, Bin Tang, Donald Franklin, Robert K. Heaton, Scott L. Letendre

Research Group: The CHARTER group

486 **CHARACTERIZING THE ROLE OF MONOCYTES IN HIV NEUROPATHOGENESIS**
Veronica Veksler, Rosiris Leon-Rivera, Susan Morgello, Joan W. Berman

487 **PLASMA A\textsubscript{42}:A\textsubscript{40} RATIOS ARE NOT REDUCED IN OLDER PERSONS WITH HIV**
Sarah Cooley, Beau Ances, Jane O’Halloran

**Poster Session-F7 COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV**

2:30 PM - 4:00 PM

488 **THE CEREBROSPINAL FLUID VIROME IN VIRALLY SUPPRESSED PEOPLE LIVING WITH HIV**
Mattia Trunfio, Valeria Fox, Rossana Scutari, Vanessa Fini, Annarita Granaglia, Cristina Russo, Elisa Vuaran, Daniele Imperiale, Carlo Federico Perno, Stefano Bonora, Giovanni Di Perri, Claudia Alerti, Andrea Calcagno

489 **DIVERGENT NEUROIMMUNE SIGNATURES AND HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS SURVIVAL**
Samuel Okurut, Elizabeth Okaf, David R. Boulware, David B. Meya, Edward N. Janoff, Yukari C. Manabe, Joseph O. Olobo, Joshua Rhein

Research Group: ASTRO Study Team and TIME Study Team

490 **CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT**
Ferron F. Ocampo, Carlo Sacdalan, Suteeraporn Pinyakorn, Misti Paudel, Donn Colby, Nathornsonn Poltubtim, Somchai Sriplietchan, Robert Paul, Nittaya Phanuphak, Denise Hsu, Serena Spudich, Phillip Chan

Research Group: RV254/SEARCH 010 Study Team

491 **CMV, SEX, AND COGNITION IN PEOPLE WITH HIV (PWH)**
Patricia K. Riggs, Gordon Honerkamp-Smith, Milenka Vargas, Gemma Caballero, Donald Franklin, Jennifer Iudicello, Leah H. Rubin, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre, Sara Gianella

**Poster Session-G3 PHARACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 TERAPEUTICS**

2:30 PM - 4:00 PM

510 **IMMUNE-VIRAL DYNAMICS MODELING OF THE BASIS FOR INDIVIDUAL VARIATION IN COVID-19**
Youfang Cao, Akshita Chawla, Brian Maas, Ruthie Birger, Laura Liao, Matthew Rizk, Julie Stone

511 **FACTORS INFLUENCING COVID-19 RISK: INSIGHTS FROM MOLNUPIRAVIR EXPOSURE-RESPONSE**
Akshita Chawla, Brian Maas, Ruthie Birger, Hong Wan, Youfang Cao, Matthew Johnson, Carisa De Anda, Matthew Rizk, Julie Stone

512 **NO DOSE ADJUSTMENTS FOR CYP3A4 SUBSTRATES WHEN COADMINISTERED WITH BEMNIFOSBUVIR**
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond
513 BEMNIFOSBUVIR HAS LOW POTENTIAL TO INHIBIT P-gp, BCRP, AND OATP1B1 MEDIATED TRANSPORT
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond

514 PHARMACOKINETICS INFORMS REMDESIVIR DOSING FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT

515 GLOBAL COLLABORATION TO PROVIDE DRUG INTERACTION GUIDANCE FOR NIRMATRELIVIR/RITONAVIR
Safia Kurjakose, Alice Tseng, Sara Gibbons, Fiona Marra, Alison Boyle, Tessa Senneker, Gregory Eschenauer, Sarita Boyd, Jomy George, Kimberly K. Scarsi, Saye Khoo, Alice K. Pau, Catia Marzolini, Page Crew, Justin Chiong, Pamela S. Belperio, Claire Lund

520 IMPACT OF BASELINE FACTORS ON VIROLOGIC RESPONSE TO bNAb VH3810109 (NgLS) IN BANNER
Peter Leone, Margaret Gartland, Judah Abberbock, Paul Wannamaker, Beta Win, Mark Baker, Viviana Wilches, Darren Bentley, Max Lataillade, Jan Losos

521 RAPID ART INITIATION USING BIC/FTC/TAF AND TDF+3TC+EFV IN PEOPLE WITH HIV IN CHINA
Shiyun Lv, Lijun Sun, Ping Ma, Lijing Wang, Yingquan Zhou, Cuisong Wu, Renfang Chen, Rugang Wang, Fengchi Zhang, Wei Hua, Lili Dai

522 LONG-ACTING LENACAPAVIR IN A COMBINATION REGIMEN FOR TREATMENT-NAIVE PWH: WEEK 80
Debbie Hagins, Ellen Koenig, Rachel Safran, Lizette Santiago, Michael Wohlfelder, Chiu-Bin Hsiao, Shan-Yu Liu, Laurie A. Vandrveene, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Samir Gupta

523 WEEK 52 SUBGROUP EFFICACY OF LENACAPAVIR IN HEAVILY TREATMENT-EXPERIENCED PWH
Onyema Ogbuagu, Sorana Segal-Maurer, Antonella Castagna, Edwin Dejesus, Anchalee Avihingsanon, Christine Zurawski, Olayemi Osyemi, Theo Hodge, Gordon Crofoot, Hui Wang, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Jean-Michel Molina

524 BASELINE nRTI HIV DRUG RESISTANCE AND EFFECT ON RECYCLED nRTIs: THE VISEND TRIAL
Suilanji Sivile, Lloyd B. Mulenga, Nyuma Mbewe, Danielle Engamba, Sombo Fwoloshi, Mundia Mwitumwa, Mpanji Siwingwa, Lameck Chirwa, Kennedy Banda, Tiza Mpata, Davison Ngandu, Kai M. Nachilima, William C. Wester, Andrew Hill, Bryony Simmons
Research Group: VISEND TRIAL GROUP

525 INITIAL SUPPLEMENTAL Dolutegravir DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL
Ying Zhao, Rulan Griesel, Zaayid Omar, Bryony Simmons, Andrew Hill, Gert van Zyl, Claire Keene, Gary Maartens, Graeme Meintjes

526 DORAVIRINE: SAFETY, TOLERABILITY & EFFICACY IN SOUTH AFRICAN WOMEN ON CONTRACEPTION

527 PLASMA AND URINE PK OF DOLUTEGRAVIR AND TENOFOVIR TO AID POINT-OF-CARE TESTING
Laura J. Else, Laura Dickinson, Stacey Edick, Ashley Zyhowski, Ken Ho, Sujan Dilly-Penchala, Beth Thompson, Saye Khoo, Rhonda Brand
**Poster Session-H4 ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS**

**2:30 PM - 4:00 PM**

537 **HIV-1 RNA DECAY IN SEMEN AND RECTUM AFTER INITIATING THERAPY WITH DTG PLUS 3TC**  
Sofia C. Scevola, Jordi Niubo, Pere Domingo, Guillermo Verdejo, Adrià Curran, Vícenz Díaz de Brito, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia, Irene Soriano, Daniel Podzamczer, Arkaitz Imaz

538 **ANTIVIRAL ACTIVITY OF LENACAPAVIR AGAINST HIV-2 ISOLATES**  
Robert A. Smith, Dana Raugi, Robbie Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut, Geoffrey Gottlieb

539 **IMMUNO-VIROLOGICAL AND CLINICAL FOLLOW-UP OF HIV-2 PATIENTS RECEIVING BIC/FTC/TAF**  
Véronique A. Joly, Valentine M. Ferré, Mélanie Cresta, Charlotte Charpentier, Marc Digumber, Florence Damond, Gilles Peytavin, Yazdan Yazdanpanah, Diane Descamps, Jade Ghosn

540 **ULTRA-LONG-ACTING BICTEGRAVIR NANOFORMULATIONS**  
Mohammad Ullah Nayan, Srijanee Das, Brady Sillman, Brandon Hanson, Siddappa Byrareddy, Howard E. Gendelman, Benson Edagwa

---

**Poster Session-H8 SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT)**

**2:30 PM - 4:00 PM**

563 **SARS-CoV-2 VIRAL LOAD CHANGE IN A RANDOMIZED TRIAL ON THREE DIFFERENT EARLY THERAPIES**  
Valentina Mazzotta, Simone Lanini, Giulia Matusali, Francesca Colavita, Alessandra Vergori, Emanuela Giombini, Silvia Rosati, Sabrina Minicucci, Martina Reuca, Francesca Gavaruzzi, Enrico Girardi, Emanuele Nicastri, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputi, Fabrizio Carletti, Federico De Zottis, Gruber Ernesto Cesare Maria, Maria Maddalena Plazzi  
**Research Group:** MONET Clinical Trial Group

564 **A RANDOMIZED TRIAL ON EARLY THERAPY IN COVID-19 HIGH-RISK OUTPATIENTS IN OMICRON ERA**  
Valentina Mazzotta, Simone Lanini, Lavinia Fabeni, Alessandra Vergori, Alessandra D’Abramo, Maria Maddalena Plazzi, Licia Bordi, Samir Al Moghaz, Enrico Girardi, Antonella D’Arminio Monforte, Loredana Sarmati, Emanuele Nicastri, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Federico De Zottis, Marisa Fusto, Alessandra Oliva, Silvia Rosati, Martina Rueca  
**Research Group:** MONET Clinical Trial Group

565 **SARS-CoV-2 OMICRON VIRAL LOAD DECREASE AFTER MONOCLONAL ANTIBODIES OR ANTIVIRALS**  
**Research Group:** INMI COVID-19 Outpatients Treatment Study Group

566 **INCIDENCE AND PREDICTORS OF CLINICAL PROGRESSION IN AN EARLY TREATED COVID-19 COHORT**  
Valentina Mazzotta, Alessandro Cozzi Legri, Simone Lanini, Silvia Meschi, Alessandra Vergori, Tommaso Ascoli Bartoli, Giulia Gramigna, Giuseppina Giannico, Alessandra D’Abramo, Claudia Cimaglia, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Emanuele Nicastri, Andrea Antinori, Carlotta Cerva, Angela Corpolongo, Massimo Francalancia, Francesca Gavaruzzi, Fabio Tucci  
**Research Group:** INMI COVID-19 Outpatients Treatment Study Group
Poster Session-I3 PRETREATMENT HIV DRUG RESISTANCE
2:30 PM - 4:00 PM

583 STATEWIDE TRENDS OF ACQUIRED HIV-1 DRUG RESISTANCE IN RHODE ISLAND: 2004-2021
Su Aung, Vlad Novitsky, Jon A. Steingrimsson, Fizza Gillani, Mark Howison, Katherine Nagel, Matthew Solomon, Thomas Bertrand, Katharine Howe, Lila Bhattacharji, John Fulton, Utpala Bandy, Joseph W. Rami, Dhamn Kantor

584 FOSTEMSARIV RESISTANCE-ASSOCIATED MUTATIONS IN HIV-1C STRAINS FROM BOTSWANA

585 NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR
Tracy Lauren Diamond, Winnie Ngo, Shih Lin Goh, Silvera Rodriguez, Min Xu, Jay Grobler, Ernest Asante-Apiah

Poster Session-J3 VIRAL HEPATITIS IN SUB-SAHARAN AFRICA
2:30 PM - 4:00 PM

598 HBV TRANSMISSION IN HOUSEHOLDS OF WOMEN ENGAGED IN DR CONGO'S HIV PMTCT PROGRAM
Camille Morgan, Patrick Ngimbi, Melchior Kashamuka Mwandagalira, Sarah Ntambua, Jolie Matondo, Martine Tabala, Nana Mbonze, Linda James, Marcel Yotebieng, Samuel Mampusza, Peyton Thompson, Jonathan Parr
599  PREVALENCE AND EVALUATION OF HEPATITIS B VIRAL REPLICATION IN PREGNANT WOMEN IN MALI
Djeneba B. Fofana, Hamadi Sissoko, Sally McFall, Aminatou Coulibaly, Adama Goita, Laurence Morand-Joubert, Joel Gozlan, Mahamadou Diakite

600  EVOLUTIONARY HISTORY OF HEPATITIS B VIRUS SUB-GENOTYPE D3 IN BOTSWANA

601  HEPATITIS C TREATMENT OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN KENYA
Grace Umutesi, Joyce Boke, Aliza Monroe-Wise, Sarah Masyuko, Helgar Masyuki, David Bukusi, William Sinkele, John Scott, Carey Farquhar, Brandon L. Guthrie

602  HEPATOCELLULAR CARCINOMA SCREENING AMONG HIV/HBV-COINFECTED INDIVIDUALS IN ZAMBIA
Carlotta Riebensahm, Guy Muula, Helen Chitundu, Kalongo Hamusonde, Belinda Chihota, Edford Sinkala, Veronica Sunkutu, Martin Maurer, Annalisa Berzigotti, Matthias Egger, Carolyn Bolton Moore, Michael Vinikoor, Gilles Wandeler

Poster Session-J4 LIFE AFTER SVR
2:30 PM - 4:00 PM

603  RISK BEHAVIOUR TRAJECTORIES AMONG PEOPLE TREATED FOR RECENT HCV INFECTION
Joanne M. Carson, Evan Cunningham, Sebastiano Barbieri, Marc van Der Valk, Jürgen K. Rockstroh, Margaret Hellard, Arthur Kim, Sanjay Bhagani, Jordan Feld, Edward Gane, Andrea Rauch, Julie Bruneau, Gail Matthews, Marianne Martinello

604  BEHAVIORAL RISK FOLLOWING HCV TREATMENT AMONG MEN WHO HAVE SEX WITH MEN WITH HIV
Kris Hage, Anders Boyd, Daniëla van Santen, Kees Brinkman, Joop Arends, Fanny Lauw, Bart Rijnders, Arne van Eeden, Marc van Der Valk, Astrid Newsum, Amy Matser, Janke Schinkel, Maria Prins

605  LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR
Jessica Martin Carmona, Anaïs Corma-Gómez, Francisco Tellez, Miriam Serrano-Fuentes, Luis Morano, Diana Corona Mata, María José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Juan A. Pineda, Juan Macías
Research Group: GEHEP-011

606  PREDICTION OF HEPATIC DECOMPENSATION AFTER SVR IN PATIENTS WITH HCV CHRONIC INFECTION
Anaïs Corma-Gómez, Francisco Tellez, Luis Morano, Mario Frías, Miriam Serrano-Fuentes, Maria José Ríos, Isabel Barroso, Francisco J. Vera Méndez, Rosario Palacios, Paloma Geijo, Dolores Merino, Ignacio De Los Santos, Arkaitz Imaz, Juan A. Pineda, Juan Macías, Carlos Galera
Research Group: GEHEP-011

607  LONG-TERM CHANGES IN LIVER STIFFNESS POST-SVR IN PATIENTS WITH HCV CHRONIC INFECTION
Anaïs Corma-Gómez, Francisco Tellez, Diana Corona Mata, Luis Morano, Miriam Serrano-Fuentes, Maria José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Dolores Merino, Juan A. Pineda, Juan Macías, Carlos Galera
Research Group: GEHEP-011
608 **METABOLOMATIC PROFILE ASSOCIATED WITH HVPG CHANGE AFTER DAA IN HCV PTs WITH CIRRHOSIS**
Ana Virseda Berdices, **Juan Berenguer**, David Rojo, Juan González-Garcia, Oscar Brochado Kith, Amanda Fernández-Rodriguez, Daniel Sepulveda Crespo, Cristina Diez, Victor Hontañon, Leire Pérez-Latorre, Rafael Micán, Teresa Aldáimiz Echevarría, Coral Barbas, Salvador Resino, María A. Jiménez-Sousa

**Poster Session-J6 PATHOGENESIS AND NATURAL HISTORY**
*2:30 PM - 4:00 PM*

617 **RISK FACTORS FOR LIVER FIBROSIS PROGRESSION IN HIV: A MULTI-CENTER LONGITUDINAL STUDY**
Giovanni Guaraldi, Jovana Milic, Stefano Renzetti, Federico Motta, Jenny Bischoff, Giulia Besuzi, Giuseppe Mancini, Sara Esperti, Marianna Menozzi, Wesal Elgretti, Dana Kablawi, Stefano Calza, Cristina Mussini, Jürgen K. Rockstroh, Giada Sebastiani

618 **INCIDENCE OF NON-HEPATIC CANCERS IN HBV, HCV, AND HBV/ HCV COINFECTED PERSONS**
Adeel Butt, Peng Yan, Obaid Shaikh
Research Group: ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans)

619 **CONTRIBUTION OF ALCOHOL USE IN HIV/HECV COINFECTION TO ALL-CAUSE MORTALITY**
Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

620 **SYNDROME OF CHRONIC VIRAL INFECTIONS ON THE RISK OF END-STAGE RENAL DISEASE**
Dahn Jeong, Stanley Wong, Jason Wong, Jean Damascene Makuza, Geoffrey McKee, Héctor A. Velásquez García, Zahid A. Butt, Prince A. Adu, Mawuena Binka, Sofia Bartlett, Amanda Yu, Maria Alvarez, Mel Krajden, Naveed Z. Janjua

621 **LIVER NEUTROPHILS EXPRESS STRONGER PD-L1 SIGNALING IN HIV/HBV THAN IN HBV ALONE**
Michael S. Wallace, Taonga Musonda, Christopher Oetheimer, Edford Sinkala, Paul Kelly, Mah Asombang, Hailey Paté, Simutanyi Mwakamui, Debika Bhattacharya, Georg Lauer, Raymond Chung, Michael Vinikoor, Nadia Alatrakchi

622 **YAP-MEDIATED HEPATOCYTE DAMAGE CONTRIBUTES TO LIVER FIBROSIS WITH HIV-RELATED INJURY**
Brian A. Fellenstein, Volney A. Spalding, Wenyu Lin, Raymond Chung, Shadi Salloum

623 **CHRONIC LIVER INFLAMMATION AND USE OF CONTEMPORARY ART AMONG PERSONS LIVING WITH HIV**
Ashley Roen
Research Group: RESPOND

624 **COVID-19 OUTCOME IN PATIENTS WITH AND WITHOUT CIRRHOSIS**
Obaid Shaikh, Peng Yan, Adeel Butt

**Poster Session-K1 NON-AIDS DEFINING CANCERS: PATHOGENESIS**
*2:30 PM - 4:00 PM*

625 **ASSOCIATION OF HIV CONTROL AND IMMUNOSUPPRESSION WITH NADC RISK AMONG PATIENTS ON ART**
Brittney Dickey, Elizabeth Yanik, Zachary Thompson, Greer Burkholder, Mari Kitahata, Richard Moore, Jeffrey Jacobson, W. Christopher Mathews, Katerina Christopoulos, Julia Fleming, Chad Achenbach, Anna E. Coghill
626 HIV-ASSOCIATED DIFFERENCES IN THE TUMOR IMMUNE MICROENVIRONMENT OF NADCs
Anna E. Coghill, Nathan Van Bibber, Brooke Fridley, Jordan Fenlon, Yoko Derose, Jon Mahlow, Gita Suneja

627 SPECIFIC EXOSOMAL PROTEOMIC PROFILE ASSOCIATED TO PLWH PRESENTING NADCs
José M. Benito, María A. Navarrete-Muñoz, Manuel Pedregal, Héctor Callata, Héctor Peinado, Sara Nistal, Alejandro Velastegui, Edinson Caviedes, María L. Hernández, María L. García-Gil, Jesús García-Fonollas, Norma Rallón

Poster Session-K2 CANCER (GENERAL): RISK AND MORTALITY
2:30 PM - 4:00 PM

628 RISK FACTORS FOR 5-YEAR MORTALITY IN PEOPLE WITH HIV AFTER CANCER DIAGNOSIS
Sally B. Coburn, Elizabeth Humes, Raynell Lang, Michael A. Horberg, Richard Moore, Michael J. Silverberg, Gypsymber D’Souza, Lesley S. Park, M. John Gill, Amy C. Justice, Maile Karris, Charles Rabkin, Sonia Napravnik, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

629 MARKERS OF IMMUNOSUPPRESSION AND MORTALITY AMONG CANCER PATIENTS WITH HIV
Emilia Ascanio Carerrra, Qianlai Luo, Cameron Haas, Meredith Shiels, Eric Engels

Poster Session-K5 ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING
2:30 PM - 4:00 PM

638 WITHDRAWN

641 ASSESSING PERSPECTIVES AMONG PEOPLE WITH HIV WHO HAVE HAD HIGH RESOLUTION ANOSCOPY
Maria C. Geba, Divya Kalluri, Benjamin Cardenas, Emma Mitchell, Tabor Flickinger, Rebecca Dillingham, Tania Thomas

642 RISK FACTORS FOR ANAL DYSPLASIA AND LINKAGE TO HRA IN TRANSGENDER WOMEN
Omar Harfouch, Andrea Lisco, Rahwa Eyasu, Amelia Cover, Ashley Davis, Emade Ebah, Phyllis Bijole, Grace Garrett, Tina Liu, Michelle Spikes, Imani Fnu, Henry Masur, Shyamasundaran Kottiltii, Sarah Kattakuzhy, Elana Rosenthal

643 IMMUNOLOGICAL BIOMARKERS ASSOCIATED WITH ANAL DYSPLASIA IN PEOPLE LIVING WITH HIV
NIS Cristina Mancebo Pérez, Joaquin Burgos, Núria Massanassa, Antonio Astorga Gamaza, Josep Castellví, Stefania Landolfi, Adrià Curran, Jorge N. García, Vicenç Falcó, María J Buzon, Meritxell Genescà
Research Group: HIV Translational Research Group

644 NADIR CD4 AND ANAL CYTOLOGY PREDICT DEVELOPMENT OF INVASIVE ANAL CANCER
Edward Cachay, Tari Gilbert, Huifang Qin, Laura Bamford, William Mathews
665  TISSUE-RESIDENT T-CELL RESPONSES IN HIV+ PATIENTS WITH HPV-DRIVEN ANAL DYSPLASIA
Rehana V. Hewavisentii, Zhong-Hong Zhang, Cecilia Chang, Tony Wang, Priyanka S. Hastak, Fengyi Jin, Mary Poynten, Fabio Luciani, Alexander Swarbrick, Andrew Grulich, Anthony D. Kelleher, Sarah C. Sasson

666  LOW CD4 NADIR AT HIV DIAGNOSIS ASSOCIATES WITH INCREASED RISK OF CLONAL HEMATOPOIESIS
Romit Bhattacharya, Aniruddh P. Patel, Md Mesbahuddin, Abhishek Niroula, Kathleen V. Fitch, Michael T. Lu, Gerald Bloomfield, Judith A. Aberg, Carl J. Fichtenbaum, Heather J. Ribaudo, Markella V. Zanni, Benjamin Ebert, Pam S. Douglas, Steven K. Grinspoon, Pradeep Natarajan

661  CIRCULATING BIOMARKERS AND CARDIAC DYSFUNCTION IN WOMEN WITH OR AT RISK FOR HIV
David B. Hanna, Adam M. Whalen, Sanyog G. Shitole, Mahim Naveed, Jason M. Lazar, Kathryn Anastos, Mario J. Garcia, Ryung S. Kim, Phyllis C. Tien, Robert C. Kaplan, Jorge R. Kizer

662  CD2/LFA-3 AXIS COSTIMULATION OF CD57+CD8 T CELLS IN HIV AND ATHEROSCLEROSIS
Nicole Winchester, Soumya Panigrahi, Anokhi Haria, Michael M. Lederman, Michael L. Freeman

663  ANTITRETROVIRAL THERAPY AMELIORATES SIV-ASSOCIATED MYOCARDITIS IN THE HEART
Jake A. Robinson, Meng Niu, Howard Fox, Tricia H. Burdo

664  EFFECT OF NICOTINE RECEPTOR AGONISTS ON INFLAMMATION AND RISK OF CHD AND DEATH IN HIV
Hilary A. Tindle, Debbie M. Cheng, Natalia Gnatienko, Elena Blokhina, Tatiana Yarovaltseva, Sally Bendiks, Leah Forman, Judith A. Hahn, Kaku So-Armah, Michael D. Stein, Kendall Bryant, Dmitry Liozovn, Evgeny Krupitsky, Jeffrey H Samet, Matthew Freiberg

665  CARDIOVASCULAR RISK AMONG PEOPLE ACCESSING DIFFERENTIATED HIV CARE IN SOUTH AFRICA
Maitreyi Sahu, Adam Szpiro, Heidi van Rooyen, Stephen Assimwe, Maryam Shahanamesh, D. Allen Roberts, Meighan Krows, Kombi Sausi, Nsika Sithole, Torin Schaufsma, Jared M. Baeten, Connie Celum, Adrienne E. Shapiro, Alastair Van Heerden, Ruianne Barnabas

666  EXERCISE CAPACITY IS REDUCED IN HIV INDEPENDENT OF SARS-CoV-2 INFECTION
Matthew S. Durstenfeld, Michael J. Peluso, Matthew A. Spinelli, Danny Li, Erica Sander, Shreya Swaminathan, Victor Aarchiga, Rebecca Hoh, Mandal A. Aras, Carlin S. Long, Steven G. Deeks, Priscilla Hsue

667  GUT MICROBIOTA ASSOCIATED WITH OBSTRUCTIVE CORONARY ARTERY DISEASE IN HIV INFECTION
Marius Troseid, Marco Gelpi, Beate Vestad, Klaus Kofode, Andreas Fuchs, Lars Kober, Hedda Hoel, Kristian Holm, Thomas Lars Benfield, Johaness Rokund, Susanne Dam Poulsen, Andreas D. Knudsen
Research Group: COCOMO study

668  TRYPOTPHAN METABOLISM, THE GUT MICROBIOME, AND CAROTID ARTERY PLAQUE IN WIHS WOMEN
669 MULTI-OmICS ANALYSIS OF GUT MICROBIOME AND ATHEROSCLEROSIS IN WOMEN LIVING WITH HIV
Zheng Wang, David B. Hanna, Wendy Post, Alan Landay, Kathleen Weber, Audrey French, Elizabeth Golub, Jason M. Lazar, Deborah Gustafson, Anjali Sharma, Kathryn Anastos, Robert D. Burk, Robert C. Kaplan, Rob Knight, Qibin Qi

670 IMPROVED GUT MICROBIOTA RECOVERY IN LATE HIV-1
PRESENTERS INITIATING DTG VS DRV/r
Carlos Blázquez Bondía, Ferran Torres, Christian Manzardo, Eva Bonfill, Adrià Curran, Pere Domingo, Daniel Podzamczer, Lluís Force, Vicenç Falcó, Mariona Parera, Francesc Català-Moll, Maria Casadellà, José Maria Miró, Marc Noquera Julian, Roger Paredes
Research Group: ADVANZ-4 MISTRAL

Poster Session-M1 DOES WHAT GOES UP ALWAYS COME DOWN?
2:30 PM - 4:00 PM

671 WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG
Bronwyn E. Bosch, Godspower Akpomienie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, François Venter

672 FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC
Sophie Degroote, Sophie Vanherewege, Els Tobbak, Elis Caluwe, Lara Vincke, Wim Tryptsteen, Mareva Delporte, Evy Blomme, Linos Vandekeerkhove, Marie-Angélique De Scheerder

673 REVERSIBILITY OF TAF- AND/OR InSTI-ASSOCIATED WEIGHT GAIN
Myrthe L. Verburgh, Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk
Research Group: ATHENA National Observational Cohort

674 WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA
Kassem Bourgi, Susan Ofner, Beverly Musik, Kara Wool-Kaloustian, Lameck Diero, Constantin Yanmoutos, Samir Gupta

Poster Session-M6 WEIGHT GAIN AND ADIPOSE TISSUE
2:30 PM - 4:00 PM

703 MITOCHONDRIAL HAPLOGROUPS AND WEIGHT GAIN AFTER INITIATING ART IN PATIENTS WITH HIV
Juan Berenguer, Inmaculada Jarrín, José M. Bellón, Cristina Díez, María A. Jiménez-Sousa, Juan Carlos López, José R. Blanco, Joaquín Portilla, Alvaro Mena, María Novella, David Dalmau, Francesc Villaroya, Pere Domingo, Salvador Resino
Research Group: Cohort of the Spanish HIV Research Network (CoRIS)

704 WEIGHT CHANGE AFTER 48 WEEKS ON DOLUTEGRAVIR: A PROSPECTIVE STUDY OF PWH IN UGANDA

705 WEIGHT GAIN FOLLOWING SWITCH TO DOLUTEGRAVIR AMONG ADULT HIV COHORTS IN WEST AFRICA
Thierry Tiendrebeogo, Karen Malaste, Armel Poda, Albert K. Minga, Cecile D. Lahiri, Oliver Ezechi, Didier K. Ekouevi, Igbo Ofotokun, Antoine Jaquet
Research Group: IeDEA West Africa Collaboration
706 CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE
Emma Kileel, Carlos Malvestutto, Janet Lo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Markella V. Zanni, Esteban Martinez, Nwora Lance Okeke, Princy Kumar, Esau Joao, Sara McCluskey, Pam S. Douglas, Heather J. Ribaudo, Steven K. Grinspoon

707 DISCOVERING SUBGROUPS WITH LARGER WEIGHT GAIN WHEN TAKING Dolutegravir
Jiabei Yang, Ann W. Mwangi, Rami Kantor, Issa J. Dahabreh, Monicah Nyambura, Allison Delong, Joseph W. Hogan, Jon A. Steingrimsson

708 SUBCUTANEOUS ADIPOSE TISSUE CELL COMPOSITION IS ASSOCIATED WITH VISCERAL FAT VOLUME

709 VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL
Roger Bedimo, Teresa Gonzalez, Colleen S. McGary, Taryn A. McLaughlin

734 CLINICAL PREDICTORS OF MPOX SEVERITY IN AN ITALIAN MULTICENTER COHORT (MPOX-ICONA)
Valentina Mazzotta, Alessandro Tavelli, Francesca Colavita, Lorenzo Biasioli, Antonella Castagna, Annalisa Mondi, Fabrizio Carletti, Davide Moschese, Luca Pipito, Daniele Tesoro, Roberta Gagliardini, Fabrizio Maggi, Andrea Antinori, Antonella D’Arminio Monforte, Simone Lanini, Massimiliano Fabbiani, Francesco M. Fusco, Miriam Lichtner, Claudio M. Mastroianni, Eliana Specchiarello

Research Group: MPOX-ICONA Study Group

735 SEVERE MPOX AMONG PEOPLE LIVING WITH HIV RECEIVING TECOVIRIMAT IN NEW YORK CITY
Elizabeth A. Garcia, Maura K. Lash, Tristan D. McPherson, Mary Foote, Karen A. Alroy, Ellen H. Lee, Wendy Wen, Jeanne Sullivan Meissner, Amma Bosompem, Alyssa Boscaren, Marcia Wong

736 MANAGEMENT OF MPOX IN PWH ATTENDING A SEXUAL HEALTH DEPARTMENT IN LONDON, UK
Nicolo Girometti, Felicity Burton, Matthew Spencer, Simisola Agunbiade, Ruth Byrne, Margherita Bracci, Rachael Jones, Ellen Dwyer, Gary G. Whiltlock, Victoria Tittle, Anton L. Pozniak, Marta Boffito

737 MOSAIC CLADE 2B MPOX COHORT STUDY: CLINICAL CHARACTERISATION AND OUTCOMES
Xavier Lescurie, Laura Merson, Cédric Lauquen, Elise Pesonel, Romain Palich, Jake Dunning, Minerva Cervantes Gonzalez, Christophe Batejat, Coralie Tardivon, Josephine Bourner, France Mentré, Yazdan Yazdanpanah, Diane Descamps, Alexandra Calmy, Piero Olliaro

Research Group: MOSAIC study group

738 DEVELOPMENT AND PILOT OF AN MPOX SEVERITY SCORING SYSTEM (MPOX-SSS)
Jason Zucker, Jacob McLean, Simian Huang, Clare Deaurentis, Shauna Gunaratne, Kate Stoeckle, Marshall J. Glesby, Timothy Wilkin, William Fischer, Inger Damon, John Brooks

739 CLINICAL PRESENTATION OF MPOX IN PEOPLE WITH AND WITHOUT HIV
Victoria Pilkington, Killian Quinn, Lucy Campbell, Michael Brady, Frank Post

Research Group: King’s College HIV and Sexual Health Research Group
Poster Session-04 NOVEL TB AND OI DIAGNOSTICS AND THEIR PREDICTIVE VALUE

2:30 PM - 4:00 PM

**759** MONOCYTE-TO-LYMPHOCYTE RATIO AND HEMOGLOBIN LEVEL TO PREDICT TB AFTER ART INITIATION
Sivaporn Gatechompol, Stephen J. Kerr, Sandra Wagner Cardoso, Wadzanai Samaneka, Srikanth Tripathy, Cecilia Kanyama, Mulinda Nyirenda, Patcharaphan Sugandhavesa, Andre Machado, Frank Van Leth, Thomas Campbell, Susan Swindells, Ananchalee Avihingsanon, Frank Cobelens

Research Group: AIDS Clinical Trials Group DR067 team

**760** IMMUNE OOMIC PROFILES TO DISTINGUISH TUBERCULOSIS AMONG ADVANCED HIV ADULTS IN INDIA
Vandana P. Kulkarni, Artur T. Queiroz, Rohidas Borse, Amita Gupta, Bruno B. Andrade, Neelu Nawani, Padmini Salgame, Vidya Mave

**761** PERFORMANCE OF URINE XPERT ULTRA VS ALERE LAM FOR DIAGNOSING TB IN HIV-IN-PATIENTS
David F. Stead, Sean Wasserman, Ebrahim Steenkamp, Andrew G. Parrish, Graeme Meintjes

**762** CSF IMMUNE RESPONSE ASSOCIATED WITH FUNGAL BURDEN IN CRYPTOCOCCAL MENINGITIS
Julia Stumpf, Elizabeth Okafor, Samuel Okurut, John Kasibante, Kenneth Ssebambulide, Caleb Skipper, David B. Meya, Tyler Bold, David R. Boulware

**763** COST-EFFECTIVENESS OF Crag SCREENING FOR PLHIV WITH ADVANCED HIV DISEASE IN MALAWI
Mary Feser, Amir Shroufi, Thulani Maphosa, Ajay Rangaraj, Eddie Matiya, Prakriti Shrestha, Nathan P. Ford, Justine Scott, Virginía Tarbot, Appolinaire Tiam, Andrew Phillips, Kenneth A. Freedberg, Emily P. Hyle

**764** MYCO/F LTIC VS STANDARD BLOOD CULTURES IN FUNGAL DETECTION IN AIDS PATIENTS
Hao T. Nguyen, Dieu Ng, Na T. Do, Lan T. Nguyen, Vinh T. Nguyen, Phuong L. Trinh, Khanh Dh, Ly Vt, Dat Q. Vu, Rogier v. Doorn, Thuy Le

**765** MULTI-CENTER PROSPECTIVE VALIDATION STUDY OF A NOVEL ANTIGEN ASSAY FOR TALAROMYCOSIS
Thu Nguyen, Hao T. Nguyen, Dieu Ng, Phuong Tl, Khanh Dh, Men Tt, Dao Pth, Thom Vt, Chau Tth, Ly Vt, Jasper Fuk-Woo Chan, Yuen Ky, Dat Vq, Rogier Doom, Thuy Le

---

**Poster Session-P1 HIV INCIDENCE AND PrEP IN PREGNANCY**

2:30 PM - 4:00 PM

**766** QUANTIFIED PRENATAL PrEP EXPOSURE AND PERINATAL OUTCOMES AMONG KENYAN WOMEN
Lauren A. Gomez, John Kinuthia, Anna Larsen, Joshua Stern, Julia C. Dettinger, Mary M. Marwa, Felix Abuna, Ben Odhiamba, Nancy M. Ngumbau, Barbara Richardson, Pascal Omondi, Jared M. Baeten, Grace John-Stewart, Jillian Pintye

**767** HIGH ACCEPTABILITY OF STI TESTING AND EPT AMONG PREGNANT KENYAN WOMEN INITIATING PrEP
Jerusha N. Mogaka, Felix Abuna, Julia C. Dettinger, Mary M. Marwa, Ben Ochieng, Salphine Watoyi, Eunita Akim, Nancy M. Ngumbau, Celestine Adogo, Peter Owiti, Lauren A. Gomez, Grace John-Stewart, Jillian Pintye, John Kinuthia

Research Group: mWAC-PREP Study team

**768** INTEGRATING PrEP INTO ANTENATAL CARE FOR HIV-NEGATIVE PREGNANT WOMEN IN SOUTH AFRICA
Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer, Dvora Joseph Davey
769 PrEP CONTINUATION AMONG PERI-CONCEPTION, PREGNANT, AND LACTATING WOMEN IN KENYA
Priyanka Anand, Jared M. Baeten, Kenneth Ngure, Nelly Mugo, Elizabeth A. Bukusi, Elizabeth Irungu, Josephine Odoyo, Jennifer Morton, Kenneth Mugwanya

770 PrEP LEVELS STRONGLY CORRELATED IN HAIR AND DBS DURING PREGNANCY AND POSTPARTUM
Linxuan Wu, Felix Abuna, Peter L. Anderson, Jared M. Baeten, Julia C. Dettinger, Laurén A. Gómez, Monica Gandhi, Grace John-Stewart, John Kinuthia, Marwa Motongori, Ben Ochieng, Pascal Omondi, Jillian Pintye

771 LONGITUDINAL PrEP ADHERENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY
Jillian Pintye, John Kinuthia, Felix Abuna, Peter L. Anderson, Julia C. Dettinger, Laurén A. Gómez, Jessica E. Haberer, Marwa Motongori, Nancy M. Ngumbau, Ben Ochieng, Joshua Stern, Salphine Watoyi, Jared M. Baeten, Grace John-Stewart, Pascal Omondi
Research Group: PrEP Implementation for Mothers in Antenatal Care (PrIMA) Study Team

772 INCIDENT HIV INFECTIONS IN PREGNANT/BREASTFEEDING WOMEN AND INFANTS IN MOZAMBIQUE
Marilena Urso, William P. Killam, Judite R. Langa, Elizabeth Carter, Laura J. McCormick Viens

773 HIV RISK PERCEPTION AND PrEP USE AMONG KENYAN WOMEN DURING AND AFTER PREGNANCY
Mary M. Marwa, Anna Larsen, Felix Abuna, Julia C. Dettinger, Ben Odhiambo, Salphine Watoyi, Pascal Omondi, Nancy M. Ngumbau, Laurén A. Gómez, Grace John-Stewart, John Kinuthia, Jillian Pintye
Research Group: PrIMA Study
Research Group: PrIMA Study

777.5 MATERNAL HIV VIRAL LOAD THRESHOLD FOR GUIDING EXTENDED INFANT PROPHYLAXIS INITIATION
Dramane Kania, Jean-Pierre Moles, David Rutagwera, Franck Edgar Kadeba, Morgane D’Ottavi, Melany Tonga, Souleymane Tassembedo, Anaïs Mennecier, Beauty Matoka, Ajani Ousmane Taofiki, Paulin Fao, Thorkild Tylleskår, Chipepo Kankasa, Philippe Van De Perre, Nicolas Nagot, Leticia Sakana
Research Group: ANRS 12397 PROMISE-EPI Study group

778 VERTICAL TRANSMISSION IN INFANTS BORN TO WOMEN WITH HIV ON ANTIRETROVIRAL TREATMENT

779 HIV DRUG RESISTANCE IN CASES OF PERINATAL TRANSMISSION IN IMPAACT 2010 (VESTED)
Marley D. Bishop, Violet Korutaro, Ceejay Boyce, Ingrid A. Beck, Lauren Ziemba, Anne Coletti, Patrick Jean Philippe, Nahida Chakhtoura, Tichaona Vhembo, Haseena Cassim, Maximaria Owor, Lameck Chinula, Shahin Lockman, Lisa M. Frenkel
Research Group: IMPAACT 2010 Team

780 MATERNAL BROADLY NEUTRALIZING ANTIBODY ACTIVITY AND PERINATAL TRANSMISSION OF HIV-1
Krithika P. Karthigeyan, Ria Goswami, John Isaac, Elena E. Giorgi, Justin Pollara, Joshua Eudailey, Jackie Li, Megan Connors, Carolyn Weinbaum, Joshua Tu, Feng Gao, Manish Sagar, Sailie R. Permar
781 RECONSTRUCTION OF THE ADCC ANTIBODY REPERTOIRE OF AN HIV-1 NON-TRANSMITTING MOTHER
Zak A. Yaffe, Kevin Sung, Vrasha Chohan, Laura E. Doepker, Duncan K. Ralph, Ruth Nduati, Frederick A. Matsen, Julie M. Overbaugh

Poster Session-Q4 COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV

2:30 PM - 4:00 PM

815 ORAL MICROBIOTA IN CHILDREN WHO STARTED ANTIRETROVIRAL THERAPY AT YOUNG AGES
Louise Kuhn, Tian Wang, Fan Li, Renate Streblau, Nicole H. Tobin, Mandisa Nyati, Faezeha Patel, Afaaf Liberty, Stephen Arpadi, Sunil Wadwa, Shuang Wang, Caroline Tiemessen, Grace Aldrovandi
Research Group: CHANGES Study Team

816 IMMUNE ACTIVATION AND NEUROCOGNITION IN UGANDAN ADOLESCENTS LIVING WITH HIV
Saheera Dirajlal-Fargo, Abdus Sattar, Monika Strah, Christine Karungi, Joy Gumiririza-Onoria, Nana Asiedu, Angel Nanteza, Anthony F. Santoro, Christopher Ferraris, Daphne Tsalas, Corey Morrison, Victor Musiime, Grace A. McComsey, Reuben N. Robbins

817 NEUROCOGNITIVE FUNCTION AMONG SCHOOL-AGED CHILDREN AFFECTED BY HIV IN BOTSWANA
Elizabeth D. Lowenthal, Tyler Moore, Ruben Gur, Ontibile Tshume, Jennifer Chapman, Boitumelo Thuto, Mogomotsi S. Matshaba, J. Cobb Scott
Research Group: Ntemoga Study

818 TRAUMATIC EVENT EXPOSURE AND MENTAL DISORDERS IN YOUTH PERINATALLY AFFECTED BY HIV

819 MULTIFACETED PREMATURE AGING IN ADOLESCENT/YOUNG ADULT WITH PERINATAL-ACQUIRED HIV
Maria Raffaella Petrara, Elena Ruffoni, Francesco Carmona, Ilaria Cavallari, Sandra Zampieri, Silvia Giunco, Paola Del Bianco, Osvalda Rampon, Paolo Polnine, Paolo Rossi, Carlo Giaquinto, Anita De Rossi
Research Group: EPIICAL Consortium

820 CHILDREN WITH PERINATAL HIV EXHIBIT HIGH GDF15 LEVELS DESPITE ANTIRETROVIRAL THERAPY
Wei Li, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

821 48 MONTHS ANTHROPOMETRIC EVOLUTION OF ADOLESCENTS SWITCHING TO DOLUTEGRAVIR IN SPAIN
Talia Sainz, Santiago Jimenez de Oro, Luis Prieto, Luis Escosa, Claudia Fortuny, Antoni Noquera, Marie Antoinette Frick, Manuel Oltra, Lola Falcon, Matilde Bustillo, Jose Tomas Ramos, Pilar Collado, Jose Couceiro, Cesar Gaviñan, Marisa Navarro
Research Group: CoRISpe (Spanish Network of pediatric HIV)

822 METABOLIC HEALTH AND BONE DENSITY IN YOUTH LIVING WITH PERINATIAL HIV
Caroline Foster, Colette Smith, Merle Henderson, Moira Cheung, Sarah Fidler
Research Group: BONDY Study Research Group

823 THE BONDY STUDY: BONE DENSITY IN YOUTH LIVING WITH PERINATALLY ACQUIRED HIV
Merle Henderson, Colette Smith, Sarah Fidler, Moira Cheung, Caroline Foster
Poster Sessions

CROI 2023

Poster Sessions • Wednesday

Poster Session-Q6 SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN AND ADOLESCENTS

2:30 PM - 4:00 PM

824 OUTCOMES IN CHILDREN LIVING WITH HIV WITH NON-SEVERE TUBERCULOSIS IN THE SHINE TRIAL
Chishala Chabala, Eric Wobudeya, Marieke van De Zalm, Monica Kapasa, Robert Mboizi, Megan Palmer, Aarti Kinikar, Syed Hissar, Veronica Mulenga, Philippa Musoke, Helen Mcllleron, Ankeke Hesseling, Anna Turkova, Diana Gibb, Angela Crook
Research Group: SHINE Trial Team

825 TUBERCULOSIS INCIDENCE AMONG ADOLESCENTS AND YOUNG ADULTS WITH HIV IN KENYA
Danae Black, Sylvia M. Lacourse, Irene Njagina, Kristin Beima-Sofie, Caren Mburu, Cyrus Mugo, Janet Itindi, Alvin Onyango, Dalton Wamalwa, Grace John-Stewart

834 NILMATREVIR-RITONAVIR TREATMENT IN CHILDREN WITH SARS-CoV-2 INFECTION
Stefania Bernardi, Costanza Tripiciano, Stefania Mercadante, Anna Markowich, Giulia Lorenzetti, Francesca Calo Carducci, Lorenza Romani, Laura Cursi, Emma Conceccita Manno, Federica Galaverna, Leonardo Vallesi, Massimiliano Raponi, Emanuele Nicastrì, Carlo Federico Perno, Paolo Rossi

835 COMORBIDITIES THAT INCREASE RISK FOR SEVERE ACUTE COVID-19 IN PEDIATRIC POPULATION
Alfredo Tagarro, Irati Gastesi, Andrea Ramirez Valera, María Lucía Mesú Rubío, Pablo Vásquez Hoyos, Gabriela Friedrich, Melissa Naranjo Vanegas, Sonia Restrepo-Gualteros, Olga Lucia Baquero, Inés Leoz Gordillo, Cristina Calvo Rey, Siobhan Crichton, Marthe Le Prevost, Carlo Giaguinto, Cinta Moraleda
Research Group: EPICO, EPICO Colombia and ORCHESTRA

836 PERSISTENT SYMPTOMS IN CHILDREN ADMITTED WITH COVID SIMILAR TO CONTROLS 1 YEAR LATER
Alfredo Tagarro, Sara Villanueva, Ana Esteban Romero, María López Luengo, Marta Conde, Lucia de Pablo, David Aguilera-Alonso, Irati Gastesi, Sara Dominguez, Cristina Epalza, Álvaro Ballesteros, Carlota Pinto, Carlo Giaguinto, Cinta Moraleda
Research Group: EPICO, EPICO Colombia and ORCHESTRA

837 PERSISTENCE OF SYMPTOMS ONE YEAR AFTER MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
Cinta Moraleda, Sara Villanueva, Olga Aldecoa Jiménez, Blanca Díaz Fuentes, Luis Prieto, Daniel Blázquez, Cristina Epalza, Elisa Fernández Cooke, Ángela Manzanares, Pablo Rojo, Serena Villaverde, Álvaro Ballesteros, Sara Dominguez, Alfredo Tagarro

838 PBMC IMMUNOPHENOTYPING AND PLASMA INFLAMMATORY PROFILE OF CHILDREN WITH LONG COVID
Jon Izquierdo-Pujol, Sara Moron-Iopez, Judith Dalmau, Maria C. Puertas, Clara Carreras-Abad, Alba Gonzalez-Aumatell, Maria Mendez, Carlos Rodrigo, Javier Martinez Picado

839 INFLAMMASOME BUT NOT IFN-I/III RESPONSE IS ALTERED IN CHILDREN WITH LONG COVID
Matteo Fracella, Leonardo Sorrentino, Federica Frasca, Mirko Scordio, Alessandra D'Auria, Giuseppe Oliveto, Carla Selvaggi, Greta Di Mattia, Maria Giulia Conti, Luigi Matera, Domenico La Regina, Gabriella D’Ettorre, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari, Luca Maddaloni

Research Group: EPICO, EPICO Colombia and ORCHESTRA
Poster Session-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV

2:30 PM - 4:00 PM

876 RACIAL/ETHNIC DISPARITIES IN TIMELY ANTIRETROVIRAL THERAPY INITIATION: 2007-2019
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of lDeA

877 IMPACT OF REDLINING ON TIME TO VIRAL SUPPRESSION AMONG PERSONS DIAGNOSED WITH HIV
Lauren J. Ostrenga, John R. Bassler, Dustin M. Long, Mariel Parman, Michael J. Mugavero, Ariann F. Nassel, Emily B. Levitan, Aadia Rana, D. Scott Batey

878 MONITORING CARE AND VIRAL SUPPRESSION AFTER HIV DIAGNOSIS IN UNITED STATES: 2017-2020
Shacara Johnson Lyons, Xiaohong Hu, Anna Satcher Johnson

879 VIRAL SUPPRESSION AND COMMUNITY VIRAL LOAD AMONG MSM WITH HIV IN 23 US CITIES: 2017
Savannah Harris, Shamaya Whitby, Silvina Masciotra, Amanda J. Smith, Jeffrey A. Johnson, Lyssa Faucher, Cyprian Wejnert, Johanna Chapin-Bardales
Research Group: NHBS-MSM5 Study Group

880 HOSPITAL READMISSIONS AMONG ADULTS LIVING WITH HIV IN THE US
Xiaming Zhu, Eshan U. Patel, Mary K. Grabowski, Thomas C. Quinn, Kelly Gebo, Aaron Tobian

881 HIV AND THE VETERANS CHOICE ACT: A GEOSPATIAL ANALYSIS IN GEORGIA, 2020-2022
Kartavya Vyas, Vincent C. Marconi, Jodie Guest

882 INTERNALIZED HIV STIGMA AND MENTAL HEALTH/SUBSTANCE USE OVER TIME
Lydia Drumright, Duncan Short, Sonia Napravnik, Edward Cachay, Ellie Moffatt, Katerina Christopoulos, Torsten Neillands, Kenneth Mayer, Mallory O. Johnson, Jimmy Ma, Andrew Hahn, Robin Nance, Timothy Crawford, Geetanjali Chander, Rob Fredericksen, Bridget Whitney

840 PROTECTION AGAINST HETEROLOGOUS CHALLENGE 1 YEAR AFTER INFANT SARS-CoV-2 IMMUNIZATION
Emma C. Milligan, Katherine Olstad, Caitlin Williams, David Montefiori, Michael Hudgens, Darin Edwards, Andrea Carfi, Kizzmekia Corbett, Christopher Fox, Mark Tomai, Rachel Reader, Dirk Dittmer, Koen Van Rompay, Sallie R. Permar, Kristina De Paris

841 mRNA VACCINES INDUCE A HIGHER ANTIBODIES RESPONSE IN CHILDREN WITH PREVIOUS COVID-19
Costanza Di Chiara, Anna Cantarutti, Francesco Bonfante, Maria Raffaella Petrara, Chiara Cosma, Matteo Pagliari, Nicola Cotugno, Alessandra Menegheli, Elisa Benetti, Luca Bosa, Paolo Palma, Anita De Rossi, Carlo Giaquinto, Daniele Dona’, Andrea Padoan
Research Group: VERDI/ORCHESTRA study teams

842 EFFECT OF BNT162B2 ANTIGEN DOSAGE ON PROTECTION AGAINST SARS-CoV-2 OMICRON INFECTION
Hiam Chemaitelly, Houssein H. Ayoub, Laith J. Abu-Raddad
Poster Sessions

Poster Session-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE
2:30 PM - 4:00 PM

916 SARS-CoV-2 SEROPREVALENCE AMONG UGANDAN BLOOD DONORS: 2019-2022
Swetha Ashokkumar, Jodie L. White, Dorothy Kyeyune, Henry Ddungu, Ronnie Kasirye, Feben Habethyimer, Owen Baker, Heather Hume, Andrew Redd, Steven J. Reynolds, Thomas C. Quinn, Paul Ness, Evan M. Bloch, Oliver Laeyendecker, Aaron Tobian

917 COVID-19 SEROPREVALENCE IN VACCINE-NAIVE POPULATIONS: DRC, GUINEA, LIBERIA, AND MALI
Sylvain Laverdure, Donatien Kazadi, Kadidia Kone, Renee Ridzon
Research Group: InVITE Study Team

918 SARS-CoV-2 SEROPREVALENCE AND RISKS FACTORS IN AFRICAN WLHIV ON ART AND THEIR INFANTS

919 SARS-CoV-2 SEROPREVALENCE AMONG PEOPLE WHO INJECT DRUGS AND THEIR PARTNERS IN KENYA

920 SARS-CoV-2 SEROPREVALENCE AMONG PEOPLE WHO INJECT DRUGS IN BALTIMORE
Eshan U. Patel, Shruti H. Mehta, Owen Baker, Becky Genberg, Catherine Schluth, Jacyque Astemborski, Reinaldo Fernandez, Thomas C. Quinn, Greg Kirk, Oliver Laeyendecker

921 QUANTIFYING POPULATION IMMUNITY TO COVID-19 IN WASHINGTON STATE AND OREGON
Mia Moore, Larissa Anderson, Jaiming Lin, Chloe Bracis, Eileen Burns, Dave Swan, Joshua Schiffer, Dobromir Dimitrov

922 WITHDRAWN

923 WITHDRAWN
Poster Session-S6 MODELLING MPOX AND COVID-19  
2:30 PM - 4:00 PM

924 RETROSPECTIVE ASSESSMENT OF THE ACCURACY OF MPOX CASE PROJECTIONS IN NEW YORK CITY  
David Kaftan, Hae-Young Kim, Charles Ko, James Howard, Anna Bershteyn

925 MODELLING THE MPOX EPIDEMIC IN THE UK OVER MAY-AUGUST 2022  
Jasmina Panovska-Griffiths, Robert Hinch, Josie Park, Thomas Ward, Andre Charlett, Fergus Cumming, Nick Watkins, Christophe Fraser, Robyn Stuart

926 MODELLING THE RISK OF FUTURE MPOX OUTBREAKS IN THE NETHERLANDS  
Marc C. Shamier, Luca Zaeck, Kai Jonas, Babs Verstrenep, Corine H. Geurtsvankessel, Rory D. de Vries, Jeroen van Kampen, Marion PG. Koopmans, David van de Vijver

927 WHAT IMPACT WILL WORSENING AIR POLLUTION HAVE ON THE BURDEN OF COVID-19?  
Sherrie L. Kelly, Andrew J. Shattock, Martina S. Ragettli, Danielle Vienneau, Ana M. Vicedo-Cabrera, Nicole Probst-Hensch, Kees De Hoogh

Poster Session-T3 HIV TESTING IN CLINICAL SETTINGS  
2:30 PM - 4:00 PM

941 NON-HIV ENTRY POINTS TO DELIVER HIV SERVICES TO TRANSGENDER WOMEN IN INDIA  
Simran Shaikh, Parthasarathy Mugundu Ramien, Allison M. McFall, Jade Bell, Saya Okram, Ajay Enugu, Shruiti H. Mehta, Maria Salvat Ballester, Viswanathan Arumugam, Rose Pollard, Aditya Singh, Alex Keuroghlian, Kevin Ard, Kenneth Mayer, Sunil S. Solomon

942 DIRECTED SCREENING FOR HIV INFECTION IN EMERGENCY SERVICES: VIHGILA STUDY  
Josep Guardiola, Emilia Miro, Daniel Iturriza, Rocio De Paz, Mireia Saura, Alexis Rebollo, Cristina Ramio, Miriam Carbo, Connie Leey, Alex Smithson, Emili Gene, Oscar Miro  
Research Group: VIHGILA SOCMUE Study Group

943 HIV TEAMS AS A TOOL TO IMPROVE HIV INDICATOR CONDITION-GUIDED TESTING  
Carlijn Jordans, Jaap Hanssen, Anna Roukens, Jeroen van Kampen, Femke Moliema, Jet Gisolf, Rachida El Moussaoui, Gonneke Hermanides, Bart Rijnders, Annelies Verbon, Casper Rokx

944 IMPACT OF MPOX OUTBREAK ON HIV TESTING IN A LARGE INTEGRATED HEALTHCARE SYSTEM  
Christopher Polk, Mindy Sampson, Jeremy Thomas, Robert Fairman, Tom Ludden, Hazel Tapp, Catherine Passaretti, Michael Leonard

Poster Session-T4 NEW DIAGNOSTICS AND USE OF TESTS  
2:30 PM - 4:00 PM

945 DNA-CONFIRMATION OF HIV-1&2 COINFECTIONS AMONG DULLY-REACTIVE WEST AFRICAN PATIENTS  
Research Group: The EDIMARK-2 Study group

946 EVALUATION OF A NOVEL MULTIPLEX IMMUNOASSAY: IMPROVEMENT FOR HTLV-2 DETECTION  
Victor A. Folgosi, Pedro L. Junior, Felipe D. Silva, Augusto C. Oliveira, Maan Zrein, Florent Salvador, Jorge Casseb
947 HIV DETECTION IN WASTEWATER AS A NEW EPIDEMIOLOGICAL TOOL
Austen Terwilliger, Justin Clark, Visanthi Avadhanyula, Karen Feliz, Eric Murphy, Loren Hopkins, Pedro Piedra, Anthony Maresso, Thomas P. Giordano

Poster Session-U3 SARS-CoV-2 DIAGNOSTICS

2:30 PM - 4:00 PM

961 ANTIBODIES TO SARS-CoV-2 VARY DUE TO ORDER AND FREQUENCY OF VACCINATION OR INFECTION
Owen Baker, Evan Beck, Andrew Karaba, Eshan U. Patel, Andrea Cox, Yukari C. Manabe, Zoe Demko, Mira Prabhu, Yu-Hsiang Hsieh, Aaron Milstone, Andrew Redd, Aaron Tobian, Thomas C. Quinn, Joel N. Blankson, Oliver Laeyendecker

962 SARS-CoV-2 REPLICON SYSTEM FOR THE PHENOTYPIC EVALUATION OF NSP GENE SUBSTITUTIONS
Dong Han, Venice Du Pont, Simin Xu, Arya Vijjapurupu, Jiani Li, Bandita Parhy, Ross Martin, Gregory Camus, Jason K. Perry, Danielle P. Porter, Charlotte Hedskog, John P. Bilello, Tomas Cihlar, Hongmei Mo, Lauren Rodriguez
Research Group: Gilead Clinical Virology

963 USE OF Ag-RDTs TO REDUCE SARS-CoV-2 INFECTIONS AT RELIGIOUS GATHERINGS IN LICs & MICS
Megan A. Hansen, Alvin X. Han, Joshua M. Chevalier, Ethan Klock, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols

964 Ag-RDT MASS TESTING IN LARGE GATHERINGS TO IDENTIFY SARS-CoV-2 INFECTIONS IN KENYA
Rose Masaba, Lise Denoeud, Stephen Siamba, Heather J. Hoffman, Mario Songane, Edyth Osire, Njoki Kimani, Magoma Kwasa

965 SARS-CoV-2 WASTEWATER SURVEILLANCE IN A US JAIL: CORRELATION, FEASIBILITY, NEXT STEPS
Lindsay Saber, Anne Spaudling, Matthew J. Akiyama, Stephen Hilton, Shanika Kennedy, Christine Moe, Victoria Phillips
Research Group: SWANSS Study Group

966 DISABILITY AND COVID-19 TESTING: A CROSS-SECTIONAL RAdx-UP STUDY
Haley R. Martin, Wensong Wu, Sabrina Sales Martinez, Jose A. Bastida Rodriguez, Angelique Johnson, Marianna K. Baum

Poster Session-V4 PrEP USE IN SPECIAL POPULATIONS

2:30 PM - 4:00 PM

982 ASSOCIATION OF METH USE AMONG GBMSM ON HIV PRE-EXPOSURE PROPHYLAXIS CARE ENGAGEMENT
Alexander Moran, Marjan Javanbakht, Matthew Mimiaga, Steven Shoptaw, Famina M. Gorbach

983 NO IMPROVEMENT IN PREEXPOSURE PROPHYLAXIS USE AMONG PWID: SAN FRANCISCO, 2018-2022
Bow Suprasert, Moranda Tate, Danyion Reagan, Raul Ruiz, Katherine Gao, Katherine McNaughton, Kassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson

984 EFFECT OF INTIMATE PARTNER VIOLENCE ON ART & PREP ADHERENCE IN SERODIFFERENT COUPLES
Dorothy Thomas, Lylianne Nakabugo, Florence Nambi, Joseph Kibuuka, Timothy Muwonge, Erika Feutz, Katherine Thomas, Jane Simoni, Elizabeth Montgomery, Norma Ware, Monique Wyatt, Ingrid Katz, Herbert Kadama, Andrew Mwugirira, Renee Heffron
985 **DETERMINANTS OF PREEXPOSURE PROPHYLAXIS RETENTION AMONG TRANSGENDER WOMEN**

Jack Andrzejewski, Heather A. Pines, Sheldon Moris, Robert Bolan, David J. Moore, Leah B. Burke, Jill Blumenthal

986 **PrEP PRESCRIPTIONS AMONG PERSONS WITH MEDICAID BY RACE AND ETHNICITY: UNITED STATES**

Karen Hoover, Weiming Zhu, Duygu Islek Yaras, Dawn Smith, Ya-Lin A. Huang

987 **BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083**


**Research Group:** HPTN 083 Study Team

---

**Poster Session-V5 EARLY STUDIES OF NEW PREVENTION AGENTS**

2:30 PM - 4:00 PM

988 **PHASE 1 TRIAL OF CAP256V2LS AND VRC07-523LS ANTIBODIES AMONG WOMEN IN SOUTH AFRICA**

Sharana Mahomed, Nigel Garrett, Edmund Capparelli, Farzana Osman, Nonhlamla N. Mkhize, Dersereey Archary, Leonid Serebryannyy, Mike Castro, Adrian B. McDermott, Kevin Carlton, Penny L. Moore, Lynn Morris, Quarraisha Abdool Karim, John R. Mascota, Salim S. Abdool Karim

989 **VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES**

Michele B. Daly, Daniel Kim, Linying Li, Archana Krov, Chasity Norton, Catalina Forero, Marie Brake, Choung Dinh, Tian Edwards, Mackenzie Cottrell, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

990 **EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS**

Natalia Makarova, Tyana Singletary, Missy Peet, James Mitchell, Angela Holder, Choung Dinh, Yi Pan, Maria Corazon Bueno Mendoza, Meredith Clark, Walid Heneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

991 **PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT**

Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

992 **LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL**

Elena Bekerman, Stephen Yant, Laurie A. Vanderveen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

---

**Poster Session-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV**

2:30 PM - 4:00 PM

1029 **INCREASED BURDEN OF ANAL HPV-RELATED POTENTIALLY PRECANCEROUS LESIONS IN HIV+ WOMEN**

Eugenio Nelson Cavallari, Letizia Santinelli, Motta Eleonora, Federica Tanzi, Luca Maddaloni, Ilaria Cuccu, Giancarlo Ceccealli, Carolina Scagnolari, Alessandra Pierangeli, Innocenza Palaia, Claudio M. Mastroianni, Gabriella D’Ettorre
1030 EFFICACY OF LATE HPV VACCINATION IN YOUNG HIV+ MSM
Eugenie Nelson Cavallari, Letizia Santinelli, Luca Maddaloni, Motta Eleonora, Mirko Scordio, Federica Frasca, Giancarlo Ceccarelli, Carolina Scagnolari, Stefano Arcieri, Alessandra Pierangeli, Claudio M. Mastroianni, Gabriella D’Ettorre

1031 HIGH PREVALENCE OF HPV, OTHER STIs, AND ANAL LESIONS AMONG MSM IN TOGO

1032 METHYLATION MARKERS ON ANAL SMEARS ARE ASSOCIATED WITH HIGHER ANAL CANCER RISK

Poster Session-Y08 HIV CARE CASCADE
2:30 PM - 4:00 PM

1064 NEW HIV DIAGNOSES IN THE SETTING OF PUBLICLY FUNDED PrEP IN BRITISH COLUMBIA, CANADA
K. Junine Toy, Raquel M. Espinoza, Jason Trigg, Erin Ready, Cora L. Keeney, Wendy W. Zhang, Chanson J. Brumme, Paul Sereda, Rolando Barrios, Julio Montaner

1065 ESTIMATING THE EPIDEMIOLOGICAL IMPACT OF FLORIDA'S INTEGRATED HIV CARE PLAN IN MIAMI
Lia Humphrey, Benjamin Enns, Michal Piske, Xiao Zang, Bohdan Nosyk, Emma Spencer, Mara Michniewicz, Daniel Feaster, Hansel Tookes, Research Group: Centre for Health Evaluation & Outcome Sciences (CHEOS)

1066 AN RCT OF HOME-BASED CARE TO REDUCE POSTHOSPITAL MORTALITY IN SOUTH AFRICA: HOMELINK
Christopher Hoffmann, Kate Shearer, Boitumelo Kekana, Tumelo Molointa, Maxine Nunu, Jonathan Golub, Ebrahim Varaja, Neil Martinson

1067 IMPROVING REINITIATION IN CARE AMONG MEN WITH HIV IN MALAWI: TWO RANDOMIZED TRIALS
Kathryn Dovel, Kelvin Balakasi, Julie Hubbard, Mishiek Mphande, Isabella Robson, Elijah Chikuse, Morna Cornell, Risa Hoffman, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, Thomas J. Coates, Augustine Choko

1068 REENGAGING PERSONS WITH HIV OUT OF CARE: RADICAL CHANGE IS NEEDED
Thomas Martin, Laramie Smith, Susan R. Little, Christy Anderson, Kari Abulhosn

1069 THE IMPACT OF FINANCIAL INCENTIVES AND A DECISION-SUPPORT APP ON THE HIV CARE CASCADE
Maxime Inghels, Hae-Young Kim, Thulile Mathenjwa, Maryam Shahmanesh, Janet Seeley, Adrian Dobra, Manisha H. Yapa, Sally Wyke, Nuala McGrath, Till Baernighausen, Frank Tanser

1070 THE HIV CARE CONTINUUM AMONG TRANSGENDER WOMEN IN 2010-2020 IN THE NETHERLANDS
Vita Jongen, Ceranza Daans, Ard van Sighem, Maarten Schim Van Der Loeff, Kris Hage, Camiel Welling, Alex Von Vaupel-Klein, Martin Den Heijer, Edgar Peters, Marc van Der Valk, Peter Reiss, Maria Prins, Elske Hoornenborg, Research Group: ATHENA observational HIV cohort
1071 PROJECTED IMPACT OF IMPROVING HIV CARE ON LIFE EXPECTANCY AMONG BLACK AND WHITE MSM


Poster Session-Y09 THE PrEP CASCADE
2:30 PM - 4:00 PM

1071.5 RETENTION IN CARE AMONG PERUVIAN MSM AND TGW IN A REAL-WORLD HIV PrEP PROGRAM


1072 PrEP KNOWLEDGE, EVER USE, AND DISCONTINUATION AMONG LAKE VICTORIA FISHERFOLK IN UGANDA


1073 STRUCTURAL INFLUENCES ON PrEP CASCADE AMONG YOUNG WOMEN IN POST-ABORTAL CARE IN KENYA

Yasaman Zia, Lydia Etyang, Felix Mogaka, Inviolata Wanyama, Margaret Mwangi, Lavender June, Cyprian Nyanwaro, Roy Njiru, Faith Ambiyo, Bernard Nyerere, Elizabeth A. Bukusi, Nelly Mugo, Renee Heffron

1074 HIGH LEVEL OF HIV PREVENTION-EFFECTIVE CONTINUATION IN A LARGE PrEP PROGRAM IN KENYA

Kenneth Mugwanya, Margaret Mwangi, Nelly Mugo, Dominic Mwangi, Simon Maina, Stephen Gakuo, Lydia Etyang, Vallery Ogello, Emma Owid, Jared M. Baeten, Kenneth Ngure

Research Group: Efficiency Study Team

1075 DEPRESSION ASSOCIATED WITH PrEP HOLIDAYS AMONG KEY POPULATIONS IN NAMIBIA

Laimi Ashipala, Kaitlyn Atkins, Leonard Bikinesi, Justine Heita, Denis Mali, Abubakari Mwinyi, Robyn Eakle, Jane Schueller, Kelly Curran, Jason Reed

Poster Session-Y10 RESPONSE DURING CRISIS
2:30 PM - 4:00 PM

1076 CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL


1077 A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI

Jean Bernard Marc, Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Homeus, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Guiteau, Jean William Pape, Serena Koenig

1078 EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA: 2022


Research Group: National and Amhara Regional Emergency Response Team
Poster Session-Y11 RETENTION IN HIV CARE

2:30 PM - 4:00 PM

1079  8-YEAR CARE TRAJECTORIES IN AN URBAN COHORT OF PWH RECEIVING CARE: WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Shannon Barth, Michael A. Horberg, Anne Monroe

1080  PREDICTORS OF RETENTION IN THE WOMEN’S INTERAGENCY HIV STUDY: 2011-2019
Caitlin A. Moran, Brittany W. Jacob, Cyra C. Mehta, Anandi N. Sheth, Sarah Krier, Zenoria Causey-Pruitt, Deborah Jones Weiss, Andrew Edmonds, Gypsamambert D'Souza, Kathleen Weber, Jennifer Cohen, Lakshmi Goparaju, Susan Holman, Adebola Adedimeji, Cecile D. Lahiri

1081  RETENTION IN OPIOID AGONIST THERAPY AMONG PEOPLE LIVING WITH HIV IN BRITISH COLUMBIA
Kiana Yazdani, Kate Salters, Katerina Dolguikh, Monica Ye, Jason Trigg, Ronald Joe, David Moore, Julio Montaner, Rolando Barrios, K. Junine Toy

1082  A RANDOMIZED CONTROL TRIAL OF AN HIV CARE INTERVENTION BUNDLE FOR PEOPLE WITH HIV
Joseph D. Perazzo, Tamilyn Bakas, Qutaibah Oudat, Joshua Lambert, Carl J. Fichtenbaum

1083  LONG-TERM OUTCOMES OF RAPID ANTIRETROVIRAL THERAPY IN AN INTEGRATED HEALTH SYSTEM
Avani Dalal, Earl Clark, Christian Lee-Rodriguez, Zahra Samiezade-Yazd, Jennifer O. Lam, Mitchell N. Luu

1084  MODELLING OF CARE ENGAGEMENT PATTERNS IN A LONGITUDINAL COHORT OF PWH: WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Shannon Barth, Michael A. Horberg, Anne Monroe

Poster Session-Y15 TREATMENT OF COVID-19 AND MPOX

2:30 PM - 4:00 PM

1101  COST EFFECTIVENESS OF NIRMATRELVIR/ritonavir FOR MILD-MODERATE COVID-19 IN SPAIN
Philip E. Wikman-Jorgensen, Miriam Navarro, Jose Maria Ibarra, Carlos Devesa, Jose Miguel Segui-Ripoll, Jorge Peris-Garcia, Vicente Giner-Galvan, Jara Llenas-Garcia

1102  OUTCOMES OF A TELEHEALTH VISIT MODEL TO DELIVER TECOVIRIMAT FOR MPOX IN NYC
Ofole Mgbako, David Ditullio, Patricia Pagan-Pirallo, Dana Mazo, Robert Pitts, Dorothy Knutsen, Andrew Wallach, Angelica C. Kottkamp, Isaac Holmes, Justin Chan
POSTER SESSIONS BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Posters should be displayed for the duration of the conference and are located in the Exhibit Hall.

A. VIROLOGY OF HIV, SARS-CoV-2, OR MPOX VIRUS
P-A1 HIV-1 ENTRY (Monday)
P-A2 IFN AND ANTIVIRAL FACTORS (Tuesday)
P-A3 VIRUS REPRODUCTION (Wednesday)
P-A4 VIRUS DIVERSITY IN POPULATIONS (Wednesday)

B. PATHOGENESIS OF HIV, SARS-CoV-2, OR MPOX VIRUS: HUMAN STUDIES AND ANIMAL MODELS
P-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL (Monday)
P-B2 HIV AND THE MICROBIOME (Wednesday)
P-B3 HIV NON IMMUNO PATHOGENESIS, COINFECTION (Tuesday)
P-B4 HIV AND AGING (Wednesday)
P-B5 HIV IMMUNOPATHOGENESIS (Tuesday)
P-B6 SARS-CoV-2 PATHOGENESIS (Monday)
P-B7 LONG COVID (Tuesday)
P-B8 MPOX PATHOGENESIS (Wednesday)

C. HIV-ASSOCIATED TUMOR VIRUSES
P-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES (Tuesday)

D. HOST IMMUNE RESPONSES, VACCINES, AND IMMUNOTHERAPIES: HIV, SARS-CoV-2, OR MPOX VIRUS
P-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES (Monday)
P-D2 ELITE CONTROLLERS (Monday)
P-D3 IMMUNE MODULATION AND VACCINES (Tuesday)
P-D4 LYMPH NODES (Wednesday)
P-D5 NK CELLS, NEUTROPHILS, AND B CELL (Monday)
P-D6 SARS-CoV-2 IMMUNOPATHOGENESIS (Monday)
P-D7 SARS-CoV-2 VACCINES AND PREVENTION (Tuesday)
P-D8 MPOX VACCINES AND IMMUNOPATHOGENESIS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-E01 CONTROLLERS AND POSTTREATMENT CONTROLLERS (Monday)
P-E02 DYNAMICS OF THE HIV RESERVOIR (Monday)
P-E03 IMMUNE PRESSURE ON THE RESERVOIR (Wednesday)
P-E04 HIV RESERVOIRS IN CELLS AND TISSUES (Tuesday)
P-E05 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR (Wednesday)
P-E06 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND (Tuesday)
P-E07 MECHANISMS OF HIV LATENCY (Monday)
P-E08 DYNAMICS OF PROVIRAL INTEGRATION SITES (Tuesday)
P-E09 HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)

F. NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-COV-2 INFECTION AND NEUROLOGIC COMPLICATIONS OF HIV IN ADULTS
P-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)
P-F2  INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV (Monday)
P-F3  ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES (Monday)
P-F4  PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV (Tuesday)
P-F5  CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES (Tuesday)
P-F6  MECHANISMS OF HIV NEUROPATHOGENESIS (Wednesday)
P-F7  COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV (Wednesday)
P-F8  POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV (Monday)

G. CLINICAL PHARMACOLOGY IN ADULTS
P-G1  CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)
P-G2  DRUG-DRUG INTERACTIONS: A FOCUS ON TB, EFAVIRENZ SWITCHING (Tuesday)
P-G3  PHARACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 THERAPEUTICS (Wednesday)

H. ANTIVIRAL THERAPY: PRE-CLINICAL DATA, RANDOMIZED TRIALS, EFFICACY, AND EFFECTIVENESS STUDIES IN HIV OR SARS-CoV-2 OR MPOX VIRUS IN ADULTS
P-H1  LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING? (Tuesday)
P-H2  ANTIRETROVIRAL THERAPY: PROSPECTIVE CLINICAL TRIALS (Wednesday)
P-H3  ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH (Monday)
P-H4  ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS (Wednesday)
P-H5  NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES (Monday)
P-H6  CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION? (Monday)
P-H7  SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESVIR (Tuesday)
P-H8  SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT) (Wednesday)

I. RESISTANCE OF HIV OR SARS- CoV-2 TO SMALL MOLECULES AND ANTIBODIES IN ADULTS
P-I1  HIV RESISTANCE EMERGENCE AND OUTCOMES (Tuesday)
P-I2  HIV RESISTANCE TO NEUTRALIZING ANTIBODIES (Monday)
P-I3  PRETREATMENT HIV DRUG RESISTANCE (Wednesday)

J. HEPATITIS VIRUSES AND LIVER COMPLICATIONS IN ADULTS
P-J1  HBV PREVENTION AND TREATMENT (Tuesday)
P-J2  NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT (Tuesday)
P-J3  VIRAL HEPATITIS IN SUB-SAHARAN AFRICA (Wednesday)
P-J4  LIFE AFTER SVR (Wednesday)
P-J5  STEATOSIS AND STEATOHEPATITIS (Monday)
P-J6  PATHOGENESIS AND NATURAL HISTORY (Wednesday)

K. AIDS-RELATED MALIGNANCIES
P-K1  NON-AIDS DEFINING CANCERS: PATHOGENESIS (Wednesday)
P-K2  CANCER (GENERAL): RISK AND MORTALITY (Wednesday)
P-K3  KAPOSI SARCOMA AND KHSV-RELATED DISEASES: PATHOGENESIS AND TREATMENT (Monday)
P-K4 CERVICAL CANCER: SCREENING AND TREATMENT (Monday)
P-K5 ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING (Wednesday)

L. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-L1 PLAQUE (Monday)
P-L2 LIPID METABOLISM (Monday)
P-L3 HYPERTENSION, VASCULAR DISEASE, AND PLATELET FUNCTION (Tuesday)
P-L4 INFLAMMATION AND CARDIOVASCULAR DISEASE (Wednesday)
P-L5 THE GUT MICROBIOME AND COMORBIDITIES (Wednesday)

M. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY IN ADULTS
P-M1 DOES WHAT GOES UP ALWAYS COME DOWN? (Wednesday)
P-M2 METABOLIC COMPLICATIONS (Tuesday)
P-M3 BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE (Tuesday)
P-M4 BIOMARKERS OF MORBIDITY AND MORTALITY (Monday)
P-M5 FRAILTY, FUNCTIONAL STATUS, AND HEALTH (Tuesday)
P-M6 WEIGHT GAIN AND ADIPOSE TISSUE (Wednesday)

N. CLINICAL COMPLICATIONS OF EMERGING DISEASES (COVID-19) IN ADULTS
P-N1 PASC (LONG COVID) (Monday)
P-N2 COVID IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS (Tuesday)
P-N3 COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS (Tuesday)

O. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS, INCLUDING THE IMPACT OF HIV OR SARS-CoV-2 IN ADULTS
P-O1 PREDICTORS OF TB TREATMENT OUTCOMES (Monday)
P-O2 ADVERSE REACTIONS ASSOCIATED WITH TB DRUGS (Monday)
P-O3 OUTCOMES ASSOCIATED WITH OPPORTUNISTIC INFECTIONS IN THE CURRENT ERA (Monday)
P-O4 NOVEL TB AND OI DIAGNOSTICS AND THEIR PREDICTIVE VALUE (Wednesday)

P. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-P1 HIV INCIDENCE AND PrEP IN PREGNANCY (Wednesday)
P-P2 OBESITY, INFLAMMATION, AND HIV IN PREGNANCY (Tuesday)
P-P3 UNDERSTANDING MOTHER-TO-CHILD TRANSMISSION (Wednesday)
P-P4 USING ANTIRETROVIRALS IN PREGNANCY (Tuesday)
P-P5 NOVEL UNDERSTANDINGS OF BIRTH OUTCOMES WITH ART (Monday)
P-P6 COVID-19 IN PREGNANCY: EVOLVING INSIGHTS (Tuesday)

Q. HIV, SARS-CoV-2, OR MPXV VIRUS, AND OTHER EMERGING INFECTIONS, IN INFANTS, CHILDREN, AND ADOLESCENTS
P-E9 HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)
P-Q1 OUTCOMES OF HIV-EXPOSED UNINFECTED (Monday)
P-Q2 INFLAMMATION AND IMMUNITY IN CHILDREN (Tuesday)
P-Q3 REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV (Tuesday)
P-Q4 COMORBIDITIES AND COMPLICATIONS IN CHILDREN AND YOUTH WITH HIV (Wednesday)
P-Q5 ARVs AND bNAbS FOR CHILDREN AND ADOLESCENTS (Monday)
P-Q6 SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)
R. EPIDEMIOLOGY OF HIV IN ADULTS
P-R1 MOLECULAR HIV EPIDEMIOLOGY (Monday)
P-R2 RECENT HIV INFECTIONS (Monday)
P-R3 HIV INFECTION CLUSTERS (Monday)
P-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES (Tuesday)
P-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION (Tuesday)
P-R6 HIV MORTALITY (Monday)
P-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV (Wednesday)

S. EPIDEMIOLOGY OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS
P-S1 COVID-19 CHARACTERISTICS AND OUTCOMES (Monday)
P-S2 IMPACT OF COVID-19 ON HIV AND MALARIA SERVICES AND OUTCOMES (Monday)
P-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA (Tuesday)
P-S4 MPOX CHARACTERISTICS AND OUTCOMES (Tuesday)
P-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE (Wednesday)
P-S6 MODELLING MPOX AND COVID-19 (Wednesday)

T. HIV TESTING IN ADULTS: NEW TESTS, POPULATION STUDIES, AND SCALE-UP
P-T1 HIV SELF-TESTING (Monday)
P-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING (Tuesday)
P-T3 HIV TESTING IN CLINICAL SETTINGS (Wednesday)
P-T4 NEW DIAGNOSTICS AND USE OF TESTS (Wednesday)

U. TESTING FOR COVID-19, MPOX, AND OTHER EMERGING INFECTIONS: DIAGNOSTIC TESTS, POPULATION STUDIES, AND SCALE-UP
P-U1 MPOX TESTING (Monday)
P-U2 SARS-CoV-2 SELF-TESTING (Tuesday)
P-U3 SARS-CoV-2 DIAGNOSTICS (Wednesday)

V. HIV PREVENTION INTERVENTIONS IN ADULTS
P-V1 COST EFFECTIVENESS OF PEP AND PrEP (Monday)
P-V2 PrEP AND PEP: ADHERENCE MEASURES AND STIs (Monday)
P-V3 OPTIMIZING PrEP ROLLOUT (Tuesday)
P-V4 PrEP USE IN SPECIAL POPULATIONS (Wednesday)
P-V5 EARLY STUDIES OF NEW PREVENTION AGENTS (Wednesday)
P-V6 PrEP PRODUCT UPDATE AND EFFECTIVENESS (Tuesday)

W. PREVENTION OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS
P-W1 MPOX PREVENTION (Monday)
P-W2 SARS-CoV-2 VACCINE STRATEGIES (Tuesday)

X. CONTRACEPTION, SEXUALLY TRANSMITTED INFECTIONS, AND REPRODUCTIVE HEALTH IN ADULTS
P-X1 SPECIAL TOPICS IN SRH AND HIV (Monday)
P-X2 STI EPIDEMIOLOGY IN POPULATIONS AFFECTED BY HIV (Tuesday)
P-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV (Wednesday)
Poster Sessions by Category

P-X4  INTERTWINED: MPOX AND STI EPIDEMIOLOGY (Tuesday)

Y. IMPLEMENTATION AND SCALE-UP OF PREVENTION AND TREATMENT FOR HIV AND IMPACT OF COVID-19 AND OTHER EMERGING INFECTIONS ON HIV-RELATED PROGRAMS

P-Y01  ACCESS TO ART (Monday)
P-Y02  MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION (Monday)
P-Y03  ACHIEVING TARGETS (Monday)
P-Y04  HIV TESTING (Monday)
P-Y05  PRESENTATION FOR CARE (Tuesday)
P-Y06  LONG-ACTING ART (Tuesday)
P-Y07  ART REGIMENS (Tuesday)
P-Y08  HIV CARE CASCADE (Wednesday)
P-Y09  PrEP CASCADE (Wednesday)
P-Y10  RESPONSE DURING CRISIS (Wednesday)
P-Y11  RETENTION IN HIV CARE (Wednesday)
P-Y12  ADVANCED HIV DISEASE (Tuesday)
P-Y13  PREVENTION AND PrEP MODELS (Tuesday)
P-Y14  COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES (Tuesday)
P-Y15  TREATMENT OF COVID-19 AND MPOX (Wednesday)
INDEX OF PRESENTERS

The following index lists CROI presenters as of January 24, 2023. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

-A-
Abassi, Mahsa 749
Abela, Irene A. 352, 353
✓ Abelman, Rebecca A 679
Abu-Raddad, Laih J 1005
Adekogbe, Adebola Sunday 939
Adesse, Daniel 496
Agarwal, Mahesh 219
Agathis, Nickolas T 811
Agusti, Cristina 949
✓ Ayemang, Nana 505
Ake, Julie A 430
Aldred, Bruce 906
Amstutz, Alain 560
Anand, Priyanka 769
Andersen, Elisabeth 1084
Anderson, Albert 485
✓ Anderson, Kim 778
Anderson, Peter L 20
Andrzejewski, Jack 985
Antar, Annukka A R 722
Arentoft, Nicoline Stender 687
Armstrong-Hough, Mari 1050
✓ Arsuffi, Stefania 700
Arumugam, Viswanathan 1043
Ashipala, Laimi 1075
Ashokkumar, Swetha 916
✓ Atkins, Kaitlyn 951, 1025
Atkinson, Andrew 1021
Augello, Matteo 344
Augustin, Max 720
✓ Aung, Sai W 862
Aung, Su 583
Avihingsanon, Anchalee 116
✓ Ayieko, James 200

-B-
Bachina, Preetham 1054
Baill, Samuel S 708
Baker, Owen 961
Baker, Pieter 1016
Balachandran, Harikrishnan 340
Balkus, Jennifer 785
✓ Bardon, Ashley R 977
Barr, Elizabeth 1023
Bassett, Ingrid 999, 1039
Bassler, John R 877
Batista, Facundo 44
Bayer, Cara 855
Baylie, Chanie Temesgen 1078
✓ Bayon-Gil, Angel 246
Bazzi, Angela R 212
Bean, David 351
Bedimo, Roger 709
✓ Begré, Lorin 586
Béguelin, Charles 8
Behrens, Georg 45
Bekerman, Elena 992
Bender Ignacio, Rachel A 571
Benet, Susana 378
Benito, José M 245
Berenguer, Juan 608, 703
Bernardi, Stefania 834
Berry, Mark 718
✓ Berton, Mattia 506
Betton, Sara 508
Betts, Michael R 3
Bhatt, Nilesh 213
Bhattacharya, Romit 660
Bieniasz, Paul D 107
Birnbaum, Michael 5
Bishop, Marley D 779
✓ Black, Danay 825
Blair, Jessica 657
✓ Blázquez Bondia, Carlos 670
Blower, Sally 1037
✓ Board, Nathan L 401
Boltz, Valerie F 240
✓ Bone, Benjamin R 450
Borghetti, Alberto 574
✓ Borgognone, Alessandra 481
✓ Bosch, Bronwyn E 671
Bow, Kristin L 180
✓ Bouba, Yufen 928
Bouhaddou, Mehdi 108
✓ Bouqday, Meryem 241
Bourgi, Kassem 674
Bramante, Carolyn 170
Brañás, Fátima 701
Brew, Bruce 715
✓ Bricker, Catherine M 252
Brooks, John 39
Brooks, Kelsey 279
✓ Brown, Erin E. 1027
Brown, Todd T 987
Brumme, zabrina 366
✓ Buck, Amanda M 424
Bunge, Katherine E 127
Burdorf, Rachel M 577
Butt, Adeel 559
Butt, Adeel 569, 570, 618, 624, 729
Byakwaga, Helen 150

-C-
Cabrera, Cecilia 222
Cachay, Edward 644
Cai, Chenrongrong 342
✓ Cai, Renying 695
Cameron, Cheryl 269
Cannon, Chase 948
✓ Caporrelli, Adam A 106
Carlin, Aaron 543
Carlson, Jesse J 1033
Carpino, Thomas 900
Carson, Joanne M 603
Cartwright, Emily J 1014
Castagna, Antonella 293
Castel, Amanda D 1004
Castel, Amanda D 1079
Cavallan, Eugenio 1029, 1030
✓ Ceriani, Cristina 444
Cevik, Muge 109
Chabala, Chishala 824
Chaganti, Joga 492
Chahroudi, Ann 29
Chalira, Gabriel 112
Chan, Justin 1102
Chan, Phillip 464
Chandasa, Hardik 832
Chang, Michelle 1010
Chappell, Catherine 597
Charalambous, Salome 745
Charpentier, Charlotte 1031
Chaturvedi, Sonali 235
Chemaitelly, Hiam 842
Chen, Wanyi 517
Chen, Yuexuan 234
Chen, Yuejuan 484
Chekov, Ashenafi S 800, 801
Chevalier, Joshua M 958
Chew, Kara W 31
Chew, Kara W 428
Cholli, Preetam A 912
Chomont, Nicolas 1, 247

158 CROI 2023 ✓ New Investigator Scholarship ✓ International Investigator Scholarship ✓ Nonauthor Presenter
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choudhary, Manish C</td>
<td>168</td>
</tr>
<tr>
<td>Chow, Felicia C</td>
<td>183</td>
</tr>
<tr>
<td>Christ, Frauke</td>
<td>216</td>
</tr>
<tr>
<td>Clark, Kolin</td>
<td>447</td>
</tr>
<tr>
<td>Clement, Meredith E</td>
<td>994</td>
</tr>
<tr>
<td>Coburn, Sally B</td>
<td>628</td>
</tr>
<tr>
<td>Coggill, Anna E</td>
<td>626</td>
</tr>
<tr>
<td>Collercandy, Nived</td>
<td>853</td>
</tr>
<tr>
<td>Collura, Randall</td>
<td>157</td>
</tr>
<tr>
<td>Contreras, German A</td>
<td>886</td>
</tr>
<tr>
<td>Cooley, Sarah</td>
<td>468, 487</td>
</tr>
<tr>
<td>Coogan, Dagan</td>
<td>865</td>
</tr>
<tr>
<td>Corley, Michael</td>
<td>383</td>
</tr>
<tr>
<td>Corley, Michael</td>
<td>480</td>
</tr>
<tr>
<td>Correa-Gómez, Anaïs</td>
<td>606, 607, 904</td>
</tr>
<tr>
<td>Corrigan, Angela</td>
<td>423</td>
</tr>
<tr>
<td>Costa, Alvaro</td>
<td>909</td>
</tr>
<tr>
<td>Cotugno, Nicola</td>
<td>458</td>
</tr>
<tr>
<td>Coutinho, Carolina</td>
<td>915</td>
</tr>
<tr>
<td>Cowan, Frances M</td>
<td>123</td>
</tr>
<tr>
<td>Cowden, Jessica J</td>
<td>1007</td>
</tr>
<tr>
<td>Crabtree-Ramirez, Brenda</td>
<td>727</td>
</tr>
<tr>
<td>Craig, Cosette</td>
<td>974</td>
</tr>
<tr>
<td>Cresse, Tim R.</td>
<td>826</td>
</tr>
<tr>
<td>Dabral, Prerna</td>
<td>448</td>
</tr>
<tr>
<td>Dahal, Subha</td>
<td>546</td>
</tr>
<tr>
<td>Dal, Lili</td>
<td>521</td>
</tr>
<tr>
<td>Dalal, Avani</td>
<td>1083</td>
</tr>
<tr>
<td>Daly, Michele B</td>
<td>989</td>
</tr>
<tr>
<td>Dasma, Josi</td>
<td>461</td>
</tr>
<tr>
<td>Dastgheyb, Raha M</td>
<td>473</td>
</tr>
<tr>
<td>Daultrey, Harriet</td>
<td>681</td>
</tr>
<tr>
<td>Davis, Dominique</td>
<td>791</td>
</tr>
<tr>
<td>de Armas, Lesley</td>
<td>808</td>
</tr>
<tr>
<td>De Ceroq, Zofiefen</td>
<td>415</td>
</tr>
<tr>
<td>De Cock, Kevin M</td>
<td>13</td>
</tr>
<tr>
<td>De La Rosa, Guy</td>
<td>541</td>
</tr>
<tr>
<td>De Ledinghen, Victor</td>
<td>589</td>
</tr>
<tr>
<td>de Oliveira, Tulio</td>
<td>18</td>
</tr>
<tr>
<td>De Paris, Kristina</td>
<td>789</td>
</tr>
<tr>
<td>de Voux, Alex</td>
<td>970</td>
</tr>
<tr>
<td>Deere, Jesse</td>
<td>459</td>
</tr>
<tr>
<td>Degli Antoni, Melania</td>
<td>733</td>
</tr>
<tr>
<td>Deleage, Claire</td>
<td>175</td>
</tr>
<tr>
<td>Deo, Rinki</td>
<td>171</td>
</tr>
<tr>
<td>Desai, Pankaja</td>
<td>889</td>
</tr>
<tr>
<td>Deshmukh, Ashish</td>
<td>638</td>
</tr>
<tr>
<td>Deveau, Tyler-Marie</td>
<td>414</td>
</tr>
<tr>
<td>Di Chiara, Costanza</td>
<td>841</td>
</tr>
<tr>
<td>Di Gennaro, Francesco</td>
<td>888, 894</td>
</tr>
<tr>
<td>Diamond, Tracy Lauren</td>
<td>585</td>
</tr>
<tr>
<td>Diaz-Garcia, Claudio</td>
<td>178</td>
</tr>
<tr>
<td>Dickey, Britney</td>
<td>625</td>
</tr>
<tr>
<td>Diedhiou, Cyrille K</td>
<td>238</td>
</tr>
<tr>
<td>Dimitrov, Dobromir</td>
<td>1002</td>
</tr>
<tr>
<td>Dirajal-Fargo, Sahera</td>
<td>285, 816</td>
</tr>
<tr>
<td>Ditchwanelo, Doreen</td>
<td>600</td>
</tr>
<tr>
<td>Dolci, Giovanni</td>
<td>732</td>
</tr>
<tr>
<td>Donoso, Ana</td>
<td>843</td>
</tr>
<tr>
<td>Dorvill, Nancy</td>
<td>742</td>
</tr>
<tr>
<td>Dos Santos, Jessica C</td>
<td>313, 314</td>
</tr>
<tr>
<td>Dovel, Kathryn</td>
<td>1067</td>
</tr>
<tr>
<td>Dragoni, Filippo</td>
<td>454</td>
</tr>
<tr>
<td>Dross, Sandra</td>
<td>373</td>
</tr>
<tr>
<td>Du, Li 549</td>
<td></td>
</tr>
<tr>
<td>Dubé, Mathieu</td>
<td>406</td>
</tr>
<tr>
<td>Duncan, Maggie</td>
<td>370</td>
</tr>
<tr>
<td>Dunk, Caroline E</td>
<td>787</td>
</tr>
<tr>
<td>Duran Castells, Clara</td>
<td>385</td>
</tr>
<tr>
<td>Durieux, Jared C</td>
<td>717</td>
</tr>
<tr>
<td>Durstenfeld, Matthew S</td>
<td>666</td>
</tr>
<tr>
<td>Dziarski, Alisha</td>
<td>495</td>
</tr>
<tr>
<td>Ebasone, Peter-Vanes</td>
<td>656</td>
</tr>
<tr>
<td>Ebenuwa, Ichikhwude</td>
<td>684</td>
</tr>
<tr>
<td>Eden, Arvid</td>
<td>189, 483</td>
</tr>
<tr>
<td>Edun, Olarewaju</td>
<td>868</td>
</tr>
<tr>
<td>Ekwanifu, Obinna I</td>
<td>930</td>
</tr>
<tr>
<td>Ellis, Ronald J</td>
<td>474</td>
</tr>
<tr>
<td>Else, Laura J</td>
<td>527</td>
</tr>
<tr>
<td>Engels, Eric</td>
<td>629</td>
</tr>
<tr>
<td>Enriquez, Ana B</td>
<td>182</td>
</tr>
<tr>
<td>Epling, Brian</td>
<td>747</td>
</tr>
<tr>
<td>Erlandson, Kristine</td>
<td>648, 697</td>
</tr>
<tr>
<td>Eron, Joseph J</td>
<td>193</td>
</tr>
<tr>
<td>Eschbach, Jenna E</td>
<td>102</td>
</tr>
<tr>
<td>Eshleman, Susan H</td>
<td>160</td>
</tr>
<tr>
<td>Espinoza, Raquel M</td>
<td>910</td>
</tr>
<tr>
<td>Eustaquio, Patrick C</td>
<td>861</td>
</tr>
<tr>
<td>Evering, Teresa H</td>
<td>721</td>
</tr>
<tr>
<td>Ezeonwumelu, Ifeanyi J</td>
<td>591</td>
</tr>
<tr>
<td>Fandl, Hannah</td>
<td>467</td>
</tr>
<tr>
<td>Farley, Shannon M</td>
<td>873, 960</td>
</tr>
<tr>
<td>Feinberg, Judith</td>
<td>594</td>
</tr>
<tr>
<td>Felizarta, Franco</td>
<td>519</td>
</tr>
<tr>
<td>Fellenstein, Brian A</td>
<td>622</td>
</tr>
<tr>
<td>Ferrand, Rashida</td>
<td>125</td>
</tr>
<tr>
<td>Ferré, Valentine</td>
<td>M 354, 359, 1032</td>
</tr>
<tr>
<td>Feser, Mary</td>
<td>763</td>
</tr>
<tr>
<td>Fielding-Miller, Rebecca</td>
<td>210</td>
</tr>
<tr>
<td>Figueroa, Jose</td>
<td>1063</td>
</tr>
<tr>
<td>Fischer, William</td>
<td>169</td>
</tr>
<tr>
<td>Fisher, Karla N</td>
<td>972</td>
</tr>
<tr>
<td>Fisher, Katie</td>
<td>416</td>
</tr>
<tr>
<td>Floren, Alexander J</td>
<td>833</td>
</tr>
<tr>
<td>Flynn, Jacob K</td>
<td>249</td>
</tr>
<tr>
<td>Fofana, Djeneba B</td>
<td>599</td>
</tr>
<tr>
<td>Fofana, Josiane</td>
<td>427</td>
</tr>
<tr>
<td>Foldyna, Borek</td>
<td>649</td>
</tr>
<tr>
<td>Folgosi, Victor A</td>
<td>946</td>
</tr>
<tr>
<td>Folkword, Joy</td>
<td>243</td>
</tr>
<tr>
<td>Fombellida-Lopez, Céline</td>
<td>429</td>
</tr>
<tr>
<td>Fonseca, Fernanda F</td>
<td>1057</td>
</tr>
<tr>
<td>Foster, Caroline</td>
<td>822</td>
</tr>
<tr>
<td>Foster, Emma G</td>
<td>784</td>
</tr>
<tr>
<td>Fracella, Matteo</td>
<td>839</td>
</tr>
<tr>
<td>Frange, Pierre</td>
<td>830</td>
</tr>
<tr>
<td>Fray, Emily</td>
<td>388</td>
</tr>
<tr>
<td>Fredericks, Megan N</td>
<td>290</td>
</tr>
<tr>
<td>Fredericksen, Rob</td>
<td>860</td>
</tr>
<tr>
<td>Frey, Sharon</td>
<td>41</td>
</tr>
<tr>
<td>Friedrich, Nikolas</td>
<td>308</td>
</tr>
<tr>
<td>Frola, Claudia E</td>
<td>859</td>
</tr>
<tr>
<td>Fromage, Yeleen</td>
<td>501</td>
</tr>
<tr>
<td>Frouard, Julie</td>
<td>421</td>
</tr>
<tr>
<td>Gachago, Rachael</td>
<td>299</td>
</tr>
<tr>
<td>Gaia, Gaurav</td>
<td>315</td>
</tr>
<tr>
<td>Gala, Akshay</td>
<td>381</td>
</tr>
<tr>
<td>Gallego Courtés, Ana</td>
<td>418</td>
</tr>
<tr>
<td>Gandhi, Monica</td>
<td>518, 1038.5</td>
</tr>
<tr>
<td>Gandhi, Rajesh T</td>
<td>392</td>
</tr>
<tr>
<td>Ganesan, Anuradha</td>
<td>689</td>
</tr>
<tr>
<td>Garcia, Elizabeth A</td>
<td>735</td>
</tr>
<tr>
<td>Garcia, Federico</td>
<td>531</td>
</tr>
<tr>
<td>Garcia-Mesa, Yovelis</td>
<td>482</td>
</tr>
<tr>
<td>Garneau, William M</td>
<td>907</td>
</tr>
<tr>
<td>Gardett, Nigel</td>
<td>1012, 1056</td>
</tr>
<tr>
<td>Garrido-Rodriguez, Vanesa</td>
<td>254</td>
</tr>
<tr>
<td>Gasca-Capote, Carmen</td>
<td>452</td>
</tr>
<tr>
<td>Gatechompol, Sivaporn</td>
<td>759</td>
</tr>
<tr>
<td>Gausi, Kamunkhwala</td>
<td>751</td>
</tr>
<tr>
<td>Geba, Maria C</td>
<td>641</td>
</tr>
<tr>
<td>Gelpi, Marco</td>
<td>253</td>
</tr>
<tr>
<td>George, Ashley F</td>
<td>337</td>
</tr>
<tr>
<td>Ghosh, Sukanya</td>
<td>316</td>
</tr>
<tr>
<td>Ghosn, Jade</td>
<td>206, 286</td>
</tr>
<tr>
<td>Gill, Michelle M</td>
<td>790</td>
</tr>
<tr>
<td>Gils, Tinne</td>
<td>1086</td>
</tr>
<tr>
<td>Giordano, Thomas P</td>
<td>947</td>
</tr>
<tr>
<td>Girometti, Nicolo</td>
<td>736</td>
</tr>
<tr>
<td>Giron, Leila</td>
<td>260, 266</td>
</tr>
<tr>
<td>Index of Presenters</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Gisslen, Magnus</strong></td>
<td>184</td>
</tr>
<tr>
<td><strong>Glenn, Jeffrey S</strong></td>
<td>167</td>
</tr>
<tr>
<td><strong>Godot, Veronique</strong></td>
<td>362</td>
</tr>
<tr>
<td><strong>Gómez, Laurén A</strong></td>
<td>766</td>
</tr>
<tr>
<td><strong>González-Hernández, Luz A</strong></td>
<td>986</td>
</tr>
<tr>
<td><strong>Goodreau, Steven M</strong></td>
<td>866</td>
</tr>
<tr>
<td><strong>Goswami, Ria</strong></td>
<td>400</td>
</tr>
<tr>
<td><strong>Goulder, Philip JR</strong></td>
<td>28</td>
</tr>
<tr>
<td><strong>Govindaraj, Sakthivel</strong></td>
<td>796</td>
</tr>
<tr>
<td><strong>Goyal, Ravi</strong></td>
<td>420</td>
</tr>
<tr>
<td><strong>Goyal, Vishal</strong></td>
<td>503</td>
</tr>
<tr>
<td><strong>Graham, Susan M</strong></td>
<td>535</td>
</tr>
<tr>
<td><strong>Grattoni, Alessandro</strong></td>
<td>165</td>
</tr>
<tr>
<td><strong>Griesel, Rulan</strong></td>
<td>110, 507</td>
</tr>
<tr>
<td><strong>Gross, Robert</strong></td>
<td>509</td>
</tr>
<tr>
<td><strong>Guaraldi, Giovanni</strong></td>
<td>617</td>
</tr>
<tr>
<td><strong>Guardiola, Josep</strong></td>
<td>942</td>
</tr>
<tr>
<td><strong>Guenthoer, Jamie</strong></td>
<td>310</td>
</tr>
<tr>
<td><strong>Guerri-Fernandez, Robert</strong></td>
<td>542</td>
</tr>
<tr>
<td><strong>Gutierrez Sanchez, Luz Helena</strong></td>
<td>6</td>
</tr>
<tr>
<td><strong>Habte, Dereje</strong></td>
<td>812</td>
</tr>
<tr>
<td><strong>Hafer, Terry L</strong></td>
<td>440</td>
</tr>
<tr>
<td><strong>Hage, Kris</strong></td>
<td>604</td>
</tr>
<tr>
<td><strong>Hagins, Debbie</strong></td>
<td>522</td>
</tr>
<tr>
<td><strong>Hahn, Judith A</strong></td>
<td>743</td>
</tr>
<tr>
<td><strong>Haidar, Lara</strong></td>
<td>659</td>
</tr>
<tr>
<td><strong>Hall, Kirsten</strong></td>
<td>893</td>
</tr>
<tr>
<td><strong>Hallmark, Camden J</strong></td>
<td>851</td>
</tr>
<tr>
<td><strong>Hamann, Martin</strong></td>
<td>425</td>
</tr>
<tr>
<td><strong>Hamilton, Deven T</strong></td>
<td>1044</td>
</tr>
<tr>
<td><strong>Han, Dong</strong></td>
<td>962</td>
</tr>
<tr>
<td><strong>Han, Win Min</strong></td>
<td>596, 612, 1053</td>
</tr>
<tr>
<td><strong>Hanna, David B</strong></td>
<td>661</td>
</tr>
<tr>
<td><strong>Hansen, Megan A</strong></td>
<td>963</td>
</tr>
<tr>
<td><strong>Harfouch, Omar</strong></td>
<td>642</td>
</tr>
<tr>
<td><strong>Harris, Savannah</strong></td>
<td>879</td>
</tr>
<tr>
<td><strong>Hartana, Ciputra A</strong></td>
<td>311</td>
</tr>
<tr>
<td><strong>Haughney, Norman J.</strong></td>
<td>446</td>
</tr>
<tr>
<td><strong>Hausler, Harry P</strong></td>
<td>1040</td>
</tr>
<tr>
<td><strong>Hazra, Aniruddha</strong></td>
<td>981</td>
</tr>
<tr>
<td><strong>Heaps, Anna</strong></td>
<td>334</td>
</tr>
<tr>
<td><strong>Hecht, Rulin</strong></td>
<td>1017</td>
</tr>
<tr>
<td><strong>Hedskog, Charlotte</strong></td>
<td>562</td>
</tr>
<tr>
<td><strong>Heidelberg, Elizabeth</strong></td>
<td>795</td>
</tr>
<tr>
<td><strong>Heinchiri, Norbert</strong></td>
<td>114</td>
</tr>
<tr>
<td><strong>Helmold Hatt, Sabrina</strong></td>
<td>307</td>
</tr>
<tr>
<td><strong>Henderson, Heather</strong></td>
<td>172</td>
</tr>
<tr>
<td><strong>Henderson, Merle</strong></td>
<td>185, 823</td>
</tr>
<tr>
<td><strong>Herrera, Carolina</strong></td>
<td>995</td>
</tr>
</tbody>
</table>

**Hewavisenti, Rehana V** | 645 |
**Hightow-Weidman, Lisa** | 21 |
**Hikichi, Yuta** | 103 |
**Hileman, Corrilynn O** | 712 |
**Hiner, Christopher R** | 411 |
**Hirsanuthikul, Akarin** | 996 |
**Ho, Yo-Chi** | 4 |
**Hodcroft, Emma B** | 19 |
**Hoffman, Risa** | 774 |
**Hoffmann, Christopher** | 1066 |
**Hogan, Joseph W** | 707 |
**Hoornenborg, Elske** | 897, 911, 1070 |
**Hoover, Karen** | 986 |
**Hligue, Sybil** | 162 |
**Hsieh, Evelyn** | 686 |
**Huang, Ya-Lin A** | 997 |
**Hughes, Michael D** | 9 |
**Hung, Ana** | 675 |
**Hylé, Emily P** | 145 |
**Ichihashi, Genki** | 166 |
**Ignacio, Caroline** | 387 |
**Imaz, Arkaitz** | 537, 677 |
**Inghels, Maxime** | 1069 |
**Isaacs, Stuart N** | 40 |
**Ishii, Hiroshi** | 177 |
**Isnard, Stephane** | 27 |
**Itell, Hannah L** | 105 |
**Izquierdo-Pujol, Jon** | 838 |
**Jackson, Charlotte** | 134 |
**Jacobs, Tom G** | 831 |
**Jacobson, Denise L** | 799 |
**Jain, Mamta K** | 728 |
**Jalloh, Sallieu** | 267 |
**Jamieson, Denise J** | 27 |
**Jang, Hyukjin** | 258 |
**Jao, Jennifer** | 775 |
**Jassat, Waasila** | 885 |
**Javanbakht, Marjan** | 982 |
**Jeger-Madiot, Raphaelé** | 332 |
**Jeong, Dahn** | 620 |
**Jiang, Danting** | 251 |
**Jilg, Nikolaus** | 283 |
**Johansson, Emil** | 335 |
**Johnson, Matthew L** | 878 |
**Johnson, Kelly A** | 204 |
**Joly, Véronique A** | 539 |
**Jommalagadda, Sasi** | 1049 |
**Jordan, Carlijn** | 943 |
**Joseph Davey, Dvora** | 786 |
**Joseph, Fokam** | 239 |
**Joy, Jaimey** | 326 |

**Kabami, Jane** | 130 |
**Kablawi, Dana** | 611 |
**Kaftan, David** | 924 |
**Kagan, Ron M** | 955 |
**Kaillembo, Alexander** | 757 |
**Kaillembo, Alexander** | 936 |
**Kakande, Elijah** | 124 |
**Kalata, Newton L** | 872 |
**Kalata, Newton L** | 872 |
**Kam, C. Yong** | 357 |
**Kangethe, James** | 635 |
**Kankasa, Chipeco** | 131 |
**Kapombe, Priscilla** | 922 |
**Karathegyan, Kritika P** | 780 |
**Katsiimi, Mary Grace** | 807 |
**Keele, Brandon F** | 391 |
**Kelley, Colleen** | 34 |
**Kelly, Sherrrie L** | 927 |
**Kengni Ngueko, Aurelie** | 984 |
**Kenny, Stephanie** | 516 |
**Kenny, Grace** | 727 |
**Kirie, James** | 35 |
**Kileel, Emma** | 706 |
**Kim, Eun Hye Grace** | 477 |
**Kim, H. Nina** | 7 |
**Kim, Sangwon** | 147 |
**Kim, Sung-Han** | 126 |
**Kinc, Laura P** | 478 |
**Kitsou, Konstantina** | 297 |
**Kizito, Samuel** | 814 |
**Klock, Ethan** | 959 |
**Knudsen, Andreas D** | 655 |
**Knudsen, Andreas D** | 667 |
**Kolossváry, Márton** | 274 |
**Koss, Catherine** | 975 |
**Koss, Catherine** | 975 |
**Kroidl, Arne** | 132 |
**Kroidl, Inge** | 869 |
**Krolickowski, Kristyn** | 1034 |
**Krolickowski, Kristyn** | 908 |
**Kuchel, George A** | 38 |
**Kufura, Joshua T** | 455 |
**Kuhn, Louise** | 815 |
**Kulkarni, Smita** | 825 |
**Kulkarni, Vandana P** | 760 |
**Kulsumatrakul, Jessie** | 228 |
**Kuo, Alexandra** | 1090 |
<table>
<thead>
<tr>
<th>Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kupritz, Jonah</td>
<td>379</td>
</tr>
<tr>
<td>Kuriakose, Safia</td>
<td>515</td>
</tr>
<tr>
<td>Kuzmichev, Yury</td>
<td>438</td>
</tr>
<tr>
<td>Kvaratskhelia, Mamuka</td>
<td>100</td>
</tr>
<tr>
<td>Lacourse, Sylvia M</td>
<td>794</td>
</tr>
<tr>
<td>Laeyendecker, Oliver</td>
<td>154</td>
</tr>
<tr>
<td>Lahiri, Cecile D</td>
<td>610</td>
</tr>
<tr>
<td>Lake, Jordan E</td>
<td>647</td>
</tr>
<tr>
<td>Lang, Raynell</td>
<td>688</td>
</tr>
<tr>
<td>Lanini, Simone</td>
<td>563</td>
</tr>
<tr>
<td>Lankowski, Alexander J</td>
<td>1071.5</td>
</tr>
<tr>
<td>Laouénan, Cédric</td>
<td>737</td>
</tr>
<tr>
<td>Lapadula, Giuseppe</td>
<td>730, 896</td>
</tr>
<tr>
<td>Larsson, Heidi J</td>
<td>48</td>
</tr>
<tr>
<td>Laverdure, Sylvian</td>
<td>917</td>
</tr>
<tr>
<td>Lebouché, Bertrand</td>
<td>534</td>
</tr>
<tr>
<td>Lee, Cheng-Yi</td>
<td>355</td>
</tr>
<tr>
<td>Lee, Eunok</td>
<td>407</td>
</tr>
<tr>
<td>Lee, Guinevere Q</td>
<td>412</td>
</tr>
<tr>
<td>Lee, Jane J</td>
<td>867</td>
</tr>
<tr>
<td>Lehner, Paul J</td>
<td>402</td>
</tr>
<tr>
<td>Leone, Peter</td>
<td>937</td>
</tr>
<tr>
<td>Leskov, Konstantin</td>
<td>262</td>
</tr>
<tr>
<td>Leslie, Hannah H</td>
<td>937</td>
</tr>
<tr>
<td>Levy, Yves</td>
<td>324</td>
</tr>
<tr>
<td>Lewis, Lara</td>
<td>1042, 1093</td>
</tr>
<tr>
<td>Li, Chenglei</td>
<td>215</td>
</tr>
<tr>
<td>Li, Jonathan Z</td>
<td>32</td>
</tr>
<tr>
<td>Li, Jun</td>
<td>702</td>
</tr>
<tr>
<td>Li, Wei</td>
<td>820</td>
</tr>
<tr>
<td>Li, Yifan</td>
<td>347</td>
</tr>
<tr>
<td>Li, Yijia</td>
<td>725</td>
</tr>
<tr>
<td>Li, Zichong</td>
<td>439</td>
</tr>
<tr>
<td>Liang, Chen</td>
<td>884, 1006</td>
</tr>
<tr>
<td>Lim, Viviane D</td>
<td>10</td>
</tr>
<tr>
<td>Linden, Noemi L</td>
<td>451</td>
</tr>
<tr>
<td>Liu, Jerry</td>
<td>349</td>
</tr>
<tr>
<td>Liu, Wang-Da</td>
<td>368, 1020</td>
</tr>
<tr>
<td>Lok, Anna S</td>
<td>16</td>
</tr>
<tr>
<td>Lombardi, Francesca</td>
<td>693</td>
</tr>
<tr>
<td>Losoli, Tom</td>
<td>576</td>
</tr>
<tr>
<td>Lopez, Brianna</td>
<td>402</td>
</tr>
<tr>
<td>Loubet, Paul</td>
<td>365</td>
</tr>
<tr>
<td>Loufty, Mona</td>
<td>498</td>
</tr>
<tr>
<td>Lowenthal, Elizabeth D</td>
<td>817</td>
</tr>
<tr>
<td>Luethemeyer, Anne F</td>
<td>120</td>
</tr>
<tr>
<td>Luo, Kai</td>
<td>668</td>
</tr>
<tr>
<td>Lvilla, Anange F</td>
<td>129</td>
</tr>
<tr>
<td>Lwin, Hay Mar Su</td>
<td>696</td>
</tr>
<tr>
<td>Ma, Tongcui</td>
<td>380</td>
</tr>
<tr>
<td>Madlala, Hlengiwe P</td>
<td>776</td>
</tr>
<tr>
<td>Mahomed, Sharana</td>
<td>988</td>
</tr>
<tr>
<td>Mainella, Vincent A</td>
<td>500</td>
</tr>
<tr>
<td>Makarova, Natalia</td>
<td>990</td>
</tr>
<tr>
<td>Makonokaya, Lucky D</td>
<td>1019</td>
</tr>
<tr>
<td>Malaba, Thokozile R</td>
<td>792</td>
</tr>
<tr>
<td>Malambo, Warren</td>
<td>719</td>
</tr>
<tr>
<td>Malech, Harry</td>
<td>545</td>
</tr>
<tr>
<td>Mancebo Pérez, Cristina</td>
<td>643</td>
</tr>
<tr>
<td>Mandomando, Inacio</td>
<td>133, 890</td>
</tr>
<tr>
<td>Manne-Goehler, Jennifer</td>
<td>704</td>
</tr>
<tr>
<td>Manzanares, Mario</td>
<td>432</td>
</tr>
<tr>
<td>Mara, Elise S</td>
<td>1000</td>
</tr>
<tr>
<td>Marc, Jean Bernard</td>
<td>1077</td>
</tr>
<tr>
<td>Marchetti, Giulia C</td>
<td>287</td>
</tr>
<tr>
<td>Martin, Miquel</td>
<td>318</td>
</tr>
<tr>
<td>Marrazzo, Jeanne</td>
<td>163</td>
</tr>
<tr>
<td>Martin Carmona, Jesica</td>
<td>605</td>
</tr>
<tr>
<td>Martin, Haley R</td>
<td>966</td>
</tr>
<tr>
<td>Martin, Thomas</td>
<td>1068</td>
</tr>
<tr>
<td>Martinello, Marianne</td>
<td>194</td>
</tr>
<tr>
<td>Martínez-Sanz, Javier</td>
<td>690</td>
</tr>
<tr>
<td>Martin-Gayo, Enrique</td>
<td>327</td>
</tr>
<tr>
<td>Marwa, Mary M</td>
<td>773</td>
</tr>
<tr>
<td>Marziali, Megan E</td>
<td>858</td>
</tr>
<tr>
<td>Marzinke, Mark A</td>
<td>159</td>
</tr>
<tr>
<td>Masaba, Rose</td>
<td>964</td>
</tr>
<tr>
<td>Mateu, Lourdes</td>
<td>723</td>
</tr>
<tr>
<td>Matic, Nancy</td>
<td>953</td>
</tr>
<tr>
<td>Matovu Kweewa, Flavia</td>
<td>685</td>
</tr>
<tr>
<td>Matrajt, Laura</td>
<td>1009</td>
</tr>
<tr>
<td>Matthews, Gail</td>
<td>198</td>
</tr>
<tr>
<td>Matubs, Taguma Allen</td>
<td>918</td>
</tr>
<tr>
<td>Matus Nicodemos, Rodrigo A</td>
<td>227</td>
</tr>
<tr>
<td>Matusalli, Giulia</td>
<td>364</td>
</tr>
<tr>
<td>Mavetey, Vitaliy</td>
<td>369</td>
</tr>
<tr>
<td>Mave, Vidya</td>
<td>45</td>
</tr>
<tr>
<td>Mayer-Blackwell, Koshlan</td>
<td>360</td>
</tr>
<tr>
<td>Mazzetelli, Maria</td>
<td>502</td>
</tr>
<tr>
<td>Mazzotta, Valentina</td>
<td>374, 375, 376, 565, 566</td>
</tr>
<tr>
<td>McAlpine, Lindsay S</td>
<td>190, 493</td>
</tr>
<tr>
<td>McCluskey, Suzanne M</td>
<td>579</td>
</tr>
<tr>
<td>McCormick Viens, Laura J</td>
<td>636, 772</td>
</tr>
<tr>
<td>McFall, Allison M</td>
<td>863, 931</td>
</tr>
<tr>
<td>McGregor, Padraig</td>
<td>653</td>
</tr>
<tr>
<td>McLaughlin, Angela</td>
<td>211</td>
</tr>
<tr>
<td>McMyn, Natalie F</td>
<td>396</td>
</tr>
<tr>
<td>McWhirter, Joseph B</td>
<td>298</td>
</tr>
<tr>
<td>Meade, Christina</td>
<td>466</td>
</tr>
<tr>
<td>Meeder, Elise M. G.</td>
<td>472</td>
</tr>
<tr>
<td>Mehta, Sanjay</td>
<td>845</td>
</tr>
<tr>
<td>Meintjes, Graeme</td>
<td>761</td>
</tr>
<tr>
<td>Mgodi, Nyaradzo M</td>
<td>23</td>
</tr>
<tr>
<td>Milali, Masabho</td>
<td>967</td>
</tr>
<tr>
<td>Miller, Michael J</td>
<td>892</td>
</tr>
<tr>
<td>Miller, Michelle</td>
<td>552</td>
</tr>
<tr>
<td>Milligan, Emma C</td>
<td>840</td>
</tr>
<tr>
<td>Mills, Anthony M</td>
<td>197</td>
</tr>
<tr>
<td>Mizushima, Daisuke</td>
<td>588</td>
</tr>
<tr>
<td>Mogaka, Jerusha N</td>
<td>767</td>
</tr>
<tr>
<td>Mogere, Peter</td>
<td>1091</td>
</tr>
<tr>
<td>Mohammadi, Abbas</td>
<td>137</td>
</tr>
<tr>
<td>Molina, Jean-Michel</td>
<td>119, 196</td>
</tr>
<tr>
<td>Monroe-Wise, Aliza</td>
<td>153</td>
</tr>
<tr>
<td>Montaner, Luis J</td>
<td>384, 431</td>
</tr>
<tr>
<td>Monterosso, Analise</td>
<td>895</td>
</tr>
<tr>
<td>Moore, Mia</td>
<td>921</td>
</tr>
<tr>
<td>Moore, Penny L</td>
<td>42</td>
</tr>
<tr>
<td>Moraka, Natasha O</td>
<td>582</td>
</tr>
<tr>
<td>Moraleda, Cinta</td>
<td>837</td>
</tr>
<tr>
<td>Moran, Caitlin A</td>
<td>1080</td>
</tr>
<tr>
<td>More, Jessica</td>
<td>777</td>
</tr>
<tr>
<td>Moreira, Rodrigo</td>
<td>654</td>
</tr>
<tr>
<td>Moreno de Lara, Laura</td>
<td>333</td>
</tr>
<tr>
<td>Moreno, Elena</td>
<td>271</td>
</tr>
<tr>
<td>Morgan, Camille</td>
<td>598</td>
</tr>
<tr>
<td>Morris, Benjamin C</td>
<td>321</td>
</tr>
<tr>
<td>Morris, Daniel</td>
<td>302</td>
</tr>
<tr>
<td>Morrison, Corey</td>
<td>818</td>
</tr>
<tr>
<td>Morrocchi, Elena</td>
<td>806</td>
</tr>
<tr>
<td>Moschese, Davide</td>
<td>377</td>
</tr>
<tr>
<td>Moscicki, Anna-Barbara</td>
<td>1028</td>
</tr>
<tr>
<td>Mosehomb, Ellen</td>
<td>804</td>
</tr>
<tr>
<td>Mosethli, Maureen</td>
<td>828</td>
</tr>
<tr>
<td>Moskovljievic, Milica</td>
<td>389</td>
</tr>
<tr>
<td>Mota, Talia</td>
<td>413</td>
</tr>
<tr>
<td>Mothe Pujades, Beatrice</td>
<td>433</td>
</tr>
<tr>
<td>Mouchati, Christian</td>
<td>288</td>
</tr>
<tr>
<td>Mozaffari, Essy</td>
<td>556, 557, 558</td>
</tr>
<tr>
<td>Mueller, April</td>
<td>410</td>
</tr>
<tr>
<td>Mugundu Ramien, Parthasarathy</td>
<td>152</td>
</tr>
<tr>
<td>Mugwanya, Kenneth</td>
<td>1074</td>
</tr>
<tr>
<td>Muhamoh, Teresa A</td>
<td>242</td>
</tr>
<tr>
<td>Mulkova, Madalo</td>
<td>956</td>
</tr>
<tr>
<td>Muñoz, Olivia</td>
<td>422</td>
</tr>
<tr>
<td>Muñoz-López, Francisco</td>
<td>887</td>
</tr>
<tr>
<td>Mustanski, Brian</td>
<td>979</td>
</tr>
<tr>
<td>Mutascio, Simona</td>
<td>174</td>
</tr>
<tr>
<td>Muyanja, Stella Z</td>
<td>744</td>
</tr>
</tbody>
</table>
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeta, Henry W 554
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
Nabeemeeah, Firdaus 746
Nabeta, Henry W 554
Naggie, Susanna 572
Naggirinya, Agnes Wbanka 202
Naidoo, Anushka 827
Namayanja, Grace 528
<table>
<thead>
<tr>
<th>Index of Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy, Upal 471</td>
</tr>
<tr>
<td>Royston, Léna 633</td>
</tr>
<tr>
<td>Rubinstein, Emma 195</td>
</tr>
<tr>
<td>Rubinstein, Paul 434</td>
</tr>
<tr>
<td>Ruudolph, Jacqueline E 155</td>
</tr>
<tr>
<td>Ruiz, Felicitas 309</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Saber, Lindsay 965</td>
</tr>
<tr>
<td>Sabin, Caroline 874</td>
</tr>
<tr>
<td>Sachdev, D. 209</td>
</tr>
<tr>
<td>Sahu, Maitreyi 580</td>
</tr>
<tr>
<td>Sain, Pratima 341</td>
</tr>
<tr>
<td>Sainz, Talia 809, 821</td>
</tr>
<tr>
<td>Saito, Suzue 199</td>
</tr>
<tr>
<td>Salloum, Shadi 295</td>
</tr>
<tr>
<td>Samet, Jeffrey H 203</td>
</tr>
<tr>
<td>Sánchez Gaona, Nerea</td>
</tr>
<tr>
<td>Savinelli, Luca 426</td>
</tr>
<tr>
<td>Sax, Paul 532</td>
</tr>
<tr>
<td>Schnittman, Samuel R 348, 646</td>
</tr>
<tr>
<td>Schuetz, Alexandra 268</td>
</tr>
<tr>
<td>Schwartzmüller, Magdalena 306</td>
</tr>
<tr>
<td>Scott, Hyman 161</td>
</tr>
<tr>
<td>Scully, Eileen P 270</td>
</tr>
<tr>
<td>Sebastiani, Giada 614</td>
</tr>
<tr>
<td>Selzer, Lisa 580</td>
</tr>
<tr>
<td>Sereti, Irini 250</td>
</tr>
<tr>
<td>Serghides, Lena 805</td>
</tr>
<tr>
<td>Serrano-Villar, Sergio 148, 405</td>
</tr>
<tr>
<td>Serwin, Karol 151</td>
</tr>
<tr>
<td>Shah, N. Sarita 755</td>
</tr>
<tr>
<td>Shahnamesh, Maryam 976</td>
</tr>
<tr>
<td>Shaik, Naveed A 504</td>
</tr>
<tr>
<td>Shaikh, Simran 941</td>
</tr>
<tr>
<td>Shams, Marc C 926</td>
</tr>
<tr>
<td>Shankwitz, Kimberly 802</td>
</tr>
<tr>
<td>Shapiro, Adrienne E 111</td>
</tr>
<tr>
<td>Shapiro, Roger 30</td>
</tr>
<tr>
<td>Sharma, Ashish 181</td>
</tr>
<tr>
<td>Shen, Yanhan 567</td>
</tr>
<tr>
<td>Shi, Guoli 232</td>
</tr>
<tr>
<td>Shi, Yuhang 223</td>
</tr>
<tr>
<td>Shinho, Teichiro 938</td>
</tr>
<tr>
<td>Shmakova, Anna 296</td>
</tr>
<tr>
<td>Sikombe, Kombatende 201</td>
</tr>
<tr>
<td>Siliciano, Janet M 26</td>
</tr>
<tr>
<td>Silva, Mayara S. T. 905</td>
</tr>
<tr>
<td>Silvera, Richard J 590</td>
</tr>
<tr>
<td>Silverberg, Michael J 1089</td>
</tr>
<tr>
<td>Simpson, Jennifer 176</td>
</tr>
<tr>
<td>Singh, Meera 465</td>
</tr>
<tr>
<td>Singh, Sonia 934</td>
</tr>
<tr>
<td>Singogo, Emmanuel 1087</td>
</tr>
<tr>
<td>Siribelli, Alessia 615</td>
</tr>
<tr>
<td>Sivile, Suijan 524</td>
</tr>
<tr>
<td>Smith, Amanda J 933</td>
</tr>
<tr>
<td>Smith, Lauren N 303</td>
</tr>
<tr>
<td>Smith, Robert A 538</td>
</tr>
<tr>
<td>Sodeke, Olotumi 758</td>
</tr>
<tr>
<td>Sogaard, Ole S 136</td>
</tr>
<tr>
<td>Solis-Leal, Antonio 417</td>
</tr>
<tr>
<td>Solomon, Sunil S 25</td>
</tr>
<tr>
<td>Songane, Mario 1085</td>
</tr>
<tr>
<td>Sousa, Ana E. 218</td>
</tr>
<tr>
<td>Spagnuolo, Vincenzo 291</td>
</tr>
<tr>
<td>Spinelli, Matthew A 1011, 1094</td>
</tr>
<tr>
<td>Sponaugle, Alexcis 409</td>
</tr>
<tr>
<td>Spudich, Serena 1</td>
</tr>
<tr>
<td>Squires, Kathleen E 192</td>
</tr>
<tr>
<td>Srinivasa, Suman 144</td>
</tr>
<tr>
<td>Stansfield, Sarah E 969</td>
</tr>
<tr>
<td>Stephens, Reno 849</td>
</tr>
<tr>
<td>Stewart, Jenell 121</td>
</tr>
<tr>
<td>Stone, Julie 510, 511</td>
</tr>
<tr>
<td>Storti, Samuelo 470</td>
</tr>
<tr>
<td>Struyve, Tine 449</td>
</tr>
<tr>
<td>Stuart, Robyn 1015</td>
</tr>
<tr>
<td>Stumpf, Julia 762</td>
</tr>
<tr>
<td>Su, Hang 404</td>
</tr>
<tr>
<td>Sudderuddin, Hanwei 575</td>
</tr>
<tr>
<td>Sudsila, Pupe 1060</td>
</tr>
<tr>
<td>Sun, Hsin-Yun 595</td>
</tr>
<tr>
<td>Sun, Jing 214</td>
</tr>
<tr>
<td>Sun, Jing 678</td>
</tr>
<tr>
<td>Sun, Weilwei 135</td>
</tr>
<tr>
<td>Suprasert, Bow 983</td>
</tr>
<tr>
<td>Surial, Bernard 117</td>
</tr>
<tr>
<td>Surial, Bernard 149</td>
</tr>
<tr>
<td>Suryawanshi, Rahul K 275</td>
</tr>
<tr>
<td>Suthar, Amitabh B. 848</td>
</tr>
<tr>
<td>Szokie, Zofia I 244</td>
</tr>
<tr>
<td>Taddese, Maraake 115</td>
</tr>
<tr>
<td>Tagarro, Alfredo 835, 836</td>
</tr>
<tr>
<td>Taha, Taya Y 233</td>
</tr>
<tr>
<td>Taiwo, Babafemi 581</td>
</tr>
<tr>
<td>Takaoji-Kondo, Akiyumi 230</td>
</tr>
<tr>
<td>Tambe, Lisa Arrah 192</td>
</tr>
<tr>
<td>Mbang 922</td>
</tr>
<tr>
<td>Tan, Darrell H. S 146, 292</td>
</tr>
<tr>
<td>Tang, Weiming 1088</td>
</tr>
<tr>
<td>Tapley, Asa 1013</td>
</tr>
<tr>
<td>Tate, Moranda 864</td>
</tr>
<tr>
<td>Tatham, Lee 555</td>
</tr>
<tr>
<td>Thongwa, Boris K 945, 957</td>
</tr>
<tr>
<td>Teerananchai, Sirinya 1046</td>
</tr>
<tr>
<td>Tefera, Fana 637</td>
</tr>
<tr>
<td>Teeyoung, Elisa 278</td>
</tr>
<tr>
<td>Thiebaut, Rodolphe 382, 1008</td>
</tr>
<tr>
<td>Thomas, Dorothy 984</td>
</tr>
<tr>
<td>Thomson, Michael M 573</td>
</tr>
<tr>
<td>Tiendrebeogo, Thierry 705, 1061</td>
</tr>
<tr>
<td>Tindle, Hilar Y 664</td>
</tr>
<tr>
<td>Titanji, Boghum K 207, 952</td>
</tr>
<tr>
<td>Tobin, Nicole H 798</td>
</tr>
<tr>
<td>Tomaika, Jeffrey A 221</td>
</tr>
<tr>
<td>Tong, Xiao 551</td>
</tr>
<tr>
<td>Torgersen, Jessle 613</td>
</tr>
<tr>
<td>Torres, Thiago S 850, 901</td>
</tr>
<tr>
<td>Townsly, Savannah 336</td>
</tr>
<tr>
<td>Toy, K. Junine 1064</td>
</tr>
<tr>
<td>Voy, K. Junine 1081</td>
</tr>
<tr>
<td>Traeger, Michael W 122</td>
</tr>
<tr>
<td>Tram, Khi Hoan 919</td>
</tr>
<tr>
<td>Treurnicht, Florette K 237</td>
</tr>
<tr>
<td>Trickey, Adam 156, 619</td>
</tr>
<tr>
<td>Trigueiros, Macedaiana 263</td>
</tr>
<tr>
<td>Trunfio, Mattia 462, 488</td>
</tr>
<tr>
<td>Truong, Hong-Ha M 1026</td>
</tr>
<tr>
<td>Tsima, Billy M 1092</td>
</tr>
<tr>
<td>Tucker, Emma 891</td>
</tr>
<tr>
<td>Tusch, Eriq 870</td>
</tr>
<tr>
<td>Tuyishime, Simeon 529</td>
</tr>
<tr>
<td>Twentyman, Kay 217</td>
</tr>
<tr>
<td>U.</td>
</tr>
<tr>
<td>Umutesi, Grace 601</td>
</tr>
<tr>
<td>Underwood, Mark 949</td>
</tr>
<tr>
<td>V.</td>
</tr>
<tr>
<td>Vaidya, Akanksha 902</td>
</tr>
<tr>
<td>van den Elshout, Mark 971</td>
</tr>
<tr>
<td>van Eekeren, Louise E 609</td>
</tr>
<tr>
<td>van Rooyen, Heidi 11</td>
</tr>
<tr>
<td>van Wijk, Rob 740, 752</td>
</tr>
<tr>
<td>Vandebergh, Lins 436, 672</td>
</tr>
<tr>
<td>Vargo, Ryan 497</td>
</tr>
<tr>
<td>Vasilidj, Yamsi 1099</td>
</tr>
<tr>
<td>Veenuhn, Rebecca 419</td>
</tr>
<tr>
<td>Veksler, Veronique 486</td>
</tr>
<tr>
<td>Velu, Vijayakumar 317</td>
</tr>
<tr>
<td>Venkatesh, Sreenidhi 356</td>
</tr>
<tr>
<td>Vera, Jaime 476</td>
</tr>
<tr>
<td>Verburgh, Myrthe L 673</td>
</tr>
<tr>
<td>Vieira, Vincius 829</td>
</tr>
<tr>
<td>Viguerie, Alex 158</td>
</tr>
<tr>
<td>Vio, Elise 179</td>
</tr>
<tr>
<td>Visquesse, Benoit 844, 852</td>
</tr>
<tr>
<td>Vos, Christoffel A 914</td>
</tr>
<tr>
<td>Vos, Wilhelm A. J. W. 676</td>
</tr>
</tbody>
</table>

**New Investigator Scholarship**  ✔  **International Investigator Scholarship**  ✔  **Nonauthor Presenter**  ✔  CROI 2023  163
Vraga, Emily 47
Vyas, Kartavya 881

-W-
Waheed, Abdul 101
Wallace, Michael S 621
Wandeler, Gilles 587
✓ Wang, Qiankun 229
✓ Wang, Zheng 669
Wanjalla, Celestine N 650
✓ Ward, Adam R 398
Wei, Yulong 142
✓ Weissman, Sam 456
✓ Wells, Alan B 261

Whitehead, Hannah 1018
Whitehill, Greg 305
Whitesell, Veronika 530
Whitney, Bridget 882

Wikman-Jorgensen, Philip E 1101
✓ Winchester, Nicole 662
Winston, Alan 463
Wise, Jenni 1096
Woodhouse, Edwin Wilbur 1003

Worobey, Michael 17
✓ Wu, Fengting 138
✓ Wu, Jinzi J. 550
✓ Wu, Linxuan 770, 998
Wu, Richard 499
Wu, Vincent 390
✓ Wu, Xinshe 1036
Wu, Yiquan 630
Wynberg, Elke 710

-X-
Xing, Enming 547

-Y-
✓ Yaffe, Zak A 781
✓ Yagnik, Bhrugu 140
Yendewa, George A 724

Yin, Anna 358
Yin, KaiLin 346
Yin, Li 797
Yoshida, Takeshi 220
✓ Young, Isabella 991
Young, Kyriell C 343
Yu, Yifan 782
Yuan, Zhe 394

-Z-
Zafilaza, Karen 281
Zalla, Lauren 876
Zang, Xiao 1065
Zaniewski, Elizabeth 1062
Zeichner, Steven 280
Zemelko, Lily 408
Zhang, Liao 437
Zhang, Weiying 259
✓ Zhao, Ying 525

Zhou, Shuntai 846
Zhou, Xiaojian 512, 513
Zhu, Weiming 980
✓ Zhu, Xianming 880
✓ Zia, Yasaman 1073
Zisis, Sokrates N 713
Zisis, Sokrates N 714
Zou, Roger S 652
Zucker, Jason 738
✓ Zuze, Bontumoeljo L 584
CROI is committed to supporting new and early-career investigators, as well as international investigators and community educators working in resource-limited countries who would otherwise be unable to attend CROI. New Investigator and International Investigator Scholarship Awardees have completed the scholarship application and are presenting authors on abstracts. Community Educator Scholarship Awardees have shown through their applications and letters of recommendation that they will greatly benefit from the opportunity to participate in CROI. Presenting authors who are New Investigator Scholarship Awardees are indicated throughout the program using the corresponding Icons.

**ACTIVITIES FOR NEW INVESTIGATOR SCHOLARSHIP AWARDEES**

**Scott M. Hammer Workshop for New Investigators and Trainees**  
Widely considered the most informative and comprehensive session at CROI, this workshop highlights advances in HIV and SARS-CoV-2 molecular virology and immunology; advances in HIV treatment strategies, biomedical prevention, and cure; and community perspectives. Scholarship recipients are required to attend the entire workshop.

**Meet the Luminary Sessions**  
Small-group sessions (up to 25 New Investigators) during Monday and Tuesday lunchtimes at CROI host a leader in the field, generally a named lecturer or plenary speaker at CROI. These sessions provide the unique opportunity to meet and network with a leading scientific expert, and to ask one-on-one questions in an intimate setting. Each New Investigator can sign up for 1 session. **Note:** Sign up in advance is required.

**Poster Walks (New for CROI 2023)**  
Daily Poster Walks take place during poster sessions on Monday, Tuesday, and Wednesday, with 6 concurrent Poster Walks per day in the areas of clinical research, basic science, and epidemiology/public health. Each 30- to 40-minute Poster Walk is led by a CROI Program Committee member (Poster Walk Leader) with up to 8 New Investigators though a selection of posters curated by the Poster Walk Leader. Each New Investigator can sign up for 1 Poster Walk. **Note:** Sign up in advance is required.

**ACTIVITIES FOR COMMUNITY EDUCATOR SCHOLARSHIP AWARDEES**

**Community Educator Scholarship Awardees Networking Area**  
A designated area for Community Educator Scholarship Awardees and other HIV community representatives and advocates in the Ballroom 3 Lobby Area provides a central meeting point for community attendees.
<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badge and Conference Materials Pickup</td>
<td>Summit Lobby Level 1</td>
<td>Saturday 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Attendee Services</td>
<td></td>
<td>Sunday 7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Housing Information</td>
<td></td>
<td>Monday to Wednesday 7:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>Continental Breakfast</td>
<td>Flex Foyer Level 2</td>
<td>Monday to Wednesday 7:30 AM – 8:30 AM</td>
</tr>
<tr>
<td>Bag &amp; Coat Check</td>
<td>Summit Lobby Level 1</td>
<td>Sunday 8:00 AM – 9:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday 10:00 AM – 6:00 PM</td>
</tr>
<tr>
<td>Cyber Café</td>
<td>Ballroom 1 Lobby Level 5</td>
<td>Sunday - Wednesday 7:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Computers with internet are available.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Media Center</td>
<td>Meeting Rooms 421 and 422 Level 4</td>
<td>Sunday 10:00 AM – 7:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday and Tuesday 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday 7:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Open exclusively to registered, accredited media, the Media Center is a workspace with WiFi and the location of the daily press conference.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office</td>
<td>Terrace 1 Level 4</td>
<td>Saturday 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday to Wednesday 7:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker Ready Room</td>
<td>Meeting Rooms 431 and 432 Level 4</td>
<td>Saturday 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday to Wednesday 6:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Oral abstract, themed discussion, and special/invited session speakers must drop off PowerPoint slides here at least 24 hours prior to their presentation.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal Considerations and Lactation Room</td>
<td>Near Room 341 (Level 3); Near Room 441 (Level 4)</td>
<td>Saturday 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday 9:00 AM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday 8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** The Personal Considerations and Lactation room is set aside for those who require a short-term private space for personal health needs. This room is available on a first-come, first-served basis.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Investigator Networking Lounge</td>
<td>Signature Room Level 5</td>
<td>Sunday 1:30 PM – 7:00 PM</td>
</tr>
<tr>
<td></td>
<td>Signature Room Level 5</td>
<td>Monday to Wednesday 8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitors Information Booth</td>
<td>Summit Lobby Level 1</td>
<td>Saturday 2:30 PM – 6:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sunday 2:00 PM – 9:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday 10:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Local information and reservations assistance.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convention Center Emergency Medical Services</td>
<td>Near Flex C Level 2</td>
<td>Sunday 8:30 AM – 9:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monday to Wednesday 8:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>TIME</td>
<td>SUNDAY, FEBRUARY 19, 2023</td>
<td>MONDAY, FEBRUARY 20, 2023</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>7:30am</td>
<td>Continental Breakfast 7:30 am–8:30 am</td>
<td>Continental Breakfast 7:30 am–8:30 am</td>
</tr>
<tr>
<td>8:30am</td>
<td>Scott M. Hammer Workshop for New Investigators and Trainees 9:00 am–12:30 pm Flex A (Level 2)</td>
<td>Concurrent Abstract Sessions 10:00 AM – 12:00 PM TD-01 HIV and the Microbiome: New Themes Flex C (Level 2) TD-02 Leptin: Excess or Insufficient Flex C (Level 2) TD-03 Predictors of TB Treatment Outcomes Ballroom 1 (Level 5) TD-04 Assessing Mortality in People with HIV Ballroom 3 (Level 5) TD-05 Predicting and Preventing HIV in Women and Children Flex C (Level 2)</td>
</tr>
<tr>
<td>10:00am</td>
<td>Plenary Session 8:30 am - 9:30 am The Path to Hepatitis B Cure Flex C (Level 2)</td>
<td>Concurrent Themed Discussions 1:30 PM – 2:30 PM TD-01 HIV and the Microbiome: New Themes Flex C (Level 2) TD-02 Leptin: Excess or Insufficient Flex C (Level 2) TD-03 Predictors of TB Treatment Outcomes Ballroom 1 (Level 5) TD-04 Assessing Mortality in People with HIV Ballroom 3 (Level 5) TD-05 Predicting and Preventing HIV in Women and Children Flex C (Level 2)</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch 12:00 PM – 1:30 PM ** Meet the Luminaries 12:15 PM – 1:15 PM</td>
<td>Lunch 12:00 PM – 1:30 PM ** Meet the Luminaries 12:15 PM – 1:15 PM</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Lunch 12:30 PM – 1:30 PM</td>
<td>** Meet the Luminaries 12:15 PM – 1:15 PM</td>
</tr>
<tr>
<td>1:30pm</td>
<td>Concurrent Technical Workshops 1:30 PM – 3:30 PM Frontiers in Laboratory Technologies Ballroom 2 (Level 5) Case-Based Liver Workshop Flex A (Level 2) Clinical Trial Design and Analysis Ballroom 3 (Level 5)</td>
<td>Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks</td>
</tr>
<tr>
<td>2:30pm</td>
<td>Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks</td>
<td>Poster Sessions 2:30 PM – 4:00 PM Exhibit Hall 2 ** Poster Walks</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Concurrent Symposia 4:00 PM – 5:30 PM S-01 Viral Origins and Evolution of HIV and SARS-CoV-2 Ballroom 2 (Level 5) S-02 From Rocket Science to Reality: Monitoring Antiretrovirals and Adherence Flex A (Level 2) S-03 Delivering on the Success of Injectable PrEP Ballroom 1 (Level 5)</td>
<td>Concurrent Symposia 4:00 PM – 5:30 PM S-01 Pediatric HIV Cure Ballroom 2 (Level 5) S-02 COVID-19: Where Are We Now? Flex A (Level 2) S-06 Getting PrEPed (and PEPped) for Sex: From HIV to STIs to Mpox Ballroom 1 (Level 5)</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Opening Session 5:00 PM – 7:20 PM Reception – 7:20 PM – 9:30 PM Garden Terrace (Level 3) Bernard Fields Lecture N’Galily-Mann Lecture Martin Delaney Presentation CROI at 30: Progress in HIV Through the Lens of CROI Special Recognition of Dr Anthony Fauci Flex C (Level 2)</td>
<td>Special Session 5:40 PM – 6:00 PM Results from the MOSAICO HIV Vaccine Trial and Future Directions for HIV Vaccines Flex A (Level 2)</td>
</tr>
</tbody>
</table>

*Please note: Poster Walks and Meet the Luminaries sessions are limited to New Investigator Scholarship Awardees. Sign up in advance is required.*